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Variegate porphyria (VP) is the clinical disorder associated with. a deficiency of the haem­
synthesising enzyme protoporphyrinogen oxidase (P~~). VP IS ~ne of the commonest 
monogenic inherited disorders in South Africa. The chmcal effects mclu~e p~otocutaneous 
sensitivity and the development of potentially life-threatening ~cute porp?ync cnses. . . 
Section 1 of this dissertation examines the molecular basIS for VP m South Africa. It IS 
shown to be a genetically heterogeneous disorder. The identification of 10 discrete mut.atio~s 
is reported and their characteristic features described. One mutation, the R59W mu:atton, IS 
highly prevalent and represents the original founder mutation imported from Holland m 1688. 
Section 2 examines the value of routine porphyrin analyses of urine, stool and plasma in 
the diagnosis of VP as correlated with the presence or absence of a PPO mutation on DNA 
analysis. Biochemical testing is shown to be imprecise and subject to individual variation in 
interpretation. All children and 30% of adults carrying a PPO mutation fail to express 
abnormal biochemistry. Using the statistical techniques of discriminant analysis and 
classification tree analysis, it is shown that an elevation of stool coproporphyrin and 
pentacarboxylic porphyrin are the most important biochemical predictors of VP. The 
predictive value of qualitative porphyrin analyses is assessed and plasma fluorescence 
scanning is demonstrated to represent the most sensitive biochemical test for VP. 
Section 3 examines the clinical expression of VP. In a study of a single kindred carrying 
the R59W mutation, it is shown that approximately 60% of adults are clinically silent, skin 
disease is present in 40% and that the probability of an acute attack is now low. The mutations 
present in 4 subjects with compound heterozygous VP are described and their biochemical 
features and clinical course described. A 10-year personal experience with the management of 
more than 100 episodes of the acute porphyric crisis in Groote Schuur Hospital is reviewed. 
Unusual presentations and complications are discussed, and the outcome of treatment 
reported. 
The significance of these findings and their implications for the care of patients with VP 














EBV Ebstein-Barr virus 
HPLC high perfonnance liquid chromatography 
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SSCP single-stranded confonnational polymorphism 
TLC thin-layer chromatography 
UCT University ofCape Town 
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In this introductory chapter, the porphyrias are briefly defined and reviewed. The history of 
variegate porphyria (VP), and of its recognition and characterisation in South Africa, is 
described. The experimental work reported in this dissertation is divided into three sections, 
corresponding to the molecular biology, the biochemical features and clinical aspects of VP 
respectively. Each section begins with a review of the pertinent literature. Thereafter the 
experimental or descriptive work follows, chapter by chapter according to the nature of the 
work. Though a brief summary of the conclusions drawn from the work of each chapter is 
provided, the results are not discussed in detail until the concluding chapter of each section 
where the results as a whole are discussed. 
1.1 THE PORPHYRIAS 
The porphyrias are a group of metabolic disorders associated with impaired activity of the 
enzymes of the haem synthetic pathway. Characteristically these disorders are accompanied 
by the abnormal accumulation of the intermediate metabolites on this pathway: the porphyrin 
precursors, o-aminolaevulinic acid (ALA) and porphobilinogen (PBG) , and the porphyrins, 
which are the oxidised form of the porphyrinogens produced during haem synthesis (Figure I­
1). Most of the porphyrias are inherited disorders. The exception is porphyriacutanea tarda 
(PCT) which is usually an acquired disease though an inherited form is also encountered. 
Most are inherited as autosomal dominant conditions with the exception of ALA dehydratase 
deficiency and congenital erythropoietic porphyria (CEP) which are recessive. The 
inheritance of erythropoietic protoporphyria (EPP), as a clinical disorder, is complex and is 
described in Chapter 15. 
In two of the porphyrias, haem synthesis within the erythroid precursor cells is 
predominantly disturbed. In these conditions, erythrocytes and plasma porphyrins are 
p~icularly elevated and erythrocytes may fluoresce under ultraviolet light. The clinical 
symptoms are of photosensitivity, and these porphyrias, CEP and EPP, are traditionally 
classified as erythropoietic porphyrias. In the remaining disorders, haem synthesis within non­
erythroid cells is predominantly affected. Since the liver is an active haem-synthesising organ 
and much of the overproduction of porphyrias is thought to occur here, these forms of 
potphyria are classified as hepatic porphyrias. The characteristic features of the porphyrias are 
summarised in Table 1-1. 
1.2 HISTORICAL ASPECTS OF VARIEGATE PORPHYRIA 
It has been known for over a century that the diseases we now know as porphyrias are 
associated with the excretion of unusual substances, particularly in the urine (Moore et al 
1987). Following the introduction of Sulphonal as a hypnotic (Kast 1888), a series of patients 
were described who developed abdominal pain and neuropathy and were noted to excrete dark 
substances in the urine. Stokvis (1889) described an elderly woman who, following the 
ingestion of Sulphonal, developed a neurological crisis associated with the passage of dark­
red urine from which she ultimately succumbed. Stokvis suggested that the pigment causing 
the discolouration of the urine was related to haematoporphyrin. A number of similar cases 











appeared that between 5 and 10% of woman treated with Sulphonal developed "haemato­
porphyria" (Geill1891, Fehr 1891). 
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The biochemical and clinical· features of variegate porphyria were first described in a 
patient in 1937 (Van den Bergh and Grotepass 1937). This patient, interestingly, may have 
been the propositus of one of the Dutch families described many years later by Te Velde et al 
(1989). Further case reports followed. Initially the features ofVP were confused with those of 
PCT, acute intermittent porphyria (AIP) and hereditary coproporphyria (HCP) and a number 
of terms were later used to describe the disease including mixed porphyria (Watson 1960), 
protocoproporphyria (Waldenstrom 1957), porphyria cutanea tarda-resulting in confusion 
with the condition we know by that name today (Calvert and Rimington 1953, MacGregor et 
al 1952, Wells and Rimington 1953, Holti et al 1958)-and porphyria cutanea tarda 
hereditaria (Cormane et al 1971, Levene 1968, Magnus 1968, Rimington et al 1967, Tio 
1958). 
The first published description of acute porphyria in South Africa was written by two 
medical students, Lennox Eales and Jack Chait, who described a patient in the medical 
students' journal of the University of Cape Town in October 1939. The first report of a series 
of cases of porphyria, then known as porphyrinuria, appeared in 1951 with a description by 
HD Barnes of the South African Institute for Medical Research in Johannesburg. A major 
contribution to the understanding of porphyria in South Africa was that of Geoffrey Dean, a 
physician in the coastal city of Port Elizabeth. He identified a large number of affected people 
amongst his patients in the eastern Cape Province. Dean showed that the disease was inherited 
as a Mendelian dominant character, recognised that the disease could manifest with skin 
lesions, acute attacks or both and coined the terms porphyria variegata or South African 
genetic porphyria to describe it (Dean 1953, Dean and Barnes 1955). 
Dean then went on to demonstrate that VP is extremely common amongst the South 
African population of Dutch descent, and to show that it was a disorder distinct from the 
genetic porphyria found in Sweden (Dean and Barnes 1959). He investigated 118 South 
African family groups in all. He showed that on average 50% of the children of a porphyric 
patient would inherit VP, that the sex distribution is equal and that patients may experience 
acute attacks and skin disease singly or together showing that they are features of a single 
disorder. He also observed that family members could be asymptomatic, yet be shown to have 
VP by the demonstration of abnormal urine and stool porphyrins. He commented that he had 
never seen a family in which both parents had VP, and thus had never seen a homozygote 
(Dean 1963). Furthermore, his meticulous genealogical studies suggested that almost all 
patients with VP were descended from a single founder. He was able to trace many of his 
affected families back to 5 of the 11 children of a Comelis van Rooyen who married 
Jacomijnlje Gerritsz, the daughter of Gerrit Jansz, in 1720. Other porphyric families were 
traced back to three other children of Gerrit Jansz, who had immigrated to the Cape of Good 
Hope from Deventer in Holland, and had married a Dutch orphan named Adriaantjie 
Adriaanse in 1688. Adriaantjie, born in Rotterdam, arrived on the Dutch East India Company 
ship China in 1688 and was married within a month of arrival. To this day it is not known 
whether VP was introduced into South Africa by Gerrit Jansz himself or by his wife, 
Adriaantjie. 
1.3 PREVALENCE OF VARIEGATE PORPHYRIA 
VP has been recognised in many countries (Mustajoki 1978), but is believed to be generally 
uncommon everywhere but South Africa. In Finland the prevalence has been estimated at 1.3 
per 100 000 (Mustajoki 1980). In Europe generally, the prevalence of clinically-overt VP is 
thought to be approximately one-third that of AIP or approximately 0.5 per 100 000 (Elder et 
al 1997). Since it is believed that many subjects with VP are clinically latent, particularly in 











(Mustajoki 1978), the prevalence of PPO mutations in Europe is likely to be considerably 
higher, and the disease may not be as rare as has previously been thought. 
The prevalence of VP in South Africa has never been accurately determined. Dean (1963) 
attempted to estimate the prevalence by screening staff and patients of European descent in 
Port Elizabeth hospitals for VP. He found that 8 of 645 nurses {1.2%) and 4 of 608 patients in 
the local mental hospital (0.66%) appeared to have biochemical evidence of VP. 5647 adults 
were tested prior to administration of thiopentone or barbiturates in the provincial hospital and 
29 positive patients were detected (0.51%). In a second hospital, 3 of 719 patients tested 
positive (0.42%). In the following year, the incidences in these hospitals were 0.46% and 
0.42% respectively. These figures suggested that the prevalence of VP amongst the white 
population of the eastern Cape Province was 4 per thousand. Dean believed that it would be 
lower in other cities, which had received a larger proportion of recent immigrants. He 
suggested an overall prevalence of 3 per thousand in the white population of South Africa and 
a total figure of 8000±2000 for the country as a whole. No better estimate has ever been made 
for South Africa. 
Following this brief introduction to VP, the molecular biology of this disorder is now 

















Section 1 of this dissertation examines the molecular basis for VP in South Africa. It is shown 
to be a genetically heterogeneous disorder. The literature pertinent to the molecular biology of 
VP is reviewed in Chapter 2. In Chapter 3, the identification of the first two mutations 
discovered in South African patients with VP is reported, and it is shown that one mutation, 
the R59W mutation, is highly prevalent and represents the original founder mutation imported 
from Holland in 1688. In Chapter 4, a further 8 mutations identified in South African patients 












THE MOLECULAR BIOLOGY OF VARIEGATE 
PORPHYRIA: A REVIEW OF THE LITERATURE 
In this chapter, the molecular and enzymatic defects underlying the biochemical and clinical 
features of VP are discussed. Following a review of the identification of protoporphyrinogen 
oxidase (PPO) as the primary site of the defect in VP, the identification of the DNA sequence 
coding for PPO, its assignment to chromosome 1 and the recognition ofmutations in this gene 
in patients with VP are discussed. The mutations encountered in patients with homozygous or 
compound heterozygous VP are not dealt with here, as they are specifically discussed in 
Chapters 15 and 19. 
2.1 THE ENZYMATIC DEFECT IN VARIEGATE PORPHYRIA 
From the pattern of porphyrin excretion-largely of coproporphyrin and protoporphyrin-in 
VP, it seemed likely that, as in EPP, a deficiency of one of the terminal enzymes of the haem­
synthetic pathway would prove to be responsible for the disorder. Reduced ferrochelatase 
activity had been shown to be responsible for EPP (Bonkowsky et al 1975, Bottomley et al 
1975, DeGoeij et al 1975). However, some investigators reported a 50% reduction in 
ferrochelatase activity in both cultured fibroblasts and bone marrow cells from patients with 
VP, and suggested that VP and EPP shared the same enzyme defect (Becker et al 1977, 
Viljoen et al 1979). Equivocal ferrochelatase activities were additionally shown in circulating 
lymphocytes (Deybach et al 1981). However, Brenner and Bloomer (1980) convincingly 
demonstrated a 50% reduction in PPO activity in cultured skin fibroblasts from patients with 
VP, and Bloomer (1981) later found the activity offerrochelatase in the fibroblasts of patients 
with VP to be normal. All subsequent experience has supported a primary role for PPO, and 
not ferrochelatase, deficiency in VP. 
Although PPO deficiency is the primary defect in VP, the disease does not occur in 
isolation from the other enzymes of the haem synthetic pathway. Evidence in the acute 
porphyrias, AIP, HCP and VP, all suggests that reduced activity of the dysfunctional enzyme 
induces an increase in ALA synthase activity, probably on the basis of haem-deficiency: this 
reduction in haem synthase activity is greater during the acute attack than it is in remission 
(Strand et al 1970, Tschudy et a11965, Nakau et al 1966, Dowdle et al 1967, McIntyre et al 
1971). Bloomer also foresaw that, in addition to the accumulation of protoporphyrinogen 
(subsequently oxidised to protoporphyrin and excreted in bile and stool) in VP, some other 
factor must operate to explain the acute attack which is always accompanied by markedly· 
elevated concentrations of the porphyrin precursors ALA and PBG, as well as those 
porphyrins which precede protoporphyrinogen in the pathway. 
Some studies have looked at erythrocyte PBG deaminase levels in patients with VP. 
McColl et al (1985) and Mustajoki (1976) had shown significant reductions in PBG 
deaminase activity, of 20% and 10% respectively, in patients with VP. Similar reductions in 
PBG deaminase activity had been reported in subjects with HCP (Brodie et al 1977, Moore et 
al 1980). PBG deaminase deficiency did not appear to result from a co-inherited mutation 
since no subjects with deficient PBG deaminase activity alone were identified in these VP 
families, and it appeared to be a secondary phenomenon expressed by a proportion of subjects 
manifesting PPO deficiency. Meissner et al (1986) simultaneously measured the activities of 











Barr virus-transformed lymphoblasts. They showed that the lymphoblasts of VP subjects 
consistently show an approximately 50% reduction in PPO activity as well as an additional 
24% reduction in PBGD activity. A 28% reduction in PBG deaminase activity in erythrocytes 
from patients with VP was also shown. In every case, decreased PBG deaminase activity co­
segregated with decreased PPO activity. In subsequent work, Meissner et al (1993) showed 
that PBG deaminase is allosterically inhibited by both coproporphyrinogen and 
protoporphyrinogen, though not by uroporphyrinogen, uroporphyrin, coproporphyrin or 
protoporphyrin. In a series of experiments, they showed increasing degrees of inhibition of 
PBG deaminase, both in lymphoblasts and in pure form, in response to the addition of 
coproporphyrinogen and protoporphyrinogen. Furthermore, they showed that removal of 
porphyrinogens from the system by column chromatography restored normal kinetic 
behaviour to PBG deaminase. We therefore believe that a secondary deficiency in PBG 
deaminase activity in response to increasing intracellular concentrations of copro­
porphyrinogen and protoporphyrinogen resulting from coproporphyrinogen oxidase or PPO 
activity in RCP and VP may be important in the development of the acute attack. 
2.2 PROTOPORPHYRINOGEN OXIDASE 
Since protoporphyrinogen IX will oxidise spontaneously to protoporphyrin IX in the presence 
of light and oxygen, the inter-conversion was initially thought to be the result of auto­
oxidation, though some investigators suggested from an early stage that the reaction might be 
enzyme-mediated (Porra and Falk 1961, Sano and Granick 1961, Porra and Falk 1964). 
Poulson and Poiglase (1974) showed that the rate of auto-oxidation ofprotoporphyrinogen IX 
in yeast cells only approximates the average rate of synthesis of haem, and that yeast cells 
contain antioxidants which inhibit auto-oxidation. Furthermore, they reported that a yeast 
mitochondrial extract appeared to facilitate 'the conversion of protoporphyrinogen IX under 
conditions unfavourable for auto-oxidation. 
Initially a single cell fraction appeared responsible for the two-stage process of oxidation 
of coproporphyrinogen, via protoporphyrinogen, to protoporphyrin, and it seemed possible 
that coproporphyrinogen oxidase might be responsible for both the oxidative decarboxylation 
of the side chain and the subsequent dehydrogenation, but stereochemical experiments using 
meso-tritium-Iabelled coproporphyrinogen III indicated that a separate, specific enzyme 
would be required for the conversion of protoporphyrinogen IX to protoporphyrin IX. 
Poulson and Poiglase (1975) then partially purified an extract from yeast mitochondria which 
selectively oxidised protoporphyrinogen IX to protoporphyrin IX and was postulated to 
contain this enzyme, now labelled PPO: neither uroporphyrinogen nor coproporphyrinogen 
served as a substrate for this reaction. This was followed by the partial purification of 
mammalian PPO from rat liver mitochondria (Poulson 1976). Poulson showed that 
coproporphyrinogen oxidase lacked the ability to oxidise protoporphyrinogen and that the rate 
of oxidation of protoporphyrinogen in the presence of partially purified ferrochelatase was 
less than 10%. Conversely, the mitochondrial fraction with PPO activity was substantially 
free of coproporphyrinogen oxidase and ferrochelatase activity, thus conclusively proving the 
existence and importance ofPPO as an enzyme in its own right. Subsequent work (Jackson et 
al 1976) confirmed that protoporphyrinogen, harderoporphyrinogens, isoharderoporphyrino­
gens and mesoporphyrinogen serve as substrates for this enzyme. PPO activity was 
additionally shown in photosynthetic bacteria (Jacobs and Jacobs 1981) and plants (Jacobs 
and Jacobs 1983), and was subsequently purified from plant organelles and shown to 
participate in both haem and chlorophyll synthesis. In 1985 the kinetic properties of partially 











Deybach et al (1985) were able to show, using the digitonin method and subsequent 
fractionation of rat liver mitochondria, that PPO was closely associated with the inner 
membrane fraction of the mitochondria. Chemical treatment suggested that the enzyme was 
anchored within the lipid bi-Iayer of the inner membrane. Protoporphyrinogen appeared to 
have equal access to the active site of the enzyme from both sides of the inner membrane 
though the catalytic site faces the cytosolic side of the membrane (Ferreira 1988). 
Furthermore, co-localisation of coproporphyrinogen oxidase and protoporphyrinogen oxidase 
was shown by experiments in which hypo-osmotic disruption of the mitochondrial 
membranes resulted in a dislocation of coproporphyrinogen oxidase from the intermembrane 
space, following which coproporphyrinogen oxidase continued to produce proto­
porphyrinogen from coproporphyrinogen substrate at the normal rate, but there was an 
accumulation of protoporphyrinogen and retarded oxidation to protoporphyrin (Deybach et al 
1985). 
The purification and characterization of PPO from various sources followed somewhat 
later, including mammalian PPO from the mouse (Dailey and Karr 1987, Ferreira and Dailey 
1988, Proulx and Dailey 1992) and cattle (Siepker et al 1987), yeast (Camadro et al 1994), 
Rhodopseudomonas sphaeroides (Jacobs and Jacobs 1981) barley and soybean (Jacobs and 
Jacobs 1987, Jacobs et al 1989); Desulfovibrio gigas (Klemm and Barton 1987); spinach 
(Matringe et al 1992); Arabidopsis thaliana (Narita et al 1996), tobacco (Lermontova et al 
1997) and potato plant (Johnston et al 1998). The molecular weights for the oxygen­
dependent protoporphyrinogen oxidases lie within the range 51000-57000 kDa and it appears 
that most of these protoporphyrinogen oxidases exist either as monomers as in Bacillus 
subtilis (Dailey et al 1994a), Saccharomyces cerevisiae (Camadro et al 1994), and bovine 
enzymes (Siepker et al 1987), or homodimers as in mouse (Dailey et al 1995), Myxococcus 
xanthus (Dailey and Dailey 1996a) and human PPOs (Nishimura et al 1995, Dailey and 
Dailey 1996b). All protoporphyrinogen oxidases are relatively specific for their natural 
substrate protoporphyrinogen IX though most will oxidise the non-physiological dicarboxylic 
mesoporphyrinogen IX to a limited extent. B. subtilis PPO can additionally use utilise 
coproporphyrinogen III for as a substrate (Dailey et aI1994). Evidence from spectral analysis 
and gene/protein sequence information shows that protoporphyrinogen oxidases are 
flavoproteins. The flavin cofactors consist principally of flavin adenine dinucleotide (FAD) 
and are generally non-covalently bound to the apoprotein (Dailey and Dailey, 1996a). 
Bilirubin has been shown to function as a weak competitive inhibitor of PPO with a 
relatively high Ki (Ferreira and Dailey 1988). A class of herbicide, the phenyl ethers, have. 
subsequently been shown to be potent inhibitors of both plant and mammalian PPO (Matringe 
et al 1989, Camadro et al 1991). The prototype for this inhibition is acifluorfen. Acifluorfen 
methyl is a more potent inhibitor and a number of other substituted diphenyl ethers (DPE) 
have been shown to be inhibitory as well (Camadro et aI1991). This effect has been shown in 
maize etioplasts and in potato, yeast and mouse mitochondria. The inhibition reported in those 
experiments was uniformly of competitive type with the exception of the yeast mitochondrial 
enzyme in which mixed-type inhibition was shown. (Camadro et al (1991). Our own work 
demonstrated that acifluorfen functions as a competitive inhibitor of PPO in homogenates of 
human liver and placenta, mouse liver and pig placenta, but interestingly, mixed-type 
inhibition was shown for pig liver (Rift et aI1994). 
Mechanisms 
The conversion of protoporphyrinogen IX to protoporphyrin IX involves a six-electron 
oxidation during which the methylene bridges in protoporphyrinogen-IX are converted into 











and more than one mechanism may operate, especially in prokaryotes since these can survive 
under both aerobic and anaerobic conditions. The reaction consumes three molecules of 
molecular oxygen and generates three H202 molecules (Dailey et al 1994, Dailey and Dailey 
1996a, Dailey and Dailey 1996b). Since PPO contains no redox-active metals and only one 
FAD molecule, it is postulated that the reaction mechanism involves three two-electron 
oxidation reactions. Two possible mechanisms may explain this. In the first, PPO would bind 
the porphyrinogen substrate and carry out the complete reaction without release of the 
macrocycles until completion. In the second, PPO might catalyse three independent oxidation 
reactions with the release of tetrahydro and dihydro- intermediates; a model similar to that of 
the decarboxylations catalysed stepwise by uroporphyrinogen decarboxylase (Dailey and 
Dailey 1997). 
2.3 	 IDENTIFICATION OF THE PROTOPORPHYRINOGEN OXIDASE 
GENE 
Protoporphyrinogen oxidase was the last enzyme of the haem-synthetic pathway to be 
identified, purified and characterised from sources such as mouse (Dailey and Karr 1987, 
Proulx and Dailey 1992), cattle (Siepker et a11987) and yeast (Camadro et a11994). Attempts 
to purify human PPO in our own laboratory and elsewhere proved unsuccessful: its 
hydrophobicity, lability; loss of the flavin cofactor during purification and the difficulty of the 
assay for PPO activity (Appendix 1) all militated against success. 
Complementary DNA (cDNA) sequences for bacterial and yeast PPO became available 
from 1994, when Dailey et al (1994) recognised that an unidentified cloned segment of the 
Bacillus subtilis chromosome labeled HemY (Hansson and Hederstedt 1992), occurring in 
close proximity to the segments coding for uroporphyrinogen decarboxylase and 
ferrochelatase activity, appeared to share sequences with some fragmentary sequences they 
had identified in mammalian tissue and believed to belong to the gene for mammalian PPO. 
They successfully cloned and expressed this sequence in Escherichia coli, and showed that 
the expressed protein indeed had protoporphyrinogen oxidase activity and therefore 
represented B subtilis PPO. This group has subsequently cloned the PPO sequence of 
Myxococcus xanthus (Dailey and Dailey 1996b), and have published important work on the 
structure and function of both prokaryotic and eukaryotic PPO. They have published the gene 
sequence for murine PPO, and have shown that PPO has significant sequence similarities to 
mammalian monoamine oxidases and plant phytoene desaturases. They propose that an 
extended region beyond the dinucleotide binding motif represents a signature motif for a 
superfamily of FAD-containing enzymes comprising protoporphyrinogen oxidases, animal 
monoamine oxidases and plant phytoene desaturases (Dailey and Dailey 1998); this region of 
similarity does not appear in any other proteins in the current gene-sequence databases. 
The gene for human PPO 
In 1995 Nishimura et a1 (1995) reported the cloning of a human cDNA for PPO, using a 
process of in-vivo complementation with a hemG mutant of E. coli. The cDNA was obtained 
from a human placental cDNA library and was shown to overcome the slow growth of a strain 
of E. coli deficient in PPO activity. Its identity as PPO was further confirmed by 
demonstrating enhanced PPO activity when the sequence was expressed in monkey kidney 
cos-J cells. The deduced amino acid sequence of the cDNA displayed a high degree of 
similarity to that for the hemY gene in B. subtilis, which encodes the bacterial PPO. They 
determined that the amino-terminal amino acid sequence could be configured as a ~a~ 











(Proulx and Dailey 1992). This was supported by the demonstration of the characteristic motif 
gxgxxg, an arrangement of glycine residues typical of the dinucleotide-binding domains of 
many flavin-containing proteins. The length and mass of the human protein product were 
estimated to be similar to that of the B. subtilis enzyme at 477 amino acids and 51 kDa. 
Both ferrochelatase and coproporphyrinogen oxidase are synthesised as precursors with a 
pre-sequence which targets importation into mitochondria, a common feature of 
mitochondrial proteins. Human PPO does not appear to contain such an amino-terminal pre­
sequence. It has however been shown (Allison and Schatz 1986) that such a sequence is not 
always necessary for mitochondrial targeting since the targeting function may depend on a 
balance between basic, hydrophobic and hydroxylated amino acids. 
Roberts et al (1995a) amplified a 4.5 kb genomic DNA fragment from a normal individual 
using sense and antisense primers located in the 5' and 3' untranslated regions of the cDNA 
for PPO as reported by Nishimura et al (1995). This fragment was partially sequenced after 
subcloning and shown to contain the entire 1431 bp coding sequence of human PPO, divided 
into 12 exons. The deduced amino acid sequence was identical to that reported by Nishimura 
(1995). 
Taketani et al (1995) showed by Southern blotting of human genomic DNA that there is a 
single copy of the PPO gene The gene was found to have thirteen exons and to span 
approximately 8 kb, and exons appeared to encode functional protein domains. Two major 
transcriptional initiation sites were found in a region with sequence motifs characteristic of a 
promoter. It appeared that the same transcripts for PPO are present in both erythroid and non­
erythroid cells. 
Dailey and Dailey (1996a) isolated normal human placental PPO cDNA by 
complementation of a PPO-deficient strain of E. coli. They recovered a clone which was 
shown to express PPO activity. The expressed PPO protein was then purified from the culture 
medium; this was facilitated by the addition of a 6-histidine leader tag attached to the amino 
terminus. The human placental PPO cDNA obtained by complementation was 1.8 kb in 
length, with 1431 nucleotides coding for a protein comprising 477 amino acids. They 
calculated a molecular weight of approximately 51,000 kDa. Sephacryl S-300 column 
chromatography in the presence of 0.2% octyl glucoside indicated that the holoenzyme has a 
molecular weight of 100,000, with a calculated pI of 8.0. No membrane-spanning regions 
(Milpetz 1995) or membrane-targeting sequences were shown. The calculated extinction 
coefficient was 48,000 at 275 nm, and a putative dinucleotide binding motif (Wierenga et al 
1986) is present near the amino terminal end. Ultraviolet/visible absorption showed the 
presence of flavin which was non-covalently bound and easily extracted with acid or SDS. Its 
pH-dependent fluorescence identified it as FAD. Sephadex G 200 gel filtration indicated that 
PPO is a dimer, and spectroscopic quantitation of the extracted flavin indicated the presence 
of a single molecule of FAD per PPO dimer. Metal analysis by plasma emission indicated the 
absence of any redox-active metal. The expressed enzyme utilised protoporphyrinogen IX as a 
substrate with a Km of 1.7 mM and a Kcat of 1O.5/min. Expressed PPO could utilise both 
mesoporphyrinogen IX and deuteroporphyrinogen IX as substrates: though Km values were 
similar to those for protoporphyrinogen IX, the Kcat values were 100-fold lower. 
Puy et a1 (1996a) subsequently sequenced the entire PPO gene in 50 unrelated French 
controls. They demonstrated that there are 13 exons located within a 5.5 kb region which 
includes a sequence 660 bp upstream from the initiation of the translation site. They 
characterised 12 introns with relatively short sequences ranging from 84 bp to 507 bp. They 
were able to demonstrate that the difference in the size of the gene reported by Taketani et al 
(1995) and Roberts et al (1995a) was explained by an incorrect approximation of the size of 
introns 4, 7 and 9. Nucleotides were more or less evenly distributed along the PPO gene 











Assignment to chromosome 1q22~23 
The gene for PPO had originally been assigned to chromosome 14q32. Bissbort et al (1988) 
reported close linkage between the gene locus for VP and the aI-antitrypsin gene, which was 
known to reside on chromosome 14. However, in a collaborative study with the University of 
Stellenbosch, we demonstrated that the assignment of the VP gene to chromosome 14 was 
incorrect (Warnich et aI1996a). Using lymphoblast PPO data to assign an accurate diagnosis 
in 79 individuals from 16 families, we demonstrated no evidence for linkage between VP and 
S microsatellite markers on chromosome l4q, closely related to the aI-antitrypsin locus. 
Subsequently, using fluorescent in situ hybridisation, the human PPO gene has been localised 
to chromosome lq23 (Roberts et a1199Sa) and to chromosome 1q22 by Taketani et al (199S). 
Further confirmation that the PPO gene resides on chromosome 1 was provided by Roberts et 
al since they showed a significant linkage between the VP phenotype in a sample of British 
patients with VP and micro satellite markers on chromosome 1. No linkage could be shown to 
markers in the alpha-l antitrypsin region of chromosome 14, though the investigators 
suggested that the possibility that a locus associated with the aI-antitrypsin gene on 
chromosome 14 might modify the expression ofVP had not been excluded. 
2.4 MUTATIONS WITIDN THE PPO GENE 
In 1996, a landmark was reached with the publication of the first papers identifying mutations 
in the PPO gene accounting for VP. Deybach et al (1996) described two PPO mutations in 
four French patients with VP. The Cape Town group reported two mutations, one of which 
appeared to account for the high prevalence of VP in South Africa (Meissner et al 1996); this 
was confirmed by an independent report by Warnich et al (1996b). 
Mutations in South African patients with VP 
In 1996 we identified two mutations carried on the maternal and paternal alleles respectively 
of a compound heterozygote who is described in detail in chapter 16. The identification of 
these mutations is described in the chapters which follow and is therefore not discussed 
further here. Working independently of the UCT laboratory, a South African group based at 
the University of Stellenbosch reported 3 missense mutations in the PPO gene (Warnich et al 
1996b). Using single-stranded conformational polymorphismlheteroduplex (SSCPIHD) 
analysis to screen all 13 exons of the PPOX gene, including the splice site sequences, they 
studied a group of 17 unrelated South African VP patients and 10 normal controls and 
demonstrated abnormal mobility in exons 1, 2, 3 and 6. These were further investigated by 
sequencing. The exon 3 and 6 abnormalities represented the RS9W and R168C mutations 
reported from Cape Town (Meissner et al 1996). The remaining patient showed an 
abnormality in exon 2. Direct sequencing revealed a 336A ..... C transversion corresponding to an 
H20P mutation. This mutation was absent in 80 normal chromosomes. Computer simulation 
suggests that in all cases, amphiphatic patterns within the wild-type protein were altered. 
Amphiphatic regions are helices described by a non-polar and an apolar face (Cooper and 
Krawczak 1984) and are thought to play an important part in the maintenance of protein 
structure. Two additional point mutations were identified in exon 1: 26 CIA and ISO C/G. 
Since these were present in both controls and patients, they were believed to represent neutral 
polymorphisms. Allele frequencies were as follows; 26C 0.65/26A O.3S, and lS0C 0.9S/lS0G 
O.OS. There was some association between haplotypes and mutations; the RS9W and H20P 
mutations were associated with haplotype 26C1150C, while the R168C mutation was 











Mutations in European and American patients with VP 
Deybach et al (1996) described two PPO mutations in four French patients by the direct 
sequencing of the PCR products of two overlapping fragments covering the entire PPO cDNA 
coding sequence. In the first patient, a heterozygous insertion (1022insG) was identified. This 
insertion results in a frameshift producing a premature TGA stop codon 31 codons 
downstream and occurs immediately after a stretch of six G repeats; it may therefore result 
from strand slippage during DNA replication. The resulting frame shift and premature stop 
codon are likely to result in the synthesis of a truncated protein with no catalytic activity. In 
the remaining 3 patients, two of whom were known to be related, direct cDNA sequencing 
revealed a G to C transversion at nucleotide 971 resulting in a glycine to arginine substitution 
at position 232 (G232R) in exon 7 of the amino acid sequence. Since this mutation creates a 
new Acyl site, the investigators were able to analyse 48 unrelated normal subjects by 
restriction digest assay; none were found to carry this mutation; No other abnormalities were 
found in the PPO coding sequences in the patients. In a pedigree of 14 members of the family 
of two related subjects, co-segregation of the mutation with reduced lymphocyte PPO activity 
was shown. They further identified an intragenic biallelic polymorphism; a G to A transition 
at position 1188 (1188 G/A). This transition occurs in exon 9 and leads to an arginine to 
histidine substitution (R304H) which creates a BssSI restriction site. Allele frequencies were 
calculated in 54 normal unrelated French subjects using BssSI restriction analysis; the allele 
frequencies were G: 0.56; A: 0.44. This mutation, in which a neutral glycine residue which is 
strictly conserved in human, mouse, yeast and Bacillus subtilis is replaced by a positively 
charged arginine residue, may possibly result in some de stabilisation of the protein, but does 
not appear to be pathogenic in its own right. 
Puyet al (l996a) demonstrated 5 intragenic polymorphic sites amongst 50 control subjects. 
Two of these were exonic: a -414 AlG polymorphism in exon 1 (which has a 5' untranslated 
sequence) and a 3101 G/A polymorphism in exon 9, which corresponds to the R304H 
substitution described by Deybach et al (1996). The other three polymorphisms are intronic; a 
821 G/A dimorphism in intron 4; 1909 AlC in intron 6 and 1996 TIC in intron 6. 
Lam et al (1997) described a 43 year-old female of German ancestry with VP in whom 
heteroduplex analysis revealed abnormalities in exon 3. Her father showed a simple 
heteroduplex in exon 3 whereas the proband showed a more complex heteroduplex. She was 
shown on sequencing to have a 2 bp insertion (165insAG) which results in a frame shift and 
premature termination codon (TAG) 8 bp downstream from the insertion. Her father carried a 
polymorphism consisting of a C to G transversion at the -47 position of intron 2, adjacent to 
exon 3. This polymorphism was studied in the family and in 20 unrelated unaffected 
individuals and the following allele frequencies were found: C: 0.72/G: 0.18. The G allele had 
a low calculated polymorphism information content (PIC) value suggesting that it is not in 
itself responsible for the VP phenotype though the authors suggest that it might contribute to 
low expression of this allele, which would aggravate the effects of a second, more severe 
mutation. Pedigree studies indicated that the insertion was present on the same allele as the 
polymorphism although it was absent in the father. Paternity was verified using micro satellite 
markers and the insertion thus represents a de novo mutation. It is postulated that the enzyme 
deficiency associated with this mutation results from nonsense-mediated mRNA decay 
(Cooper 1993). Alternatively, dominant-negative interference by small amounts of the mutant 
polypeptide with wild-type PPO (Maquat 1991) may occur, since PPO is known to function 
as a homodimer (Dailey and Dailey 1996a). 
Frank et al (1998a) investigated a proband with VP and three clinically unaffected family 
members. Heteroduplex analysis, automated sequencing and allele-specific hybridisation 











substitution of glutamic acid by a nonsense codon at position 133 (E133X). The mutation was 
shown in the proband and a clinically unaffected son. Both are shown to be heterozygous. 
This transversion occurs in a region of the PPO gene which is strictly conserved in human, 
mouse and yeast, suggesting that this glutamic acid residue is important for PPO function. 
Such nonsense mutations are likely to result in dramatically reduced amounts of cytoplasmic 
mRNA, and thus a significant decrease in protein concentration (Cooper 1993, Maquat 1996). 
The same group have subsequently reported a number of other mutations, and have 
repeatedly pointed out the incomplete penetrance of the VP-associated mutations they have 
identified. In most cases, clinically unaffected relatives bearing the same mutations have been 
identified. The clinical expression of mutations in the PPO gene in families of VP is thus 
highly variable, underlining the incomplete penetrance of the disease. Returning to a patient 
with homozygous VP first reported in 1990 (Norris et al 1990), Frank et al (1998b) proved 
that she is a compound heterozygote. A heteroduplex was shown in exon 6 in the proband and 
her father and a G to A transition at nucleotide 505 of the PPO cDNA was shown. This leads 
to a substitution of glycine by glutamic acid at position 169 (GI69E) in the paternal allele. A 
second heteroduplex was noted in exon 10 in the proband and mother, and was shown to be 
associated with a G to A transition at nucleotide 1071 of the PPO cDNA resulting in a glycine 
to arginine substitution at position 358 (G358R). The G169E mutation causes an amino acid 
change from a neutral glycine residue to a negatively charged glutamic acid residue while the 
G358R mutation results in a change from a neutral glycine to a positively charged arginine. 
Neither of these mutations were demonstrated by heteroduplex analysis in 50 unrelated 
control individuals, suggesting that they are not common polymorphisms, but are likely to be 
pathogenic. 
This group have subsequently reported a missense mutation (1348T ..... c) in a 32 year-old 
female ofItalian, German, Scottish, Irish and French ancestry (Frank et aI1998c), resulting in . 
a serine to proline substitution at position 450 (S450P). Heteroduplex analysis of exon 13 in 
15 control subjects showed no heteroduplex formation. Heterozygosity was confirmed by 
allele-specific oligonucleotide hybridisation. This mutation results in a change from a polar 
serine residue, which is conserved in human, mouse and B. subtilis, to a non-polar proline 
residue. Subsequently two apparently unrelated probands were found to carry a further 
missense mutation (Frank et al 1998d). The first proband was a 57 year old female of German 
ancestry, the second an unrelated 38 year-old female of Armenian and North American 
ancestry. Heteroduplex analysis followed by automated sequencing of exon 6 revealed a G to 
A transition at nucleotide position 502 of the PPO cDNA, leading to the substitution of 
arginine by histidine at position 168 (RI68H). This mutation was not present in 50 unrelated 
controls, but was present in the first proband's clinically unaffected mother and daughter. This 
mutation has also been reported in a Dutch patient (De Rooij et al 1997) and in patients from 
France and Britain (Whatley et al 1999). None of these patients are known to be related. 
Though it is possible that all carry an ancestral allele bearing the R168H mutation, it seems 
more likely that the 168 position represents a mutational hot spot since the R168H gene 
consists of a G to A transition at a suspected hypermutable CpG dinucleotide. Such 
dinucleotides have been shown to represent hot spots for mutations in vertebrate genomes 
(Cooper and Krawczak 1990); and 35% of all single base-pair substitutions causing human 
genetic diseases have been found to occur within CpG dinucleotides (Cooper and 
Youssoufian 1988). We have identified a R168C mutation in a South African family 
(Meissner et al 1996) (Chapter 3) providing further evidence that this codon is particularly 
mutation-prone. 
In a further paper, Frank et al (1999) described two unrelated patients of Lebanese 
extraction and of Irish and Polish. origin respectively. Abnormal heteroduplex formation was 











1 of the PPO cDNA-the first base of the initiating methionine. This corresponds to a 
missense mutation with a conversion from methionine to leucine (MIL). In the second 
proband, a T to C transition was shown at nucleotide position 2 of the PPO cDNA, resulting 
in substitution of methionine by threonine (MIT). Both mutations resulted in loss of a 
restriction site for Hsp92II on the mutant alleles. Restriction analysis discriminates between 
wild type and mutant alleles, but does not discriminate between the MIlL and MIT 
mutations. Heteroduplex analysis of exon 2 in 70 unrelated control individuals showed no 
abnonnality. These are the first missense mutations affecting the initiation methionine codon 
of the PPO gene. This class of mutation offers some interesting possibilities. Several 
examples of mutations in the translation initiation codon (AUG) have been reported 
previously in diseases other than VP (Cooper 1993). Though an AUG codon is thought to be 
an absolute requirement for the initiation of mRNA translation in eukaryotic ribosomes, some 
exceptions have been reported. These include the inefficient but detectable initiation of 
translation at ACG or CUG codons, particularly in viral mRNA. The authors speculate that in 
transcripts containing the MIL or the MIT mutation, translation may either begin 
downstream or not at all. There are no ATG triplets upstream of the first residue of the PPO 
cDNA, but 4 are present within the first 500 base pairs downstream. The first 3 are not in 
frame and none are flanked by purines at positions -3 and +4 with respect to the A residue of 
the ATG triplet, which is a favourable arrangement for alternative translation initiation. The 
first in-frame ATG codon is at nucleotides 486 to 488 but lacks a purine at the -3 position. 
Even if transcription did start at the site, the mature PPO polypeptide would lack 162 amino 
acids from the N tenninus, including the entire putative dinucleotide-binding motif for the 
FAD cofactor. It is therefore highly unlikely that such a protein would be functional. 
De Rooij et al (1997) investigated 22 Dutch families with VP. Five were found to carry the 
R59W mutation which is highly prevalent in South Africa (Chapter 3). A number of new 
mutations were discovered in the remaining families. Two missense mutations were shown in 
exon 9; L291P and H333L. A further missense mutation was noted in exon 6--the same 
R168H mutation reported by Frank et al (1998d), and occurring in the same codon as the 
R168C mutation reported by us (Meissner et al 1996) and Wamich et al (1996b). Three 
additional families carried insertions in exons 8, 11 and 12 respectively. All resulted in frame 
shifts introducing a premature stop codon. 
Kauppinen et al (1997) found that a single point mutation (RI52V) accounts for 60% of all 
VP families in Finland. An extensive pedigree analysis failed to reveal a common ancestor 
during the previous two centuries, suggesting that this mutation had occurred several 
generations previously. Expression studies confinned a dramatic decrease in PPO activity for 
this mutation. A further 2 mutations were identified in a patient with compound heterozygous 
VP. An I12T mutation occurred in an evolutionary conserved region of exon 2 and severely 
affected PPO activity. The second mutation, a P256R substitution in exon 7, appear to result 











The Anglo-French experience 
Whatley et al (1999) studied a large number of patients with VP from both England and 
France. This study is particularly informative in that the large number of mutations identified 
allowed some general conclusions to be drawn. In total, 108 unrelated patients were studied 
and in only four did the investigators fail to identify a mutation. A total of 66 mutations were 
identified, bringing the number of VP mutations reported to at that point to 79, with a further 
9 mutations having been identified only in the homozygous state. Of these 66 mutations, 60 
had not previously been described. 54 mutations were detectable by abnormalities on either 
heteroduplex (HD) analysis or denaturing gradient gel electrophoresis (DGGE); thus, overall, 
these techniques used in combination would be expected to identify approximately 77% of 
new mutations in a typical VP population. Direct automated DNA sequencing is the most 
sensitive method, detecting 66 mutations. Mutations could not be identified in 4 patients and 
the sensitivity of direct automated sequencing is therefore 94%. Complete deletion of the PPO 
gene could be excluded in the four subjects in whom the mutation was not identified since 
they were shown to be heterozygous for known intragenic single nucleotide polymorphisms. 
The authors concluded that the causative mutations must lie outside those regions of the gene 
which they had sequenced, or that the mutations comprised partial deletions or insertions not 
detectable by PCR-based methods. Though earlier reports had suggested a clustering of 
mutations in exon 6 (Frank et al 1998d), the 66 mutations were evenly distributed throughout 
the coding region of the PPO gene, and no exon had more than 10 or fewer than 2 mutations 
with the exception of exon 1, the untranslated region of the gene, where no mutations were 
detected, despite the suggestion by Kotze et al (1998) that exon 1 is particularly mutation­
prone. 
The types of mutation encountered were variable, comprising small insertions or deletions 
introducing a frame shift and a premature stop codon (36%), missense mutations, including 
one codon deletion and three that altered the initiation codon (38%), a change in invariant 
nucleotide at a splice site (14%) and a change to a premature stop codon (11 %). In one patient 
a base change adjacent to the splice acceptor site of exon 8 apparently creates an additional 
splice acceptor site used in preference to the normal site, since sequencing of this product 
showed a mixture of similar quantities of two cDNA species; one from the normal allele and 
one showing the addition of 8 base pairs to the 5' end of exon 8. 
There was considerable allelic heterogeneity. Five of the 66 mutations were present in 
more than three families, accounting for 26% of the families in total. Furthermore, two 
mutations (LI5F and G435X) were associated with at least two different haplotypes 
indicating that neither is likely to have been inherited from a single common ancestor. For the 
other three mutations, common ancestry could not be excluded. All other mutations were 
present in three or fewer families, and 47 mutations were restricted to a single family only. 
The disease appear to be more heterogeneous in France than the UK. Only two mutations 
were found in both countries, but neither was common. Both occur at potentially 
hypermutable sites: a CpG dinucleotide on the antisense strand (Cooper and Krawczak 
1993)-the R168H mutation described in two other populations (De Rooij et al 1997, Frank 
et al 1998d)-and a polyG tract (745deIG). VP shows less allelic heterogeneity in western 
Europe than that shown by other acute porphyrias. In France and the UK, all the mutations of 
the PBG deaminase gene in 166 unrelated patients with AIP have a prevalence of less than 
5% with the exception of a single mutation in the UK with a prevalence of 10% (Puy et al 
1997, Whatley et al 1999). HCP is also heterogeneous in France and the UK. Yet in VP, 5 of 
the mutations have prevalences of 7-12%, and haplotype analysis suggests that at least two of 











present in South Africa, and to a lesser extent in Finland (Kauppinen et al 1997). Though 
polymorphisms are similar in France and the UK, there was an almost complete separation of 
mutations between the two countries, which suggests a relatively recent origin for the 
mutations in these families. The R59W mutation is not present in any British or French 
patient. 
No significant correlation could be shown between the type of mutation-missense, 
nonsense, splice site or frameshift-and a specific clinical presentation, such as 
photosensitivity or the acute attack. Furthermore, the frequencies of each type of presentation 
are similar in France, the UK and South Africa. This suggests that that allelic heterogeneity 
does not substantially alter the pattern of clinical expression of the disease, and that VP in 
South Africa is clinically representative of the disease elsewhere. The genotype does not 
appear to be a significant determinant ofclinical severity. 
Homozygous VP 
The mutations present in a number of patients with homozygous or compound heterozygous 
VP have now been described. Our own experience with four such patients is reviewed in 
chapter 16. Accordingly, the literature pertinent to this interesting and unusual clinical 












THE R59W MUTATION AND THE HIGH PREVALENCE OF 
VARIEGATE PORPHYRIA IN SOUTH AFRICA 
Published experience with the mutations identified in patients with VP was reviewed in the 
preceding chapter. In this chapter, our identification of the first two mutations in South 
African patients with VP is described. The identification of eight further mutations in South 
African patients is reported in Chapter 4 and the significance of these results is discussed in 
Chapter 5. 
3.1 INTRODUCTION 
In a collaborative project, the UCT porphyria group and Prof Dailey's group at the University 
of Georgia, USA, already had extensive experience and some success with the cloning of the 
PPO gene (Dailey et al 1994). Following the publication of the cDNA sequence for human 
PPO by Nishimura et al (1995), we were able to initiate an immediate search for the mutation 
underlying the high prevalence of VP in the South African population. This experimental 
work is described in this chapter. 
The study proceeded in four stages. In the first study, two mutations were identified in a 
young South African compound heterozygote and her immediate family. These mutations 
were then sought in a small sample of apparently unrelated South African families with VP. 
One of these mutations was demonstrated in all four. In the third study, this mutation was 
shown to co-segregate with biochemical and clinical evidence of VP in a single kindred. The 
mutation was then shown to be present in the majority of a sample of South African families 
with VP. 
3.2 OBJECTIVES 
• 	 To identify mutations in the PPO gene in South African patients with VP. 
• 	 To identify the putative founder mutation underlying the high prevalence of VP in 
South Africa. 
3.3 SUBJECTS 
Detection and identification of the R59W and R169C mutations 
The initial subject of the investigation was LO, a child with phenotypically severe VP who 
was suspected to be either a VP homozygote or compound heterozygote. She is described in 
detail in Chapter 16. Neither parent had experienced any symptoms ofVP, and there was no 
family history ofVP. 
Screening for the R59W and R168C mutations in a sample of South African 
VP families 
Eight subjects with biochemically-proven VP from four apparently unrelated families were 











been traced back to the original Dutch immigrant couple postulated by Dean (1963) to 
represent the founder of the South African VP families. Three normal individuals served as 
controls. 
Correlation with the VP phenotype in a single family 
All members of one of these families, a large well-characterised kindred previously studied by 
our laboratory, were screened for the mutation (Figure 3-1). For the first two generations the 
diagnosis was based on the reporting of unequivocal clinical evidence of VP. From 1966 
onwards, which includes some members of generation II and all members of generations III 
and IV, the diagnosis was based on the demonstration of classic VP porphyrin excretion 
patterns. 
Determination of the proportion of South African families who carry the 
R59W mutation 
A further 45 individuals from 27 well-characterised South African families with VP were 
tested. All had unequivocal evidence of VP by biochemical testing. 
3.4 METHODS 
Biochemical diagnosis of VP 
Urine, stool and plasma were analysed by quantitative fluorometric porphyrin analysis using 
the methods described in Appendix 1 and the diagnostic criteria established in Chapter 7. 
Kinetic studies on EBV -transformed Iymphoblasts 
Lymphocytes derived from peripheral blood were transformed to lymphoblasts by co-culture 
with Epstein-Barr virus as described in Appendix 2. Approximately 100 ml ofculture medium 
containing 3-4 million cells per ml were washed twice in Hanks balanced salt solution. 
Lymphoblast viability was determined by Trypan blue exclusion. PPO was liberated by 
sonication into 100 ml of 100 mM TrislHCl, 3 mM DTT, 1 mM EDTA, 0.1% Tween 20, pH 
8. Aliquots of the sonicate were assayed for PPO activity using a fluorometric detection 
process as described by Meissner et al (1986). The method is described in detail in Appendix 
3. 
Screening for the R59W mutation 
The mutation was first identified by manual sequencing of reverse-transcribed DNA as 
described below, and this method was used for diagnosis until the genomic DNA sequence for 
human PPO had been established (and was kindly shared with us by Prof George Elder, 
Cardiff, UK). The R59W mutation abolishes an Ava] restriction enzyme cutting site, and the 
R59W mutation was subsequently diagnosed by direct sequencing or by Aval restriction 
digest, as stated. 
DNA sequence analysis 
Total RNA was extracted from Epstein-Barr virus-transformed lymphoblast cultures as 
described in Appendix 4.1. The RNA was reverse-transcribed and amplified by PCR (RT­











LO DO ULN 
Urine precursors (umolllO mmol creatinine) 
ALA 16 24 <45 
PBG 9 7 <16 
Urine (nmolllO mmol creatinine) 
Uroporphyrin EEEEE<20
7-COOH Porphyrin <1.5 
6-COOH Porphyrin 0 0 
5-COOH Porphyrin 0 3 
Coproporphyrin 101 73 <240 
Stool (nmollg dry weight) 
Uroporphyrin 5 4 <1.7 
7-COOH Porphyrin 0 0 
6-COOH Porphyrin 0 0 
Pseudo 5-COOH Porphyrin 0 0 
5-COOH Porphyrin 13 19 
Isocoproporphyrin 0 0 
Coproporphyrin 67 384 <50 
3-COOH Porphyrin 0 0 
Protoporphyrin 698 1241 <200 
Plasma (nmolll) 
Uroporphyrin 2 0 <2.5 
7-COOH Porphyrin 0 0 
6-COOH Porphyrin 0 0 
5-COOH Porphyrin 0 0 
PU 0 0 
Coproporphyrin 26 0 <1.0 
Protoporphyrin 46 o I <4.5 
RBC (nmolll) 
Uroporphyrin 0 0 
7-COOH Porphyrin 0 
6-COOH Porphyrin 0 0 
5-COOH Porphyrin 0 0 
Coproporphyrin 0 106 <80 
Protoporphyrin 4406 1301 <800 
Table 3-1. Biochemical results in the proband (LO) and her mother (DO). 











chosen in order to generate four fragments covering the entire published cDNA sequence. 
These primers were as follows: 
PF1 5' CTACCTATTGTGGGTTTCCG 
PR1 5' CTTGGTCAGCTCCCTCAG 
PF2 5' CTGCATGCCCTACCCACTG 
PR2 5' TTCAAGGCCTGAGGCAACA 
PF3 5' ACTTCGTGGAGGTCTAGAGA 
PR3 5' CCGTCCTGCTCAGGGAAAGCAAC 
PF4 5' GGAATCGTGTATGACTCA 
PR4 5' TTTTCATGAATGAGAGTTGGGGATC 
The specificity of the PCR product was assessed on a 6% acrylamide gel (Appendix 4.4). 
Thereafter the product was extracted from MS8 agarose using a Qiaex II gel extraction kit 
(Appendix 4.5) prior to sequencing. The PCR-generated fragments were then sequenced 
manually using the Sequenase PCR product sequencing kit (Appendix 4.6). Sequencing was 
performed on all four DNA fragments in both a forward and a reverse direction. 
AvaI restriction digest 
Genomic DNA was isolated from blood (Parzer and Mannholter 1991, Appendix 4.8) and 
amplified by PCR using the following primers: 
• forward primer 5' GAATA TGCCT CTTCC CCTCC CC 
• 	 reverse primer 5' CACAA CCTCT CCTAG ACATC CC 
This generates a 252 base-pair fragment which includes exon 3. This was digested with the 
Ava] restriction enzyme (Promega), The products of digestion were fractionated on a 6% 
polyacrylamide gel and visualised with ethidium bromide under ultraviolet light. All methods 
are described fully in Appendix 4. 
3.5 RESULTS 
Note that the sequencing and restriction analysis gels are shown at the end of this chapter. 
Negative rather than positive images are reproduced here, since the detail is more easily 
visible. 
Porphyrin chemistry 
Both LO and her mother (DO) showed the classic biochemical profile of VP (Table 3-1), 
whereas her father (BO) was biochemically normal. 
PPO activity 
A severe reduction in activity to less than 10% of the control value was demonstrated in the 
proband. Her mother showed a 50% reduction in activity in keeping with heterozygous VP. 
PPO activity in her father was reduced by approximately 25%, which is significantly less than 
the 50% reduction shown in a large group of heterozygous South African patients with VP 
(Meissner et al 1986). 
Mutations in Proband LO and her parents 
Two deviations from the sequence published by Nishimura et al (1995) were identified in the 
proband at the University of Georgia: a C to T transition in codon 59 (Figure 3-2, end of 











substitution), and a C to T transition in codon 168, resulting in a change in amino acid 
sequence from arginine to cysteine (R168C substitution). Direct sequencing of the four PCR­
generated fragments derived from PPO cDNA confirmed the presence of both the R59W and 
the R168C mutations in the proband (LO), the R59W mutation in her mother (DO) and the 
R 168C mutation in her father (BO) (Table 3-2). Neither of these mutations, nor any other 
abnormality, were identified in 4 control cDNA samples prepared from normal individuals. In 
all cases, all four fragments, spanning the entire cDNA for PPO, were sequenced, and no 
other deviations from the published sequence were shown. 
LO (proband) DO (mother) 80 (father) 
Exon 3 and 6 3 6 
Sequence change C452rr452 and C779rr779 C452rr452 C779/T779 
Amino acid 
substitution 
R59W and RI68C R59W RI68C 
" 
Table 3-2. Mutations detected in proband and her parents. 
Screening of a further 8 South African subjects with VP 
All 8 subjects studied by sequence analysis of cDNA were shown to carry the R59W 
mutation. Neither the R168C mutation nor any other mutation were shown in these SUbjects. 
Neither mutation was present in the controls. 





R59W+ R59W· R59W- Ava!-
Ava 1+ Ava I· Ava I· 
Figure 3-1. Screening for the presence of the R59W mutation in a single kindred, 
Positive and negative direct sequencing results are indicated asR59W + and R59W 
-, Positive and negative Ava! restriction digest assay results are indicated as Ava! 
+ and Ava! -, Half-shading indicates the presence of VP confirmed biochemically 
(generations II-IV) or clinically (generation I, some members of generation II). A 
diagonal slash indicates that the subject is deceased, 
Informative members of the family are shown in Fig 3-1. The R59W mutation was 
demonstrable in every member of the pedigree with a diagnosis of VP by a positive Ava} 











Where both and restriction analysis were the results 
Conversely, the mutation was not shown any subject in was no clinical or 
biochemical VP. 
Screening of 34 African families 
With the families to families studied and the families of the mother 
LO, data were on 46 subjects apparently unrelated 
R59W mutation was present in 43 whereas a further two 
subjects, a mother son, carried R59W nor the Rl mutations. They were 
subsequently shown to carry an H20P mutation (Chapter 4). 
R168C 1 (3%) 
1 (3%) 
33 (100%) 
Table 3-3. Contribution of the R59W mutation to the prevalence of VP in South 
Africa. 
3.6 CONCLUSIONS IN BRIEF 
We have shown our initial proband, is a compound carrying two 
missense mutations: the R59W substitution exon 3 and the R168C substitution in exon 6. 
These mutations are inherited from her ..AV'"'''' and father We have further 
shown that the mutation 94% of a sample 
South African with VP, at to Dean's 
kindred. We conclude that mutation is present in 
South African VP !JVI."H""''-'" and represents South African founder mutation. The other 
mutations identified South African population are described in the chapter which 











G A T c G A T c 

+-T/C 
Figure 3-2. Direct sequence determination reveals the R59W missense mutation. Shown on the left is a 
portion of the cloned sequence from a nonnal subject. The sequence reads GGGGCTCCA. Shown on the 
right is the sequence from a R59W heterozygote. The sequence reads GGGGCITTCCA. The altered base 
is indicated by the arrows. 
11 2 3 4 5 
__ .....t----- 252 bp 
- 168 bp• 
84 bp 
Figure 3-3. Restriction digest assay of a fragment corresponding to exon 3 in a subject with the R59W 
mutation. The lanes are as follows: 1 =control pre-digestion, 2=control post-digestion, 3=patient pre­
digestion, 4=patient post-digestion, 5=size markers. In the wild-type allele, Ava! cuts the 252 bp fragment 
into two smaller fragments of 168 bp and 84 bp. In the mutant aBele, the Ava! cutting site is abolished. 













OTHER PROTOPORPHYRINOGEN OXIDASE MUTATIONS 
IN THE SOUTH VP POPULATION 
The identification of two n'>llt"t. in a young patient with compound heterozygous 
described in Chapter 3, 
has a very 
tested however had 
encountered are 
it was that one of these mutations, the 
South African families with VP. One of 
4.1 INTRODUCTION 
In the to 2000, approximately 250 new patients with VP 
identified by Oloich(;ml.cal laboratory. Wherever possible, 
have been ;:)\.,l\.,\.,ll\.,U Nearly all have been found, as pV'''IPI'TPt1 
the R59W "'''''''''''', prevalence of this mutation _H'~",", 

African VP popUlation. In a R59W mutation 

subjects who have unequivocal biochemical .~~..~_ of In such cases we 

for other mutations. are described this cha ter. 

4.2 OBJECTIVES 
411 To identify the PPO gene in R59W -negative South African with 
VP. 
4.3 METHODS 
Diagnosis of VP 
was confirmed by the thin-layer chromatographic and 
in urine, stool and plasma, supported or replaced some later 
of a characteristic plasma fluorescence peak at 625 nm on 






were interviewed personally. A full history 
symptoms indicating an acute 
part of a full examination, 




nset and the 
cases, subjects were established patients of the VCT porphyria 
well-known to us their course adequately documented. 
in Cape Town and could not travel to Cape Town for assess:me:n 











Identification of mutation 
The mutation other than R59W, 68C mutation, was identified sequencing of 
four fragments as described in Chapter 3. For the detection subsequent a 
standard, sequential approach was established as follows. 
Ava1 restriction analysis for R59W 
A sample was initially screened Ava} restriction analysis to exclude the 
mutation. If this was negative, biochemical evidence for a of VP was 
and if further samples were tested biochemically to confirm that was indeed 
a further for an unknown mutation was justified. Samples which tested 
known mutations were then screened for unknown mutations as follows. 
Single-stranded conformational polymorphismiheteroduplex (SSCpmD) analysis 
A set primers, to include all exons of the PPO gene their flanking 
regions, were employed (Table 4-1). Primers were designed such that the PCR product did not 
'"''''''''''''''''"' 400 base pairs larger products increased the possibility a false-positive result 
on SSCPIHD analysis. All PCR products were analysed on a 6% acrylamide before 
analysis, and only products were absolutely (running as a single on 
the gel) were for analysis (Appendix 4). In three cases however, the R59W, 
537delAT and 569deIG,570T-+A mutations, the mutant products ran as double bands on 
acrylamide; this finding alerted us to the of a mutation in that exon. double 
bands were never visible on agarose 
SSCPIHD analysis was performed on a 1 gel in 0.6% TBE in both the 
of glycerol. Two control drawn from normal subjects were 
included on each as negative controls to the chances of inadvertent a 
non-significant polymorphism. mobility of each product was assessed silver 
staining. If a particular product ran corresponding exon was again amplified by 
the SSCPIHD analysis was repeated. same result was obtained, DNA 
corresponding to exon was submitted for automated sequencing in both the forward and 
the reverse direction at the core sequencing facility the University of Stellenbosch, 
utilise a Dye terminator cycle sequencing kit. 
Once an apparent mutation has been identified, the following steps were undertaken in an 
to validate its causal role in porphyria. 
.. The PCR sequence analysis were repeated to exclude errors. 
.. 	 A suitable enzyme sought and a restriction 
established; a positive with in the served as further 
confirmation that a mutation was present. 
.. Approximately 50 normal controls were tested for mutation to exclude the 
possibility of a common polymorphism. 
.. Family members were biochemically and by restriction assay to demonstrate co­
the mutation with VP. 
Where a suitable restriction pn7'UTYl site could not be found, analysis 


























5'TCTGCCTGTCCAT A TCGC 
5'AITAAATGAAGCTCCCTC 
5 'GAA T A TGCCTCITCCCCTCCCC 










Exon 6. 317 
Exon 7. 272 



















Table 4-1. Exon specific 







were always included 
used for the PCR generation of DNA fragments 
and direct sequencing. 
peripheral whole blood by the method of 1.'''''''7'''''' 
exon-specific primers (Table 4-1), the 
peR product was digested with the appropriate 
a sufficient quantity to allow for complete 
recommended by the manufacturers 
"'1'1'..1'\....,h,.."r"''''~t1 on a 6% polyacrylamide gel and 
post-digestion products for both patient and a control 













heteroduplex and restriction analysis gels and automated sequencing printouts, are 
at the of chapter. the case the the negative rather than the positive 
image is shown, the reproduces more clearly. 
Including the mutation, ten mutations have been identified. Seven are associated 
with the phenotype heterozygotes; three were identified in compound heterozygotes in 
association with the R59W Clinically VP has not been seen in association 
with the compound generally show 
with a more severe phenotype. mutations we identified in the South African 
popUlation are summarised in Table 4-2 and their genomic positions are indicated in 







5 R138P None 
6 537 deLAT Mval Hetero:zVQote' typical VP 
R168C BsaJJ R59W compound heterozygote: phenotypically severe HVP 
7 c769delG; 770T>A HpaJl 
8 V290M BsiYl 
10 Y348C MaellI 
11 Maelll ptp,"V7"IUC'lI-p' typical VP 
R59W compound heterozygote: phfm01typlcal 
Table 4-2. .:>UIUHI<11 of the U'U""'U'JUi), suitable restriction enzymes for 





R168C: (Family Olivier) 
The proband is young female compound described in 3 who carries 
both the R59W mutation and thus, R168C mutation. 
DNA analysis 
The mutation was initially identified by manual 
PCR a 
sequencing (Figure 4-4). 6 contains two BsaJJ cutting one of which is abolished 
by the R168C mutation 4-5). 
Family studies 
""''''V''''a of a 
cDNA clone (Chapter 3) and has subsequently been shown on 
proband and father.68C mutation 
that family is originallyfather belongs to a small 











of German extraction. He has few living relatives, none whom will to 
Neither he nor any ofhis relatives have experienced symptoms u_........"'u 
H20P: (Family De Reuck) 
proband is a woman of European extraction in whom clinically 
biochemically by solvent extraction (stool protoporphyrin 
J..Lglg) in 1971 at the age of 43. Subsequently son, now was also 
have VP on biochemical testing. Both have typical cutaneous VP, but never 
acute symptoms. These two subjects formed part the initial test group of South African VP 
"''> •• <>... ',,, studied both by ourselves and Warnich et al (1996) and were found to be R59W­
The mutation was first identified by Wamich et al was subsequently confirmed 
in our laboratory as described here. 
DNA analysis 
PCR of all thirteen exons and OUU''''-'4 sequencing were performed 
as described above. The primer Table 4-1 and produces a 
167 bp fragment. 
Simultaneous SSCPIHD mobility shift in exon 2 in the.... 0 ...."." 
proband (not shown). No in the exons. Direct 
sequencing revealed an A to C a histidine to proline substitution 
(H20P). No suitable restriction 
Family studies 
Carriage of the H20P mutation was "''-'Lau ......''"'' son by direct sequencing of 
the exon 2 PCR product. One of the H20P mutation whereas 
the remaining 2 children are negative. All are 
L15F: (Family Middleton) 
The proband is a 44 year-old demonstrated typical 
photocutaneous sensitivity and acute symptoms prior to diagnosis. 
Biochemical analysis in the VP as shown in Table 4-3 (Subject ArlC,tr'.>ti>ti 
A) and she has a ..,.~.u..,,~ fluoroscanning. 
DNA analysis 
PCR of all exons 
performed as describ





subsequent SSCPlheteroduplex analysis and sequencing were 
and R168C mutations. On SSCPIHD analysis, an 
exon 2 (Figure 4-6). All other exons appeared normal. 
reverse, revealed a G to C transversion resulting 
substitution of phenylanaline (Figure 4.7). This mutation abolishes an 














Urine precursors (umolJ10 mmol creatinine) 
I 
I ALA <45 182 31 65 49 16 106 
PBG <16 38 18 151 36 8 106 I -
• Urine (nmolJ10 mmol creatinine) 
Uro <20 72 79 142 0 12 1464 16 
C7 <1.5 19 30 0 0 18 570 5 
C6 3 12 0 0 0 178 0 
C5 232 33 258 0 6 1296 6 
. 
<240 1585 63 1175 91 177 4538 195 • 
· 
Stool (nmolJg dry weight) 
Uro <L7 0 0 0 0 2 33 0 
I 
C7 0 0 0 0 0 73 0 
C6 0 0 0 0 0 120 0 
pseudo C5 I 87 94 15 22 23 376 30 
•
C5 43 24 10 0 2 161 15 
Isocopro 0 0 0 0 0 114 0 
Copro <50 224 146 272 109 69 1212 274 
C3 0 0 0 0 0 634 0 
Proto <200 1029 664 576 371 432 1804 409 
Table 4-3. Biochemical values in the probands described in this chapter. 
Family studies 
restriction analysis of other four further positive 
this mutation: the proband's father, and twin sons, all of whom are adult. With 
ex(;eouon of the proband, none show VP biochemically or on 
fluoroscanning, all are asymptomatic. 
537 delAT (Family Henderson) 
proband is a mixed-race female who first presented with photocutaneous symptoms 
suggestive VP at the of and was shown on biochemical testing to VP (Table 
3, 13). 
DNA analysis 
genomic DNA, amplification by and of all exons followed by 
sequencing were as described above. An aberrant SSCP mobility and a 
(Figure 4-9) were clearly visible in the product of exon 6 in proband. Sequence 
analysis a 2 bp deletion fol1owing nucleotide position (537 deIAT), numbering 
from A of the methionine of PO cDNA sequence reported by 












analysis. This mutation creates an Mval cutting site (Figure 4-11), and restriction analysis 
was subsequently used to screen for the mutation. An additional 48 unrelated control 
individuals drawn from the same racial group all tested negative for this mutation. 
Family studies 
31 family members were screened by Mval restriction analysis (Figure 4-1). Seventeen tested 
positive for the mutation. Of these 17 subjects, 13 showed positive biochemical evidence for 
VP on TLC analysis of urine, stool and plasma. A further four subjects had negative stool 
biochemistry; however, subsequent plasma fluoroscanning has shown a small peak in each, 
including a 13 year-old boy. Thus in all four subjects in whom an initial biochemical 
diagnosis of "silent VP" was made; plasma fluoroscanning has revealed an abnormality 
consistent with VP. The mutation co-segregated with both clinical and biochemical evidence 
of VP, and was present in all subjects demonstrating positive biochemistry or a fluorescence 
peak. All 31 individuals were examined clinically; only three (all carrying the mutation and 
showing positive biochemistry) had clinical evidence of disease. None had had acute 
symptoms. Two of these, the proband and a female cousin, both manifested a somewhat 
severe form of skin disease but both suffered from severe acne vulgaris, which may have 





B+ B+ :8+ B­ B-
Figure 4-1. Abridged pedigree of a family carrying the 537delA T mutation. Mval 
restriction analysis was used to determine the presence or absence of the mutation. 
The presence of the mutation is indicated by a solid symbol, absence by a hatched 
symbol : an open symbol indicates that the subject was not tested. Positive 
biochemical evidence of VP is indicated by 8+ and of normal porphyrin chemistry 
by 8-. No subject in generation IV was tested biochemically since all are 
prepubertal. 
Thus, of 31 family members tested, 55% carry the mutation; 76% of these show abnormal 
stool chemistry whereas 100% show either abnormal stool chemistry or a positive plasma 











31 family members 
17 positive for mutation 14 negative for mutation 
13 VP chemistry 
3 clinically affected 10 unaffected 
Figure 4-2. Association of positive biochemical and clinical expression of the 
537delA T mutation in a single family. 
4.5 C769delG; 770T -+ A : (Family Breda) 
The initial subject is a male of mixed race who first presented at the age of 12 with skin 
disease. Biochemical analysis is shown in Table 4-3 (Subject C) and is compatible with VP, 
though the marked elevation in erythrocyte protoporphyrin level is notable. Subsequently a 
diagnosis of VP was made in a sister, in whom the initial DNA studies were perfonned, and 
his mother. 
DNA analysis 
PCR of all exons, screening by SSCPIHD and sequencing were perfonned as described 
above. An aberrant mobility shift as well as a heteroduplex (Figure 4-12) were noted in the 
PCR products of exon 7 derived from the proband's sister. Direct sequencing revealed a 
deletion at position 769 followed by a T to A transversion (C769delG;770T- A) (Figure 4-13). 
An Hpall cutting site is abolished by the deletion and was subsequently used to screen for its 
presence (Figure 4-14). Fifty controls were screened by restriction analysis and were negative. 
Family studies 
Restriction analysis and direct sequencing of exon 7 of the proband's mother and brother 
confinn the presence of the mutation. His father is negative by restriction assay. All four 
subjects carrying this mutation show strongly positive stool biochemistry. 
V290M: (Family Dunga) 
The proband is a 30 year-old woman of African ancestry. She is not known to have any 
European ancestry. She presented with a problem of severe abdominal pain which was shown 
to due to a typical porphyric acute attack. Urine analysis confinned elevated ALA, PBG and 
urine porphyrin concentrations. Since VP had not previously been encountered in the black 
South African popUlation, a diagnosis of AlP was initially made. Her symptoms settled 
completely following treatment with haem arginate. At a subsequent consultation it was noted 
that her skin was abnonnal with scarring and blistering in sun-exposed areas. Full 
biochemical analysis was perfonned and revealed features typical of VP (Table 4-3, subject 
D). 
DNA analysis 
Amplification of the 13 exons by PCR, screening by SSCPIHD and sequencing were 
perfonned as described above. The proband tested negative for the R59W mutation by 
restriction analysis. An aberrant mobility shift of a fragment corresponding to exon 8 was 











resulting in a valine to methionine substitution codon 290 (V290M), 
abolishes a BsiYl enzyme cutting 4-17), which was 
subsequently used for screening. control individuals drawn from the African population 
were for this mutation. 
Family studies 
is positive for the V290M mutation and has a at 625nm on 
but has nonnal A brother 
V ....../HIH on plasma has not 
Y348C: (Family Van der Merwe) 
proband is a seven-year-old white female of descent. She presented 
photosensitivity shortly after birth. has a severe clinical phenotype compatible with 
homozygous VP syndrome and is in detail in 16. Her biochemical 




exons, screening by analysis and direct automated sequencing were 
as described above. proband tested positive R59W mutation by Aval 
analysis. Additionally, an aberrant mobility was noted in exon lOon 
18). All exons other than 3 and 10 were nonnal on analysis. 
fragment containing exon 10 revealed an A to transition in codon 348 
4-19) resulting in a substitution cysteine for tyrosine This mutation creates an 
MaeIII restriction which was subsequently for screening 
the proband is both the R59W Y348C mutations. Fifty control 
negative assay. 
F amity studies 
proband's mother tests positive for the R59W mutation biochemical 
though she is clinically The proband's tests negative for the 
but positive for mutation. Biochemical porphyrin analysis is within 
limits but he shows a peak at 625 nm on fluoroscanning. A brother 
are also positive Y348C; the brother has a biochemical profile 
an unexpectedly nonnal plasma fluorescence scan) while the half-sister (aged 12), is 
both biochemistry fluoroscanning. 
proband's paternal and both paternal aunts are negative for the 
Haplotype polymorphic 
was perfonned by of Human University of 
was consistent with the being the biological parents of the father, 
mutation would therefore to be a de novo mutation in the father. These 


















B­ B+ B- B+ B­
s- s+ s- s- s-
Figure 4-3. Abridged pedigree illustrating 4 generations of a family carrying both 
the R59W and the Y348C mutations. The presence of the R59W mutation is to 
noted by a central black circle and of the Y348C mutation by grey shading. Open 
figures indicate that no mutation was identified. B+ and B- indicate positive and 
negative evidence for VP on stool biochemistry respectively; S+and S- indicate 
positive and negative plasma fluorescence scanning respectively. 
R138P: (Family Du Pont) 
The proband (DdP) is a 26 year-old mixed-race female. She presented at the age of 19 with 
symptoms suggestive of an acute attack of porphyria. A diagnosis of VP was made 
biochemically (Table 4-3, subject F). She has experienced two milder acute attacks 
subsequently. She has an unusually severe degree of skin disease with chronic blistering of 
the hands and face, hypertrichosis and photomutilation of the hands with progressive 
shortening of the fingers and deformities of the finger joints. Her general health has otherwise 
been good and she has two healthy children. 
DNA analysis 
Confirmation of the presence or absence of the R59W mutation was by Ava} restriction assay. 
Amplification by PCR of all exons, screening by SSCPIHD and sequencing were performed 
as described above. The proband tested positive for the R59W mutation by Ava} restriction 
analysis. An aberrant mobility shift and a heteroduplex were additionally noted in exon 5 on 
SSCPIHD analysis (Figure 4-21). All other exons were normal. Direct automated sequencing 
of the PCR product of exon 5 (Figure 4-22) in the proband shows a G to C transversion in 
codon 138 resulting in an arginine to proline substitution (R138P). No suitable restriction 
enzyme is available for this mutation. Fifty normal control subjects from the mixed-race 
popUlation were screened by SSCPIHD analysis for this mutation and were negative. 
Family studies 
A 25 year-old sister (AN) was also known to have clinical VP. She had typical VP skin 
disease with abnormal photosensitivity, blistering and scarring of a degree felt to be in 











analysis is in keeping with VP. She screened posItive for both the R59W and R138P 
mutations. Proband DdP has two prepubertal sons, both of whom are positive for the R59W 
mutation. Sister AN has a 13 year-old daughter who is positive for the R138P mutation. No 
child has biochemical evidence of VP. No further family members have come forward for 
testing. 
Q375X: (Family Dodd) 
The proband is a 37 year-old white woman with a short history of blistering on the backs of 
the hands. Biochemical testing confirmed a diagnosis of VP (Table 4-3, subject G). She had 
recently entered the country from Canada, were she was born. 
DNA analysis 
Amplification of the 13 exons by PCR, screening by SSCPIHD and sequencing were 
performed as described above. SSCP analysis revealed aberrant mobility of a DNA fragment 
corresponding to exon 11 (Figure 4-23). Direct automated sequencing of exon 11 (Figure 4­
24) showed a C to T transition in codon of 375. This results in the replacement of a codon 
coding for glutamine with a nonsense codon (Q375X). The Q375X mutation abolishes an 
Mae!!! cutting site (Figure 4-25). 
Family studies 
This patient has subsequently returned to Canada, and no further information is available on 
the family. 
4.6 CONCLUSIONS IN BRIEF 
Eight further mutations associated with VP identified in South Africa have been described. 
VP in South Africa is therefore, as in Western Europe, genetically heterogeneous. Three of 
these mutations were first identified in association with the R59W mutation in compound 












Normal eTC T Gee G T G G A 
eTC T G C T G T G G 
Figure 4-4. The R 168C mutation identified on automatic sequencing. The site of the C to T transition is 
arrowed . 
2 3 4 5 
-
- ....--~_~- 317 bp -
.........----.211 bp
... 
- 195 bp 
106 bp 
Figure 4-5. Restriction analysis of a fragment corresponding to exon 6 in a subject with the R168C 
mutation. One of 2 BsaJ 1 cutting sites is abolished. The mutation is disclosed by the presence 00 rather 
than 2 fragments owing to partial digestion. (A third fragment resulting from normal digestion is, at size 
16 bp, invisible). (Lanes: ]=control pre-digestion, 2=control post-digestion, 3=patient pre-digestion, 
4=patient post-digestion, 5=size markers.) 
2 2 

Figure 4-6. SSCP (left) and HD analysis (right) of a fragment corresponding to exon 2 in a subject with 











Normal G G C T T G G C C G C C 
G G C T T C G C C G C C Mutant 
~~/\jcf'~~ 

Figure 4-7. The Ll5F mutation revealed by automatic sequencing. The G to C transversion is arrowed. 
2 3 4 5 
167 bp 
.4----- 85 bp 
~ - 82 bp 
Figure 4-8. Restriction analysis of a fragment corresponding to exon 2 in a subject with the Ll5F 
mutation. An Eae!cutting site is abolished. Since the patient is a heterozygote, bands corresponding to 
both digested and undigested PCR fragments are present. (Lanes: 1 =control pre-digestion, 2=control post­
digestion, 3=patient pre-digestion, 4=patient post-digestion, 5=size markers.) 
1 2 1 2 

Figure 4-9. SSCP (left) and HD analysis (right) of a fragment corresponding to exon 6 in a subject with 











Normal eTC AGe ATe A G GTe C T G T 
eTC AGe C A G GTe C T G T T T Mutant 
Figure 4-10. The 537deiAT mutation shown by automatic sequencing. Following the deletion, the 
sequence is seen to be 2 bases out of phase. 




Figure 4-11. Restriction analysis of a fragment corresponding to exon 6 in a subject with the 537 delA T 
deletion. An Mvaf cutting site is created. The subject is heterozygous and therefore both digested and 
undigested fragments are seen. (Lanes: I =control pre-digestion, 2=control post-digestion, 3=patient pre­
digestion, 4=patient post-digestion, 5=size markers.) 
1 2 1 2 

Figure 4-12. SSCP (left) and HD analysis (right) of a fragment corresponding to exon 7 in a subject with 











Normal C A G C C G G T C T G T G G G eTC 
C A G C C G A C T G T G G G C TeA Mutant 
Figure 4-13. The C769deIG;770T- A mutation shown by automatic sequencing. A G base is deleted at 
position 769 (arrowed); the following T is replaced by an A, all subsequent bases are out of phase by I 
base. 
2 3 4 5 
w,; .. 272 bp 
.­ 200 bp 
........ .... 
72 bp 
Figure 4-14. Restriction assay of a fragment corresponding to exon 7 in a subject with the 
C769delG;770T-A mutation. An Hpall cutting site is abolished. The subject is heterozygous and 
therefore both digested and undigested fragments are seen. (Lanes: I =control pre-digestion, 2=control 
post-digestion, 3=patient pre-digestion, 4=patient post-digestion, 5=Size markers.) 
1 2 1 2 

Figure 4-15. SSCP (left) and HD analysis (right) of a fragment corresponding to exon 8 in a subject with 











Normal GeT TeA G 9 t a a t 
GeT TeA A 9 t a a t Mutant 
Figure 4-16. The V290M mutation revealed by automatic sequencing. The G to A transition is arrowed. 
This codon spans exons 8 and 9: the normal and abnormal sequences read GGT and AGT respectively. 
1 2 3 4 5 
4' 197 bp 
107 bp 
90 bp 
Figure 4-17. Restriction analysis of a fragment corresponding to exon 8 in a subject with the V290M 
mutation. A BsiYl cutting site is abolished. The subject is a heterozygote and both digested and 
undigested fragments are therefore visible. (Lanes: I =control pre-digestion, 2=control post-d igestion, 
3=patient pre-digestion, 4=patient post-digestion, 5=size markers.) 
2 
Figure 4-18. SSCP analysis of a fragment corresponding to ex on lOin a subject with the Y348C 











Normal T C G T G TAT G ACT C A 
T C G T G T G T G ACT C A Mutant 
Figure 4-19. The Y348C mutation as shown by direct automatic sequencing. The position of the A to G 
transition is arrowed. 





Figure 4-20. Restriction assay of a fragment corresponding to exon lOin a subject with the Y348C 
mutation. An additional Mae111 cutting site is established, leading to the appearance of additional bands at 
96 bp and 50 bp (not visible in this figure). (Lanes: I =control pre-digestion, 2=control post-digestion, 
3=patient pre-digestion, 4=patient post-digestion, 5=Size markers.) 
1 2 1 2 

Figure 4-21. SSCP (left) and HD analysis (right) of a fragment corresponding to exon 5 in a subject with 











Normal A AGe C C eGG G G C A A A 
A AGe C C C eGG G C A A A Mutant 
v 
Figure 4-22. The Rl38P mutation shown by automated sequencing. The position of the G to C 
transversion is arrowed. 
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Figure 4-23. SSCP analysis of a fragment corresponding to exon 11 in a subject with the Q375X 
mutation. Lanes: 1 =patient, 2=control. 
Normal T T A C A G A c A 
T T A T A G A c A Mutant 
Figure 4-24. The Q375X mutation as shown by automated sequencing. The position of the C to T 











1 2 3 4 5 

257 bp 
. .,. 161 bp 
... 96bp 
Figure 4-25. Restriction analysis of a fragment corresponding to exon 11 in a subject with the Q375X 
mutation. An Maelll cutting site is abolished. (Lanes: 1 =patient post-digestion, 2=patient pre-digestion, 















et al (1997) who have demonstrated by haplotype 
patients with VP share a common haplotype with 
could be 
5: 
DISCUSSION: THE MOLECULAR BIOLOGY OF 
VARIEGATE PORPHYRIA IN SOUTH AFRICA 
The identification of ten mutations in South patients with VP has been 
the chapters. these, the R59W mutation, has been shown to be reSl00nlSl 
for most South African with VP. are in this chapter. 
5.1 R59W: THE SOUTH AFRICAN FOUNDER MUTATION 
of her severe 	 and her reduced PPO we believed the 
subject our to have 
more specifically, was likely to This was further 
supported by the unequally These predictions 
were borne out by finding of both an missense mutation the 
one of these mutations was likely to represent the South African 
mother nor father had a family history of VP, thus no 
Our In next of 
mutation alone was present in a of four African 
strongly that this mutation indeed represents the South African 
founder mutation, particularly since one of these families was known to to the 
.......u,'''''.''' child who served as 
and 
proof was provided by our subsequent demonstration 
was present 31 of 33 South Africa is therefore 
in that a mutation is reSloonlSl 
studied by 
R59W 
amounting to approximately 94% 
provided by 
of South 
the R59W Unfortunately none of 
genealogically to demonstrate a common ancestor with the Dutch immigrants who 
at the in 1688. 
Functional of the mutation 
lines of suggest that R59W mutation is pathogenic and accounts for the 
clinical disease our patients. In the place, we have demonstrated of the 
R59W defect with clinical and VP in a single (Figure 
Co-segregation subsequently kindred, our study of which is 
described in Secondly, an experiment by the group at the 
University of (Meissner et al 1996), and th",1""'i',,",1"'" not described here, the 
R59W mutant was by 
introduced into pTrcHis B vector which expressed mutant protein, 
cDNA was 
purified to homogeneity. A kinetic demonstrated a nearly undetectable though 
relatively Km (Table 1). indicates severe of functionality, which would 
accord with the hypothesis that the R59W mutation is responsible for the VP phenotype 
these families. Certainly, the demonstration of a 50% reduction in lymphoblast PPO activity 
heterozygous (Meissner et at 1986) is in keeping with compete or near-











Kat (min-I) Km (JiM} 
Wild type 10.5 1.7 
R59W <0.2 l.l 
Table 5-1. Functional activity of expressed site-directed mutation and wild-type 
PPO after Meissner et al (1995). 
The RS9W mutation occurs in a CpG trinucleotide, known to confer a high probability of 
mutation, particularly with a C to T transversion (Cooper and Krawczak 1990). It falls within 
the 60 bp flanking region of the putative FAD dinucleotide-binding motif of PPO (Nishimura 
et al 1995, Dailey and Dailey 1996a), an extended region conserved in a large superfamily of 
flavoproteins of which PPO is a member. This appears to account for the severe loss of 
catalytic activity of the RS9W mutant enzyme. Dailey and Dailey (1997) have subsequently 
shown that the RS9W mutant is less stable than the normal enzyme and is proteolytically 
degraded by the expressing cells, with consequently both lower enzyme yields and decreased 
stability during storage. The UV Ivisible spectrum showed minimal absorption in the 300-S00 
nm range, reflecting a reduced FAD content. Since crude cell extracts from cells producing 
RS9W also have much lower PPO activity, it appears that this mutation leads to an inability to 
bind FAD in vivo, rather than the FAD merely being lost as a consequence of purification. 
The expressed enzyme exhibits a normal Km for protoporphyrinogen, but has a greatly 
decreased :K:at as would be expected. We believe that the RS9W mutation, by disrupting the 
dinucleotide-binding motif coding for the cofactor binding site, results in reduced affinity for 
F AD and ultimately in reduced catalytic activity. This is a situation similar to that found in 
pyridoxine-responsive x-linked sideroblastic anaemia, where the mutant enzyme S ALA 
synthase has decreased affinity for its cofactor, pyridoxal S'- phosphate. In a manner 
analogous to the supplementary pyridoxine given to elevate subcellular levels of this cofactor 
in x-linked sideroblastic anaemia, Dailey and Dailey suggest that riboflavin supplements 
might be useful in the treatment of RS9W-positive VP. 
l n 
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MGR SERLGGWI RSVRGPNGAI FELG~ . IRPACAl.GARTLLLVSELGLDSEVLPVRGDHPAAQNRFLYVGGALHuma n 
SKRLGGWI RS [RGSDGA I FEW I RPAc;A..I..Q\RTLLLVSELGLESEVLPVRGDH PAAQNRFL YVGGTLS Mouse 
KDRVGGNI IT . REENGPLWEOO FQPSD ... PML1'MVVDSG . LK ... DDLVLGDP. TAPRFVLWNCKLA. Chalani.a 
'AjlvcIOOV!IClLCPTYllt.SXUtPDVBl QNRTGGWI YSDMSGNP 1 HLEKG LRGYSo::;TVLl MDTLKDLGKEAVI OS I DKGCI ADKKFLLDPSDKLS. cerevi.s1ae 
ISGLTAAYaLRW.~l ORLGGVLRT . EC\IGGQPMD . FLLRR . . PEVPALLAELGLS .. ERORAlT .. DAAPLI YSOQRLH. clLberculosls 
SPRVGGKI (Jr . VKKI:C Y I I ERG FLERK .. KSAPQLVKDLGLEH . ..• LLVNNATGQSYVLVNRTLB . subcl 1is 
SARLGGAVGT. HA.l...A.G YLVEQG FLDRE .. PATRALAAALNLE .. GRI RAADPAAKRRYVYTRGRLM. xanchus 
DDHFGGKVVT. DRR[XjPLVE'QG f'VAYR.. PAALKLIEELGLS. . OQVIAPGG . GRRVSLLSRGKLP. freudenreichli 
Figure 5-1. Derived amino acid sequence for the fIrst 100 amino acids of human PPO and 

aligned PPO sequences from mouse, plant (Arabidopsis thalania, yeast (Saccharomyces 

cerevisiae) and bacteria (Mycobacterium tuberculosis, Bacillus subtilis, Myxococcus 

xanthus and Propionibacterium freudenreichii). The putative dinucleotide binding motif is 

indicated by the fIrst shaded box; the extended sequence shared by the flavoprotein 

superfamily extends for approximately 60 residues beyond this. The site of the R59W 













Mutations and haplotypes in the PPO gene in South African families of VP 
Confinnation of our findings has come from the University of Stellenbosch who have 
independently reported the R59W and Rl68C mutations (Warnich et aI1996b). They initially 
showed that the R59W mutation was present in 15 of 17 South African subjects with VP and 
then demonstrated that the R59W mutation appeared to co-segregate with the disease in 
subjects drawn from 43 families. Furthennore, 80 nonnal chromosomes were screened for the 
R59W mutation and were negative indicating that the R59W mutation is not merely a 
common polymorphism in the South African population. 
Since codon 59 contains a mutation-prone CpG trinucleotide, there is a a possibility that 
the R59W mutation might have arisen independently in the South African population on more 
than one occasion. Warnich et al (1996b) have shown that the R59W mutation was associated 
with only one of four potential haplotypes defined by two diallelic polymorphisms in exon I 
which suggests that this is not so. However, since those alleles associated with the R59W 
mutation are also the more common alleles in the nonnal population for each of the 
polymorphisms, this is not totally conclusive. They have subsequently used linkage 
disequilibrium and haplotype analysis to characterise the haplotypes associated with the 
R59W mutation further (Groenewald et al 1998). Their original 15 nuclear families with the 
R59W mutation were extended to include 132 members, of whom 58 were affected. These 
families were unrelated to the second degree. Using 15 micro satellite markers spanning a 
region of approximately 21 cM around the PPO gene, they identified disease-associated 
haplotypes from alleles that were transmitted from affected parent to affected offspring. Their 
observed combinations limits the location of the PPO gene to a 2.4 cM region between 
markers DIS2705 and DIS2707; the highest resolution genetic mapping of this gene yet. 
Their results suggest that there are two distinct groups of haplotypes, differing in flanking 
markers; however both appeared to descend from the same founder, as they share the same 
core haplotype. Additionally, a highly significant linkage disequilibrium score is shown for a 
continuous area of 10 cM; these results are in agreement with data from other popUlations in 
which the historical age of the founder effect is estimated to be 12 generations, as it is for VP 
in South Africa (310 years: approximately 12 generations). One ofWarnich et aI's 15 families 
however appeared to have a completely different haplotype; which may indicate that a small 
percentage of South African families with the R59W mutation do indeed represent either 
recurrent mutations at the CpG hot spot, or a second, more recent, importation of the gene. 
R168C 
This site is evolutionarily conserved in man, mouse and yeast. The mutation has been 
expressed in E. coli by Dailey and Dailey (1997) and has been shown to have reduced enzyme 
activity, with a lower Kcat but unaltered Km for protoporphyrinogen. Though the Kcat is not 
stated in this paper, it would appear that the R168C mutation is not associated with a 
complete loss of function. The evidence for this is twofold: firstly, the measured PPO activity 
in lymphoblasts derived from the proband's father is reduced by only 30%, rather than the 
50% expected in a heterozygote carrying an allele associated with complete loss of function 
as is seen with the R59W mutation. Secondly, there is evidence to suggest that mutant alleles 
associated with complete loss of function are always balanced by alleles coding for some 
residual function in compound heterozygotes (Roberts et al 1998). This is discussed further in 
Chapters 15 and 19. Indeed, current work using the expressed protein resulting from site­
directed mutagenesis in our laboratory has recently confinned that the R168C mutation is 
associated with some residual activity (M Maneli, personal communication). The R168C 
mutation occurs at a hypennutable CpG site and appears to be a frequent site of mutation 











patients (Frank et al 1998d, De Rooij et al 1997, Whatley et al 1999), and it is one of the two 
mutations found in both the United Kingdom and France (Whatley et al 1999). The R168H 
mutation would appear to be a more severe mutation than the R 168C since it is asso~iat~d 
with phenotypically expressed VP, whereas we have not identifi.ed the.RI6~C m~~tion m 
association with clinically expressed VP, suggesting that a cysteme resIdue m posItiOn 168 
may be less damaging to the protein then a histidine residue. 
H20P 
This mutation occurs in a region of PPO which can be configured as part of the of the a hel~x 
of a typical FAD-binding domain of a flavoprotein and as such would be exp~cted. to re~ult m 
a loss of catalytic activity. This area may also be constructed as ~ ~-amph~phatIc .regIOn; a 
helix described by a polar and an apolar face (Eisenberg 1984), WhICh IS consI~ered Imp0:tant 
in the maintenance of protein structure. An unusually high frequency of mutatIOns assocIated 
with the replacement of the wild-type amino acid by proline has been reported by Whatley et 
al (1999). 35% of their missense mutations represent a substitution by proline, with most of 
these being leucine to proline mutations. A similar serine to proline mutation (S450P) has also 
been reported elsewhere by Frank et al (1998c), and we have identified two further such 
mutations-this and the R138P mutation described later. This is an unusually high frequency 
for this type of mutation. Proline is known to decrease protein flexibility (Tian et a11998) and 
to interrupt a-helical regions; which may indicate that the PPO protein is very sensitive to 
small structural changes. 
L15F 
The L15F mutation is situated in the putative FAD-binding domain which is likely to account 
for its functional effect. The leucine in this position is highly conserved in both plant and 
animal PPO species. This mutation has been identified in 7 families from the United Kingdom 
(Whatley et al 1999) and is therefore one of the commoner mutations in Europe. Intragenic 
polymorphism analysis in the UK has shown that this mutation is associated with at least two 
different haplotypes suggesting that it has risen independently on more than one occasion. It 
is likely that the L15F mutation has been imported into South Africa from Britain, though in 
the absence of haplotype analysis, this cannot be established with certainty. Yet it appears to 
be an uncommon mutation in South Africa, and to this point has been identified in only one 
family. 
537 delAT 
The family in whom this mutation was found is of mixed racial ancestry, and the gene may 
have been of European, Asian or indigenous origin; interestingly, this mutation has 
subsequently been reported from the United Kingdom (Whatley et al 1999). This mutation 
clearly co-segregated with biochemical evidence for VP in this kindred. The 537 delAT 
mutation results in a frame shift and produces a premature TGA stop codon 11 codons 
downstream. It is therefore likely to result in the synthesis of a truncated protein with reduced 
or absent catalytic activity. Nonsense or frameshift mutations may result in a reduction in 
mRNA levels and several possible reasons for this have been advanced: reduced transcription 
rate, reduced efficiency ofmRNA processing, decreased transport to the cytoplasm or reduced 
mRNA stability (Cooper 1993). 
In this family, plasma fluoroscanning was a more sensitive screening test for the 
inheritance of the in VP allele than was conventional porphyrin analysis. Whereas 











all. The sensitivity of plasma fluoroscanning is discussed in Chapters 13 and 14. It therefore 
appears that this mutation is accompanied by a high level of phenotypic expression as 
rev~aled by P?rphyrin abnonnalities. In tenns of clinical expression however, only 3 of 17 
subjects carrymg the mutation (17.6%) had clinical evidence of VP. This was restricted to 
skin disease and no patient had suffered acute symptoms. The rate of clinical expression is 
therefore less than that shown for R59W-positive VP (Chapter 16) though the difference is 
not statistically significant (p=0.16, K2). 
c769DELG; 770T ...... A 
The C769deIG;770T ....... A mutation introduces a premature stop codon 16 codons downstream. 
This is likely to be associated with the fonnation of unstable mRNA and the production of a 
truncated and nonfunctional protein. The unusually severe presentation in the original 
proband and the presence of elevated erythrocyte protoporphyrin concentrations suggested 
that he might be a compound heterozygote. Screening of all other exons by SSCPfHD 
analysis has produced no evidence of any other mutation in the proband and his sister. In the 
experience of Whatley et al (1999), a combination of DGGE and heteroduplex analysis has a 
sensitivity of 77% in detecting new PPO mutations. The authors suggest therefore that a 
screening approach using DGGE cannot be applied to the whole PPO gene and that 
heteroduplex analysis alone may lack sensitivity as has been shown in AlP (Tchernitchko et al 
1999). They recommend a combination of heteroduplex analysis and DGGE with direct 
automated sequencing of exons and their flanking regions. A small possibility hence remains 
that we may have failed to detect a second mutation, though this would appear unlikely. 
V290M 
Though the valine at position 290 is not evolutionarily conserved, the V290M mutation 
results in the substitution of an aliphatic, hydrophobic amino acid by methionine, which 
contains a sulphur atom in a thioether linkage. There thus exists a possibility of 
confonnational change with concomitant loss of activity. Clinically it is a significant 
mutation, resulting in both photo cutaneous sensitivity and the acute attack. A related V290L 
mutation has been described from a European family (Whatley et al 1999). 
This is the first African family yet described in South Africa with VP, and the V20M 
mutation is the first reported VP mutation in a black subject. VP would appear to be rare in 
black popUlations, with individual cases described in a Caracao negroid woman (Vander Sar 
and Den Ouden 1981), an African-American male (Hughes and Davis 1983) and an 11 year­
old Nigerian girl who presented with both skin disease and acute symptoms, and finally died 
of respiratory failure (Durosinmi et aI1991). The first two patients are however of unspecified 
ancestry, though the third would appear to be of pure African stock. The reason for the 
infrequency with which VP is identified in African populations is unknown. Though there is 
evidence that melanin may protect against photosensitisation (Westerhof et al 1981), a dark 
skin alone does not, in our experience with PCT in African people and with VP in those of 
mixed race, mask the cutaneous symptoms of porphyria. It therefore appears unlikely that the 
under-representation of black people with VP is due only to shortcomings in recognition and 
diagnosis. It is however surprising that, with more than 90 mutations associated with VP 
having been reported throughout the world, mainly in people of European extraction, the 












, ' ' 'b t'tut' n that is from an aromatic to The Y348C mutation results m a tyros me to cysteme su SIlO , . ' h 
a sulphur-containing amino acid, which may alter the secondary structure of the protem with 
consequent reduction in activity. This tyrosine is present in both ~uman and mouse, tho~g 
not in yeast or bacteria. Since this mutation is found het~roalleh~ ~o th,e ~5~W mutatIOn, 
which codes for a mutant protein with essentially no resIdual activIty, It IS bk~ly that the 
Y348C allele is associated with at least some residual activity, The observatIon that no 
heterozygote has experienced clinical symptoms is theref~re not ,unexpected, ~d ~e Y348C 
and R168C mutations are similar in this regard, An mterestmg observatIOn IS that the 
proband's half-brother, who carries the Y348C mutation, appears to express VP 
biochemically suggesting that this mutation is in itself sufficient in the heterozygous state to 
result in biochemical expression of VP. We have recently produced objective evidence for 
this in our laboratory: the expressed protein, following site-directed mutagenesis, has been 
shown to have some catalytic activity; furthermore, the activity would appear to be 
intermediate between that of the R168C mutant protein and the normal protein (M Maneli, 
personal communication). 
R138P 
The R138P mutation results in an arginine to proline substitution, representing in a change 
from a basic to a non-polar amino acid with an aliphatic hydrocarbon R group. This arginine 
is conserved in both human and mouse, though not in yeast or bacteria. The R138P mutation 
is a further instance of a proline subsitution; an unusually high incidence of substitutions with 
which has been noted in the PPO gene (Whatley 1999). As with the R168C and Y348C 
mutations, this mutation was first identified in a compound heterozygote. We have not studied 
enough family members to allow us to comment on the clinical effects of this mutation. 
However, the clinical evidence would suggest that it is likely to be a mild mutation, with 
relatively well preserved activity, since even in the compound heterozygous state, the proband 
and her sister are not as severely affected as are our R59WIR168C and R59WN348C 
compound heterozygotes. 
An interesting finding is the discrepancy in clinical severity between these two sisters, both 
of whom are compound heterozygotes. The proband is clearly more severely affected than a 
typical R59W heterozygote, in keeping with our observations in compound heterozygous VP. 
Her sister would be expected to be similarly affected, and yet appears not to be so. The 
clinical effect of the co-inheritance of these two mutations is therefore variable. This is 
examined in more detail in Chapters 16 and 19. 
Q375X 
The Q375X mutation is a nonsense mutation which, by introducing a premature stop codon, is 
likely is to abolish PPO activity, primarily by accelerating mRNA decay (Culbertson 1999). It 
is interesting that this mutation was not reported in the large series from United Kingdom and 
France (Whatley et al 1999) since we believe that this Canadian patient is likely to be of 














We have thus identified 10 mutations associated with VP in South Africa. Eight of these are 
novel whereas one (L15F) had been described in the United Kingdom and a second, 
apparently limited to South Africa, had been reported by Warnich et al (1996b). The 537 
delAT mutation has subsequently been reported in Europe by Whatley et al (1999). Seven are 
missense mutations, one a nonsense substitution and two are deletions. The two deletions 
were both found in mixed-race families, one missense mutation in an African family and the 
remaining mutations in white families. The common R59W mutation is present in both white 
and mixed-race families. Three of the missense mutations were only identified in association 
with the R59W mutation; none has been shown in association with clinical symptoms in the 
heterozygous state, though one subject with the Y348C mutation had had biochemically­
expressed VP. Preliminary evidence (M Maneli, personal communication) suggests that this 
mutation is indeed associated with a fair degree of residual activity. Our experience, though 
smaller, is similar to that of Whatley et aI, with the demonstration that VP is genetically a 
heterogeneous disease associated with a variety of mutation types spread across the entire 
gene. 
5.3 	 SIGNIFICANCE OF OUR FINDINGS FOR THE DIAGNOSIS OF 
VP IN SOUTH AFRICA 
The most important difference between the South African and European findings is our 
demonstration of the extraordinarily high prevalence of a single mutation within this 
background of genetic heterogeneity. We have shown that a single mutation accounts for 94% 
of all cases of VP in South Africa. This has important implications for diagnosis. Work to be 
described in Chapter 10 has shown that conventional biochemical porphyrin analysis is 
relatively insensitive for the diagnosis ofVP. Furthermore, intermediate results are difficult to 
interpret and lead to a reduction in specificity, the techniques are labour-intensive and time­
consuming, and experience has shown that many candidates for testing find providing a stool 
sample distasteful and a disincentive to diagnosis. Though plasma fluoroscanning, discussed 
in Chapters 13 and 14 has many advantages, it will still fail to detect some adults and all 
children carrying a gene for VP. 
A DNA-based test for porphyria offers many advantages: it may be performed at any stage 
of life, including antenatally, it requires only a blood test and relatively simple techniques. It 
is 100% sensitive and specific for the mutation for which one is testing. There are however 
two major drawbacks. Firstly, it tests only for a specific mutation and not for disease; where 
several mutations occur within a population, testing will be inaccurate. Secondly, DNA 
testing reveals only the presence or absence of the potential to develop clinical disease, but 
says nothing about the severity ofclinical expression. 
Any single DNA-based test is of no use for the diagnosis of AIP in Europe, where facilities 
for DNA testing have been available for several years, since more than 70 mutations are now 
described (Grandchamp et al 1998). Even in Scandinavia, where a single mutation is 
particularly prevalent as a result of a founder effect (Lee and Anvret 1991), DNA testing is 
made more difficult by the range of mutations within the population. To some extent this 
problem may be overcome by offering a batch of tests covering all the more frequent 
mutations known to exist in the population or by performing a complete SSCPIHD analysis 











problems will apply to the diagnosis of VP in Europe, with in excess of 70 mutations 
described (Whatley et aI1999). . . 
The situation in South Africa is different. Our results suggest that .screenmg ?atlents 
suspected of having VP by Ava} restriction analysis would detect approxImately 94 Yo of. all 
cases of VP. This would appear to be a reasonable approach provided that t~e followmg 
cautionary warnings are born in mind. Firstly, the absen~~ of the R59W mutah~n does not 
exclude VP entirely, since there remains a small probablht.Y that anoth~r mutatlOn may be 
present. Secondly, proving the presence of the R59W m~tat1on does n?t m any way confirm 
that a patient's symptoms are due to VP. Since South African laboratones o~her t~an our 0v:n 
have offered DNA testing for the R59W mutation, we have begun to Idenhfy errors m 
diagnosis and management arising from a failure to understand these points. 
A rational protocol for the diagnosis of VP in South Africa 
We have therefore set out the following protocol for the diagnosis of VP in South Africa. 
1. For the screening ofan asymptomatic subject with afamily history ofVP 
Since there appear to be a considerable number of people in South Africa who erroneously 
believe they have VP has a result of previous inadequate biochemical testing, it is prudent to 
test the family member believed to have VP first. If VP is confirmed biochemically or by 
plasma fluorescence scanning, then he or she can be tested for the the presence of the R59W 
mutation. A positive result for R59W indicates that DNA testing is suitable for further family 
screening (Figure 5-2). 
Alternatively, the subject presenting him or herself for screening on the grounds of a 
family history may be tested for the R59W mutation directly. If positive, the inheritance of 
VP is confirmed and all family members are appropriately tested for the R59W mutation. If 
the R59W result is negative, then it is again imperative to prove the presence of VP 
biochemically in whichever member of the family was believed to have originally tested 
positive biochemically. If VP is proven, he or she should be tested for the R59W mutation. 
However, if on review no evidence for VP can be found, then further testing is unlikely to be 
useful. 
In view of the ease and simplicity of plasma fluorescence scanning (Chapter 13), this 
should additionally be carried out on every subject presenting for testing on whatever 
grounds. 
Where a subject reports symptoms suggestive ofVP 
Two approaches are reasonable (Figure 5-3). Our own preference is to test the subject 
biochemically first, based on the premise that all patients in whom VP is symptomatic will 
show positive biochemistry. If positive, the diagnosis is confirmed and some assessment of 
the biochemical activity of the disease made. The subject is thereafter tested for the R59W 
mutation, so that the result can be used subsequently for family screening. 
An alternative approach is to test for the R59W mutation directly. If positive and the 
patient's symptoms characteristic of VP, it is reasonably likely that the symptoms are indeed 
due to VP and he or she can be managed accordingly. Ifthe R59W mutation result is negative, 
the patient's symptoms must be re-evaluated. If highly atypical, it is improbable that VP is 
present and further testing is unlikely to be helpful, therefore another diagnosis should be 
sought. If the clinical picture is indeed suggestive of porphyria, then it is essential to test the 
patient biochemically so as not to overlook a diagnosis of a porphyria other than VP or of VP 











Assessing the significance ofsymptoms in a patient with VP 
It is essential to test patients with symptoms biochemically to prove that their symptoms are 
due to porphyria, even where they have been proven to be R59W-positive. This is still 
neglected in South Africa, where some patients with any complaint having a vague 
resemblance to the symptoms of the acute attack are assumed to be having such an attack. Not 
infrequently, subsequent investigation in our laboratory has shown conclusively that the 
assumption was unjustified. 
These recommendations form the basis of our recommendations to South African doctors 
and the public as published in our informative pUblications. The guidelines we issue to the 
medical profession for the diagnosis ofVP in South Africa are reproduced in Appendix 6. 
'r---------- ,,-----,,-------., .-,-.-....---------- ...---.-.--­
Subject reports a family history of VP 
R59W known In family 
Screen for R59W 
Either: Approach A 

Screen for R59W directly 

Or: Approach B 

Test affected family member for VP 

Figure 5-2. Algorithm for a diagnostic approach to a patient who reports a family 
history ofVP in South Africa. The approach is based on the premise that 95% of all 
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1AlP, HCP, PCT, non-R59W vpI.1 Porphyria excluded I 
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Figure 5-3. Algorithm for a diagnostic approach to a patient with symptoms 
suggestive of VP in South Africa. The approach is based on the premise that 94% of 
















Section 1 of this dissertation examined the molecular biology of variegate porphyria, with 
particular reference to the mutations present in South African families. Section 2 now 
examines the value of routine porphyrin analyses of urine, stool and plasma in the diagnosis 
of VP as correlated with the presence or absence of a PPO mutation on DNA analysis. The 
section begins with a review of the literature. In the chapters which follow, the extent to 
which observers agree on the interpretation of porphyrin excretion profiles is examined, and 
the basis on which a diagnosis of VP is made biochemically is retrospectively analysed. 
Biochemical testing is shown to be imprecise and subject to individual variation in 
interpretation. In Chapter 10, porphyrin excretion profiles are correlated with the presence or 
absence of PPO mutations. It is shown that all children and approximately 30% of adults 
carrying a PPO mutation fail to express abnonnal stool porphyrin excretion patterns. Using 
the statistical techniques of discriminant analysis and classification tree analysis, we show that 
an elevation of stool coproporphyrin and pentacarboxylic porphyrin are the most important 
biochemical predictors of Vp~ Thereafter the place of simple screening tests and of plasma 
fluorescence scanning in the diagnosis of VP are assessed. Though the more important 
conclusions to be drawn from each study appear at the end of each chapter, the results are not 












THE BIOCHEMICAL FEATURES OF VARIEGATE 
PORPHYRIA: A REVIEW OF THE LITERATURE 
6.1 	 RECOGNITION OF THE PORPHYRINS AND THEIR PLACE IN 
THE DIAGNOSIS OF PORPHYRIA 
Historically, laboratory work on the porphyrias was largely confined to the biochemistry of 
porphyrins, and to a description of those characteristic profiles of porphyrin excretion in urine 
and stool which allow a diagnosis to be made. Thereafter followed the identification and 
eventual purification and characterisation of the enzymes of the haem synthetic pathway. In 
some porphyrias, particularly AlP, direct determination of enzyme activity proved more 
sensitive for a diagnosis than porphyrin quantitation alone. More recently, with the 
development of sensitive techniques in molecular biology, identification and characterisation 
ofporphyria at the molecular level has become possible. 
That the diseases we now know as porphyrias are associated with the excretion of unusual 
substances has been known for over a century. Following the introduction of Sulphonal as a 
hypnotic (Kast 1888), a series of patients were described who developed symptoms 
compatible with porphyria and were noted to excrete pigments in the urine (Stokvis 1889, 
Harley 1890, Geill 1891, Fehr 1891, GUnther 1911, GUnther 1922). Initially these substances 
were thought to be haematatoporphyrin, the compound obtained by adding concentrated 
sulphuric acid to dried powdered blood, washing it to remove iron and then heating it in the 
presence of alcohol. During the first years of the 20th century however it was shown that these 
substances, urinary porphyrins, were distinct from haematoporphyrin, and this led ultimately 
to the identification of uroporphyrin, coproporphyrin and protoporphyrin (WillsHitter and 
Mieg 1906, WillstaUer and Sto111913, Fischer and Zerweck 1924, Fischer and Orth 1934). 
Variegate porphyria was described clinically and biochemically in 1937 (Van den Bergh 
and Grotepass 1937) and it was realised that, unlike AlP and CEP, the biochemical hallmark 
of this disease was the over-excretion of porphyrins in the stool (Barnes 1945, Barnes, 1958). 
Separation experiments showed that the stools of patients with VP contained large amounts of 
protoporphyrin and, to a lesser extent, coproporphyrin. 
6.2 	 ORIGIN OF THE STOOL PORPHYRINS 
Bile appears to contain both coproporphyrin and protoporphyrin (Aziz and Watson 1969). 
England et al (1962) showed that the porphyrin in stools from normal subjects was largely 
coproporphyrin and protoporphyrin, with small amounts of at least three other porphyrins. 
Two of these were identified as deuteroporphyrin and mesoporphyrin. The final porphyrin 
was provisionally named pemptoporphyrin. They suggested several sources for the origins of 
stool porphyrins. These included endogenous pigments excreted in the bile, exogenous 
pigments-which might be ingested with foodstuffs, derived from chlorophyll or haem 
pigments in meat or from bleeding within the bowel-and porphyrins synthesised by micro­
organisms within the bowel. Indeed, they demonstrated diminished faecal porphyrin 
excretion-particularly of deuteroporphyrin and mesoporphyrin, which lie outside the direct 











antibiotics, suggesting a bacterial -origin for a considerable proportion of faecal porphyrins. 
Since bile contains more coproporphyrin than protoporphyrin, it appears that much of the 
dicarboxylic porphyrin present in stool is formed within the gut, particularly by microbial 
metabolism of haem derived from the diet and other sources (Elder 1980). Additionally, 
protoporphyrin may itself be converted to other porphyrins such as mesoporphyrin by 
intestinal bacteria which have the ability to reduce or remove vinyl groups. Consequently 
stool contains a mixture of dicarboxylic porphyrins, though protoporphyrin is usually present 
as the main component. 
More recently it has been shown that different bacteria have varying effects on stool 
porphyrin excretion. Beukeveld et al (1987) observed strong fluctuations in faecal porphyrin 
content while determining reference values for stool porphyrins by HPLC. They discovered 
that suppression of aerobic flora by selective antibiotic use had no effect on faecal porphyrin 
excretion. Suppression of the anaerobic flora however completely inhibited the transformation 
of protoporphyrin to pemptoporphyrin and deuteroporphyrin, and the effect persisted for five 
days after stopping medication. When the flora were suppressed for long periods, the 
production of both protoporphyrin and coproporphyrin was decreased, and the production of 
deuteroporphyrin, pemptoporphyrin and mesoporphyrin was abolished. Thus, though aerobic 
gram-negative bacteria have little effect on porphyrin synthesis, anaerobic organisms appear 
variously to produce mesoporphyrin, convert porphyrins to pemptoporphyrin and 
deuteroporphyrin, or produce coproporphyrin and protoporphyrin. Problems with the 
diagnosis ofporphyria resulting from variations in these faecal porphyrins were shown. 
Though gastro-intestinal bleeding appears to result in an increase in the amount of 
porphyrin- predominantly protoporphyrin-recovered in stool, a gross excess of faecal 
porphyrin sufficient to complicate the diagnosis of VP is rarely observed, an observation with 
which both Eales and Dean concurred (Barnes 1963). The ingestion of yeast tablets has also 
been implicated in the production of falsely elevated stool porphyrin levels (Day 1978). 
6.3 BIOCHEMICAL TESTS FOR PORPHYRIA 
Screening methods 
Elder (1980) and Moore and Disler (1985) have summarised appropriate methods for the 
screening of urine and stool for abnormal amounts of porphyrin following their concentration 
and partial purification by solvent extraction, using methods developed by Rimington (1958) 
and Eales et al (1966). Screening tests for urine have a lower limit of sensitivity of 
approximately 0.7-1 Ilmolll, and stool porphyrin screening is sensitive enough to detect 
porphyrins even in some normal samples. It is therefore recommended that all positive tests 
should be followed by the direct measurement of porphyrin concentrations. Newer, 
fluorometric screening tests for porphyrins have been described (Pudek et al 1991). 
Solvent extraction 
For many years the mainstay of porphyrin analysis was the quantitation of porphyrins by 
solvent extraction techniques (Schwartz et al 1960, Fernandez et a11966, Rimington 1971) or 
anion-exchange chromatography (Sobel et al 1974) followed by spectrophotometry 
(Rimington 1971) or fluorometry (Schwartz et 'al 1960). These techniques are based on the 
premise that porphyrins which contain acid side chains are ampholytes and are soluble in both 
acids and bases (Fuhrhop and Smith 1975). At the isoelectric point they are least soluble and 
at this pH can be transferred from aqueous solutions to organic solvents such as ether, ethyl 











dilute mineral acids. Solubility in the organic solvent is inversely proportional to the number 
of acid side chains. . ' 
Spectrophotometry was initially employed for ~~ quanti~ative ana~ysls of the porphyn~s. 
This technique is relatively insensitive. In addItIon, unn~ contam~ .compounds which 
themselves absorb in the Soret region, and spectrophotometry IS not senSItIve enough to allow 
sufficient dilution to reduce the influence of these confounding substances. Methods 
suggested to increase specificity included adsorption to calcium phosphate (Rimin~ton & 
Sveinssen 1950) or preceding anion-exchange resin chromatography (Doss 1974, WIth and 
Pedersen 1977). 
Fluorescence detection by examination under ultraviolet light with a peak output at 365 nm 
allows very low concentrations of porphyrins to be detected, particularly if a red-sensitive 
photomultiplier is used (Chisholm and Brown 1975, Sassa et al 1975a). Fluorometry is 
therefore superior to spectrophotometry in terms of a greater sensitivity and lesser 
susceptibility to interference by impurities. Its greater sensitivity allows interfering 
compounds to be neutralised by dilution (Schwartz et al 1976, Martinez and MilIa 1971), 
though other sources of inaccuracy remain. These include quenching or enhancement of 
fluorescence, especially by organic solvents, and the formation of no -fluorescent metal 
chelates with contaminating metal ions resulting in under-reading. Fluorometry also requires 
very pure porphyrin standards (Chisholm and Brown 1975). The sensitivity of fluorometry 
allows the visualisation of extremely small quantities of porphyrin on thin-layer 
chromatography plates developed with kerosene or iso-octane (Fuhrhop and Smith 1975), and 
a sensitivity threshold of as little as 10 pM has been reported. 
Chromatography 
The major advantage of solvent-partition methods is that no special apparatus is required, nor 
are porphyrins standards necessary if spectrophotometric techniques are employed for the 
actual quantitation. The disadvantage is that porphyrins are poorly separated and the extracted 
fractions are usually mixtures (Deacon and Ledden 1998). The main component may not even 
be identified accurately. These factors are particularly limiting in the case of samples 
containing low porphyrin concentrations, such as blood (Wranne 1960, With 1976). Thin­
layer chromatography for detail d analysis of porphyrin mixtures (Doss and Bode 1968, Doss 
1970, Eales et a11975, Elder 1975, With 1975, With 1977) proved superior in that it was both 
more sensitive and was able to resolve a porphyrin mixture into individual species, depending 
on the number of carboxyl groups carried on the porphyrin. In the 1970s, thin-layer 
chromatography (TLC) and high-performance liquid chromatography (HPLC) completely 
replaced earlier forms of chromatography including column chromatography, paper 
chromatography, counter-current distribution and electrophoresis. 
Conversion of free acids to their ester derivatives greatly facilitates the separation of 
porphyrins by chromatography. Suitable substances for the esterification of urinary, faecal 
and tissue porphyrins include diazomethane (Carlson and Dolphin 1976), methanol with 
hydrochloric acid or concentrated sulphuric acid (Falk 1964, Fuhrhop and Smith 1975) and 
boron fluoride in methanol (Grosser and Eales 1973, Petryka and Watson 1978). Sulphuric 
acid-methanol 10% (v/v) has proved a convenient reagent (With 1973, Wilson et a11978) and 
is currently used in the UCT porphyria laboratory. Following TLC, porphyrins can be 
quantitated by one of two methods. The first is by elution with chloroform-containing 
methanol (Doss 1974). The second, still used in the UCT laboratory, is by fluorescence 
scanning on a scanning densitometer equipped with a fluorescence detector and integrator 











Dayet al (1978a) standardised 'the procedure for esterification, extraction and quantitative 
TLC of porphyrins which is still used in the VCT laboratory today. They advocated 
development of the TLC plate in a mixture of chloroform, dodecane and hexadecane: this 
simple step enhances fluorescence ten-fold on silica gel TLC plates. An advantage of the 
introduction of TLC with fluoroscanning is that it provided a detailed permanent quantitative 
record of all the porphyrins present in the sample. 
Several problems are recognised with quantitation of stool porphyrins by TLC. Porphyrin 
isomers are not easily separated by standard techniques, though this is possible, particularly 
for coproporphyrin series I and III, provided specific techniques are employed (Doss 1974, 
Sears et a11974, Schermuly and Doss 1975, Smith 1978). The various dicarboxylic porphyrin 
esters are poorly resolved. Porphyrin esters may remain at the origin or migrate more slowly 
than uroporphyrin; this residual material may represent partially esterified porphyrin or true 
hydrophobic porphyrins such as X-porphyrin (Elder 1980). 
Other techniques 
A number of other techniques for the determination of porphyrins were described in the 1970s 
(Elder 1980), These included mass spectrometry, nuclear magnetic resonance spectroscopy 
(Smith 1975, Jackson 1977), magnetic circular dichroism (Ivanetich et al 1984), atomic 
absorption spectrophotometry (Bourdon et al 1972), electrophoresis (Fischl et al 1970, 
Lockwood and Davies 1962), second derivative spectroscopy (Jones and Sweeney 1979), gel 
filtration (Rimington and Belcher 1967, Bachman and Burnham 1969) and fast-atom 
bombardment mass spectrometry (Luo et al 1997). In many centres, TLC has been replaced 
by HPLC (Gray et al 1977, Jackson 1977, Petryka and Watson 1978) for the separation and 
measurement ofporphyrins. A variety ofcolumns have been employed and several techniques 
have been described. Fluorometric rather than spectrophotometric greatly increases sensitivity 
(Sagen and Romslo 1985), and further refinements in technique continue to be published 
(Lam et al 1998). An important advantage of HPLC, particularly when coupled with the use 
of a fluorescence detector, is that better resolution of individual porphyrins is obtained. 
Porphyrins are fairly easily resolved into their constituent isomers (Jackson et a11982, Kuhnel 
et al 1999), and dicarboxylic porphyrin esters can be resolved into their component 
porphyrins. Elder (1980) concluded that the easier quantitation, better resolution and more 
rapid separation of porphyrins by HPLC is to some extent offset by the higher cost, but that 
qualitative identification by TLC is adequate for clinical purposes, particularly where large 
numbers of samples must be examined. 
6.4 	 THE PRACTICAL DIAGNOSIS OF PORPHYRIA IN THE 
LABORATORY 
A practical approach to the laboratory diagnosis of porphyria has been reviewed many times, 
including reviews by With (1978), Elder (1980), Moore and Disler (1985) and more recently, 
Bonkovsky and Barnard (1998). With the exception of enzyme-based and DNA-based 
diagnosis however, it should be borne in mind while reviewing the suggested biochemical 
methods for the diagnosis of porphyria that they will detect only those cases who express 
biochemical abnormalities. Elder pointed out that failure to examine appropriate samples, 
particularly stool, was an importance source of diagnostic error. In patients presenting with 
acute symptoms, the first investigation is to examine a fresh sample of urine for PBG excess 
using the Watson-Schwartz or Hoesch reactions. Occasional false positives may occur and 
therefore positive results support but do not prove a diagnosis of acute porphyria (Eales et al 











PBG with or without the measurement of ALA. A negative test however abso~utel~ exc~u.des 
the acute attack. This should be followed by the screening of stool for porp~ynns: If posItIve, 
porphyrins should be quantitated by solvent extraction, HPLC or TLC, WhICh WIll a~low the 
differentiation of AIP, HCP and VP. The possibility that faecal blood loss may result I~ f~lse­
positive screening results (Eales et al 1966); is recognised, as also that haem-denvatives 
produced by the gut flora may also lead to a positive screening result. ... 
In patients with skin lesions, the first step is to exclude CEP and EPP; thIS IS ea~Ily 
accomplished by looking for erythrocyte fluorescence, followed ifnecessary by the separatIon 
and quantitation of erythrocyte and plasma porphyrins. Thereafter PCT sho?ld be 
distinguished from VP. Screening tests alone may not differentiate these two porphynas, and 
quantitation or chromatography is important. In PCT, the earlier and more hydrophilic 
porphyrins predominate in urine (Doss 1974), whereas in VP, the concentration of 
coproporphyrin is greater than that of uroporphyrin. Examination of stool porphyrins should 
unequivocally separate PCT, VP and HCP. 
In the non-acute phase, AlP is best diagnosed by determination ofPBG deaminase activity 
(Sassa et al 1975b). Owing to the difficulties inherent in assaying PPO activity, Elder (1980) 
suggested that the most appropriate diagnostic test for VP was the biochemical measurement 
of faecal protoporphyrin, coproporphyrin and X-porphyrin fractions, though he recognised 
that obligatory latent porphyrics with normal faecal porphyrin levels are encountered and 
would not be detected. 
Most authors, including Moore and Disler (1985), recommend a preliminary screening of 
samples before one proceeds to the actual determination of porphyrin concentrations. Day 
(1986) recommends that quantitative assays for porphyrins and precursors be preceded by 
rapid screening tests which have proved of great value in practice, especially in suspected 
acute attacks where urgent therapy is required (Eales et al 1966). A dangerous practice is the 
screening of urine samples alone when investigating the porphyrias. This will not differentiate 
the three acute porphyrias and will not exclude a wide range of non-porphyric conditions 
accompanied by raised urine porphyrins such as coproporphyrinuria. Other screening tests, 
particularly faecal screening, must be used. Rapid qualitative screening methods for the 
presence of elevated PBG concentrations in urine include the Watson-Schwartz and Hoesch 
tests. Urine and stool extracts may be screened by methods which maximise fluorescence with 
minimal quenching. In the standard method, using Dean's solution, porphyrins are extracted 
into a solution of equal volumes of diethyl ether, amyl alcohol and glacial acetic acid; stool 
porphyrins are additionally extracted into 1.5 M HCI. The extract is then viewed under 
ultraviolet light for fluorescence. 
In assessing the results of chromatography, it is important to realise that the relative 
proportions of the individual porphyrins offer important information and this aspect is often 
of greater value in diagnosis than a mere comparison of porphyrin concentrations with normal 
values. In latent porphyria, porphyrin values may lie within normal limits, and yet distribution 
on chromatography may reveal the presence of the porphyria. (Moore and Disler 1985). 
More recently, Bonkovsky and Barnard (1998) have reviewed the diagnosis of porphyria in 
the era of molecular biology They recommend the following approach to a suspected 
porphyria. In the presence of acute symptoms, a rapid screening test for PBG should be 
performed; urine should also be sent to a laboratory for confirmatory quantitative testing for 
ALA and PBG. In the presence of cutaneous symptoms, suggestive of HCP, VP or PCT, they 
recommend a urine screening test. If positive, urine should be screened for ALA and PBG and 
porphyrins. If elevated, the diagnosis of an acute cutaneous porphyria (HCP or VP) is 
established. As an alternative, ALA and PBG quantitation coupled with the measurement of 
plasma porphyrin concentration should be made since plasma porphyrins are always elevated 











plasma fluoroscanning should be carried out. Urine, stool and plasma porphyrins should then 
be measured. An assay of biliary porphyrins and porphyrinogens can help to distinguish RCP 
from VP (Logan et al 1991) but is not necessary for routine diagnosis. We would however 
disagree with the importance placed on showing an elevated ALA and PBG in the diagnosis 
ofVP and RCP. We would recommend a more direct approach: initial plasma fluoroscanning 
coupled with the chromatographic quantitation of urine and stool porphyrins, which is a 
simpler approach to the identification ofVP, RCP and PCT. 
Since family screening using biochemical methods alone will fail to detect biochemically 
silent porphyria, enzymatic or DNA-based tests are in theory superior. A number ofmolecular 
methods are available for the determination of unknown mutations in porphyria (Bonkovsky 
and Barnard 1998). These include oligonucleotide specific hybridisation, direct sequencing, 
single-stranded conformational polymorphisms (SSCP) analysis or denaturing gradient gel 
electrophoresis (DGGE). SSCP and DGGE are however not 100% sensitive; in Finnish AlP 
families, SSCP detected 89% of 19 mutations (Kauppinen et al 1995), and these procedures 
failed to identify the mutation in some European patients with VP (Whatley et al 1999). 
Asymmetric PCR amplification or repeat cycling may facilitate sequencing by enriching one 
PCR strand (Mgone et al 1994, Lee and Anvret 1991) and PCR ca  be used with allele­
specific amplification such that a PCR product is or is not produced depending on the mutated 
sequence within the primer region. In the situation where a few mutations are responsible for 
the porphyria phenotype, it is appropriate to screen by rapid molecular methods. Examples of 
the few situations where this is appropriate include the R116W mutation in Dutch patients 
with AlP, the Wl98X mutation in Swedish patients with AlP, the R59W mutation in South 
African patients with VP and the C73R mutation in CEP. Bonkovsky and Barnard conclude 
however that the traditional biochemical screening methods may still be best when the 
specific mutation is not known or when there is genetic heterogeneity in the disease and 
population served. 
6.S THE LABORATORY DIAGNOSIS OF VARIEGATE PORPHYRIA 
Much of the early literature around the diagnostic biochemical features of VP originated from 
the University of Cape Town as a result of the high prevalence ofVP in South Africa and the 
interest of Lennox Eales and his colleagues in the disease. Large amounts of coproporphyrin 
and protoporphyrin are present in the stool in both the acute and the remission phase of VP 
(Eales 1963, Eales 1974). Though typically the predominant porphyrin is protoporphyrin, 
some investigators have occasionally found coproporphyrin in greater quantity than 
protoporphyrin in the stools of patients with VP (Rimington and Lockwood 1968, Poh­
Fitzpatrick 1980). A high combined level has been found to be indicative of VP in doubtful 
cases (Dean 1971, Eales 1974). It was shown however that there were both qualitative and 
quantitative differences in porphyrin excretion patterns between the two phases. In the 
remission phase, small amounts ofporphyrins with more than 4 carboxyl groups are excreted 
in the stool, whereas in the acute attack, the excretion ofurinary PBG is greatly increased and 
is accompanied by an increase in faecal uroporphyrin and, to a lesser extent, heptacarboxylic 
porphyrin (C7), hexacarboxylic porphyrin (C6) and pentacarboxylic porphyrin (C5). Even in 
remission, patients with VP excreted as much as 10 mg of coproporphyrin daily, of which 
more than 75% was of the series III isomer. During the acute attack, a relative increase in 
coproporphyrin I occurs. Though the increased excretion of protoporphyrin is described as the 
most characteristic feature ofVP, Sweeney (1963) has been pointed out that what is recovered 
from the stool as protoporphyrin is almost certainly not protoporphyrin alone. 
Gray et al (1948) described a case ofVP in which faecal porphyrins decreased and urinary 











hepatitis. They described this as a reciprocal e~cretion of~orphyrins in VP, high faecal and 
low urine porphyrins in the quiescent phase WIth revers~l In the ~cute ph~e .whereas Eales 
(1963, 1974) believed that it was the diversion of~orphyrm from bIle to u~ne In th~ presence 
ofcholestatic hepatitis which underlay this change In the pattern ofporphyn~ excretIO~. . 
The initial biochemical methods for the determination of stool porphynns establIshed In 
Johannesburg (Barnes 1958) and Cape Town (Eales 1959) were based on the solvent 
extraction method of HoIti et al (1958). This was selected in preference to the method of 
Schwartz et al (1960) since it is a simpler method, though it has the disadvantage of not 
extracting uroporphyrin as a separate species. Grosser and Eales (1973) con:pared solvent 
extraction and TLC for the differentiation of PCT and VP. The solvent extractIOn profile for 
VP was dominated by a marked increase in the protoporphyrin fraction and a lesser though 
considerable increase in the coproporphyrin fraction. The profile for PCT showed a lower 
total porphyrin concentration, and the coproporphyrin fraction constituted nearly 60% of the 
totaL With TLC, all intermediate porphyrins were shown. The marked increase in 
protoporphyrin and the lesser but considerable increase in coproporphyrin were confirmed in 
VP. Other intermediate porphyrins were present in much smaller amounts, and uroporphyrin, 
though variable in amount was visible in 89%. A C3 porphyrin was noted in many 
chromatograms. Eriksen (1962), Doss (1969) and Chu and Chu (1962) had all observed this; 
and Eriksen had suggested that at least some of the C3 porphyrin represents a 
coproporphyrinogen precursor. Interestingly, TLC was no more efficient than solvent 
extraction in differentiating VP and PCT. 
Also shown in VP was the presence of a characteristic hydrophobic porphyrin complex in 
stool termed X-porphyrin (Rimington et al 1968). The X-porphyrin fraction comprises the 
peptide conjugates of a dicarboxylic porphyrin along with traces of uroporphyrin, 
heptacarboxylic and pentacarboxylic porphyrins. Though the X-porphyrin is most markedly 
raised in VP, it is also increased in PCT and so cannot of itself be used as a diagnostic feature 
for VP (Eales et al 1975). 
Eales et al (1980) stated that the definitive diagnosis of VP depends on: 1) the consistent 
presence of a strongly positive faecal screening test which may be accompanied by a positive 
urinary test; 2) the finding of a raised total faecal porphyrin consisting mainly of 
protoporphyrin on solvent extraction analysis; 3) the presence in the plasma of porphyrin PU, 
running between coproporphyrin and C5, and 4) the presence of X-porphyrin in the stool. 
PCT could be distinguished by the finding of a high urinary uroporphyrin and C7 and a 
normal or only slightly raised faecal porphyrin; the diagnosis is made beyond doubt by the 
demonstration of a high faecal isocoproporphyrin (Elder 1972). Day et al (1978b) had 
suggested the utility of TLC plasma porphyrin profiles for the diagnosis of VP. Though the 
erythrocyte protoporphyrin in VP is normal, plasma porphyrin profiles show elevated 
protoporphyrin concentrations, sometimes a slightly increased uroporphyrin and a diagnostic 
marker, a then unidentified porphyrin, labelled peak unknown (PU) which ran between the 
coproporphyrin and C5 markers on the TLC plate. PU has since been identified as a complex 
between coproporphyrin and a non-fluorescent molecule, which may be cholesterol, and is 
therefore quantitated against the coproporphyrin standard. A further feature said to be 
characteristic of VP is the presence of a so-called pseudopentacarboxylic porphyrin noted on 
TLC of faecal porphyrin esters, which runs immediately before the pentacarboxylic 
porphyrin. This has been identified as a hydroxylated dicarboxylic porphyrin (Moore and 
Disler 1985). Eales et al (1980) stated that TLC and quantitative fluoroscanning of porphyrin 
methyl esters (Day et al 1978b) is over 100 times more sensitive than previously-employed 
routine methods. This is due in part to the enhancement of fluorescence produced by 
development in a dodecanelhexadecane solvent. Diagnostic and distinctive plasma porphyrin 











were only slightly elevated. Day et al stated that all porphyrias could clearly be distinguished 
on the TLC plasma porphyrin profile alone with one exception: VP and HCP, which produce 
identical patterns. More recently, Hindmarsh et al (1999) have examined the proposition that 
careful separation and quantitation of plasma porphyrins by HPLC might replace urine and 
stool porphyrin analyses in the diagnosis of porphyria. They concluded that on the basis of 
their studies, plasma HPLC was insufficiently specific, though it appeared to have some 
utility in PCT. 
Day (1986) provided the definitive description of VP in its various phases. He defined the 
quiescent phase as a phase in which excessive porphyrin concentrations are often found only 
in the stool and plasma: the diagnostic features are an elevated coproporphyrin and 
protoporphyrin, though lesser amounts of C5 and C3, together with traces of 
isocoproporphyrin, are almost invariably present. In the quiescent phase, the plasma is 
dominated by the coproporphyrin/cholesterol complex, PU, (Day et al 1978b) with lesser 
amounts of protoporphyrin and traces of uroporphyrin. The plasma of quiescent VP often 
contains a large amount of porphyrin not extracted by normal methods, but bound to the 
protein fraction (Day et al 1978b, Longas and Poh-Fitzpatrick 1982). 
In the acute phase, the main abnormalities shift to the urine. Uri e coproporphyrin and 
especially uroporphyrin are markedly increased, accompanied by a striking increase in the 
precUrsors ALA and PBG. Stool coproporphyrin levels become more elevated than is seen in 
the quiescent phase. There is a further increase in the plasma porphyrin levels, largely due to 
an increase in the uroporphyrin fraction, and plasma precursor levels are mildly increased. 
Dual porphyria is the name given to a biochemical picture suggestive of PCT 
superimposed on quiescent VP (Day et al 1982, Martasek et al 1983), and was only 
recognised after the introduction of sensitive analytical methods such as TLC. Dual porphyria 
could be misdiagnosed as PCT in view of the elevated urinary porphyrins: this is an important 
reason for recommending that no case of porphyria be screened by urine analysis without 
stool analysis (Day 1986). 
Silent variegate porphyria is defined as a phase of VP distinguished by an absence of 
clinical or biochemical signs of the disease other than reduced PPO activity. Though obligate 
gene carriers with silent VP were occasionally reported in family surveys (Mustajoki and 
Koskelo 1976, Fromke et al 1978, Muhlbauer et a1 1982), the only reliable way to detect 
silent cases until recently has been by demonstrating reduced PPO activity (Meissner et al 
1986). Disler et al (1982) had suggested that up to 40% of gene carriers might have silent VP. 
Day (1986) stated that it is important to identify these silent carriers as they were believed to 
be at risk of developing the acute attack if exposed to porphyrinogenic drugs; additionally, 
their offspring require appropriate screening and education. 
For practical purposes VP does not present biochemically before puberty, and exceptions 
are extremely rare. Day reports uncommon cases of patients who developed cutaneous or 
acute symptoms in childhood. Two young boys described by Kramer (1980) developed acute 
and cutaneous symptoms following treatment for epilepsy with porphyrinogenic drugs, 
recovered following removal of the medication and were found to be heterozygous for VP 
(Day and Eales 1983). Day (1986) also stated that a surprisingly high incidence ofprepubertal 
VP had been discovered in the Pretoria area of South Africa. In the light of our own 
experience, we believe that this should be discounted since the laboratory whose results Day 
quoted, using qualitative TLC alone, have in our experience substantially over-diagnosed VP. 
The usual reason advanced for the excess ofprotoporphyrin in stools of patients with VP is 
that deficiency of PPO results in a reduction in the conversion of protoporphyrinogen to 
protoporphyrin, resulting in the accumulation and excretion of protoporphyrinogen which is 
then non-enzymatically oxidised to protoporphyrin. Logan et al (1991) analysed the 











They found a complete separation in total porphyrin level~ in bile betw~en the VP group ~d 
the control group, with a 9-fold difference between the highest value m any control subject 
and the lowest value in any patient with VP. In contrast, the mean faecal level of tot~l 
porphyrin in the patients with VP was higher than that of the controls, but th~ f~ecallev~ls m 
VP patients overlapped those of the control group. The prominent :t:0rphynn m t~e bIle of 
normal subjects was coproporphyrin, whereas in VP the predommant porphynns w~re 
protoporphyrin and other dicarboxylic and tricarboxylic p~rphyrin~. They concluded ~at bIle 
porphyrin concentration is a more sensitive and speCIfic predIctor ~f VP than IS. stool 
porphyrin concentration. They ascribe this discrepancy to the observatIOn that, as reVIewed 
above, a substantial proportion of the porphyrin in faeces is not ofbiliary origin. 
Plasma fluorescence scanning 
Poh-Fitzpatrick and Lamola (1976) described the determination of the fluorescence maxima 
ofunextracted native porphyrin-protein complexes in patients' erythrocytes and plasma when 
diluted with phosphate-buffered saline, and showed that this method reliably differentiated 
patients with EPP from those with PCT or CEP. Subsequently, Poh-Fitzpatrick (1980) studied 
10 patients shown biochemically to have VP. Heparinised blood was separated by 
centrifugation. 1 ml of plasma was diluted with 9 m1 of phosphate-buffered saline, and the 
fluorescence emission spectra were scanned from 550 to 700 nm at a fixed excitation 
wavelength of 400 nm since she had shown that the fluorescence emission maximum 
remained the same whether excited at 400 nm or at the specific excitation wavelength 
maximal for each specimen. In all specimens from patients with VP, a sharply defined 
fluorescence emission maximum at 626 ± 1 nm was noted. Blister fluid from a patient gave 
the same fluorescence maximum. This emission maximum was easily distinguished from the 
maxima of plasma specimens from patients with PCT, CEP and AlP, all of which lie at 619 ± 
1 nm and cannot be distinguished one from the other. Poh-Fitzpatrick (1980) concluded that 
the fluorescence emission wavelength maximum observed with unextracted porphyrin and 
plasma is a useful diagnostic indicator for VP. Indeed, several patients with an original 
diagnosis of HCP or PCT, when tested by plasma scanning, yielded a peak characteristic of 
VP and on subsequent biochemical analysis were shown to have been misclassified initially. 
Poh-Fitzpatrick and Lamola (1976) further noted that the fluorescence maxima noted in the 
plasma samples of patients with VP did not correspond to those of any native porphyrin. The 
porphyrin present in the plasma of VP is relatively resistant to extraction by acidified ethyl 
acetate, a solvent which is 90% efficient in extracting porphyrins from plasma samples of 
patients with PCT or CEP. This phenomenon had been noted by Rimington et al (1968) who 
suggested the possibility of an unusual porphyrin-protein complex related to the porphyrin­
peptides (X-porphyrin) of urine and stool observed in VP. Poh-Fitzpatrick (1980) reported 
that this plasma porphyrin is more effeciently though still incompletely extracted into 
perchloric acid, followed by methyl alcohol. Though it was not possible to identify the 
porphyrin completely, she noted that mixtures of protoporphyrin and coproporphyrin in ratios 
of 8:2 in perchloric acid and methyl alcohol produced spectra indistinguishable from those of 
the extracts from VP plasma specimens. The values also overlap with those for the 
tricarboxylic porphyrin harderoporphyrin, and it is possible that the characteristic 
fluorescence maximum reflects a mixture of porphyrins, analogous to the heterogeneous 
mixtures of porphyrins and peptide conjugates in the X-porphyrin fractions of urine and stool 
(Rimington et al 1968), When separated chromatographically, these mixtures frequently 
include bands suggestive of tricarboxylic and dicarboxylic porphyrins. Belcher et al (1969) 
have isolated porphyrins behaving chromato-graphically as tricarboxylic porphyrins and 











bile of patients with VP. Porra and Falk (1964) reported that during the enzymatic conversion 
of coproporphyrinogen to protoporphyrinogen, porphyrin intermediaries are covalently bound 
to a protein from which they are unextractable by ethyl acetate/acetic acid. Though Fitzpatrick· 
therefore suggested that a dicarboxylic or tricarboxylic porphyrin intermediary might be the 
source of the fluorescence maximum seen in this study; it may also be related to the 
coproporphyrin-peptide conjugates labelled PU described by Day et al (1978b). 
Longas and Poh-Fitzpatrick (1982) subsequently analysed the porphyrins present in the 
plasma of a single patient with VP in more detail. They found that two major classes of 
porphyrin were present. The first-class was loosely bound, and the porphyrins were readily 
extracted from plasma with an ethyl acetate/acetic acid mixture. Uroporphyrin, 
harderoporphyrin, isoharderoporphyrin, protoporphyrin and a small amount of penta­
carboxylic porphyrin were identified on HPLC. Coproporphyrin was not detected despite the 
statement by Day et al (l978b) that coproporphyrin III was the major porphyrin in the plasma 
of patients with VP. They then attempted to isolate and identify the second, tightly-bound, 
group of porphyrins, by a process which included acid hydrolysis. HPLC analysis suggested 
that this consisted ofuroporphyrin. However, acid hydrolysis of a protoporphyrin IX standard 
itself resulted in extensive derivitisation yielding a substance with the chromatographic 
properties of uroporphyrin. The authors therefore suggested that this uroporphyrin-like entity 
represents the decomposition or derivitisation product of a tightly-bound dicarboxylic 
porphyrin. The molecule carrying the tightly-bound porphyrin appeared to be albumin. They 
concluded that the VP plasma porphyrin fluorescence marker is a dicarboxylic porphyrin 
bound to albumin. This complex is possibly formed by the reaction of porphyrinogen with 
sulphydryl groups as this type of reaction is known to take place in vitro (Sano et aI, 1961). 
Meanwhile, loosely bound porphyrin such as protoporphyrin IX, harderoporphyrin and 
uroporphyrin (in a molar ration of 1.2: 1 :0.5) and traces of a pentacarboxylic porphyrin are 
also present. 
The utility ofplasma fluoroscanning for the diagnosis ofVP has been confirmed by others. 
Enriquez da Salamanca et al (1993) assessed the value ofplasma scanning in 75 patients with 
PCT, 14 with EPP, 10 with VP, 7 with AIP, 2 with HCP and 1 with CEP. All diagnoses had 
been established by clinical and standard biochemical criteria. In PCT, emission maxima were 
found at 618-622 nanometers and the intensity of this major peak depended on the activity of 
the porphyria; it was noted that PCT patients in remission may show normal plasma scanning 
in keeping with their normal plasma porphyrin concentration. Plasma from patients with EPP 
exhibited a pathognomonic peak at 636 nm, and plasma from VP at 626-628 nm. The typical 
porphyrin plasma marker of VP was found in patients both with and without cutaneous 
involvement, in contrast with the authors' expectation that a normal plasma fluorometric 
profile should be expected in people who were merely carriers of the VP defect. They also 
noted that the presence of plasma shifts the emission maxima ofporphyrins slightly. Standard 
porphyrins diluted in phosphate-buffered saline showed the following maxima: 613 nm for 
coproporphyrin, 617 nm for uroporphyrin and 633 nm for protoporphyrin. When incubated in 
porphyrin-free plasma, the emission maxima shifted to 619 nm, 620 nm and 635 nm 
respectively which are close to the maxima noted in porphyria plasma samples. They suggest 
that an absent or minimal peak in the emission spectrum of PBS-diluted plasma means that 
the diagnosis of an active cutaneous porphyria may be rejected, and that plasma scanning has 
the ability to differentiate plasma samples ofpatients with VP and EPP from those of patients 
suffering from PCT, CEP or HCP. 
Long et al (1993) evaluated qualitative fluorescence emission scanning of saline-diluted 
plasma as a method for identifying asymptomatic VP gene carriers. They screened 36 
unrelated patients with VP and 136 of their asymptomatic relatives aged 15 or older. Some 











nonnal subjects showed no peak, or a very small peak with an emission maxi,mum of 6,1~ ~ 
or less and whose height above baseline did not exceed 3 mm at a specIfied sensItivIty. 
Patients with VP showed a peak between 621 and 627 nm and the height exceeded baseline 
by at least 15 mm, In most patients, the fluorescence emission maximum was at 625 nm. By 
statistical comparisons with the expected frequency of a gene for VP in the asymptomatic 
relatives, they estimated that the sensitivity of plasma fluoroscanning was 0.86, with a 95% 
confidence interval of 0.71-0.98. They estimated therefore that the posterior risk of an adult 
first- or second-degree relative of having a negative plasma scan was 1 in 8 and 1 in 22 
respectively. They also found that 10 of 55 asymptomatic relatives had elevated faecal 
porphyrin concentrations, and that all of these had had an abnonnal plasma scan, as did 16 
who had nonnal faecal porphyrin concentrations. They calculated therefore that the sensitivity 
of an increased faecal porphyrin concentration in the detection of asymptomatic carriers ofVP 
is 36-38%. 
Da Silva et al (1995) examined the utility of plasma fluoroscanning for the detection of 
silent VP. They demonstrated that all of 32 biochemically expressed VP patients had a 
fluorescence emission peak at 630 nanometers. However, in 56 asymptomatic carriers proven 
by the demonstration of a 50% reduction in PPO activity, this peak was found in only 50% of 
adults and in none of the children. They concluded that though plasma fluoroscanning will 
pick up symptomatic VP patients, it is insufficiently sensitive in the screening of 
asymptomatic relatives and is ofno use in children aged less than 18. They recommended that 












CHAPTER 7: .. . 
THE BIOCHEMICAL DIAGNOSIS OF VARIEGATE 
PORPHYRIA IN THE VCT LABORATORY 
The experimental work which follows .is based to a large extent on an analysis of the 
accumulated porphyrin data of the University of Cape Town porphyria laboratory. Diagnoses 
are in most cases based on the expert interpretation of urine and stool porphyrin profiles 
determined by thin-layer chromatography. Since these techniques, and the process of 
diagnosis, are crucial to the interpretation of the results described in the following chapters, 
aspects of porphyria diagnosis as currently performed in the UCT laboratory are reviewed 
here. Additionally, the statistical techniques of discriminant analysis and classification tree 
analysis are briefly described since they are used extensively in the analysis of the porphyrin 
data in the chapters which follow. 
7.1 BIOCHEMICAL TECHNIQUES EMPLOYED IN THE UCT 
PORP~ALABORATORY 
The standard biochemical technique for the diagnosis of porphyria in the UCT laboratory is 
thin-layer chromatography (TLC). All samples initially undergo a screening test. Erythrocytes 
are screened under ultraviolet light for fluorescence as a simple test for CEP and EPP. Urine 
is screened for PBG by the Watson-Schwartz test. Urine and stool are treated with Dean's 
solution and screened for fluorescence under ultraviolet light. All methods are described in 
detail in Appendix 1. 
7.2 THE UCT PORPHYRIA DATABASE 
This database is central to the data-handling, record-storing and record-retrieval functions of 
the UCT porphyria service diagnostic laboratory. Complete records of all biochemical tests, 
routine R59W screening and plasma fluoroscanning results are contained within the database 
and extensive software programming in dBase language was undertaken by the author to 
automate most of the laboratory's data-handling operations. Thus the database software 
calculates the final porphyrin concentrations from the raw data obtained from the fluorescence 
integrator by making appropriate corrections for sample volumes and weights, dilution factors 
and comparisons with porphyrin standards. Once the results for a patient are stored within the 
database, they are reviewed and interpreted by one of three senior professionals: a 
professional nurse with 30 years of experience in porphyria, the principal biochemist or the 
principal clinician working within the porphyria service. The result is coded by biochemical 
diagnosis and, where appropriate, by a DNA diagnosis. This, with additional interpretative 
comments, is entered into the database and the results are then printed and sent out. An 
example of the laboratory result form is shown in Appendix 7. 
The porphyria database and its associated diagnostic codes were introduced into full-time 
use from January 1993. In developing algorithms for the diagnosis of porphyria, the concept 
ofprior probability is important; it is essential to know the proportion of samples submitted 
to a laboratory which might reasonably be expected to carry a particular diagnosis in terms of 
defining methods for their identification. Accordingly, the calculations which follow are 











reflect the total number of samples during this six-year period for which a particular 
diagnostic code was assigned; the percentage in the adjacent column therefore reflects the 
prior probability of that particular diagnosis. 
Diagnostic categories employed in the UeT porphyria database 
The following diagnostic codes are routinely assigned to porphyria diagnostic tests in our 
laboratory (Table 7-1). 
%nCategoryCode 
Major categories 












Suggestive of variegate porphyria: confirmation needed (VPH) 
3.6189







Porphyria cutanea tarda 31 

5.5Acute intermittent porphyria 
Minor categories 
0.1No diagnosis entered 0 
0.92 
 Minor abnormalities: probably normal 




 Variegate porphyria: dual phase I 
 0.0 
21 
 Variegate porphyria (dual phase) or porphyria cutanea tarda 8 
 0.2 
32 
 Suggestive of porphyria cutanea tarda 18 
 0.3 
51 
 Congenital erythropoietic porph ria 0.1 
55 
 Erythropoietic proto porphyria 24 
 0.5 
56 
 Suggestive of erythropoietic protoporphyria 0.15 

61 
 Hereditary coproporphyria 0.16 

71 
 Suggestive of porphyria: unclassified 0.02 

72 
 Coproporphyrinuria 0.3~ 
76 
 Abnormal porphyrin profile: unclassified 64 I 1.2 

77 






Table 7-1. Diagnostic categories used in the porphyria database and number of 
times each was recorded for the period 1993-1998. 
It is seen that the following are the prior probabilities for samples submitted to the VeT 
porphyria laboratory: normal 56.9%, VP 9.2%, VPH 2.2%, VPL 3.6%, peT 4.6%, AlP 5.5%. 
The only other large category is that where samples are inadequate for diagnosis; this is 
usually where either the urine or stool alone is submitted, but not both. This accounts for 
14.3%. Note too that these represent samples received and not patients. Patients with AIP in 
particular, and to a lesser extent peT, are over-represented since they tend to be tested 
repeatedly to assess disease activity. This is rarely so for VP, most of whom are tested once 











7.3 	 EVALUATION OF DIAGNOSTIC TECHNIQUES FOR THE 
ROUTINE LABORATORY 
Until the identification of the PPO gene, biochemical diagnosis by quantitative TLC coupled 
with careful evaluation of the clinical symptoms remained the final arbiter of diagnosis in our 
laboratory, and therefore in the country as a whole. The system has served us, and the 
country, well for many years. There are however two important problems associated with 
biochemical diagnosis of porphyria, and ofVP in particular. These are discussed here. 
Problems with the diagnosis of VP 
Laborious nature ofthe technique 
Preparation, measuring and weighing of urine and stool, drying and weighing of stool, 
extraction of porphyrins, application of sample to TLC plate, running, developing and 
scanning of the plate, and transferring of data into the database is labour-intensive. Exposure 
to stool and to the fumes of organic solvents are unpleasant for staff. Nor do patients enjoy the 
necessity to provide stool samples. Indeed, more than 20 years ago Day et al (1978b) wrote: 
"Excreta are unpleasant to work with and may take several days to collect. Porphyrin 
concentrations are prone to large fluctuations from day to day in both urine and stool, 
whereas RBC and plasma porphyrin levels very only slightly according to measurements by 
ourselves and others (Allen et al 1975; Copeman et al 1966). Many subjects are reticent to 
donate excreta for analysis, most are prepared to give a few millilitres of blood. This is 
especially the case in surveys of families exhibiting porphyria where most members feel they 
are well even if they do prove biochemically porphyric." 
Lack ofa definitive test for VP 
The single largest obstacle to the efficient diagnosis of VP in South Africa has been the 
absence of a practically useful and highly accurate test with which ultimately to confirm or 
refute a diagnosis of VP. In the absence of such a test, it was impossible to reach a final 
conclusion in the individual with an equivocal result other than by repeat testing, nor to assess 
the significance of equivocal findings as a group and hence to devise objective TLC criteria 
by which to remove this uncertainty. 
This lack of precision sometimes encountered in assigning a diagnostic category has 
proved a problem in issuing diagnoses efficiently and in recommending appropriate 
management to patients and their doctors. It seemed that further refinement is of these 
techniques for the biochemical separation, identification and quantitation of porphyrin species 
in excreta would not overcome these problems. Therefore, from an early stage, the necessity 
for the identification ofnew methodology is which would result in a much higher accuracy for 
the diagnosis ofboth presence and the absence ofVP in South Africa was recognised. 
Determination of PPO activity and the diagnosis of VP 
A diagnostic technique which has proved useful in some circumstances is the determination of 
PPO enzyme activity. Determination of erythrocyte PBG deaminase activity in particular is 
widely used for the diagnosis of AlP, though a number of problems with this technique have 
been recognised. Some families with classic AlP have been shown to have normal erythrocyte 
PBG deaminase activity. It has been shown that in these families, PBG deaminase activity in 
tissues other than erythrocytes is reduced by 50%, and the mutations in these families have 
been shown to reside in the initial part of the DNA sequence, encoding a part of the protein 











significant proportion of patients show results falling into an indeterminate range which 
complicates diagnosis. . . . 
The determination of enzyme activity is not suitable for the routme diagnostic laboratory. 
As a mitochondrial protein, PPO is absent from mature erythrocytes. Accordingly its activity 
can only be Measured in non-erythroid tissues. Hepatocytes might e~pected to show the 
greatest activity, but the risks in obtaining hepatic tissue by biopsy rule this out for the routine 
diagnosis of VP. Though skin fibroblasts and peripheral lymphocytes express PPO, they have 
little activity and therefore express extremely low levels of PPO activity. Furthermore, the 
PPO activity assay is poorly suited to routine use. Our extensive experience with the assay 
shows that in most cases the enzyme contribution to the total return of fluorescence is a 
fraction of the non-specific background rate of protoporphyrinogen auto-oxidation, and the 
difference between normal and reduced activity from normal activity is often less than the 
intra-assay variation. Furthermore, the assay is difficult, time-consuming and potentially 
hazardous since the operator is exposed to mercury vapour during the production of the 
sodium-mercury amalgam used for the reduction of the substrate. Our unit has shown that 
EBV-transformed lymphoblasts express sufficient PPO activity for a reliable estimation of 
that activity, and that the 50% reduction in activity typical ofVP persists after transformation 
(Meissner et al 1986). Yet the techniques of transformation and subsequent culture of the 
lymphoblasts are themselves time-consuming and costly and are therefore not suited to 
routine use. 
Biochemical criteria for the diagnosis of VP 
Thus, the biochemical diagnosis of VP by urine, stool and plasma porphyrin analysis has 
remained the mainstay of porphyria diagnosis in our laboratory. A shortcoming of the 
biochemical descriptions ofVP reported by previous authorities (Eales et a11963, Dean 1971, 
Grosser and Eales 1973, Eales 1974, Day 1986, Day et al 1978b, Eales et al 1980, Day and 
Eales 1983, Moore and Disler 1985) is that they largely describe the classic and characteristic 
profiles of clearly expressed VP. Thus a diagnosis is easy in the patient with a high stool 
coproporphyrin, protoporphyrin, C5 and pseudopentacarboxylic porphyrin (pseudo-C5) in the 
stool who also has PU in the plasma. Problematic is the patient with minimal abnormalities, 
particularly a moderately raised stool protoporphyrin. This has led us to introduce 
indeterminate categories into our diagnostic categorisation (Table 7-2) as follows: 
Probable VP. Though not entirely diagnostic, there is a substantial suspicion (>50% 
probability) that VP is present. This is represented by category 17 on the database, and will be 
referred to by the abbreviation VPH (VP: high probability) in the following chapters. 
Possible VP. The results are not entirely consistent with normality, and there is a low order 
of suspicion «50% probability) that VP is present. This is represented by category 18 on the 












Code Category Definition Abbreviation 
1 No evidence of 
porphyria 
With nonnallimits: porphyria not suspected. Non*VP,NAD 
11 Definite VP Unequivocally diagnostic ofVP. VP 
17 Probable VP VP (high probability). Not unequivocally diagnostic ofVP but 
thought to have a high probability of being VP. 
VPH 
18 Possible VP VP (low probability). Results do not fall clearly within nonnal 
limits but there is insufficient evidence to suspect VP strongly. (In 
practice, such patients often show an elevated stool protoporphyrin 
in the absence of any other porphyrin abnonnality.) 
VPL 
Table 7-2. Possible diagnostic categories following interpretation of biochemical 
results for patients suspected ofhaving VP. 
Broadly speaking, the features of each classification category are as follows: 
Diagnostic ofVP 
• Raised stool protoporphyrin 
• Raised coproporphyrin 
• Raised C5 
• Raised pseudo-C5) 
• Raised tricarboxylic porphyrin (C3). 
• Presence ofPU in plasma 
• Presence ofraised urine porphyrins, with or without raised ALA and PBG. 
Apparently normal; VP not suspected 
• Stool protoporphyrin nonna! or at most mildly elevated 
• Nonnal coproporphyrin 
• Absence ofpseudo-C5 and C3 
• Absence of "porphyrin activity" in urine 
• Absence ofPU in plasma 
Indeterminate category 
This we separated into two categories: "probable" VP and "possible VP", in which the 
probability ofthe actual presence ofVP was thought to be higher and lower respectively. 
• 	 Probable VP (VPH): A markedly elevated stool protoporphyrin on its own, with or 
without slight elevations in other characteristic porphyrins. 
• 	 Possible VP (VPL): Presence of a moderately elevated stool protoporphyrin with little 
other evidence ofporphyrin activity. 
These diagnostic categories are elastic and there remains an important subjective and 
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Figure 7-1. Some illustrative thin-layer chromatograms. On the left is a trace from a DNA­
positive patient with the classic profile of VP, including elevations in pseudo-C5, C5, 
coproporphyrin, C3 and protoporphyrin. In the middle panel is a trace from a DNA-positive 
patient who shows a mild elevation of pseudo-C5, C5 and coproporphyrin but by 
quantitation, a low protoporphyrin. On the right is a trace from a patient with a markedly 
elevated protoporphyrin alone. This was initially diagnosed as "VPL". This patient is 
however DNA-negative. 
7.4 DIAGNOSIS IN OTHER SOUTH AFRICAN LABORATORIES 
No South African laboratory has had the benefit of the sustained interest and wide access to 
diagnostic specimens and to patients as the VCT laboratory. However, a number of State and 
private chemical pathology services in South Africa have offered a biochemical diagnostic 
service to patients. Typically this consisted ofno more than the Watson-Schwartz test and the 
screening of urine and stool for porphyrins. One or two have offered solvent extraction or 
qualitative TLC, where porphyrins have been separated by TLC but have not been 
quantitated: the relative proportions of porphyrin present on the chromatogram are assessed 
visually (and therefore subjectively). 
As the national referral centre for porphyria in South Africa, we have over the years had 
contact with a large number of patients who have been given diagnoses, both positive and 
negative, by the laboratories practising these techniques. It has been apparent that both the 
sensitivity and the specificity of these techniques is poor, particularly in the case of VP, and 
that this was distorting the spectrum of VP in South Africa. We became increasingly 
concerned about the numbers of patients diagnosed in other laboratories in whom symptoms 
quite atypical for VP were being ascribed to a porphyria. The problem was compounded by 
indeterminate laboratory results interpreted by both patient and doctor as giving support to the 
diagnosis, rather than as disproving it. In some instances patients were even admitted to 
hospitals as having acute attacks, yet subsequent testing in our laboratory failed to provide 
evidence of porphyria at alL It appeared that a tentative clinical diagnosis of VP, often based 
on spurious grounds, tended to become a self-fulfilling prophecy. Doctors send specimens to 
laboratories labelled "Suggestive VP symptoms". The technologist, making a subjective 
assessment of stool fluorescence, is influenced by the clinical information and issues a 
tentative report such as "Suggestive of VP"; thus establishing a vicious cycle in which both 











7.5 OBJECTIVES OF THE STUDIES WHICH FOLLOW 

i ..• 
• To determine the degree of agreement in the interpretation of quantitative porphyrin 
data between experienced interpreters. 
• To determine by means of the mathematical techniques of discriminant analysis and 
classification tree analysis the most appropriate criteria for a diagnosis of VP by 
chromatography. 
• To assess the accuracy of simple screening procedures. 
• To assess the accuracy of plasma fluoroscanning for the recognition ofVP. 
7.6 	 STATISTICAL TECHNIQUES USED IN THE FOLLOWING 
CHAPTERS 
Two statistical techniques which are useful for the recognition of the factors most predictive 
of a given outcome and which may be useful in establishing criteria for diagnosis of the 
techniques of discriminant analysis and classification tree analysis. Their use, and 
interpretation of the values they return, is briefly discussed below. 
Discriminant analysis 
Discriminant analysis is used to determine those variables which best discriminate between 
two or more groups. Computationally, discriminant functional analysis is related to analysis 
of variance (ANOV A). The underlying concept is that the test determines whether two or 
more groups are significantly different from each other with respect to the mean of a 
particular variable: if so, then it is fair to infer that this variable discriminates between the two 
groups. The final significance test of the ability of a variable to discriminate between groups 
is the F test, which is computed as the ratio of the between-groups variance in the data over 
the average within-groups variance. If the between-group variance is significantly larger, this 
suggests a significant difference between means. 
In many instances, multiple variables are used (as will be the case in the analysis of our 
porphyrin biochemical data). All variables are then studied to determine those which 
contribute most to the discrimination between groups. This gives rise to a matrix of total 
variances and co-variances and a matrix of pooled within-groups variances and co-variances. 
These matrices are compared via multivariate F tests to determine whether any significant 
differences exist between groups with regard to all variables. This procedure is fundamentally 
identical to that ofmultivariate analysis ofvariance (MANOVA). 
The discriminant function analyses in the following chapters are performed with the 
Statistica software package (StatSoft Inc, Tulsa, USA) which automatically determines some 
optimal combination of variables to produce independent functions for this distinction. The 
number of functions that are produced is equal to n-l (where n is the number of diagnostic 
classes which must be distinguished), or the number of variables, whichever is the smaller. 
Whereas discriminant functions indicate which factors most reliably discriminate between 
diagnostic classes, the related classification functions may be used prospectively to determine 
to which group a particular case most likely belongs. There as many classification functions 
as there are diagnostic groups. Cases are classified as belonging to the group for which they 
have the highest classification score; these are additionally weighted in terms of the prior 












The classification matrix represents a cross-tabulation of predicted diagnostic class (predict~d 
on the basis of the classification functions returned by the discriminant function analysIs)' 
versus the actual diagnostic class recorded on the database. This allows us to determine, for 
each diagnostic class, the probability of both the correct diagnosis bein~ ret~med, ru:d ~e 
probability of an incorrect diagnosis and the ov~ra~l accuracy.~f~he class~fic~tlOn ~~tton In 
terms of diagnosis, from which such charactenstlcs as sensItIvIty, speCIfiCity, posItIve and 
negative predictive values may be calculated. 
Ranking ofindividual variables by relevance to diagnosis 
In the process of forward stepwise discriminant analysis each variable is entered into the 
function sequentially, and its overall contribution to the discriminant power of the function is 
assessed. This allows us to determine which variables are most useful in directing the 
diagnosis toward one diagnostic category or another. These data are combined with the 
preceding data in some of the tables which follow. The statistical terms shown in the tables 
are defined as follows: 
• 	 Variable: the variable entered at each step 
• 	 Step: the step number 
• 	 Wilks' lamda: a measure of the power of discrimination between different categories. 0 
represents perfect discrimination; 1 represents no discrimination at all. Where shown 
as part of a stepwise analysis, the overall lamda becomes progressively smaller as 
additional variables are entered, reflecting at;l increasing power of discrimination with 
successive steps. 
• 	 F value: the higher the F value, the greater the contribution of a particular variable to 
the diagnostic power. In the tables which follow, variables are classified from the 
highest F value to the lowest F value; this implies that the first-mentioned variables 
have the highest discriminating power whereas the last variables are the weakest in 
terms of discrimination. 
• 	 Partial lamda: this is Wilks' lambda associated with that particular variable's unique 
contribution to power of discrimination of the model. Again it ranges between 0 
(perfect discrimination) and 1 (no discrimination). 
• 	 F value associated with the partiallamda 
• 	 r2--defined as I-tolerance; a measure of redundancy. A value of 0.1 for instance means 
that the variable is 90% redundant with a respect to other variables. The higher the 
tolerance, the more important the variable is to the discrimination. 
Classification tree analysis 
Classification trees are used to predict membership of a particular category based on the 
measurement of one or more predictor variables. Essentially a classification tree analysis 
produces an algorithm; the analysis determines decision points (or nodes) at which critical 
values of a single variable are used to steer the diagnosis in one or other direction. The 
analysis attempts to determine the combination of variables, and their critical values, which 
will best fit the eventual diagnosis. 
Classification tree analysis is a valuable technique for the identification of underlying 
predictors in determining eventual assignment to a diagnostic category, and may also result in 
the production of clinically useful algorithms. However, trees must always be examined 











smaller classes until every single exception and aberrant value has been correctly assigned; 
this leads to the incorporation ofmisleading, counter-intuitive and even erroneous steps which 
will not be useful in a priori prediction. 
7.7 EPIDEMIOLOGICAL TERMINOLOGY 
The utility of both diagnostic techniques and of statistical manipulation of porphyrin data are 
discussed in the chapters which follow. Table 7-3 defines the epidemiological terms employed 
in those chapters. 
Disease present Disease absent 
Test positive a (true positive) b (false positive) 







: False-negative rate 
I False-positive rate 
Positive predictive 
• value (PPV) 
! Negative predictive 
• value (NPV) 
I Overall accuracy 
Formula Definition Explanation 
(a+c)/ All patients with VP/all patients tested 
(a+b+c+d) 
a/(a+c) True-positive test/all patients with VP % of subjects with VP correctly 
identified by the test 
d/(b+d) True-negative test/all patients without % of subjects without VP correctly 
VP identified by the test 
c/(a+c) ~nog,.vo ,,01,11 ",.on" w;th % of subjects with VP missed by the 
test 
b/(b+d) alse-positive test/all patients without % of subjects without VP erroneously 
VP labelled positive 
a/(a+b) True-positive tests/all positive tests % of positive tests which actually 
denote VP 
d/(c+d) True-negative test/all negative tests % of negative tests which actually 
denote the absence ofVP 
(a+d)/ (true-positive test+true-negative 
(a+b+C+d) test)/ all tests 












THE CORRELATION OF DIAGNOSTIC CATEGORIZATION 
BETWEEN EXPERT INTERPRETERS 
In the following three chapters, the practical utility of biochemical porphyrin analysis in the 
diagnosis of VP is assessed. In this chapter, the correlation between the interpretation is 
placed on biochemical data by three expert observers is studied. In the following chapter, 
statistical techniques are employed to assess, retrospectively, the importance of specific 
abnormalities of porphyrin excretion in the diagnosis of VP and to determine which, if any, 
objective criteria account for the equivocal diagnostic categories. These two chapters lay the 
groundwork for the work of Chapter lOin which the biochemical effects of VP are for the 
first time correlated with the presence or absence of a VP-associated mutation, on the basis of 
which the most appropriate predictors for a diagnosis of VP are selected. 
8.1 INTRODUCTION 
There is a SUbjective element in the interpretation of biochemical tests for porphyria. This 
subjective element enters the interpretation process at two levels: 
• 	 In assessing the outcome of a biochemical test per se. This is particularly an issue in 
assessing the degree of deviation from normal in tests such as the Watson-Schwartz 
reaction, porphyrin fluorescence under ultraviolet light, and thin-layer chromatograms 
assessed qualitatively without recourse to direct quantitation by fluoroscanning. 
• 	 In interpreting the significance of the results returned by testing. Even where 
chromatography is employed, ultimately the decision must be made as to whether a 
particular chromatographic pattern and the porphyrin concentrations associated with it 
represent normality or not. In particular, the diagnosis of VP may be complicated by a 
class of chromatographic porphyrin results which appear to exceed normal limits and yet 
are not unequivocally diagnostic of VP (Chapter 7): these are assigned to the diagnostic 
categories high-probability (VPH) and low-probability (VPL). 
Throughout the period covered by this study, the issuing of final diagnostic reports in our 
laboratory has been in the hands ofjust three people, a biochemist, a professional nurse and a 
clinician (and author of this dissertation). None has fewer than 12 years' experience, and their 
opinions are, in South Africa, regarded as definitive. This study set out to assess how well the 
diagnoses made by these three experienced interpreters agree. 
8.2 OBJECTIVES 
• 	 To assess the degree of inter-interpreter variation in interpreting urine, stool and 
plasma screening data and quantitative porphyrin data produced by TLC. 
8.3 METHODS 
A representative sample of laboratory results were extracted from the database and 
reproduced in the form of a table from which all identifying data and diagnostic information 












Urine and stool screening results alone were presented. The three interpreters were asked to 
assign a diagnosis, chosen from a list of possible answers (Table 8-1), to each set of results. 
Interpreters had no opportunity to modifY their choice in the light of their subsequent 
exposure to the corresponding quantitative data, nor were results discussed. 
TLC results 
Urine, stool and, where available, plasma data were presented to each interpreter in the form 
of a table. The three interpreters were asked to assign a diagnosis, chosen from a list of 
possible answers (Table 8-2), to each set of results. 
I The screenings suggest a normal result. 
2 The screenings are equivocal could be either normal or VP 
3 The screenings suggest either VP or peT 
4 The screenings strongly suggest VP. 
Table 8-1. Diagnostic categorization for screening results. 
There is no doubt about the biochemical diagnosis ­ either VP or normal. 
I The trace is unequivocally normal 
4 The trace is unequivocally diagnostic ofVP 
There is an element ofdoubt about the biochemical diagnosis as results are not unequivocally 
diagnostic. 
2 There is a suspicion that VP may be present, but the probability is low. 
3 There is a suspicion that VP may be present, but the probability is high. 
Table 8-2. Diagnostic categorization for TLC results. Categories 1,2,3 and 4 
correspond to the classes NAD, VPL, VPH and VP as defmed previously. 
Following completion, the results were entered into a database and related to the original 
diagnostic information. The final number ofsamples available for comparison was 210. 
Data handling 
Data were entered into a Microsoft Access database and analysed with the Statistica software 
programme. 
Statistical methods 
The coefficient of concordance was calculated by Friedman analysis of variance. Partial 
correlations were compared by Kendall tau correlations; and gamma correlations were 
performed as a second test. The Kendall tau represents a probability and is the difference 
between the probability that two variables are in the same order in the observed data versus 
the probability that they are in different orders. The gamma statistic is preferable to the 
Kendall tau or Spearman R in the case of data which contain many tied observations as is the 
case here, and is computed as the difference between the probability that the rank ordering of 
the two variables agree minus the probability that they disagree divided by one minus the 












These are summarised in Tabie 8-3. The three interpreters are identified by the letters A, B 
and C. The routine diagnostic category actually assigned to that sample in the database at the 
time of testing is labelled as Original. 
Screening results 
The spread of categorizations issued by the three interpreters is shown in Figure 8-1. It is seen 
that one interpreter (A) recognises a result as abnormal more frequently than the other two 
interpreters. 
Correlalion of Screening Assignments 
4 
3 
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Figure 8-1. Spread of screening categorizations issued by the three interpreters. 
A statistical difference was shown for the screening results (p<0.000l, Friedman ANOVA 
x2): the major difference lies between the scores of interpreter A and those of Band C. The 
Kendall coefficient of concordance of 0.36090 indicates a rather poor agreement between 
interpreters overall. 
TLC results 
The spread of categorizations issued by the three interpreters is shown in Figure 8-2. It is seen 
again that interpreter A recognises a result as suspicious of VP slightly more frequently than 
do interpreters B and C, though in this case no significant difference in mean scores was 
shown between interpreters (p=0.97, ANOVA). 






Figure 8-2. Spread of TLC categorizations issued by the three interpreters and as 











The coefficients of concordance are 0.13 between interpreters and 0.09 between 
interpreters and the database, suggesting week agreement. Indeed, it is considerably weaker 
than the paired correlation coefficients between interpreters, the lowest of which is 0.84, 
suggesting that, whereas two of the three interpreters agreed reasonably frequently, agreement 
by all three was less common. 
Screening 
Kendall Tau Correlations Gamma Correlations 
A B C A B C 















iFriedman ANOVA chi square p<0.000} 
Kendall coefficient of concordance 0.36090 
TLC 
i 
Table 8-3. Partial correlations for three interpreters A, Band C independently 
assigning diagnostic categories to 210 sets of porphyrin results. For the TLC results, 
the correlations with the original assignment in the porphyrin laboratory database 
are additionally included. A correlation of 1 represents perfect agreement; 0 
represents no agreement at all. 
Extent of agreement on diagnosis between interpreters 
In Table 8-4, the interpretation is are broken down by the degree of agreement between 
interpreters. "Agree" signifies that all three interpreters made the same diagnosis. "Close" 
means that the range of diagnoses spanned at most 2 adjacent categories; i.e. VP and VPH, 
VPH and VPL or VPL and Normal. "Remote" signifies that there were widely discrepant 
diagnoses spanning more than two categories, i.e. VP and VPL or Normal, VPH and Normal. 
It is seen that in only 69% of cases in which at least one interpreter diagnosed VP, was there 
complete agreement; in a further 13% the remaining interpreters allowed a high probability 
, VP, whereas in 18% at least one interpreter put forward a diagnosis of low-probability or even 
of normality. For the categories of VPH and VPL, the agreement is poor. Inspection of those 
77 
Kendall Tau Correlations Gamma Correlations 
A B C Original A B C Original 
A 0.79 0.82 0.73 A 0.96 0.96 0.92 
B 0.79 0.84 0.84 B 0.96 0.97 0.97 
C 0.82 0.84 0.8} C 0.96 0.97 0.94 
Original 0.73 0.84 0.81 1.00 Original 0.92 0.97 0.94 
Friedman ANOVA chi square P<O.OOO} 
Kendall coefficient of concordance 
between interpreters 0.13 










records in which the greatest discrepancy occurred showed that these were largely those with 
high stool protoporphyrin values but little other evidence for VP. A smaller group showed 
elevations of C5 or pseudo-C5 alone. 
Highest level selected by any interpreter 
1 (Normal) 2 (Low probability) 
2 
3 (High probability) 4(VP) 
100%10710%21%469%43Agree 
90% -1911%213%8Close 
68% -18% 13 -11Remote 
Table 8-4. Degrees of agreement on diagnostic category between three independent 
interpreters independently assigning diagnostic categories to 210 sets of porphyrin 
results. Close agreement implies a difference in agreement of no more than one class 
between highest and lowest assignments; remote implies a spread of more than one 
class between highest and lowest assignments. 
8.S CONCLUSIONS IN BRIEF 
There is a subjective element in the diagnosis ofVP among the three interpreters~ resulting in 
a degree of variability, and there is frequently disagreement on diagnostic categorisation in 
borderline cases. This may result from inconsistencies in the weight placed on specific 
abnormalities of the porphyrin excretion profile. In the chapter which follows, an attempt is 
made to determine retrospectively which factors are rated most heavily in the diagnostic 
categorisations contend in the VCT porphyria laboratory database, following which, in 
Chapter 10, new biochemical criteria are sought and validated against the presence or absence 













THE CHROMATOGRAPHIC DIAGNOSIS OF PORPHYRIA 
The preceding chapter has shown that there is a degree of variability in the interpretation of 
biochemical excretion profiles, particularly in the equivocal group which overlaps both the 
unequivocal VP and the normal groups. In this chapter, the reasons for this are studied further. 
9.1 INTRODUCTION 
The standard diagnostic technique in the UCT porphyria laboratory is the chromatographic 
diagnosis of porphyria by TLC. Samples of urine, stool, plasma and erythrocytes are screened 
for the presence of porphyrins and are then subjected to chromatographic separation and 
quantitation. 
The biochemical diagnosis of VP has traditionally been based largely on the finding of an 
elevated stool protoporphyrin. Our experience has shown a considerable overlap in 
protoporphyrin values between patients with clinically confirmed VP and patients believed on 
clinical and other grounds to be normal. This has led to the identification of a significant 
number of patients, occupying this overlap or grey area, whose diagnosis is in doubt. During 
the period reflected in this study, these have been further subdivided into the categories VPH 
and VPL. The criteria for the two intermediate categories VPH and VPL have never been 
formally defined, but arose from the need to make some sense of those results of an 
indeterminate nature at a stage when there was no easy recourse to enzyme activity assays or 
DNA studies to support or refute a diagnosis ofVP. It would seem that VPH includes patients 
with either a markedly elevated protoporphyrin alone or with moderately elevated stool 
protoporphyrin coupled with at least some other non-diagnostic indication of abnormal 
porphyrin activity while patients with VPL typically have modest elevations in stool 
protoporphyrin alone. Thus the interpretation of porphyria biochemical profiles in our 
laboratory is largely intuitive and based on long experience. For the purposes of 
standardisation, it is always preferable to establish objective, numeric and mathematical 
criteria for individual diagnoses. There are two statistical techniques well-suited to the 
analysis predictive data which may serve this purpose: discriminant analysis and classification 
tree analysis. Both are applied retrospectively to the accumulated data of the porphyria 
laboratory database for the period 1993-1998. 
9.2 OBJECTIVES 
• 	 To characterise VP biochemically. 
• 	 To identify, retrospectively, those variables most predictive of assignment of porphyrin 
results to a specific diagnostic class. 
9.3 METHODS 
Samples 
All samples recorded on the UCT porphyria laboratory from January 1993 to December 1998 











Screening tests and quantitative TLC 
Biochemical tests were performed as described in Appendix 1. 
Diagnostic categories 
Results were categorised as described in Chapter 7. In the case of suspected VP, results are 
classified as definite VP (VP), probable or high-probability VP (VPH) and possible or low­
probability VP (VPL). All diagnoses are as recorded in the database and no attempt has been 
made to alter them post hoc. 
Categorisation ofcontinuous porphyrin data 
Discriminant analysis suggested that in most instances the fact of elevation of a particular 
porphyrin was of greater importance than the actual measured concentration. To assess this, 
porphyrin values were reworked to introduce a categorical element (present/absent) for each 
variable, further refined by the introduction of a semi-quantitative scale for each variable, to 
give some indication of degree of elevation. Thus, for each variable, a ranking of 0 was 
applied if the variable fell within the laboratory normal range, and values. of 1, 2 and 3 for 
progressive elevations. These were defmed on an arbitrary scale, selected as to span the range 
of values encountered in laboratory practice, as reflected in Table 9-1. Discriminant analysis 
was then performed with the substitution of the categorical values for the original data. 






















<=1.7 >1.7 >3.4 
>50 >100 >200<=50 >75 
>400<=200 >200 >250 >300• Stool protoporphyrin 
>2 >8 >640 >0• All other porphyrins which are 
normally undetectable by TLC 

Urine ALA 




>45 >60 >90 
<=16 >16 >64 >128>32 
Table 9-1. Defmitions for the categorisation of porphyrin variables for discriminant 
analysis. 
Data handling 
Data were entered into a Microsoft Access database and analysed with the Statistica software 
programme. 
9.4 RESULTS 
Figures 9-1 to 9-3 show the stool protoporphyrin, coproporphyrin and CS categorised by the 
diagnostic classes VP, VPH, VPL and NAD. Values are not normally distributed but tend to 
cluster at the lower levels with a long tail extending upwards. Note that a logarithmic scale is 
used for protoporphyrin and coproporphyrin, and a linear scale for CS. The large box includes 
















c:::::::::J Median; 5-95% VP VPH VPL NAD 
DIAGNOSIS 
Figure 9-1. Stool protoporphyrin concentrations (nmol/g dry weight) categorised by 
diagnosis. 















VP VPH VPL NAD 
DIAGNOSIS 
Figure 9-2. Stool coproporphyrin concentrations (nmol/g dry weight) categorised by 
diagnosis. 











VP VPH VPL NAD 0 Outliers 
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The classification functions returned by discriminant analysis of the porphyrin data have a 
sensitivity for detection of VP of only 76.9% (Table 9-2). The sensitivity for PCT and AlP is 
better. The model fails to recognise the categories VPH and VPL most of the time, preferring 
to classify these as normal. However, discriminant analysis using the categorised data as 
defined in: Table 9-1 is more discriminatory. Table 9-3 shows the relative importance of the 
variables, listed in order of their importance in the discrimination between diagnoses. It is 
seen that the categorical data are in general more discriminatory than the original numeric 
data, particularly in the case of the stool porphyrins, and substitution of these semi­
quantitative values improves the ability of the discriminant analysis to discriminate between 
diagnostic classes (Table 9-4). The accuracy of a predicted diagnosis for both PCT and VP is 
now over 90%, and there is a major increase in the detection rate of the two indeterminate 
categories VPH and VPL. For the rest of this chapter, only these categorical variables are 
employed. 
Predicted diagnosis 









100.0 88 0 0 0 0 
76.9 27 93 1 0 0 
14.3 6 0 I 0 0 
0.0 9 0 0 0 0 
84.2 6 0 0 0 32 
100.0 0 0 0 0 0 
81.5 136 93 2 0 32 











Table 9-2. Accuracy of classification functions applied to raw urine, stool and 












Stool isocopro (categorised) 384.8 
Urine PBG (actual) 167.1 
Stool copro (categorised) 115.0 
Urine copro (actual) 74.9 
Plasma C5 (categorised) 24.4 
Stool proto(categorised) 23.6 
Urine copro (categorised) 12.8 
Stool pseudo C5 (categorised) 10.4 
Urine uro (categorised) 8.0 
Plasma proto (actual) 4.9 
Plasma uro (categorised) 4.2 
Urine ALA (actual) 2.6 
Urine PBG (categorised) 2.6 
Stool C5(categorised) 2.6 
Stool C5 (actual) 2.4 
Stool isocopro (actual) 1.7 
Urine C7 (categorised) 1.4 
~PU (cate••""") 1.2 
Stool C6 (actual) I.l 
Table 9-3. Ranking of the variables in order ofdiscriminatory value. (The higher the 
F value, the greater the contribution of the variable to discriminatory power of the 
model.) Those labeled "categorised" have been reworked on to an arbitrary scale 
reflecting elevation above normal or otherwise. It is seen that for most variables, the 
fact of elevation is more useful than the actual value in predicting the presence of 
porphyria correctly. 
Predicted diagnosis 
Actual diagnosis Sensitivity NAD VP VPH VPL PCT AlP 
NAD 92.0 81 0 3 4 0 0 
VP 91.7 4 III 2 3 0 1 
VPH 28.6 2 0 2 3 0 0 
VPL 55.6 2 0 2 5 0 0 
peT 97.4 I 0 0 0 37 0 
AlP 100.0 0 0 0 0 0 2 
Total 89.8 90 III 9 15 37 3 
PPV 90.0% 100.0% 33.3% 22.2% 100.0% 66.7% 
Table 9-4. Classification accuracy of classification functions applied to categorical 











Ranking the variables in terms ofdiscriminatory power 
Table 9-5 shows the tabulation of porphyrin variables in the order of their contribution to the 
discrimination between the various forms of porphyria. 
Step Variable Lambda F-value 
1 Stool isocopro 0.1l86 384.79 
2 Stool copro 0.0369 216.92 
3 UrinePBG 0.0205 146.03 
4 Stool proto 0.0142 110.94 
5 PlasmaC5 0.0098 93.69 
6 Stool pseudo-C5 0.0081 79.10 
7 Urine uro 0.0069 68.92 
8 PlasmaC6 0.0065 59.95 
9 Urine co pro 0.0062 53.07 ! 
10 Plasma copro 0.0058 47.94 
11 Stool C3 0.0055 43.77 
12 Plasma proto 0.0052 40.18 
13 Plasma uro 0.0050 37.19 
14 UrineC7 0.0049 34.49 
15 PlasmaC7 0.0048 32.18 
16 Stool C5 0.0047 30.15 
Table 9-5. Ranking of the categorical values in terms of their contribution to the 
power of the discriminatory model. It will be seen that as each variable is 
introduced, so the overall value of Wilk's lamda approaches 0 (perfect 
discrimination) more closely; the F value is a reflection of the discriminatory power 
of the variable. 
Resolving the "grey area": discriminating between VP, AlP, peT and normal alone. 
Where the two categories of VPH and VPL are omitted from the calculations, the diagnostic 
accuracy of the of discriminant analysis improves further, with sensitivities of 97%, 94%, 
97% and 100% for normality, VP, PCT and AIP respectively (data not shown). Clearly it is 
these two intermediate categories which the model has difficulty in resolving. 
Resolving the "grey area": discriminating between VP, VPH, VPL VP and NAD 
In an attempt to maximise discrimination between the various grades of VP, that is NAD 
versus VP, VPH and VPL, the analyses were repeated on those samples diagnosed as NAD, 











Actual diagnosis Predicted diagnosis 
Sensitivity NAD VPL VPH VP 
NAD 96.8% 2430 39 42 0 
VPL 39.4% 43 74 71 0 
VPH 29.4% 19 32 4 
VP 86.5% 31 7 328 
Total 89.9% 2523 180 152 332 
PPV 96.3% 41.1% 21.1% 98.8% 
Table 9-6. Results of discriminant analysis using urine, stool and plasma porphyrins 
(though not ALA or PBG) to distinguish between the grades ofVP. 
Whereas the predictive value for both nonnality and for unequivocal VP is good, the 
difficulty in resolving these grades of VP persists. VPH is largely identified as VPL, whereas 
VPL is frequently confused with VPH and NAD. Both however appear to be fairly well 
distinguished from unequivocal VP. The following ranking (Table 9-7) indicates which 
variables are most important in predicting the appropriate diagnostic class: NAD, VP, VPH or 
VPL. It appears that the major distinction is based on the height of the stool coproporphyrin 
and protoporphyrin; these make approximately equal contributions to the discrimination. By 
contrast, the other porphyrins including stool C5, pseudo-C5 as well as the precursors ALA 






Stool copro I 0.2390 443.65 0.5899 95.94 
Stool proto 2 0.1150 270.83 0.5411 117.02 
Stool C5 3 0.1056 170.91 0.9603 5.71 
Stool pseudo-C5 4 O.i04Ol 123.81 0.9863 1.92 
Table 9-7. Breakdown of discriminant analysis using urine, stool and plasma 
porphyrins to distinguish between the grades ofVP. 
Sequential investigation 
Each adjacent pair of categories was then compared to assess which predictors best 




















Percent Correct VP VPH Predictors (ranked in order of 
importance) 
Distinguishing VP from VPH 
89.7% 340 39 Stool copro 
88.1% 13 96 
89.3% 353 135 
Distinguishing VPH from VPL 
52.9% 46 41 Urine C7, stool copro, stool proto, 
85.8% 21 127 
stool pseudo-C5 
73.6% 67 168 
Distinguishing VPLfrom NAD 
79.7% 118 30 Stool proto 
95.8% 62 1401 
94.3% 180 1431 
I 
Table 9-8. Distinction between the grades of VP (VP, VPH, VPL and NAD) by 
discriminant analysis using urine, stool and plasma porphyrins. Where a variable is 
not listed as a predictor, it may be assumed that it is of negligible importance. 
Classification tree analysis 
If one allows sufficient complexity on the tree, it can be guaranteed to produce 100% 
accuracy. This positive aspect is offset by two factors: firstly that the tree becomes 
excessively complicated, and secondly, that it will increasingly diverge from the true situation 
in that it will now exhaustively cover every possibility, including such perverse predictors as 
outliers, unusual cases or incorrectly classified samples. Thus, in analyzing the examples 
which follow, the intention is to identify those factors most predictive of a particular 
diagnosis, and to draw tentative conclusions as to how best to combine these factors to 
maximise diagnostic accuracy. Classification tree analysis is in the first instance an 
exploratory technique (though clinically useful algorithms may follow), and it is not our 
intention to imply that the following trees are of immediate utility in the diagnostic 
laboratory . 
Discrimination between all hepatic porpbyrias 
The software programme returns the classification tree diagram depicted in Figure 9-4. The 
branching points represent decision points; the tenninal boxes represent the tenninal nodes 
where the eventual diagnosis is read. 
With 15 decision splits and 16 tenninal nodes, a high degree of accuracy is achieved as 
shown in Table 9-9. Indeed, the only inaccuracy is at a single node where, along with 79 
nonnals, 1 VP and 1 VPL are trapped on the basis of the following sequence: low pseudo-5­













Stool pseudo-C5 <= 7.5 
Urtne uro <= 40.5 
Stool copro <= 35.35 PBG <= 210.8 
[;] 
Stool proto <= 543,5 
, , 
Urine COprO <= 96.45 
G;J
,...--L" 
Stool oopro .... <Q.1 
Figure 9-4. Classification tree for the diagnosis of porphyria based on porphyrin 




Sensitivity NAD VP VPH VPL PCT AlP 
NAD 100.0% 88 0 0 0 0 0 
VP 99.2% 1 120 0 0 0 0 
VPH 100.0% 0 0 7 0 0 0 
VPL 88.9% 1 0 0 8 0 0 
PCT 100.0% 0 0 0 0 38 0 
AlP 100.0% 0 0 0 0 0 2 
PPV 97.8% 100.0% 100.0% 100.0% 100.0% 100.0% 
Table 9-9. Accuracy of the classification tree depicted in Figure 9-4 (n=265) 
How useful are plasma values? 
The plasma values are relatively unimportant and are not used at all in the initial tree. 
Accordingly, the calculations were rerun to see the effect of omitting the plasma porphyrins 
(Table 9-10); this had the additional advantage of greatly increasing the number of cases 











Actual diagnosis Predicted diagnosis 
Sensitivity NAD VP VPH VPL PCT AlP 
100.0% 226 0 0 0 0 0 
VP 97.8% 3 225 0 0 2 0 
VPH 87.0% 2 1 20 0 0 0 
VPL 71.0% 7 I 0 22 1 0 
PCT 98.7% 1 0 0 0 77 0 
AlP 77.8% 0 2 0 0 0 7 
PPV 94.6% 98.3% 100.0% 100.0% 96.3% 100.0% 
Table 9-10. Accuracy of a classification tree including urine and stool porphyrins 
and urine precursors, but excluding plasma (n=597). 
The model suffers a slight loss in discriminatory ability between VP, VPH, VPL and PCT, 
but overall accuracy remains high. Inspection of the variables found by the model to be most 
predictive of the eventual classes reveal the following ranking, ranked from 100 (most useful) 
to 0 (least useful): (Table 9-11). 
Ranking 
Stool pseudo-C5 100 
Stool proto 98 
Stool C5 88 
Stool copro 85 
Stool isocopro 71 
Stool C6 63 
UrineC7 62 
Stool C7 62 
Urineuro 60 
UrineC6 57 
Urine C5 53 




Stool C3 14 
Table 9-11. Ranking of variables for their predictive value in the model. 
How important are the urine precursors? 
The following classification tree is directed at the diagnosis ofVP, PCT and the grades VPH 
and VPL alone and performs well (Figure 9-5, Table 9-12). Addition of the Ehrlich's screen 














Classification Tree for Diagnosis of porphyria 
Stool ps,eudQ..C5 <=1,1 
172 r----'--...., 
Stoo! proto <- 560.83 
Figure 9-5. A classificatiou tree for the diaguosis of VP, Pcf aud the grades VPH 
aud VPL. 
92 \1 
Stool pseudo-GS <~ 61.6 
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$1001 copro <II 49.6 
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Actual diagnosis Predicted diagnosis 
Sensitivity NAD VP VPH VPL PCT 
NAD 97.9% 1414 6 2 23 0 
VP 95.0% 5 305 4 3 4 
VPH 65.5% 6 14 57 10 0 
VPL 54.5% 41 8 17 79 0 
PCT 93.1% 2 0 5 0 94 
PPV 96.3% 91.6% 67.1% 68.7% 95.9% 
Table 9-12. Accuracy of the classification tree shown in Fig 9-5, including urine 
and stool porphyrins, but excluding plasma and urine precursors (n=2099). 
Discriminating between the grades of VP 
The same approach may be used to further define the distinction between VP, VPH, VPL and 
NAD. In contrast to discriminant analysis, classification tree analysis produces a simple tree 
which functions well (Figure 9-5, Table 9-14). Experimentation shows that neither the urine 
precursors nor the plasma porphyrins are ranked highly in the analysis. Accordingly they are 
omitted from the model; this allows a larger and therefore more representative sample. The 











Siool proia <= 534.2 
SIOOl PI!lIo <= 325.2 
Figure 9-6. Classification tree for the diagnosis ofVP. 
Actual Predicted diagnosis 
diagnosis 
Sensitivity NAD VP 
NAD 97.4% 1425 7 0 
VP 91.8% 13 303 7 
VPH 29.9% 5 12 26 
VPL 57.4% 45 6 12 85 
PPV 95.8% 92.4% 57.8% 50.9% 
Table 9-13. Accuracy of an abbreviated classification tree including urine and stool 
porphyrins, (n=2028). 
Predictive accuracy of the Classification Tree 
Since incorrectly classified or atypical values may bias the classification tree, it is advisable to 
test the algorithm against a subset of samples for which the correct classification is known, 
but which were not used in the detennination of the algorithm. In this way the true predictive 
accuracy of the tree can be assessed. Such a test of the classification tree follows. 
The database was randomly divided into two groups; a learning group and a test group by 
assigning all those with an odd laboratory number to one group and with even laboratory 
number to the other. AlP was excluded because of the small numbers. All variables were 
incorporated. The classification tree was then developed based on the learning group only 











StllOl copm <= 43.8 
All variables, including ALA and PBG as well as plasma porphyrins, were used. The tree 
shown in Figure 9-7 was produced. One counter-intuitive decision point is noted: node 14 
which traps 2 VP cases with low porphyrin values. 
Classification Tree for the Diagnosis of Porphyria 
Learning sample 
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Figure 9-7. Classification tree for the diagnosis of porphyria as applied to the 
learning sample (n=137). 
This tree was then applied to the test sample (n=139) with the results as shown in Table 9-14. 
Actual diagnosis Predicted diagnosis 
I Sensitivity NAD VP VPH VPL PCT· 
NAD 85.4% 35 1 3 2 
VP 98.2% 56 1 
VPH 25.0% 3 I 
VPL 25.0% 3 I 
PCT 95.0% I 19 
PPV 89.7% 98.2% 14.3% 33.3% 95.0% 
Table 9-14. Performance of the classification tree shown in Figure 7 on a test 
population of samples (n=139). 
A high degree of accuracy (considerably higher than that shown for discriminant analysis) 
is shown for NAD, VP and peT, though the intennediate categories of VPH and VPL are 











9.5 CONCLUSIONS IN BRIEF 
This study has shown that patterns of porphyrin excretion, whether measured as categorical 
variables by discriminant analysis or by classification tree analysis, are more important than 
absolute values in the diagnosis of porphyria. Classification tree analysis yields better results 
than discriminant analysis, and produces algorithms with a high degree of diagnostic 
accuracy. The stool coproporphyrin emerges as an important predictor of VP. Even where 
stool pseudo-C5 and stool protoporphyrin are used to branch in the direction of VP, it is 
frequently the stool coproporphyrin on which the final distinction is based. It is also noted that 
the grades VP and VPH, and VPH, VPL and NAD are subject to a large degree of overlap, 
suggesting that the criteria used for the diagnosis are not absolute. 
The traditional biochemical criteria for a diagnosis of VP are now, in the following 
chapter, tested against the presence or absence of VP as defined by the carriage of a VP­












CORRELATING BIOCHEMICAL DATA WITH THE DNA­
BASED DIAGNOSIS OF PORPHYRIA 
10.1 INTRODUCTION 
The great majority of patients with VP in South Africa carry a single mutation, the R59W 
mutation. This enables us, by reference to DNA analysis, to state with a high degree of 
accuracy whether an individual carries a VP gene or not: the only exceptions will be those 
subjects carrying other mutations, many ofwhich we have in any event identified (Chapter 4). 
It is now possible to correlate biochemical porphyrin profiles produced by TLC with the 
absolute presence or absence of a gene for VP, and to apply this simply and quickly for large 
numbers of subjects in a way that would not be possible using the determination of PPO 
activity in EBV-transformed lymphocytes. We are therefore now in a position to determine 
accurate normal reference ranges for porphyrin excretion, and to determine which variables 
most reliably predict a diagnosis ofVP. 
10.2 OBJECTIVES 
• To determine normal ranges for porphyrin and precursor concentrations in urine and 
stool 
• To identify the most reliable biochemical predictors ofVP. 
10.3 METHODS 
Subjects 
All subjects with adequate urine and stool quantitative data whose DNA status for the R59W 
and 537deiAT mutations were known were included in the study. These two mutations were 
included since data on a large number of subjects, both DNA-positive and DNA-negative, 
were available, and since both mutations are thought to be associated with complete loss of 
function of the protein coded by the mutant allele. Subjects carrying other mutations were 
excluded, as were an additional four subjects whose DNA status is in doubt. Two subjects 
showed high levels of stool coproporphyrin and protoporphyrin, but when retested one month 
later showed values well within the normal range. Two additional subjects showed repeated 
high levels of coproporphyrin and protoporphyrin and are R59W -negative. One has not been 
further investigated; in the second subject, SSCPlheteroduplex analysis has shown no 
abnormality of any exon, including the untranslated region of exon 1 and as yet no mutation 
has been identified. 
DNA analysis 
DNA samples were screened for the R59W mutation by Ava} restriction assay. Samples were 
screened for the 537deiAT mutation by direct sequencing and/or MvaJ restriction assay as 












Urine, stool and plasma porphyrins were measured by quantitative TLC. Urine precursors 
were measured by ion-exchange chromatography. The methods are described in Appendix 1. 
Data handling 




The effect of puberty on porphyrin excretion patterns is clearly seen. In Figures 10-1 and 10­
2, which use a logarithmic scale, no subject with VP aged less than 16 years shows a stool 
coproporphyrin or protoporphyrin higher than those shown by normal children. It is also 
apparent that the lowest quartile of adults carrying a VP mutation have porphyrin values 






DNA STATUS; Non-YP DNA STATUS: yP D Median value 
Figure 10-1. Biochemical expression of VP as reflected by stool coproporphyrin 
excretion. Adult is defmed as age ~16 years. 
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DNA STATUS: Non-YP DNA STATUS: yP 
Figure 10-2. Biochemical expression of VP as reflected by stool protoporphyrin 











10.5 VALIDATION OF A NORMAL RANGE FOR THE LABORATORY 
Using the absence of the R59W and 537delAT mutations to define normality, the following 
values are obtained for the mean and standard deviation (SD) (Table 10-1). Potential upper 
limits of the normal range (ULN) defined by the mean+2*SD, mean+3*SD levels, 95th and 
98th percentiles, in addition to the ULN currently defined for the UCT porphyria laboratory, 
are shown. In the analyses which follow, the ULN is defined as mean+2*SD. 
Statistical values Prospective values for ULN 
Current Percentile Upper limits 
n Median Mean SD 95th 98th Mn+2SD Mn+3SD 
Urine ALA 41 9.5 12.0 7.0 45 • 27.4 29.6 25.9 32.9 
UrinePBG 41 2.1 2.8 2.3 16 6.7 9.5 7.4 9.7 
Urine uro 94 6.0 6.9 6.5 20 18.4 24.6 20.0 26.5 
UrineC7 94 0.0 0.1 0.6 0 0.3 2.2 1.4 2.0 
UrineC6 94 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0 
UrineC5 94 0.0 0.0 0.2 0 0.0 0.0 0.3 0.5 
Urine copro 94 79.6 92.3 71.0 240 230.0 288.5 234.2 305.2 
Stool uro 125 0.0 0.4 1.0 0 2.3 3.7 2.3 3.3 
Stool C7 125 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0 
Stool C6 125 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0 
Stool ps5 125 0.0 0.7 3.0 0 3.1 10.3 6.6 9.6 
Stool C5 125 0.0 0.2 0.9 0 1.9 2.4 2.0 2.8 
Stool isocopro 125 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0 
Stool copro 125 16.7 19.0 11.1 50 39.3 44.2 41.2 52.4 
Stool C3 125 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0 
Stool proto 125 105.3 170.2 187.5 200 481.7 913.3 545.3 732.8 
Table 10-1. Current upper limit of the normal range for porphyrin and precursor 
values in the Porphyria Laboratory, with potential values derived from subjects 
shown not to have VP by DNA screening. Units are nmol/10 rnrnol creatinine 
(urine) and nmol/g dry weight (stool). 
The current reference range is comparable to the updated ULN indicated by mean+2SD 
with the following exceptions: the ULN for stool protoporphyrin must be substantially 
increased to 545.3 nmolJg dry weight; the ULN for stool coproporphyrin should be slightly 
reduced to 41.2 nmolJg dry weight and, the values for urine ALA and PBG should be reduced 
to 25.9 and 7.4 mmolJI0 mmol creatinine respectively. 
10.6 COMPARATIVE STATISTICS 
Significant differences at the 5% level were shown between normal and VP subjects for the 
following porphyrins and precursors: stool protoporphyrin, stool coproporphyrin, urine 
uroporphyrin, urine C5, stool C5, stool pseudo-C5, urine ALA, urine coproporphyrin, urine 













Statistically significant differences 
Stool proto Non-VP 0.0000 125 11.8 21.4 105.3 482.4 966.7 
VP 73 18.7 42.0 332.0 2155.7 2620.1 
Stool copro Non-VP 0.0000 125 3.0 4.4 16.7 39.5 53.5 
VP 73 4.6 9.0 87.5 368.0 557.2 
Non-VP 0.0000 60 0.0 0.0 6.0 21.0 38.0 
0.0 0.0 14.0 260.0 1329.0 
5 0.0 0.0 0.0 1.6 
0.0 0.0 56.4 431.5 
0.0 0.0 7.3 
0.0 
Stool ps5 Non-VP 0.0000 125 0.0 
VP 73 0.0 16.1 
ALA Non-VP 0.0000 41 3.2 4.2 9.5 
VP 37 6.2 7.8 19.8 
Urinecopro Non-VP 0.0002 94 12.3 15.7 79.6 236.7 
VP 63 9.6 21.8 148.7 557.7 
Urine C7 Non-VP 0.0002 94 0.0 0.0 0.0 0.8 
VP 63 0.0 0.0 0.0 156.6 
Urine C6 Non-VP 0.0004 94 0.0 0.0 0.0 0.0 
VP 63 0.0 0.0 0.0 17.7 
PBG Non-VP 0.0062 41 0.3 0.8 2.1 6.7 
VP 37 0.4 0.6 3.8 40.8 51.3 
PlasmaPU Non-VP 0.0237 13 0.0 0.0 0.0 0.0 0.0 
VP 25 0.0 0.0 0.0 26.2 32.1 
!Differences not statistically significant 
Plasma uro Non-VP 0.0518 13 0.0 0.0 0.0 0.0 0.0 
VP 25 0.0 0.0 0.0 8.3 8.3 
Stool uro Non-VP 0.0710 125 0.0 0.0 0.0 2.3 5.6 
VP 73 0.0 0.0 0.0 4.1 12.5 
Plasma proto Non-VP 0.1572 13 0.0 0.0 0.0 0.0 0.0 
VP 25 0.0 0.0 0.0 27.0 46.9 
Stool C7 Non-VP 0.2141 125 0.0 0.0 0.0 0.0 0.0 
VP 73 0.0 0.0 0.0 0.0 2.4 
Stool C6 Non-VP 0.2141 125 0.0 0.0 0.0 0.0 0.0 
VP 73 0.0 0.0 0.0 2.4 
Stool isocopro 0.0 0.0 0.0 
0.0 0.0 11.6 
C7 0.0 0.0 0.0 
0.0 8.2 8.2 
Plasma C6 0.0 0.0 0.0 
VP 25 0.0 0.0 0.0 26.7 26.7 
PiasmaC5 Non-VP 0.3291 13 0.0 0.0 0.0 
VP 25 0.0 0.0 0.0 
Stool C3 Non-VP 1.000 125 0.0 0.0 0.0 
VP 73 0.0 0.0 0.0 
Plasma copro Non-VP 1.000 13 0.0 0.0 0.0 0.0 
VP 25 0.0 0.0 0.0 0.0 
0.0 
0.0 
Table 10-2. Porphyrin and precursor concentrations in subjects separated by DNA analysis 
into normals and carriers of VP. Units are as defmed earlier. VP subjects are aged 16 years 











10.7 SIGNIFICANCE OF ELEVATED PORPHYRINS 
The newly-derived ULN values for stool coproporphyrin and protoporphyrin, defined by 
mean+2SD, were then applied to those subjects with DNA-proven VP: these limits were 
therefore set at stool coproporphyrin :::41.2 nmol/g dry weight and stool protoporphyrin 
~545.3 nmol/g dry weight respectively. With these limits, 22 of 73 adult subjects (30%) with 
DNA-proven VP fell within the normal range for stool coproporphyrin, and 54 of 73 subjects 
(74%) fell within the normal range for stool protoporphyrin. All porphyrin data for these 22 
subjects in whom both stool coproporphyrin and protoporphyrin fell within normal levels 
were then individually reviewed. 19 subjects, by our subjective assessment, showed normal 
urine and stool porphyrin profiles, and all had been diagnosed as biochemically normal. One 
subject, R59W-positive, has a trace suggestive of low-level PCT, but does not meet the 
definition for dual porphyria, since there is no biochemical evidence for VP. The remaining 
two subjects had been labelled VPH on the basis of moderately raised stool protoporphyrin 
values alone. 
10.8 CORRELATION WITH BIOCHEMICAL RESULTS: PREDICTIVE 
VALUES 
The sensitivity of biochemical testing for the diagnosis of VP is now examined. All the 
following analyses are confined to VP subjects aged 16 or more: the control group includes 
non-VP subjects of any age, since no statistical difference can be demonstrated in the 
porphyrin concentrations shown in normal adults and children. 
Correlation with expert interpretation 
Table 10-3 illustrates the agreement between the diagnostic category assigned to a particular 
sample by the panel of expert interpreters (Chapter 8) and DNA status. Categories are 
grouped by majority opinion: if 2 of 3, or 3 of 3 interpreters agree, then their score is 
accepted; ifnone agree, then the average is taken. Seven children with DNA-proven VP aged 
less than 16 were encountered: all were unequivocally negative for VP biochemically and are 
excluded from the calculations which follow. 
Diagnosis by DNA status 
Biochemical consensus 
opinion 





Normal 97 15 112 0.87 0.13 
VP: low probability 21 6 27 0.78 0.22 
VP: high probability 6 3 9 0.67 0.33 
VP: definite 1 47 48 0.02 0.98 
Total 125 71 196 
Table 10-3. Probability of being DNA-positive or negative for VP classified by the 











Interpretation: Predictive values 
The result is similar to that derived by reference to the new normal values. Of 71 adult 
subjects with DNA-positive VP, IS (21 %) will have unequivocally normal porphyrin profiles, 
a further 12% will have equivocal results, of which two-thirds are regarded as being of low 
probability. For an adult, an unambiguously normal TLC trace carries a probability of having 
VP of 0.13; this increases to 0.22, 0.33 and 0.98 for TLC diagnoses ofVPL, VPH and definite 
VP respectively. Note however that these probabilities are calculated on diagnoses assessed 
by three independent interpreters; in view of the variation seen between interpreters, these 
probabilities may not hold true for individual interpreters. Furthermore, these probabilities 
hold for a special set of results: largely drawn from family screening studies in which the 
prior probability for VP will be high. The probabilities will be considerably lower in routine 
laboratory practice. The effects of progressively relaxing the threshold for making a diagnosis 
ofVP on TLC results from VP to VP and VPH, and to VP, VPH and VPL are shown in the 
Table 10-4. 
Criterion for a positive biochemical test 
VP VPNPH VPNPHNPL 
Sensitivity 66.2% 70.4% 78.9% 
Specificity 99.2% 94.4% 77.6% 
PPV 97.9% 87.7% 66.7% 
NPV 83.8% 84.9% 86.6% 
False Positive Rate 0.8% 5.6% 22.4% 
False Negative Rate 33.8% 29.6% 21.1% 
Prevalence 36.2% 36.2% 36.2% 
Overall Accuracy 87.2% 85.7% 78.1% 
Table 10-4. Predictive perfonnance of biochemical profile, using successively more 
lenient diagnostic criteria (VP alone, VP or VPH, VP, VPH or VPL). 
Is it possible to predict the mutation status of a subject with an equivocal biochemical 
diagnosis? 
Individual values as well as the mean values for each porphyrin were then inspected for all 
subjects with a consensus diagnosis of VPH. Only one consistent difference was noted: the 
urine coproporphyrin is markedly and significantly higher in those positive for VP by DNA 
than for those negative (p=0.02, Student's t-test). The stool coproporphyrin also tended to be 
higher; by contrast, the pseudo-CS and CS porphyrins were indistinguishable; the stool 
protoporphyrin was actually lower in the VP group than in the non-VP group. 
Repeating this procedure with consensus diagnosis of VPL, the following trends were 
noted: a higher urine ALA, stool pseudo-CS, stool CS and stool coproporphyrin in the VP 
group (all significantly p=O.OS or less by Student's t-test). When the two uncertain categories 
are examined jointly, the informative porphyrins are stool CS and stool coproporphyrin; 
perversely, the stool protoporphyrin is lower in the VP group than in the non-VP group. A 













A discriminant analysis (not shown) correlating all porphyrins with sufficient variance with 
the results ofR59W or 537deiAT testing yields a sensitivity of 58.3% for DNA-positive VP, 
with a PPV for a function-returned diagnosis of VP of 100%. It incorporates only the stool 
coproporphyrin and uroporphyrin, all others, including stool protoporphyrin, are non­
discriminatory. 
Classification tree 
A computer-generated classification tree (not shown) suggests that only the stool 
coproporphyrin contributes substantially to the distinction between those who are DNA­
positive and those who are DNA-negative, with a cut-off value of44.2 nmollg dry weight. 
DNA status As predicted by the function 
Sensitivity Non-VP VP 
VP 67.2% 22 45 
Non-VP 97.8% 87 2 
PPV 97.8% 87.9% 95.7% 
Table 10-5. Sensitivity and predictive value of using stool coproporphyrin alone to 
diagnose DNA-positive VP. 
10.9 CORRECTION FOR VP EXPRESSION 
Thus both discriminant analysis and classification tree analysis leave an irreducible minimum 
of approximately 30% of patients with DNA-positive VP who are not detectable 
biochemically, the same proportion who were shown earlier to have both normal 
coproporphyrin and protoporphyrin levels. These appear to represent those VP patients who 
are truly biochemically silent, and no further statistical manipUlation is likely to provide 
useful predictors for their identification. It would appear to be more useful to divide all 
subjects with DNA-positive VP into two classes: biochemically expressed and biochemically 
silent. The problem is as always how best to define these classes. For the purpose of this 
analysis, we have chosen to define, and tentatively, biochemically expressed VP initially as 
an elevation of anyone of the follOWing stool porphyrins above the new URL defined as 
mean+2SD: C5, pseudo-C5, coproporphyrin and protoporphyrin. 
Table 10-6 shows the results of applying these biochemical parameters to the subjects. All 
subjects with expressed VP have (by definition) elevated porphyrin markers; conversely, all 
subjects with silent VP have normal porphyrin markers, as do all DNA-positive children. 
However, and isolated elevation of any of the stool porphyrins is clearly not specific for VP 
since an elevated concentration of at least one of these markers was shown in 13 normal adult 
subjects as well, yielding a specificity of 92.2% and a positive predictive value of just 81.2% 
(Table 10-7). Using discriminant analysis and classification tree analysis, we therefore 











Expressed VP Non-VP Child-VP Silent VP 
At least one elevated porphyrin 
marker 56 \3 0 
Normal porphyrin markers 0 154 9 17 
Table 10-6. Refming the defmition of biochemically-expressed VP. Elevated 
porphyrin markers imply an increase above mean +2SD in at least one of the 





False Positive Rate 7.8% 
False Negative Rate 0.0% 
Prevalence 25.1% 
Overall Accuracy 94.2% 
Table 10-7. Diagnostic utility of elevated porphyrin markers defmed in Table 10-6 
for the diagnosis of biochemically expressed VP. 
Discriminant analysis 
A discriminant analysis using all porphyrins for which sufficient variance is present results in 
the following classification matrix. The discriminant function is 100% sensitive in detecting 
normality, but still fails to recognise VP in nearly 40% of cases (Table 10-8). 
DNA status As predicted by the function 
Sensitivity Non-VP Expressed VP 
Non-VP 100.0% 89 0 
Expressed VP 62.5% 18 30 
PPV 83.2% 100% 
Table 10-8. Performance of a discriminant function for the diagnosis of 
biochemically expressed VP using fully-quantitative porphyrin data. 
If however, the raw porphyrin values are replaced by categorical values on a semi­
quantitative scale has described in Chapter 9, the performance improves though the function 
is still somewhat insensitive in detecting biochemically expressed VP (Table 10-9). Table 10­
10 indicates the relative utility of the various porphyrins in classification: it is seen that stool 
coproporphyrin and stool C5 between them account for almost all the discriminatory power of 













DNA status As predicted by the function 
Sensitivity Non-VP Expressed VP 
Non-VP 100% 89 0 
Expressed VP 81.3% 9 39 
PPV 91% 100% 
Table 10-9. Performance of a discriminant function for the diagnosis of 





Stool copra 0.304154 41.05533 0.2766470.754241 
tool C5 0.251978 0.910420 12.39766 0.453518 
---1 
Stool C7 0.240206 0.955038 5.93186 805 
Stool UfO 0.234990 3.06734 0.1351270.976235 
Stool proto 0.230828 0.78149 0.3024220.993836 
Table 10-10. Relative contribution of the various porphyrins to the predictive power 
of the analysis. 
Classification tree analysis 
Classification tree analysis produces the algorithm shown in Figure 10-3. This simple 
algorithm uses just two variables: stool coproporphyrin and stool C5, and appears to 
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DNA status . Sensitivity As predicted by the function 
Non-VP Expressed VP 
Non-VP 98.4% 122 2 
Expressed VP 94.7% 3 54 
PPV 97.6% 96.4% 
Table 10-11. Results returned by the classification tree shown in Figure 10-3. 
The three individuals erroneously predicted by the function to have expressed VP include 
an 81 year-old man with a stool coproporphyrin of 53.5 nmollgram dry weight though a low 
stool protoporphyrin of 173.7 nmollg dry weight, a 51 year-old man with a very mild 
elevation in stool C5 and a 50 year-old man with marked elevations of stool C5 (25.9 nmollg 
dry weight) and stool pseudo-C5 (7.3 nmollg dry weight) though a normal stool 
coproporphyrin and protoporphyrin: Though he is R59W negative, these results are 
concerning and it is possible that he has one or other disturbance of porphyrin metabolism, 
whereas the first two subjects would appear to be real false positives. 
Two subjects classified as expressed VP were misclassified as normal by the algorithm. 
Their stool coproporphyrin values are 46.2 and 47.3 nmollg dry weight respectively which 
closely approach the cut-off value of 48.9 nmollg dry weight. In neither were stool C5 or stool 
pseudo-C5 detectable; the first had a stool protoporphyrin of 482 nmollg dry weight whereas 
stool protoporphyrin was low in the second. Both were only classified as expressed VP since 
their stool coproporphyrins exceeded the level of 41.2 nmollg dry weight set at Mean+2SD: it 
would not be inappropriate to regard these two individuals, particularly the second, as non­





False Positive Rate 2.4% 
False Negative Rate 3.6% 
Prevalence 30.9% 
C>verall Accuracy 97.2% 
Table 10-12. Utility of the diagnostic algorithm shown in Figure 10-3. 
Table 10-13 shows the relative importance of the various porphyrins as predictors of the 
presence of biochemically-expressed VP. 
Stool C5 100 
Stool copro 82 
Stool pseudo-5 67 
Stool proto 33 
Stool C7 14 
Stool uro 3 
Table 10-13. Relative importance of individual porphyrins in the prediction of 











Application of the classification tree to the porphyria database. 
This algorithm was then retrospectively applied to the entire porphyria database. The 
following correspondence with the diagnoses recorded on the database were obtained (Table 
10-14). This algorithm is highly predictive, agreeing with the diagnosis recorded in 95.0% of 
cases ofVP and in 97.3 % of cases judged NAD. It would classify 17.6% of those recorded as 
VPL and 43.1 % of those recorded as VPH as having VP, which accords well with the 
probabilities for the presence ofVP of 0.22 and 0.33 calculated earlier. 
Recorded diagnosis As predicted by the algorithm 
Non-VP Expressed VP 
NAD 2443 68 
VP 19 360 
VPH 62 47 
VPL 155 33 
Table 10-14. Comparison. of the algorithm applied retrospectively with the 
diagnoses originally made. 
10.10 CONCLUSIONS IN BRIEF 
All children and at least 30% of all adults carrying a PPO mutation associated with VP exhibit 
normal TLC porphyrin profiles, and cannot be detected by urine and stool chromatography. 
The distinction between biochemically expressed and non-expressed VP' is somewhat 
arbitrary. Analysis suggests values of 48.92 nmoVg dry weight for coproporphyrin and 2.72 
nmoVg dry weight for stool C5 as critical values which are highly discriminatory between 
normal subjects and DNA-positive subjects in whom VP is biochemically expressed as 
indicated by an elevation in at least one of the terminal porphyrins excreted in stool. Stool 
protoporphyrin is a poor predictor of the presence or absence of VP. These results, and 












PORPHYRIN PROFILES WITHIN BILE, SMALL BOWEL 
AND COLON 
The preceding chapters have shown that it is impossible to diagnose VP with 100% sensitivity 
and specificity on the basis of porphyrin excretion profiles alone. Furthermore, despite the 
belief that the protoporphyrin is the porphyrin most relevant to a diagnosis of VP on the 
grounds that protoporphyrinogen is the natural substrate for PPO, this work has shown that 
protoporphyrin is less predictive of VP than the stool coproporphyrin and stool C5. A small 
project we had undertaken to assess the fidelity of stool porphyrin profiles as a reflection of 
hepatic porphyrin metabolism is therefore relevant, and is discussed briefly in this chapter. 
11.1 INTRODUCTION 
The biliary porphyrin profile has been shown to be dissimilar to that of stool, with a 
preponderance of coproporphyrin (Aziz and Watson 1969, Logan et al 1991). The 
discrepancy between faecal and biliary porphyrins is thought to be due largely to the effects of 
bacterial metabolism within the bowel: other possible sources of variation include the effects 
of intestinal bleeding and dietary sources of haem. The contribution of these factors to the 
stool porphyrin profile were discussed in Chapter 6. We had previously undertaken a study to 
delineate the differences between biliary and faecal porphyrins and to determine at which 
level of the bowel the transition from the biliary pattern to the faecal pattern occurs. This is 
relevant to our finding that stool protoporphyrin appears to be a poor predictive ofVP and this 
study is accordingly described here. 
11.2 SUBJECTS AND METHODS 
Subjects 
Permission was obtained from the relatives of 7 subjects to take samples of bile and bowel 
content when the organs were removed for transplantation. All subjects met the medical and 
legal criteria for brain-death. Vital functions were being supported on a ventilator and their 
legally-competent relatives had given their consent for the subjects' organs to be removed for 
transplantation. The stool values are those of 125 subjects shown to be negative for the R59W 
and 537deiAT mutations (Chapter 10). 
Methods 
During laparotomy, samples for porphyrin analysis were taken from four sites. Using a 
syringe, 5 ml of bile were aspirated from the gallbladder, and liquid bowel contents were 
aspirated from the mid-jejunum. Solid or semi-solid samples of the bowel contents were 
removed from the caecum and from the sigmoid colon through a small incision. Samples were 
esterified with 5% sulphuric acid in methanol and porphyrins were extracted into chloroform. 
Porphyrins were separated by thin layer chromatography and quantified by fluoroscanning as 
described in Appendix 1. Results for liquid samples (bile and jejunum) were expressed in 












Data were entered into a Microsoft Access database and analysed with the Statistica software 
programme.The data were analysed for significant differences by ANOVA. 
11.3 RESULTS 
Absolute values are not reported since It IS the comparison of the proportions of each 
porphyrin present in each type of sample which are meaningful. The mean porphyrin profiles 
for samples derived from each source are listed in Table 11-1 and are shown graphically in 
Figure 11-1. Sigmoid porphyrin profiles were very similar to those encountered in normal 
stool samples, and both consisted largely of protoporphyrin with a small contribution from 
coproporphyrin and little or no C3. In contrast, the bile contains a large proportion of 
coproporphyrin and a significant proportion of C3 with very little protoporphyrin. The change 
is highly significant (p<0.00001, ANOVA). Post-hoc comparison of means by Tukey's honest 
significant difference test for unequal n demonstrates a highly significant difference between 
the porphyrin profiles of both bile and jejunum and those of caecum, sigmoid or stool; bowel 
and jejunal profiles do not vary significantly, nor do caecum, sigmoid and stool profiles. 
Source N Copro % C3% Proto % 
Bile 7 55 .0±4.8 23.3± 3.7 20.9±5 .7 
Jejunum 7 52.0±5.6 20.1±3.0 27.9±6.3 
Caecum· 7 22.2±6.1 7.2±2.0 70.6±7.1 
Colon* 7 11.5±2.8 7.9±4.0 80.6±2.9 
Nonnal stool* 125 O.15±O.J I O.OO±O.OO O.85±O.ll 
Table 11-1. Porphyrin profiles (proportional) at varying sites. *Significant with 
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11.4 CONCLUSIONS IN BRIEF 
The porphyrin of bile and stool are highly dissimilar. The porphyrin content of 
and jejunum are similar, as are the of caecal sigmoid colonic content 
Thus the stool porphyrin profile is at reflection of metabolic 
on)cesse:s occurring within the liver. account in predictive value of 












SIMPLE SCREENING TESTS FOR THE DIAGNOSIS OF 
PORPHYRIA 
In the following two chapters, two further biochemical methods for the diagnosis of VP are 
examined. The first is the method of simple qualitative screening for porphyrins in urine and 
stool; though an old (indeed the original) method of porphyrin analysis, this is still used in 
some South African laboratories for diagnosis. The second, to be discussed in chapter 13, is 
the method of plasma fluorescence scanning, which has been suggested to represent a more 
sensitive test for the diagnosis ofVP than chromatography. 
12.1 INTRODUCTION 
Simple screening tests for the presence of urinary PBG, urinary porphyrins and stool 
porphyrins have been widely used in South Africa for the diagnosis of porphyria. These tests 
are largely qualitative, but are usually performed in a semi-quantitative fashion using such 
intervals as negative, trace, one plus, two plus and three plus positive. In practice, urine which 
screens strongly positive for PBG is considered likely to represent AlP (either in remission or 
in an acute attack) or VP in the acute phase; a markedly positive stool screen is regarded as 
strongly suggestive of VP and an isolated strongly positive urine porphyrin screen as 
suggesting PCT. Difficulty however arises when fluorescence is more equally spread between 
the urine and stool; in South Africa, such a situation is not unusual and the diagnosis may lie 
between PCT and VP . 
Though the use of screening tests as an initial step in the diagnostic evaluation of patients 
with suspected porphyria is still recommended (Bonkovsky and Barnard 1998), .we believe 
that it should always be followed up with quantitative methods. Even today, qualitative 
screening tests as the only test for porphyria are still performed by some private and hospital 
laboratories in South Africa. 
In the VCT laboratory, porphyrin quantitation by TLC is always preceded by qualitative 
screening for two reasons. Firstly, screening results give a prompt indication of the likelihood 
of an abnormality, and secondly, they suggest the amount of sample to be extracted and 
applied to the TLC plate so as to maximise the yield while reducing the possibility of 
quenching. Thus we have accumulated a large body of data comprising both qualitative 
screening results and quantitative results on the same specimen. In the work described here, 
the data resulting from six years' qualitative porphyrin screening in the VCT laboratory are 
compared with the quantitative and diagnostic results subsequently obtained by quantitative 
TLC on the same specimens. 
12.2 OBJECTIVES 
• To determine the correlation between results of screening tests and actual porphyrin 
values as measured by quantitative methods 











Correlation of stool screening results with stool porphyrin concentrations 
There is a strong correlation between the stool screening results and total porphyrin 
concentration as measured by quantitative techniques. The relationship is again not linear (~ 
=0.39), but logarithmic (~=0.51) (Figure 12-3). Figure 12-4 shows a large degree of overlap 
of porphyrin concentrations at all values of the stool screening result. The median values, 
interquartile distance and range attached to the various classes of stool screening are shown in 
Table 12-2. 


















Stool screen result 
Fi~ure. 12-3. Correlation of o?served stool screening results with subsequent 




































Table .12-2. Stool screening. Quantitative porphyrin concentration compared with 
screenrng category. 
Stool Screening vs Total Faecal Porphyrins 
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:r: Min-Max 
c:J 25%-75% 
o Median value 
Stool Screening 
Fi.ghure Ih2~. Total stool porphyrin concentrations (nmol/g dry weight) associated 












Correlation of urine PBG screening results with urine PBG concentrations 
This is shown in Figure 12-5. ill this case, the relation is linear rather than logarithmic. Again 
there is a fair correlation (~ =0.55), however a large degree of overlap exists for each 
screening intervaL 
PBG Screening vs Urinary PBG 
1000 
100f·············-­ +--_......................... + ..............................+ 
10 . 
1 L­____~______~____=====-__~ I Min-Max 025%-75% 
o 1 2 4 D Median value 
PBG Screening 
Figure 12-5. PBG concentrations (J.1molllO mmol creatinine) associated with each 
interval of the PBG screen. 
Predictive accuracy of screening results 
Table 12-3 shows the perfonnance of stool screening as a diagnostic test for the presence of 
VP. The effect of changes in perfonnance as a result of altering two variables are shown: (1) 
establishing the diagnostic threshold for VP at decreasing degrees of positivity of the stool 
screening test result, and (2) broadening the TLC criteria for a diagnosis of VP to include not 
only definite VP, but also probable VP (VPH), as defined in Chapter 7. 
Diagnostic class 
VP only VPandVPH 
Screening result defined as 
positive: 
2·4 3-4 4 only 2-4 3-4 4 only 
!Sensitivity 95.6% 80.9% 54.6% 92.5% 73.3% 45.3% 
Specificity 73.3% 91.6% 98.2% 75.1% 92.9% 98.6% 
PPV 28.5% 51.8% 77.4% 35.7% 60.7% 83.0% 
NPV 99.3% 97.7% 95.1% 98.5% 95.9% 92.3% 
False Positive Rate 26.7% 8.4% 1.8% 24.9% 7.1% 1.4% 
False Negative Rate 4.4% 19.1% 45.4% 7.5% 26.7% 54.7% 
Prevalence 10.1% 10.1% 10.1% 13.0% 13.0% 13.0% 
Overall Accuracy 75.5% 90.5% 93.8% 77.4% 90.4% 91.7% 











Use of urine screen alone for the diagnosis of VP 
Urine screening tests alone are entirely worthless in the recognition of.~P. A s~on.gly positive 
urine screening result (grade 4) has a sensitivity o~ 16.4% and.a p.osltlve pr~dl.ctlV: v~lue. of 
only 30.9% for definite VP, interestingly however, It has a specIfiCIty of 96.2 Yo, an mdlcahon 
of the high prevalence ofVP in this sample. 
Discriminant analysis 
Discriminant analysis returns the following classification when applied to these data (Table 
12-4). 

































































Table 12-4. Predictive accuracy of a discriminant function using observed screening 
values for the diagnosis ofporphyria. 
Classification tree analysis 
Analysis returns the classification tree shown in Figure 12-6. Diagnoses of AlP are excluded 
from the analysis; since relatively few samples are included in the database, they result in a 
more complicated tree without materially altering the diagnostic accuracy of the tree for VP 
and peT. The diagnostic matrix returned by the tree is shown in Table 12-5. 
Stool screening <= 2 
~______L-____~. ~ 
GJ 
53 ~ 40 
Urine screening <= 3 
[NO:MAL [ 
167 66 


















As recorded on 
database 
















peT 41% 48 39 30 
PPV 93.3% 69.5% 75.0% 
Table 12-5. Predictive accuracy of the classification tree using observed screening 
values for the diagnosis of porphyria. 
Correlation of screening with TLC result 
How good is the correlation between a screening result and the eventual diagnostic 
classification? For the following statistical tests, the TLC and screening scores were adjusted 
so as to fall into three categories: unequivocally normal, equivocal and unequivocally VP. 
Cross-correlations for each of the three interpreters tested in Chapter 8 are shown in Table 12­
6. The correlations for each interpreter were then assessed; the Kendall tau values were 0.46, 
0.74 and 0.74 respectively, the gamma coefficients were 0.86, 0.96 and 0.93. This suggests 
that, in experienced hands, screenings are quite predictive of the final outcome, though the 
extent will vary between individuals. 
I As diagnosed on screening 
results alone As diagnosed on TLC results 
NAD Equivocal VP 
Interpreter A 
NAD 89.4% 7.5% 3.0% 
Equivocal 16.1% 39.2% 44.6% 
: VP 4.8% 9.5% 85.7% 
Interpreter B 
: NAD 86.8% 11.1% 1.9% 
Equivocal 40.3% 26.1% 33.6% 
VP 0.0% 0.0% 100.0% 
: Interpreter C 
NAD 85.1% 9.3% 5.6% 
Equivocal 3.8% 30.7% 65.4% 
VP 0.0% 0.0% 91.3% 
Table 12-6. Correlation of an interpreter's diagnosis based on screening tests only 
with their eventual diagnosis based on quantitative porphyrin data. The figures 











12.5 CONCLUSIONS IN BRIEF 
Though screening results correlate well with final TLC results, there is a wide spread within 
each class which makes prediction of actual porphyrin content inaccurate. In experienced 
hands however, screening results are fairly predictive of the eventual diagnosis returned by 












PLASMA SCANNING AS A DIAGNOSTIC TOOL IN VP 
13.1 INTRODUCTION 
Long et al (l993) have suggested that plasma scanning is a more sensitive test for VP than 
faecal porphyrin analysis. A study was therefore undertaken to assess the sensitivity and 
specificity of this test in comparison with the technique of chromatographic detection of 
porphyrins in urine, stool and plasma; both were compared with DNA status as the ultimate 
arbiter ofVP carriage. 
13.2 OBJECTIVES 
• 	 To determine the utility of plasma fluoroscanning as a method for the diagnosis of VP 
in the South African context. 
13.3 lVIETHODS 
Subjects 
Samples were largely drawn from family studies in two extended families shown to carry the 
R59W and 537deiAT mutations. Some additional subjects in whom both biochemical analysis 
and DNA analysis had been performed were included. 
Methods 
The R59W and 537 delAT mutations were recognised by restriction assay and/or direct 
sequencing as described in Appendix 4. Biochemical porphyrin quantitation was by 
quantitative TLC. Plasma was diluted 1:10 with phosphate-buffered saline and the emission 
spectrum was scanned from 580 nm to 650 nm with the excitation monochromator set at 405 
nm. Peak heights quoted in this chapter are those measured at a standard sensitivity and are 
therefore comparable. All methods are fully described in Appendix 1. 
Data handling 
Data were entered into a Microsoft Access database and analysed with the Statistica software 
programme. 
13.4 RESULTS 
Correlation with DNA status 
In 86 subjects both a DNA result and a plasma scanning result were available. Of these 65 
were aged 16 or more; 21 were children. A typical plasma scan is shown in Figure 13-1, and 











Figure 13-1. Typical plasma fluorescence scan in VP. The emission spectrum has 
been scanned from 580 nm to 650 nm with a constant excitation wavelength of 405 
nm. A fluorescence peak is shown with a maximum at 625 nm. 
DNA status Peak at 625 urn 
absent 





Mutation negative 38 2 4 44 
Mutation positive 5 37 0 42 
Table 13-1. Summary of results: correlation of presence of peak at 625 nm with 
presence of a VP-associated mutation. 
Four subjects showed plasma fluorescent peaks at other wavelengths: three at 619 run 
suggesting peT, 1 at 630 run suggesting EPP. These diagnoses were confirmed by TLC in 
these subjects. 
False negatives 
Of 42 subjects with mutation-proven VP, 37 were positive by plasma scanning. Of the 5 
subjects negative by plasma scanning, 3 were children aged 6, 11 and 12; the remaining two 
subjects were aged 23 a d 55. Thus, only two false-negative results were encountered in 
adults. The first patient, aged 55, was positive for the R59W mutation. His urine precursors, 
urine porphyrins and stool porphyrins were low, with a stool coproporphyrin of 20.9 and a 
stool protoporphyrin of267 runollg dry weight. The second, aged 23, was positive for the 537 
delA T mutation. No stool data were available. 
False positives 
Two DNA-negative subjects showed peaks at 625 run. One patient, aged 70, demonstrated a 
peak of 4 mm but is clearly free ofVP since she belongs to the family carrying the 537delAT 
mutation and was shown to be negative. Her stool protoporphyrin was somewhat high at 482 
runollg; however coproporphyrin and all other porphyrins were low. In all subjects with 
DNA-proven VP who demonstrated a peak, the height of the peak was at least 5 mm. Long et 
al (1993) set their threshold for positivity at a 3 mm deflection: it would appear appropriate 
for us to set our limit at 5 mm. The second subject, aged 19, had been tested biochemically at 
age 16, apparently in view of a family history of porphyria though further information is 











the negative R59W result. Though VP is unlikely, the possibility of a non-R59W mutation is 
however not excluded. . •. 
Applying the criteria that the test is only indicated in adults aged more than 16, and that a 
peak must exceed 5 mm or more in height to be significant, the results of the test may be 
summarised as follows (Table 13-2). 
Plasma scan 
DNA status Positive Negative 
DNA-negative 1 28 
DNA-positive 30 2 
Table 13-2. Results returned by fluoroscanning in a sample of patients in whom 
mutation status is known: restricted to adults and a positive scan defined as a peak 
height exceeding 4 mm. 
The diagnostic utility of this test in the identification of VP in adults may be calculated as 
follows (Table 13-3), and is contrasted with the results ofTLC assessment in the same group 
of patients: strict criteria for the diagnosis of VP (unequivocal VP) had been applied. Similar 
results are obtained where the biochemical diagnosis is based on an elevated stool 
coproporphyrin and C5 as described in Chapter 10. 
Scan TLC 
Sensitivity 93.8% 66.7% 
Specificity 96.6% 100.0% 
PPV 96.8% 100.0% 
NPV 93.3% 70.4% 
False Positive Rate 3.4% 0.0% 
False Negative Rate 6.3% 33.3% 
Prevalence 52.5% 55.8% 
Overall Accuracy 95.1% 81.4% 
Table 13-3. Utility of plasma fluorescence scanning in comparison with 
chromatography as a diagnostic test for VP. 
The test is therefore highly sensitive and specific, with excellent predictive value in this 
population. It is considerably more sensitive than TLC diagnosis which, though specific, is of 
poor sensitivity. 
Correlation with biochemistry 
A quantitative measure was applied to the height of the peak by measuring its displacement in 
mm at the standard settings of the fluorescence detector. Though these values are arbitrary, 
they will correlate with intensity of the plasma fluorescence. Some features of the peak at 625 












Mutation positive Mutation negative 
N 32 33 
Mean 95.0 1.2 
Minimum o o 
Maximum 467 23 
SD 4.5 
Table 13-4. Height (rum) of the peak at 625 run. 
Correlation with individual porphyrin concentrations in urine, stool andplasma. 
The height of the peak at 625 run correlates positively with stool pseudo-C5 (r=0.68), stool 
C5 (r=0.76), stool coproporphyrin (r=0.87), stool protoporphyrin (r=0.82), plasma PU 
(r=0.96) and plasma protoporphyrin (r=0.6); these correlations are significant at the 5% level. 
Multiple regression analysis indicates that the height of the peak correlates most strongly with 
the stool coproporphyrin. The relationship between the height of the fluorescence peak and 
the stool C5, coproporphyrin and protoporphyrin concentration is shown graphically in 
Figures l3-2, l3-3 and l3-4 . 
COITelalion: r =0.076 
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Figure 13-3. Correlation between height of peak at 625 nm and stool 
coproporphyrin. 













Figure 13-4. Correlation between height of peak at 625 nm and stool 
protoporphyrin. 
Sensitivity of plasma scanning in comparison with TLC 
The results ofplasma fluoroscanning were then compared with the chromatographic diagnosis 
originally assigned to the specimens; these had been assigned without reference to plasma 
fluoroscanning results. Not all of these have had their DNA status checked. Of those with a 
negative peak (Table 13-5), 13 could not be assigned owing to the inadequacy of the 
specimens received (e.g. insufficient stool received), and 12 were assigned to categories of 
uncertain diagnostic significance: probably nonnal or VPL: only one of these 8 samples was 
positive by fluoroscanning. Since we have detennined a false negative rate of approximately 
6% (Table 13-3), no more than 1 of these 12 specimens is likely to represent VP. Using 
plasma fluoroscanning therefore, these samples could with a high degree of confidence be 
reported as non-VP. Conversely, 9 of 116 samples which were nonnal biochemically had a 
positive scan result. In view of the false-positive rate of 3.4% shown for plasma 
fluoroscanning (Table 13-3), it is likely that at least 8 of these samples are indeed from 
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patients with VP. Thus plasma fluoroscanning would detect a further 8-9 subjects with VP 
over and above the 32 with biochemical evidence ofVP. 
Chromatographic diagnosis Peak at 625 nm 
absent 
Peak 625 nm 
present 
Normal 107 9 
Probably normal 1 0 
Inadequate specimen 13 0 
VP 1 32 
VPL 11 1 
Unclassified abnormal 0 1 
Table 13-5. Assigned biochemical diagnoses in adult subjects tested by plasma 
fluoroscanning. 
13.5 CONCLUSIONS IN BRIEF 
Plasma fluoroscanning is a sensitive test for the detection of VP. In this study, it was 100% 
sensitive for patients with biochemically-expressed VP and over 90% sensitive for all subjects 
carrying the R59W and 537delAT mutations: the sensitivity of TLC by contrast is 
approximately 67%. (We have however subsequently identified 2 patients, not included in this 
study, in whom biochemically-expressed VP was associated with a negative plasma scan: one 
subject carrying the Y348C mutation, the other the R59W mutation.) Plasma scanning 
appears to be a most useful test as a first-line investigation in the recognition of VP and will 
be associated with fewer erroneously classified or equivocal cases than stool porphyrin 
quantitation. It is also suited to screening studies in the family of affected patients, though 
occasional cases will be missed; it is of no value in children. The height of the fluorescence 
peak correlates well with the stool porphyrin concentration, and most strongly with the stool 
coproporphyrin concentration. These results are discussed further in Chapter 14, and 
additional experience with plasma fluoroscanning in a single kindred with the R59W mutation 













DISCUSSION: THE BIOCHEMICAL FEATURES OF 
VARIEGATE PORPHYRIA 
This sequence of studies illustrates the relationship between the presence of an inherited 
mutation in PPO and biochemical expression of VP. We have shown that the biochemical 
criteria for a diagnosis of VP are imprecise: tliough many subjects have profiles which appear 
unequivocally nonnal or unequivocally diagnostic of VP, there remains a group with minor 
changes in porphyrin concentrations-particularly elevated protoporphyrin-whose 
significance was unknown. Furthennore we have shown that three experienced interpreters 
may place different weights on abnonnalities of porphyrin excretion. We have attempted to 
define more predictive biochemical criteria for diagnosis of VP, by analysing urine and stool 
porphyrin data in the light of a knowledge of the DNA status of the subject. Finally we have 
assessed two further diagnostic methods: screening analyses, which are shown to be at best 
moderately predictive, and plasma fluorescence scanning, which appears to be an important 
addition to the diagnostic armamentarium. These individual studies are now discussed. 
14.1 VARIABILITY IN DIAGNOSIS 
The initial study (Chapter 8), in which the predictions of three experienced interpreters were 
compared, highlights the diagnostic problems inherent in the biochemical diagnosis of VP. 
The variability shown in diagnosis does not in any way invalidate the diagnostic work of our 
laboratory over many years. Firstly, the samples we studied constitute a small subset of all the 
profiles produced by our laboratory and were deliberately selected to include a range of 
diagnoses, amongst which the equivocal group are over-represented: between them, the two 
equivocal categories constitute just 5% of the positive diagnoses on our database. Secondly, 
the data were presented to the interpreters without any accompanying clinical data whereas a 
knowledge of the clinical circumstances is often helpful in assessing the prior probability of a 
positive result. Thus an equivocal result in a young person with a strong family history of VP . 
is very much more likely to represent a true positive result than a similar result in an older 
person with no family history and atypical symptoms. Thirdly, when an equivocal diagnosis is 
made, the patient is always advised to submit further specimens which may then help to 
confinn or reject a diagnosis ofVP. 
Our analysis of the diagnoses assigned to a specimen set of porphyrin results by three 
experienced interpreters suggested a significant degree of individual variation. One interpreter 
predicted the presence of VP more readily than the other two on screening tests, and a 
Kendall's coefficient of concordance of 0.36 suggests that agreement on individual results 
may be poor. Similarly, the Kendall's coefficient of concordance of 0.13 for the results of 
TLC diagnosis Indicates poor overall agreement among interpreters. Interestingly, as shown 
in Table 8-3, the agreement between pairs of interpreters is close while the overall agreement 
is poor; suggesting that whereas two interpreters may agree, agreement between all three is 
less frequent. Thus complete agreement on a diagnosis of VP was only seen in 69% of cases. 
In 18%, at least one interpreter suggested a diagnosis of low-probability VP or even 
interpreted the profile as nonnal. When the original records were reviewed, it appeared that 
the greatest discrepancy occurred as a result of one interpreter having placed more emphasis 











disagreement was the weight placed on elevations of C5 or pseudo-C5 in the absence of other 
markers ofVP (Appendix 8). . . ., fi th 
These results suggest that the three interpreters are not usmg .umfo~ cntenavao: i: 
diagnosis of VP The two intermediate categories of VPH and VPL m partlcular are . g 
e 
their definitions: No explicit biochemical criteria for ~e diagnosis of VP, nor for asslgnment 
to the equivocal categories outlined in Chapter 7 eXlst, largely because there could be no 
certainty about diagnosis in the absence of absolute proof of the pre~ence or absence of VP. 
Until recently, such proof could only be determined on the basls of lymphoblast PPO 
activities. The number of samples in which PPO activity would have to be assayed .to allow 
for correlations between biochemical findings and PPO status is too large to be feaslble. The 
literature offers no help in this regard. The biochemical criteria put forward by Day (1978), 
Eales et al (1980) and others serve usefully to define that group of patients ,:ith unequivocal 
biochemically-expressed VP but offer little assistance with t~e interpretation Of. the ~ore 
difficult borderline TLC profile. They may be regarded as cancatures: when dealmg wlth a 
sample set of several thousand cases, exceptions are to be expected. Hence the biochemical 
criteria for a diagnosis of VP have always been somewhat subjective, relying largely on 
abnormalities of stool protoporphyrin in particular, as well as on ab ormalities in stool 
coproporphyrin, stool pseudo-C5, urinary porphyrins and plasma PU. 




The subsequent study (Chapter 9) defined the porphyrin excretion profiles observed in our 
subjects and attempted retrospectively to determine which patterns most reliably predicted the 
diagnoses which had been assigned to those subjects in the course of our routine laboratory 
work. Figures 9-1 to 9-3 show that there is a continuous range of stool coproporphyrin and 
protoporphyrin values, with no obvious distinction between patients with VP and those who 
are normal. This led us to introduce the categories of low-probability and high-probability VP 
(VPL and VPH) to accommodate specimens yielding intermediate values. Though stool 
porphyrins are on average highe  in those with a diagnosis of VPH, there is significant 
overlap with both the VPL and the unequivocal VP categories, as well as some overlap with 
the normal category. These results suggest that it will be difficult to distinguish these 
categories on absolute values of porphyrin alone; if they are to be resolved, it may be on the 
basis of the pattern of accumulation of porphyrins as suggested by Moore and Disler (1985). 
Statistical analysis 
To determine which porphyrins contribute most to our diagnostic categorisation, we 
undertook a discriminant analysis, a form of multifactorial analysis which, in addition to 
determining which variables contribute most strongly to an observed outcome, has the ability 
to predict membership of a diagnostic class on the basis of those variables. Discriminant 
analysis suggests that normality is relatively easy to diagnose, but that mathematical models 
have difficulty in predicting VP as a diagnosis and largely fail with VPH and VPL. 
Interestingly, discriminant analysis became significantly more predictive when variables were 
categorised into present/absent with an element of semi-quantitative scoring. This supports 
the contention that it is not so much the absolute values ofporphyrins, but rather the pattern of 
their accumulation, which is of greatest diagnostic significance. In differentiating all forms of 
porphyria, the stool isocoproporphyrin and urine PBG (Table 9-5) appear most 
discriminatory. This will be due to their utility in recognising PCT and AIP respectively. (Had 











would presumably have been less useful.) The nibst important finding however, one which 
recurs repeatedly is the diagnostic utility of the stool coproporphyrin as a reliable predictor of 
VP. 
The equivocal groups, VPH and VPL, greatly complicate the biochemical diagnosis of 
porphyria. If these categories are omitted, discriminant analysis produces a sensitivity 
exceeding 90% for all forms of porphyria. We then investigated the range of "VP like 
profiles" obtained in our patients, by contrasting adjacent categories: Table 9-6 reaffirms the 
difficulty in reliably separating these categories when the categories VP and VPH, VPH and 
VPL, and VPL and NAD are contrasted. This clearly has implications for the biochemical 
diagnosis of porphyria both at the upper end (likely to be VP) and at the lower end (likely to 
be normal) of the spectrum. Breakdown of the analysis (Table 9-7) indicates that the major 
discriminators are the stool coproporphyrin and stool protoporphyrin. Stool C5 and pseudo­
C5 are of poor discriminatory ability, at least in discriminant analysis. In comparing 
contrasting pairs of diagnoses however (Table 9-8) an interesting pattern emerges. It would 
appear that the distinction of VP from the VPH is largely on the basis of stool 
coproporphyrin, and this distinction is fairly sensitive. The distinction of VPH from VPL is 
however less sensitive: it appears to pick out the presence of urinary porphyrins and stool 
pseudo-C5 in addition to the stool coproporphyrin and protoporphyrin. The major distinction 
between normality and VPL is on the basis of the stool protop rphyrin, suggesting that the 
VPL category largely contains those results in which the only abnormality is an elevation of 
stool protoporphyrin. 
Classification tree analysis has advantages over discriminant analysis. Firstly, it is 
intrinsically more suited to categorical predictors than discriminant analysis; and the 
importance of categorization has been shown above. Secondly, it lends itself to the production 
of algorithms which, unlike discriminant analysis, may be tested against common sense, and 
may also be used for the development of diagnostically useful clinical algorithms. 
Classification trees function well with the original quantitative porphyrin data since in effect 
they categorise the data themselves by splitting sets of samples into groups which fall above 
or below critical values. The classification tree shown in Figure 9-4 is highly predictive, with 
an overall accuracy of 99.2%, easy to apply and lends itself to an automated diagnostic 
process. The logical path may be traced as follows: 
Step 1 
Stool pseudo-C5, (cut-off 7.5 nmol/g dry weight). Most cases ofVP (95%) are trapped at this 
point. 
Step 2 
Urine uroporphyrin (cut-off 40.5 nmol/lO mmol creatinine). This traps all cases of PCT 
(I 00%) along with cases of AIP, which are easily distinguished by a raised urine PBG. 
Step 3 
Stool coproporphyrin (cut-off 35.4 nmol/g dry weight). This branch gives rise to two 
hierarchies, leading to the identification of the two major classes: NAD and VPH on the one 
hand; the remaining VP and VPH on the other. 
Subtree 1 
Step i. 
Stool protoporphyrin (cut-off 297.1 5 nmol/g dry weight) 
This traps 90% ofnormal samples. 











Stool protoporphyrin, stool coproporphyrin and stool C5 serve to split off 2 cas~s of VPH 
from VPL and a further 2 cases ofNAD as well as 5 cases ofV~L; however the splIt between 
VPL and NAD appears counter-intuitive, with VPL havmg lower .value~ of .sto?l 
coproporphyrin and stool C5 than the normals; these are likely to represent mconslsten~les m 
classification. Indeed, by tracing this sequence of key values through the d~tabase, It was 
possible to identify the anomalous results; they tum out to be that group WIth moder~tely 
raised stool protoporphyrin but no other abnormalities, which appear to have been classified 
as NAD or VPL arbitrarily. 
Subtree 2. 
Numbers are small on this branch, which uses rather subtle distinctions to trap the remaining 
2 cases of VP and 5 cases of VPH, as well as 3 cases of NAD and 3 of VPL. The algorithm 
employs two parallel systems; the use of an elevated stool pseudo-C5, and evid~nce of a 
modest increase in urine porphyrin activity, with some use of the stool coproporphynn. 
The rather complicated classification tree for all porphyrias shown in Figure 9-4 is 
diagnostically highly accurate (Table 9-9). The important information is encapsulated in the 
first few nodes. Stool pseudo-C5 detects the majority of patients with VP (114 of 120), 
suggesting an importance for this porphyrin which was not revealed by discriminant analysis. 
PCT is detected along with AlP on the basis of a high urine uroporphyrin; PCT and AIP are 
then distinguished on the basis ofthe PBG. 
Figure 9-5 shows an interesting variation on this model. A high stool C7 is used to detect 
some cases of VP and most cases of PCT; the stool pseudo-C5 being used to make this 
distinction. Thereafter, most cases of VP are trapped by a high stool pseudo-C5. In the next 
step, stool protoporphyrin divides the remainder into two sub-trees. An important observation 
is that the VP cases are evenly divided by the stool protoporphyrin value of 370.9 nmol/g dry 
weight: stool protoporphyrin is by itself a poor predictor of VP. In both sub-trees, stool 
coproporphyrin is used to distinguish VP from the other categories of NAD, VPL and of 
VPH. This is supported by the classification tree shown in Figure 9-6 which is restricted to 
samples from the VP spectrum: NAD, VPL, VPH and VP. The stool protoporphyrin 
discriminates poorly between VP and the other grades, and as many cases of VP have stool 
protoporphyrin values below the cut-off as above it. It is the stool coproporphyrin which 
separates normality from VP. The stool protoporphyrin alone effectively serves only to 
distinguish normality from VPL. 
Incomplete data 
Whereas discriminant analysis suggested slight reductions in accuracy when plasma 
porphyrin and urine precursor concentrations were omitted, classification tree analysis 
identifies them as unimportant, and classification proceeds on the basis of urine and stool 
values alone. In the case of the diagnosis of VP in particular, even urine values are rejected 
and classification is on the basis of stool results only. This suggests that in practice our 
diagnosis need be based almost entirely on stool data, and urine and plasma data, contrary to 
our teaching, are for practical purposes unnecessary for the diagnosis of VP. Clearly however, 
they retain importance for the diagnosis of AIP and PCT, and in assessing the biochemical 
activity of VP. In effect, classification tree analysis tells us that, while diagnostic urine and 
plasma profiles may be seen in overt cases ofVP (as described in the classic descriptions by 
Day and Eales), diagnostically they add Httle or no value to a careful interpretation of the 
















The purposes of porphyria diagnosis are essentially two-fold. Firstly, one needs to diagnose 
porphyria in people presenting with suggestive symptoms and signs. Secondly, it is important 
to identify the asymptomatic relatives ofpeople with a positive diagnosis ofporphyria so that 
they may be adequately counselled and protected. The final arbiter of a diagnosis ofVP is the 
presence or absence of a causal mutation in the PPO gene, and this provides the "gold 
standard" with which other diagnostic tests should be compared. Following our identification 
of the R59W mutation and the other mutations which have followed, we are for the first time 
in a position to validate our biochemical tests against a real and not an assumed standard, and 
thus potentially to improve their accuracy. 
Our results confirm the observation that the biochemical expression of VP is a post­
pubertal phenomenon. No subject aged less than 16 years in this study showed evidence of 
VP biochemically. Biochemical screening for VP in prepubertal children is therefore useless, 
and alternative methods must be employed. Hitherto the only reasonably reliable test was the 
measurement of PPO activity, held by most to be an unsuitable test for the routine laboratory 
(Long et al 1993, Hift et al 1997) though it has been used to detect the inheritance ofVP in 
experimental studies (Meissner et al 1986, Da Silva et al 1995). 
The porphyrin reference values in use in the UCT laboratory were established at least ten 
years ago, at a time when, for practical purposes, VP or its absence could only be diagnosed 
on the basis of biochemical testing. By DNA screening, we are now able to determine the 
presence or. absence of VP with near-l00% accuracy: the only reason for less than perfect 
sensitivity is the ever-present possibility of novel mutations in the population referred for 
testing. The ability to prove normality allowed us to determine a new normal normal range of 
porphyrin concentrations. The results suggest that the upper limit of the normal range in use 
in our laboratory is valid with two exceptions with an important bearing on the diagnosis of 
VP. It is clear that the stool protoporphyrin concentration of 200 nmollg dry weight is 
inaccurate. This ULN was originally set approximately 15 years ago by Dr RS Day at a 
somewhat low level in order to increase the sensitivity of TLC for the diagnosis of VP (PN 
Meissner, personal communication). A new upper limit of normal (ULN) set at Mean +2SD 
would suggest a limit of 545.3 nmollg dry weight. Secondly, the stool coproporphyrin, 
currently set at 50 nmollg dry weight, should be reduced to 41.2 nmollg dry weight to 
encompass Mean+2SD. Raising the cut-off value for stool protoporphyrin will immediately 
reduce the number of suspected cases ofVP, particularly that group labelled VPL, a diagnosis 
which appears largely to be influenced by elevations in the stool protoporphyrin in the 
absence of other diagnostic markers of VP. Conversely, lowering the stool coproporphyrin 
will to a lesser extent increase the number ofabnormal results. 
When the upper limit of normal for the most significant stool porphyrins was set at 
mean+2SD, 33% of DNA-positive adults fell within the normal range. We may therefore 
conclude that at least 33% of all adults subjects carrying a PPO mutation known to be 
associated with severe loss of functional activity will demonstrate normal stool porphyrin 
excretion patterns. Indeed the figure may be higher as a result of some referral bias since 
those patients who are biochemically or clinically expressed are more likely to present 
themselves for DNA testing than their asymptomatic relatives. Since most of the subjects 
entered into these calculations are however members of two large families in whom all 
members, irrespective of symptoms, were screened, this effect is likely to be small and the 
figure of 30% is probably valid. Furthermore, this is in keeping with our findings in the large 
R59W kindred to be described in Chapter 17 where only 52% of adult gene carriers showed 











Therefore, in any family screening project, all children and app~oxima~elY 30% o~saf~~~:: 
adults will escape detection if screening is c?nfined t~ bIOchemIcal analys ested 
Interestingly, these figures are similar to those predIcted by DIsler et al (1982) who sugg 
that up to 40% of gene carriers might have silent VP. . 
Highly significant statistical differences between normal an~ VP subjects :vere found for 
stool coproporphyrin, protoporphyrin, C5 and pseudo-C5, for unne uroporphynn, C5, C7, C6, 
ALA and PBG, and for plasma PU. Unfortunately, as shown in Table 10-2, there are l~ge 
areas of overlap between normal and VP. We determined that .33% of our adult subjects 
carrying a PPO mutation demonstrated faecal concentratIons of pseudo-C5, C5, 
coproporphyrin and protoporphyrin which fell withi~ the n~w normal range. In~e~d, 20 of 22 
subjects had originally been diagnosed as normal bIOchemIcally, and the ~emallllllg two had 
been diagnosed as equivocal VP on the basis ofa raised stool protoporphynn only. 
Using DNA testing as the diagnostic standard for VP, we were now able to assess the 
significance of the low probability and high probability (VPL and VPH) diagnoses assigned 
in our database. In this study, the probabilities of carrying a VP mutation were as follows: for 
a normal VP result, 0.13; for VPL, 0.22; for VPH, 0.33; for definite VP, 0.98. Examined 
retrospectively, several trends became apparent. A diagnosis of definite VP was favoured in 
subjects with higher stool coproporphyrin and stool C5 values whereas the stool pseudo-C5, 
urine coproporphyrin and urine ALA were of lesser value and the stool protoporphyrin non­
predictive. Classification tree analysis (Figure 10-3) suggests, in retrospect, that the stool 
coproporphyrin served as the most predictive porphyrin. 
Since 30% of all DNA-positive subjects appeared to be truly biochemically silent, there is 
little purpose in attempting to define biochemical values to detect 100% ofthese subjects. We 
therefore divided all the subjects with DNA-positive VP into two classes: biochemically­
expressed and biochemically silent. The distinction itself raises the problem as to how to 
distinguish the two groups since, as shown in Figures 10-1, 10-2 and 10-3, all the important 
stool porphyrins appear to be widely distributed, rather than falling into distinct normal and 
abnormal classes. There is therefore a danger of establishing a circular argument: first 
establish the criteria which define a diagnosis of biochemically-expressed VP, then prove 
retrospectively that those criteria meet the diagnosis. It would appear logical that 
biochemically expressed VP will at the very least be associated with elevation of at least one 
of the terminal porphyrins excreted in stool: elevations of these porphyrins are readily 
recognised in unequivocal VP and have emerged repeatedly as the most relevant porphyrins in 
the discriminant and classification tree analyses. As an initial step in definition, we therefore 
selected all DNA-positive subjects showing an elevation of anyone of the following stool 
porphyrins above the new ULN defined as mean+2SD: C5, pseudo-C5, coproporphyrin and 
protoporphyrin. We made the assumption that biochemically-expressed VP would constitute a 
subset of this group of subjects, and then undertook discriminant and classification tree 
analyses to determine the best criteria for separating those with DNA-proven VP from those 
who are DNA-negative. Table 10-7 shows that the larger group, those with an elevation in any 
one of these porphyrins, overlaps the normal group to an unacceptable extent, thus these loose 
criteria are not themselves sufficiently predictive of VP for an elevation in any of these 
porphyrins to define biochemically-expressed VP. 
Tables 10-8 and 10-9 shown that discriminant analysis is still rather poor at detecting this 
group of expressed VP; though the use of categorical rather than ordered data improves the 
sensitivity. Stool coproporphyrin and stool C5 emerge as the most important predictors (Table 
10-10) whereas stool protoporphyrin has very little discriminatory power. Classification tree 
analysis returns a diagnostically useful result (Figure 10-3, Table 10-11). The stool 












positive VP within this group. The stool pseudo-C5 atidstool protoporphyrin are shown to be 
less discriminatory. 
This would therefore suggest that the most appropriate biochemical predictors ofVP are: 
• a stool coproporphyrin exceeding 48.92 nmoVg dry weight or 
• a stool pentacarboxylic porphyrin exceeding 2.72 nmoVg dry weight. 
Note however that these criteria are, standing alone, suitable only for the differentiation of 
normal results from VP. Many samples from patients with PCT will meet these criteria, but 
these will in most cases be easily distinguished by including critical values of urinary 
porphyrins and stool isocoproporphyrin. As with all diagnostic algorithms, exceptional cases 
will be encountered which give false results: it may be expected that that small group of 
subjects with active phases of VP, who show the increased excretion of urinary porphyrins, 
along with patients with dual VP, will have to be separated from those with PCT. 
These values are based on a relatively small learning sample of 181 cases. As experience 
grows, the learning sample will increase and classification tree analysis will further refine the 
algorithm. It is unlikely however that the fmal values will diverge much from those given 
here. An important conclusion is that the true "equivocal VP" result is not that with an 
isolated high protoporphyrin, but rather that whose stool coproporphyrin or C5 values straddle 
these critical values. 
This algorithm was then retrospectively applied to the entire porphyria database, excluding 
those samples with diagnoses other than NAD and the grades of VP, with the following 
results shown in Table 14-1. There is a slight increase in the number of cases diagnosed as 
VP, and 5% of cases originally diagnosed as VP would now be regarded as normal. An 
important advance is that the VPL and VPH groups disappear completely: 17.6% of the 
former and 43.1 % of the latter would satisfy the criteria for VP: these values agree well with 
the values obtained in the small sample for whom DNA values are available. 
Original diagnosis As predicted by the new values 
VP Normal 
NAD 2511 68 (2.7%) 2443 (97.3%) 
VPL 188 33 (17.6%) 155 (82.4%) 
VPH 109 47 (43.1%) 62(56.9%) 
VP 379 360(95.0%) 19 (5%) 
Table 14-1. Effect of applying the new criteria retrospectively to the porphyrin 
values on the porphyria laboratory database. 
14.4 PORPHYRIN PROFILES WITHIN BILE, SMALL BOWEL AND 
COLON 
An important finding emerging from this study is the dethroning of the stool protoporphyrin 
as the most important predictor of VP: it appears that coproporphyrin is most suited to this, 
with pentacarboxylic porphyrin assisting this role. In large part this would appear due to the 
significant and variable switch in porphyrin profiles from coproporphyrin predominance to 
protoporphyrin predominance between bile and stool, which introduces an element of 
uncertainty into the assessment of the significance of an elevated stool protoporphyrin. The 
results of the study described in Chapter 11 clearly show that the belief that faecal porphyrins 











be sought to account for the shift in porphyrin predominance fron:: copro~orph~n in bile to 
protoporphyrin in caecum and stool. Two mechanisms seem possIble. It IS possIble that the 
earlier, more hydrophilic porphyrins are preferentially reabsorbed from th~ smal~ bowel, ~r 
secondly, that there is an interconversion of porphyrins from coproporphynn t? dlcarbox>-:hc 
porphyrins within the bowel itself. That intestinal cells are capable o~ reabs~rbmg porph~ns 
has been well shown by the convincing evidence for an enterohepatlc cychng of porphynns 
put forward by several investigators (Ibrahim and Watson 1968, Lemberg and Legge 1949, 
Stathers 1966, Pimstone et al 1982, Pimstone et al 1987). Pimstone et al (1987) showed a 
significant reabsorption of porphyrins over the first few centimetres of the duodenum 
downstream of the hepatopancreatic ampulla, but did not suggest that any particular porphyrin 
was absorbed in preference to another. Furthermore, since jejunal and biliary profiles are 
essentially similar, such selective reabsorption would have to take place in the ileum. This 
must remain conjectural: no study has ever examined the ileal absorption ofporphyrins. 
There is however good evidence that the intestinal microflora actively alter porphyrin 
profiles as discussed in Chapter 6 (England et al 1962, Elder et al 1980, Beukeveld et al 
1987). The abrupt change in porphyrin profile between small bowel and large bowel would be 
entirely consistent with a major role by intestinal bacteria, since the small bowel is sterile 
whereas caecum and and sigmoid are not. It would seem unlikely that exogenous sources of 
dicarboxylic porphyrin, whether from diet or from intestinal bleeding, could contribute in any 
meaningful fashion to this major difference in profiles. Indeed, the essential similarity of 
biliary and jejunal porphyrin profiles argues against the significant addition of exogenous 
dicarboxylic porphyrin to bile as it enters the duodenum. 
Were accurate quantitation of the total amounts of porphyrin present over the length of the 
bowel possible, it would be easier to delineate the precise nature of this change in bowel 
porphyrins more definitively. Unfortunately, as the total volume of intestinal content passing 
through the bowel changes so dramatically as a result ofwater reabsorption, it is impossible to 
extrapolate from the porphyrin concentrations determined here to total amounts of porphyrin 
present, and therefore impossible to determine whether the net aggregate porphyrin present 
increases or decreases with transit through the bowel. 
Logan et al (1991) have shown, as we have, that the predominant porphyrin in bile is 
coproporphyrin and in stool is protoporphyrin. They have also demonstrated that the 
difference in porphyrin content noted between normal subjects and those with VP is far higher 
in bile than in stool. To believe, as many do, that the raised stool protoporphyrin of VP is a 
direct consequence of the reduction in conversion of protoporphyrinogen to protoporphyrin in 
the liver as a result of diminished PPO activity may therefore be false. Clearly factors 
operating within the bowel, most probably bacterial-mediated breakdown of haem and 
interconversion of porphyrins, is substantially modifYing the porphyrin profile present in bile 
such that it is almost unrecognisable in stool. The limited literature available on this process 
has all suggested that it is predominantly the dicarboxylic porphyrins which result from this 
process. It is probably the extreme variability in stool dicarboxylic porphyrins, coupled with 
the TLC reporting system which labels all dicarboxylic porphyrins generically as 
protoporphyrin, which leads to the inaccuracy of protoporphyrin in predicting the presence of 
VP. 
14.5 THE DIAGNOSTIC UTILITY OF SIMPLE SCREENING TESTS 
Though the median values for urine PBG, urine porphyrin and stool porphyrin concentrations 
correlate well with the results of simple screening tests, several difficulties are evident. 
Firstly, the relationship is logarithmic rather than directly proportional; thus strongly positive 











intennediate values. Secondly, the range of porphyrin concentrations associated with any 
given degree of positivity on screening tests is wide. This results in a poor compromise 
between sensitivity and specificity. A strongly positive stool screen (+++) is highly specific 
for the diagnosis of VP (Table 12-3) but this is at the expense of sensitivity, and were the 
threshold for a positive result set that this level, nearly 50% of patients with unequivocal VP 
would be missed. Clearly shown is the reciprocal decline in specificity which results if lesser 
grades of positivity are set as the threshold for diagnosis in order to improve sensitivity: thus 
setting the threshold at + would have a positive predictive value ofonly 28.5%. 
Even the higher grades of stool porphyrin positivity are not entirely specific for VP, and a 
significant proportion have other diagnoses (Table 14-2). Approximately half of the non-VP 
cases at the higher levels in fact have PCT; most of these will however be recognisable by a 
strongly positive urine screen, the utility of which is shown in the discriminant and 
classification tree analyses. In practical tenns, a high grade stool porphyrin screening result is 
highly suggestive of VP; however 3% with a grade 4 screening result will in fact be nonnal 
and 11% will have other diagnoses, of which about half will be PCT. For patients whose 
stools are scored as grade 3, 28% will be nonnal, 15% will have a diagnosis other than VP 
and a further 13% will have indetenninate values: thus 58% of such patients will have neither 
definite nor even probable VP. These data show the limitations of simple screening tests for 
diagnosis even in a reference laboratory with extensive experience and expertise in their use. 
Stool screening alone is clearly inadequate for the detection ofVP; sensitivity is low and even 
a strongly positive (+++) result has a positive predictive value of only 83%. 
These calculated values are dependent on the population from which the samples are 
drawn. Therefore, in extrapolating the results to other laboratories, caution must be exercised. 
The results are heavily influenced by the high prevalence of VP in our database (10% for 
definite VP; 13% for probable VP). This will not hold true for laboratories attempting 
porphyria diagnosis for any population other than a South African popUlation. However, the 
results should be generalisable to other S uth African laboratories, with the proviso that a 
small element of bias may have crept into our database sample owing to a proportion of 
"difficult" diagnostic problems having been submitted to the VCT porphyria laboratory as the 
referral centre offering definitive diagnoses. 
Screening result 0 1 2 3 4 
Definite VP 10 7 56 101 209 
Probable VP 7 13 39 38 15 
Possible VP 20 38 82 42 7 
Normal 1767 573 428 89 7 
peT 19 24 44 29 13 
Other 17 9 23 18 15 
Total 1840 664 672 317 266 
Table 14-2. Predictive value of stool screening results for VP as assessed against 
eventual TLC-based diagnosis. 
Discriminant function analysis 
Several of our patients with AlP are sampled repeatedly as a result of frequent presentations 
with acute symptoms. This will have the effect of a weighting the AlP results in favour of the 
more severely expressed cases. In practice therefore, the diagnostic accuracy of this 











the diagnosis of the more severe form. With PCT, some of these patients have be~n sam~led 
serially during treatment during which time they have sho~n a trend to~ar?s bIOchemIcal 
improvement. The effect of this redundancy will be to o~er~stImate the predIctive value of the 
discriminant analysis for AIP and to reduce the predIctive value. for PCT. H~wev:r, the 
problem of redundancy is not a significant pr~blem with VP, . smce few patlents m our 
database are sampled repeatedly once the diagnosIs has been establIshed. ., . 
The only factor which is strongly weighted is the PBG score, because of Its ~tIhty f?r 
diagnosis of AIP. Interestingly, the stool screening result is only moderately weIghted m 
favour ofVP indicating the lack of precision of this variable in diagnosing VP. Use of these 
classification functions, in which all subjectivity is removed (other than in the determination 
of the original screening grades) provides an upper limit for the diagnostic accuracy of these 
screening tests. In particular it yields the highest accuracy in that it is derived a posteriori ­
which must yield more accurate results than a priori arguments. This suggests that the use of 
simple screening tests for the diagnosis is of porphyria in South Africa is no more accurate 
than a maximum value of 49.2% for VP, 72.8% 7% for AlP and 67% for PCT. Even then, 
these figures will represent an over-estimate, since they are compared only with patients with 
biochemically expressed porphyria and not with all patients, both silent and expressed. 
Classification tree analysis 
The diagnostic algorithm returned by classification tree analysis in Figure 12-6 appears 
sensible, and approximates the process of diagnosis an experienced interpreter would 
intuitively make. The initial step is to separate out those samples screening ++ or +++; these 
are then successively assigned to VP and Normal depending on the magnitude of the urine 
and stool screenings. Those with low stool screenings, on the other hand, are successively 
subclassified into peT and Normal. Note that this tree rejects the PBG screening result as 
being unnecessary to the classification. The predictive accuracy is shown in Table 12-5. It is 
seen that use of the classification tree approach is less sensitive for the detection of VP than 
decision analysis; approximately 60% versus 74%, but has a higher PPV. Negative screening 
tests are shown to have imperfect negative predictive value; 7% of all samples returned as 
negative will in fact be diagnosed as VP or PCT by TLC. 
Use of stool screening results alone results in a fall in the detection rate of VP from 60% to 
45% and a drop in PCT detection from 41 % to 0%. Use of urine screening results alone 
results in a drop in detection ofVP to just 15%; a further 13% will be recognised as abnormal 
but misclassified as PCT. As shown in Table 12-4, the best positive predictive value reached 
by a stool screening test is 77.4%: this is if only a very strongly (+++) result is regarded as 
positive. If lesser grades of reaction are regarded as positive, the PPV drops to 28.5%. A 
negative screening results however has a negative predictive value of 99.3%, though a false-
negative rate of 4.4% remains. ~ 
Despite the poor predictive accuracy of screening tests as contained in our database, 
screening tests in the hands of our three experienced interpreters proved surprisingly 
predictive of the eventual diagnosis (Table 12-6). For a screening diagnosis of VP, the 
agreement was 85-100%; for normality, it was 85-89%. It is possible to improve the 
reproducibility of screening tests by modifying the methods more precisely. Thus the 
proportions of urine or stool and Dean's solution employed can be standardised and results 
corrected for urine concentration. Colour detection can be improved by automation, by 
replacement with spectroscopy or even by the provision of colour-comparison charts. 
Modifications of the Watson Schwartz reaction, including the use of anion exchange resin to 
separate PBG from interfering substances in urine, with PBG being measured by absorbance 
at 555 nm, will improve sensitivity: it was suggested that this may be useful for the detection 











of clinical biochemists porphyrin working party showed good sensitivity (75-97.5%) for 
urinary porphobilinogen screening, this appears to be over-optimistic. Buttery et al (1990) 
have evaluated the Watson-Schwartz method for PBG detection and found a lower sensitivity 
(42-69%); this declined further to 28-53% in the presence ofcoloured or concentrated urine. It 
has been shown that in practice, screening tests alone for porphyria perform poorly. In an 
assessment of 201 cases referred to a British hospital, routine screening in the referring 
laboratories was shown to be unreliable, with both false negative and false-positive results. 
Only 43% of porphyrics were correctly identified. It was suggested that alternative semi­
quantitative tests for porphyrins employing spectrophotometric scanning of acidified urine or 
faecal extracts would be preferable (Deacon 1988). 
This study has shown that screening of samples by the Watson-Schwartz and Dean's 
methods in the South African popUlation will correctly classify less than 70% of patients with 
biochemically proven VP, and will fail to identify approximately 6% of patients with normal 
screening values as being porphyric. Even where a porphyria is recognised, screening tests are 
poorly discriminatory in separating VP from PCT with a substantial degree of overlap 
between the two diagnoses. Furthermore, neither urine nor stool screenings in isolation have 
worthwhile predictive value. We conclude that there can be no justification for the continued 
practice of some laboratories issuing screening results as the final laboratory result. Without 
exception, every subject in whom the diagnosis of porphyria is entertained requires diagnostic 
testing with higher predictive values than are achievable with screening. 
14.6 PLASMA FLUOROSCANNING 
Several authors have suggested that plasma fluoroscanning is a more sensitive test for the 
detection of VP than porphyrin analysis. In the study by Da Silva et al (1995), 50% of 
biochemically negative VP gene carriers, as identified by lymphocyte PPO activity, were 
positive by plasma fluoroscanning. Long et al (1993) report that that the sensitivity of an 
increased faecal porphyrin concentration as a test for asymptomatic VP is 36 to 38%, whereas 
the sensitivity of plasma fluorescence scanning is 93% (95% confidence interval 78-99%). 
Our fmdings are in accordance with these results. We determined a sensitivity of 93.8% for 
plasma fluoroscanning as compared with a sensitivity for stool porphyrin analysis of66.7%. 
Accepting the false-positive and false negative rates shown in Table 13-3, plasma 
fluoroscanning would prove very useful in refining our diagnostic criteria for VP. As shown 
in Table 13-5, in a sample of 176 subjects, plasma fluoroscanning would detect a further 9 
subjects with VP over and above the 32 positive by TLC, and would exclude 11 of 12 subjects 
with equivocal TLC results as normal. 
The height of the porphyrin peak correlated closely with the concentrations of stool 
porphyrins, suggesting that the intensity of the fluorescence peak is proportional to the 
activity of the porphyria as measured by porphyrin excretion. Interestingly, coproporphyrin 
correlated most strongly with the plasma fluorescence peak. The preliminary work done on 
the nature of the compound responsible for the fluorescence in the plasma (Poh-Fitzpatrick 
1980, Longas and Poh-Fitzpatrick 1981) suggested that the plasma contained a mixture of 
unbound porphyrins as well as a tightly-bound complex, probably of a dicarboxylic 
porphyrin, with albumin. Coproporphyrin was not shown, though Day had suggested that 
coproporphyrin was the major porphyrin present in the plasma of patients with VP, and that 
the PU porphyrin present in plasma and characteristic of VP was most likely a 
coproporphyrin-peptide conjugate (Day et al 1978). We have not yet studied a sufficient 
number of plasma samples chromatographically as well as by plasma fluoroscanning to make 
such correlations. The association between faecal coproporphyrin and plasma fluorescence 











just be that the correlation reflects a non-causal relationship between two powerful markers of 
VP. . . 001 f 
Da Silva et al (1995) view their failure to identify the VP earners status 1~ 5 ./0 0 
biochemically-silent carriers pessimistically. However, if the purpose of the test IS Vl.ewed 
differently, plasma fluoroscanning is a most useful addition to our range of avaIlable 
diagnostic techniques. It is possible to establish a DNA-based diagnostic test for more than 
90% of all families with VP without much difficulty: currently, in our experience reported in 
Chapter 4, it rarely requires more than 4-6 weeks to determine diagnostically useful 
information at the DNA level for a family with a novel mutation. Even before the exact 
mutation is determined, it is often possible to use the abnormal behaviour of the relevant exon 
on SSCP or heteroduplex analysis to identify gene carriers. The primary purpose of plasma 
scanning therefore is not for family screening studies, but rather for the immediate 
identification of VP in patients presenting to the laboratory for the first time. If positive by 
plasma scanning, it is appropriate to proceed to urine and stool porphyrin analysis and 
thereafter to DNA studies. We have shown that plasma fluoroscanning is almost 100% 
sensitive in detecting those patients with VP who will prove positive by chromatographic 
examination of urine and stool: just 2 subjects--one being R59W-positive, the other Y348C 
positive-have shown negative plasma fluoroscanning results in the face of positive stool 
biochemistry. The reason for this perverse result is unknown. Thus, other than in exceptional 
circumstances, faecal porphyrin analysis need not be undertaken in subjects who test negative 
by plasma fluoroscanning. 
14.7 THE PREVALENCE OF VP IN SOUTH AFRICA 
Dean (1963) suggested an overall prevalence of 3 per thousand in the white population of 
South Africa, and a figure of 8000 ± 2000 for the country as a whole. Allowing for the natural 
increase in the popUlation-the white population currently stands at 5 million-the current 
figure would be approximately 15 000. It must be noted however that testing was performed 
by relatively insensitive stool screening, Our own results, reported in Chapter 12, indicate a 
sensitivity for stool screening for chromatographically-proven VP of 50-90% (a mean of 
70%), depending on the intensity of the screening reaction regarded as positive. A 
chromatographic diagnosis of VP in tum has a sensitivity of approximately 70% for DNA­
positive VP (Chapter 10). This suggests that Dean's prevalence should be increased by a 
factor of 1/(0.72), that is approximately doubled. The projected prevalence, assuming that 
Dean's figure was correct, would then be 6 per thousand population and a current total of 

















Sections 1 and 2 of this dissertation described the molecular biology and biochemical features 
of variegate porphyria respectively. In Section 3, the clinical expression of VP is examined. 
The relevant literature is reviewed in Chapter 15. In the following chapter, we report our 
experience with four patients with homozygous VP, and the underlying mutations and clinical 
features are described and correlated. In Chapter 17 we describe a study of a single, large 
family carrying the R59W mutation, and show that approximately 60% of adults are clinically 
silent whereas skin disease is present in 40% and the probability of an acute attack now low. 
In Chapter 18 a personal experience with the management of more than 100 episodes of the 
acute porphyric crisis in Groote Schuur Hospital is reviewed. Unusual presentations and 
complications are discussed, and the outcome of treatment reported. The results presented in 












THE CLINICAL FEATURES OF VARIEGATE PORPHYRIA: 
AN INTRODUCTION AND REVIEW OF THE LITERATURE 
The principal clinical features of variegate porphyria are two-fold: the acute attack and skin 
disease. The following areas of interest are relevant to the original work of this dissertation: 
the proportion of patients carrying the R59W mutation who express VP clinically, a 
description of the acute attack observed in a large cohort of patients in the Groote Schuur 
Hospital, Cape Town, and the clinical and molecular features of the homozygous VP 
syndrome. For this reason the published clinical experience with VP including the prevalence 
of skin disease, and the pathogenesis, clinical features and management of the acute attack are 
described in detail, but the pathogenesis of the skin disease is not discussed. 
This chapter begins with a review of homozygous or compound heterozygous VP (both of 
which are collectively abbreviated here as HVP), which has been mentioned on several 
occasions in Section 1. Both the molecular biology and the clinical features of HVP are 
reviewed, reported and discussed in this section, and our personal experience is reported in 
Chapter 16. 
15.1 HOMOZYGOUS PORPHYRIA 
Introduction 
Two of the porphyrias are described as autosomal recessive conditions. These are Doss 
porphyria (ALA dehydratase deficiency, plumboporphyria) and congenital erythropoietic 
porphyria (CEP). The other porphyrias are inherited as autosomal dominant traits and may 
therefore present clinically in the heterozygous state. All have now additionally been reported 
in the homozygous state. The clinical features of these homozygous subjects tend to fall into 
two groups: firstly, those symptoms characteristic of the heterozygous state, but usually 
presenting earlier in life-usually in early childhood-and often in exaggerated fashion, and 
secondly, unusual features peculiar to the homozygous state and possibly relating to haem 
deficiency during embryonic development, as has been postulated for the skeletal and 
neurological features of homozygous AlP, HCP and VP (Roberts et aI1998). 
Most of these homozygous variants were described before the introduction of molecular 
investigation. The presence of severe symptoms in an infant or child with a biochemical 
profile suggestive of porphyria raised the possibility of the homozygous state, and in some 
cases, corroboration by the demonstration of severely reduced activity of the appropriate 
haem-synthetic enzyme in the subject, perhaps accompanied by evidence of a reduction in 
activity in keeping with the heterozygous state in the parents, was offered. Conclusive proof 
followed years later when heteroallelic inheritance of two mutations-the compound 
heterozygous state--or homoallelic inheritance of a single mutation were shown. 
Occupying an interesting and as yet not fully defined position is EPP. The mode of 
inheritance is known to be complex, and to have features suggestive of both dominant and 
recessive inheritance, usually described as "autosomal dominant with low penetrance". It has 
been suggested that biochemical evidence of disturbed porphyrin synthesis alone is a feature 












The homozygous porphyrias are summarised in Table 15-1 and are described more fully 
below. 
Enzyme Inheritance Heterozygosity Homozygosity ! 
ALA dehydratase AR Nil Doss porphyria 
PBG deaminase AD AIP Homozygous AIP 
UropOlphyrinogen 
cosynthase 
AR Nil CEP 
Uroporphyrinogen 
decarboxylase 








AD VP Homozygous VP (HVP) 
F errochelatase AD/AR? EPP (?) EPP (?) 
EPP with hepatopathy (?) 
Table 15-1. Summary of the mode of inheritance of the porphyrias and of the 
clinical syndromes associated with the heterozygous and the homozygous or 
compound heterozygous state. AD: autosomal dominant, AR: autosomal recessive. 
Homozygous porpbyrias otber tban VP 
ALA dehydratase (ALAD) deficiency 
Also known as plumboporphyria or Doss porphyria, this is a rare autosomal recessive disorder 
of haem synthesis. Five cases have been reported since the first description by Doss et al 
(1979). In each case, both parents have been shown to have substantially reduced ALAD 
deficiency, in keeping with the heterozygous state, but are not clinically affected. The patients 
however exhibit a predominantly neurological syndrome similar to the acute attack, with 
abdominal pain and vomiting progressing to a motor neuropathy and paralysis. Two of the 
reported patients first developed their symptoms at the age of 15 (Doss et al 1979); a third 
patient was noted to have severe symptoms at birth (Thunnell et al 1987). This child 
underwent a liver transplant at the age of 6 for recurrent crises with paralysis and his clinical 
condition has subsequently improved (plewinska et al 1991). A fourth patient presented with 
neuropathy for the first time at the age of 63 (Hassoun et al 1989). The fifth patient is an 
elderly Japanese woman who presented for the first time with a severe acute attack at the age 
of 69 (Muraoka et al 1995). A 20 year follow-up has now been reported on the first two 
patients. The initial acute attacks had been successfully treated by infusion of glucose and 
haem arginate and both patients have remained free of symptoms since (Gross et al 1998). 
The diagnostic features on biochemical analysis include marked elevations of ALA and 
normal or near-normal PBG excretion-the reverse of the pattern seen with AIP. Erythrocyte 
ALAD activity is barely detectable, in keeping with the homozygous state. The molecular 
defects have been reported in three of these patients; all are shown to be compound 













Homoz ous AlP was first described in 1990 (Beukeveld et al 1990).. !his was a 
retrosp:c~ive diagnosis in a Dutch female child W~lO had died in 19~4. ClImc~l featu~es 
included severe neurological abnormalities, includmg menta~ ret~datlOn, .assoclated w.Ith 
porencephaly. Her teeth fluoresced under UV l.ight. She. remamed m a persIstent vegetatIve 
state and required tube-feeding for her entire lIfe and dIed at the. ~ge of ~. Her mother had 
typical AlP; her father was initially thought to be no~al, but s~n~ItIve testmg ~ate~ suggested 
that he too had a subtle deficiency in PBG deammase actIvIty. Re-exammatlOn of .the 
proband's urine indicated features of AlP, though with so~e departures from the typIcal 
pattern, including an abnormal uroporphyrin isomer I:III ratI~ (Be~keveld et al 1990). Her 
parents were ultimately shown to carry two different mu~atIons m exon 10 of th~ PBG 
deaminase gene; each parent was heterozygous for one mutatlOn and presumably the chIld had 
been a compound heterozygote (Picat et al 1990). Both these mutations ha~e been s~own to 
be associated with AlP in heterozygotes (Delfau et al 1990). An unusual patient descnbed by 
Gregor et al (1977), a child who experienced convulsions and bilateral cataracts and 
demonstrated the biochemical features of AlP as well as an increased erythrocyte 
protoporphyrin concentration, is likely to have been an umecognized case of homozygous 
AlP (Llewellyn et alI992). 
Subsequently Llewellyn et al (1992) described a three-year-old girl admitted to hospital 
following febrile convulsions. She was described at the age of 18 months to have ataxia, 
intention tremor and dysarthria, partial agenesis of the cerebellar vermis, bilateral cataracts 
and right optic nerve hypoplasia. She was found to have an elevated PBG excretion and 
severely depressed erythrocyte PBG deaminase activity. Her younger brother had a markedly 
reduced erythrocyte PBG deaminase activity and elevated urinary PBG excretion. Though he 
initially showed no obvious clinical deficits, he subsequently developed ataxia. Their parents, 
who were umelated and asymptomatic, were shown to have elevated PBG levels and 
moderately reduced erythrocyte PBG deaminase activities, in keeping with latent AlP. They 
were shown to be heterozygous respectively for a C to T and a G to A transition in the same 
codon in exon 10; the children were compound heterozygotes. A further patient, reported 
from Spain, presented clinically with psychomotor retardation, hepatosplenomegaly and 
bilateral cataracts (Xu et al 1995). 
All the patients described with homozygous AlP have shown markedly elevated urinary 
ALA and PBG excretion and severely reduced erythrocyte PBG deaminase activities. They 
have been shown to be either homozygous or compound heterozygotes for mutations which 
are known to be associated with AlP in the heterozygous state, but which appear in in vitro 
studies to retain some residual catalytic ability (Elder 1997). An interesting point is that none 
of these children have developed acute attacks (Elder 1997). 
CEP 
The clinical features relate directly to the accumulation of large quantities of uroporphyrin, 
C7, C6, C5 and coproporphyrin, all of isomer series I, in bone marrow, erythrocytes, plasma, 
the skeleton, skin and urine. Characteristic clinical features include haemolysis, mild 
splenomegaly, anaemia, and photo cutaneous sensitization which frequently gives rise to a 
severely destructive process. In addition to the development of erosions and blisters in sun­
exposed areas, there may be photomutilation with contraction of digits, loss of nose, lips and 
ears, and hypertrichosis. These changes usually begin in early life, rather than post-pubertally 
as is the case with the more typical autosomal dominant disorders. 
In keeping with the recessive nature of the condition, uroporphyrinogen co-synthase 
(UROS) activity is reduced to less than 50% of normal values. The molecular basis of CEP 











in the UROS gene, comprising deletions, insertions, splice mutations and single-base 
substitutions. All but one of the known CEP missense mutations occurred in apparently highly 
conserved peptide sequences of the UROS gene. Some patients are homo allelic for a specific 
mutation whereas other patients are heteroallelic for two mutations. CEP is encountered in 
populations around the world, and several shared mutations have been identified in patients 
from apparently unrelated families. Particularly striking is the C73R mutation which was 
homo allelic in five of the subjects and was present in 22 unrelated families in total. 
There is some evidence for genotype-phenotype correlation in CEP. The C73R mutation 
results in the loss of more than 99% of normal activity when expressed in E coli; human 
homozygotes for this mutation demonstrate an extremely severe phenotype which may 
include profound anaemia, hydrops fetalis and transfusion-dependency at birth. Patients who 
carry both C73R and a second mutation expressing somewhat more residual activity may 
demonstrate a moderately severe phenotype; whereas patients who carry two mutations 
associated with a higher degree of residual activity have milder forms of CEP (Desnick et al 
1998). 
PCT 
34 uroporphyrinogen decarboxylase (UROD) gene mutations have been identified in patients 
with familial PCT (Elder 1998, Mendez et al 1998, Christiansen et al 1999, McManus et al 
1999). Most are restricted to single families. Where patients are homoallelic for a UROD 
mutation, or are heteroallelic for two such mutations, a severe phenotype known as 
hepatoerythropoietic porphyria (HEP) may result. This is associated with a severe deficiency 
of UROD activity in all tissues and is expressed clinically as severe photosensitivity and 
photomutilation, with onset in childhood (Hift et al 1993a, Elder and Roberts 1994, Meguro et 
al 1994, Roberts et al 1995b, Moran-Jimenez et al 1996). The clinical expression is variable; 
severely affected subjects may resemble patients with CEP, whereas others show a milder 
disease more in keeping with PCT (Elder 1997). Rarely, HEP may be associated with 
hepatosplenomegaly (Smith 1986) or other features, including hemiparesis (Parsons et al 
1994). Interestingly, the mutations associated with HEP are rarely identified in patients with 
heterozygous familial PCT (Elder 1997). Presumably, in order to be compatible with life, 
these mutations must code for proteins with significant residual activity, and in the 
heterozygous state, this residual activity is sufficiently high not to result in clinical expression 
(Roberts et al 1995b, Meguro et al 1994). 
RCP 
In addition to 5 polymorphisms, at least 19 mutations have been identified in patients with 
HCP (Rosipal et al 1999). These include missense mutations, nonsense mutations, deletions, 
frameshift mutations and splicing mutations. HCP was first described in the homozygous state 
in a patient who showed evidence of growth retardation, skin pigmentation and hypertrichosis 
(Grandchamp et al 1980, Grandchamp et al 1977). Acute attacks were not encountered in 
early childhood, though she later had typical acute attacks at the age of 10 years and again at 
the age of 20 years. She was shown to be homozygous for an R231 W mutation in the gene for 
coproporphyrinogen oxidase; this mutation decreases but does not entirely abolish the activity 
and stability of the enzyme, and a residual activity of approximately 22% has been measured 
(Martasek et al 1994). Compound heterozygous HCP has subsequently been described (Doss 
et aI1999). 
Recently a variant coproporphyrinogen oxidase deficiency syndrome has been described 
and labeled harderoporphyria (Lamoril et al 1995, Lamori1 et al 1998). The oxidation of 
coproporphyrinogen to protoporphyrinogen proceeds in two steps, with the first step leading 











.' . .' d' t mulates giving rise to the
mutation the second step alone IS ImpaIred, thIS Illte~~ Ia e accu . . ' 
'.. d (Eld 1997) In this condItIon haematologIcal mamfestatIons
charactenstIc syn rome er· '. d h t I megaly as 
predominate and include jaundice, severe haemolytic anaemIa an epa osp eno I 1984)' I 
well as skin photosensitivity present from birth (Nordmann et al 1983, D?ss e: a . n 
one family three affected siblings were homo allelic for a K404E mutatIon; III the secong 
family affected subjects were heteroallelic for the K404E mutation .and for a ~ to 
transv~rsion in the third position of the donor splice site in intron 6 WhIC~ resulted III ~xon 
skipping (Lamoril et a11998). Thus the K404E mutat.ion appears to be specI~cally assoCIated 
with a deficiency in the conversion ofharderoporphynnogen to protoporphynnogen. 
EPP 
The inheritance of EPP is complex. Though typically described as an autosomal dominant 
trait with incomplete penetrance, there is evidence to suggest that, ,in some fa~ilies at least, 
particularly those in whom hepatopathy occurs, an autosomal recess~ve mechamsm ap~e~rs ~o 
explain the observed pattern of inheritance more accurately. StudIes of enzyme actIVIty III 
affected families further suggest complex patterns of inheritance. Most patients with manifest 
disease have severely reduced ferrochelatase activity, which is in keeping with a disorder 
carried on both alleles. This has led to the belief that co-inheritance of two defects; one, 
presumably more severe, from the biochemically abnormal parent and the second, less severe, 
from an apparently normal parent, is necessary before clinical EPP becomes apparent. Since 
only one parent can be shown biochemically to carry EPP, the disease appears to be dominant, 
yet its actual inheritance will be recessive (Sarkany et al 1994). A family has been reported in 
which a clearly mutated allele was complemented by a poorly expressed ferrochelatase allele 
associated with markedly reduced mRNA expression (Gouya et al 1996). It is not known 
whether a similar mechanism is common to all families with EPP. 
Homozygous VP 
The first report of HVP appeared in 1984 (Kordac et al 1984) and further reports have 
followed (Murphy et al 1986, Coakley et al 1990, Gandolfo et al 1991, Norris et al 1990, 
Mustajoki et al 1987). The eight reported cases were, with one exception, remarkably similar. 
Both sexes were affected. Typically patients presented with photosensitivity within days to 
months of birth. Many were mentally retarded. Delayed neurological development was 
common and most experienced seizures. Nystagmus was common. Structural abnormalities of 
the hands were frequently reported, ranging from clinodactyly to severe deformity. Growth 
retardation was frequent. Reported activities of PPO in these cases ranged from 0 to 20%. 
With one exception, none were reported to have developed elevated porphyrin precursor 
concentrations ~or the acute attack. These clinical features are discussed more fully in 
Chapters 16 and 19, and are summarised in Table 19-1. 
Molecular biology of HVP 
The mutations present in several patients with HVP have now been reported. Kauppinen et al 
(1997) identified heteroallelic 1I2T and P256R mutations in a Finnish child believed to have 
HVP. The first mutation occurs in an evolutionarily conserved region of exon 2 and may thus 
have a significant functional effect, whereas the second mutation was shown to affect enzyme 
activity in bacterial cells but not in mammalian cells: this may indicate that the second 
mutation is less deleterious to the activity ofPPO than the first. Frank et al (1998b) identified 
the patient with homozygous VP first reported in 1990 (Norris et al 1990) as a compound 
heterozygote. Heteroduplex analysis of exon 6 revealed a heteroduplex in the proband and her 











substitution of glycine by glutamic acid at position 169 (GI69E) in the paternal allele. A 
second heteroduplex was noted in exon lOin proband and mother, and was shown to be 
associated with a G to A transition at nucleotide 1071 of the PPO cDNA resulting in a glycine 
to arginine substitution at position 358 (G358R). 
Roberts et al (1998) investigated the genetic basis of apparently homozygous variegate 
porphyria in 5 of 11 unrelated patients. Two of these had not previously been reported; three 
had been reported previously (Kordac et al 1984, Norris et al 1990) One subject is the same 
subject characterised by Frank et al (1998b). Mutations were confirmed by sequencing or 
restriction digests of genomic DNA. Two of the five patients were shown to be homo allelic 
for missense mutations (D349A and A433P). Both were the product of consanguineous 
unions. The remaining three were heteroallelic (GI69E/G358R; G358R1Intron 7 deletion; 
A219KANAlIntron 11 transversion). Both intronic mutations are functionally significant. The 
intron 11 transversion results in a decrease in normal mRNA content in excess of 90% 
whereas the intron 7 deletion results in the compete deletion of exon 7. Six of these mutations 
produce an abnormal pattern on DGGE or heteroduplex analysis. A further 104 unrelated 
patients with heterozygous VP were screened using these techniques; none of these mutations 
were identified nor have they been previously reported in heterozygous VP. The seventh 
mutation (the Intron 11 transversion) was not present in any of 28 VP patients in which this 
region had been sequenced or in 55 normal subjects screened by allele-specific 
oligonucleotide hybridisation. This paper draws some important conclusions on the nature of 
the mutations which, in combination, lead to the development ofHVP. These are discussed in 
more detail in Chapter 19. 
15.2 	 THE CLINICAL PROFILE 0 F PATIENTS WITH VARIEGATE 
PORPHYRIA 
There have been relatively few descriptions of series large enough to give insight into the 
typical patterns of clinical expression ofpatients with VP. Summarised here are those reports 
which attempt to delineate those patterns, described by the country of origin, as there is some 
evidence that the relative frequency of skin disease is determined by the country of residence, 
presumably as a result ofvarying exposure to sunlight (Mustajoki 1978). 
South Africa 
Eales et al (1980) delineated the clinical spectrum of VP as seen at Groote Schuur Hospital 
over a 30 year period preceding 1980. More than 300 index cases had been seen, and this 
abundance of clinical material allowed the authors to give a definitive clinical and 
biochemical description of VP. The sex and clinical presentation of these 300 index patients 













• Male 129 43 
Female 171 57 
Clinical presentation 
Pure acute 51 17 
Acute/cutaneous 62 21 
Pure cutaneous 156 52 
Biochemical only 31 10 
Table 15-1. Details of the presentation of 300 patients in Cape Town drawn from 
Eales et al (1980). 
. There was a slight female preponderance. 260 patients were white and 40 of mixed race; a 
ratio of 0.87/0.13. Most cases presented for the first time in the third and fourth decades of 
life; smaller numbers were encountered in the 5th, 6th, 7th and even 8th decades. A small 
proportion presented between the ages 10 and 20, but there were no clinical or biochemical 
presentations before puberty. 
A striking observation is the large proportion of patients who had developed an acute 
attack-34% of the total group. Also striking is the small proportion (just 10%) of patients 
known to have porphyria who were clinically silent. Thus 90% of all patients with VP 
manifested symptoms; 52% with skin disease alone, 73% in total with skin disease and 17% 
with acute symptoms alone. What is however not clear from this study is how many of these 
patients with acute symptoms alone develop skin disease subsequently; our own experience 
suggests that it is rare for a patient with VP who has suffered acute symptoms to remain free 
of skin disease. 
The Netherlands 
Several Dutch families with VP have been described. Westerhof and Smit (1981) examined a 
three-generation kindred in Amsterdam. The biochemical diagnosis of porphyria was based 
on the quantitation of ALA, PBG, uroporphyrin and coproporphyrin in the urine and 
coproporphyrin and protoporphyrin in the stool. This family's genealogy could be traced back 
to 1630, though it was unfortunately not possible to demonstrate kinship with the South 
African immigrant families. 27 adults drawn from 3 generations were physically examined. 
VP was diagnosed biochemically in 10 subjects. Thus, 37% of the adult members of this 
family were shown to have biochemical evidence ofVP. Since 50% of family members would 
be expected to carry VP, this may indicate that a substantial proportion (approximately a 
further 10%) are both biochemically and clinically silent. Only 4 subjects were reported to be 
symptomatic: all had skin disease and three had had acute attacks. The remaining six 
biochemically-positive subjects were asymptomatic and were described as latent cases. 
Subsequently two Dutch families were described by Te Velde and Noordhoek (1970). In 
each family, the first male progenitor had been born in Deventer. Since it is known that Gerrit 
Jansz, one of the ancestral couple thought to have imported VP to South Africa, was born in 
Deventer, it was believed possible that one or other of these Dutch families might be related 
to the South African kindred, though this could not then be proved. VP was diagnosed 
biochemically in 6 of 18 members in the first family and in 6 of 16 members in the second 











expressed VP would not be expected ih these youngsters, thus the incidence of expressed VP 
in these families is 37% and 43%, as compared with an expected 50%, respectively. This 
study therefore suggested that approximately 40% of a patient family carrying VP will be 
proven biochemically to carry the disease, suggesting that approximately 10% will be 
biochemically silent and and undiagnosable by biochemical means alone. Since half the 
family members are expected to have inherited VP, the implication is that approximately 20% 
ofgene carriers are not detectable biochemically. 
Te Velde et al (1989) revisited four families who had been described previously, in the 
years between 1920 and 1933, to have "cutaneous porphyria" and "acute porphyria". Two of 
these families were shown to have HCP and AlP respectively. A third family appeared to 
have VP. This investigation provided no useful evidence about the penetrance of VP in this 
family since insensitive qualitative tests alone were used: 4 subjects were detected by the 
screening of urine for porphyrins whereas a further 22 subjects tested negative. The fourth 
family, shown to carry VP, was however informative. 62 members of the second family were 
tested (of whom 12 fall in the last generation; ages are not given but some may be 
prepubertal). 19 members had biochemical evidence of the disease; 17 had porphyric skin 
lesions and 3 had had acute attacks. There are therefore substantially fewer patients with 
biochemically proven VP than would be expected from a condition with autosomal dominant 
inheritance, suggesting a significant rate of "silent" carrier status, which, by inference, is 
about 38%. Furthermore, one may induce that . a high proportion of patients with 
biochemically expressed VP will demonstrate skin disease (17 of 19 patients, 90%), which is 
of interest as it does not support the contention that patients with VP in Europe are less likely 
to express skin disease than those in South Africa. 
Finland 
Though the number of patients with VP in Finland is substantially less than in South Africa, 
and also less than the number of patients with AlP, many useful reports have emanated from 
that country, largely because of the excellence of clinical record keeping, the maintenance of 
a central registry of porphyria, as well as the careful interest shown in the disease by Finnish 
workers. An unexpectedly large numbers of patients with VP were identified (Mustajoki and 
Koskelo 1976). Tellingly, all were diagnosed only during the 10 year period following the 
introduction of faecal porphyrin analysis. This suggested that VP might be considerably more 
prevalent than had hitherto been suspected. The authors suggested that VP might escape 
recognition because of a lower incidence of skin disease in temperate climates or because of 
misdiagnosis as some other form of porphyria. Thus VP with skin disease might be 
misdiagnosed as PCT and acute symptoms as evidence of AlP in the absence ofcareful faecal 
porphyrin analysis. 
Subsequently Mustajoki (1980) described a 12 year experience with VP in Finland. During 
this period, 57 persons with VP were diagnosed in the Helsinki laboratory. Since this is the 
only laboratory in Finland where faecal porphyrins were tested, it was thought likely that this 
included all patients with diagnosed VP in that country. Of these 57 patients, 37% were male 
and 63% female. The patients belonged to 9 families. Using church records, the investigators 
were able to trace family trees back to the first half of the 19th century. Of all first-degree 
adult relatives studied, 45% were found to have VP, which might suggest a silent-carrier rate 
ofapproximately 5% in a family, or about 10% ofall gene carriers. 
An acute attack had been diagnosed in 18 patients (32%), of whom only two were male 
and 16 female. Using the population older than 14 years as a basis for calculation, Mustajoki 
computed the prevalence of VP in Finland to be 1.3 per 100 000. His studies led him to 











elsewhere. He commented that the prevalence of VP is by European standards high in 
Finland. He surmised that this might be due to a founder effect, as in South Africa, or that 
more careful screening with faecal porphyrin analysis in Finland was detecting patients with 
VP whereas such cases might be missed elsewhere as a result of a failure to employ faecal 
testing, as had been suggested by several authors (Doss et al 1978, Fromke et al 1978, 
Hamnstrom et al1967, Perrot et aI1978). 
Penetrance of the gene had been reported to be almost complete by Dean (1971) and 
Fromke et al (1978). The occurrence of porphyria in 45% of the first degree relatives of the 
Finnish families in this study was in keeping with this. However, Mustajoki identified several 
obligate carriers without detectable biochemical or clinical abnormalities which demonstrated 
that the gene is not always expressed. He also pointed out factors which would make accurate 
estimation of penetrance impossible. Thus the selection of clinically manifest cases would 
exaggerate the penetrance while the inclusion of cases with new mutations or "spurious" 
offspring would lower it. 
New EngJand 
Muhlbauer et al (1982) identified 5 families with VP in the space of 2 years in New England, 
a restricted geographical area, which led them to believe that VP may be more prevalent than 
previously appreciated. This study confirmed that cutaneous disease appeared to be milder in 
non-South African patients, an observation thought to be due to the less intense sunlight of the 
higher latitudes. They sounded a warning therefore that patients with VP and acute symptoms 
but no skin disease might erroneously be diagnosed as having AlP. 
Forty individuals belonging to five unrelated families with VP were evaluated. A female 
preponderance of symptomatic patients was shown. Nine patients had manifest porphyria 
diagnosed on the basis of skin disease (6 females, 2 males) with or without acute symptoms (5 
females, 1 male). No patient died during an acute attack. A striking finding was the propensity 
of female patients to present with clinical symptoms. 
All nine symptomatic patients had characteristic VP excretion patterns with elevated stool 
coproporphyrin and protoporphyrin. A further six family members were regarded as having 
latent VP since faecal porphyrin excretion was increased but they had no symptoms. The 
faecal porphyrin content was lower in this group than in the manifest group. A further 6 
subjects were thought to have questionable porphyria because of slight elevations of faecal or 
urine porphyrin excretion. 19 patients were classified as normal on the basis of lack of 
symptoms and normal stool examinations. This points to a significant rate of silent carriage, 
with only 15 of an expected 20 patients having clear biochemical evidence of VP, of whom 
nine were symptomatic. Muhlbauer et al (1982) quote references suggesting that patients with 
VP may complain of neuropsychiatric or abdominal symptoms in the absence of an acute 
attack, including headaches, depression, abdominal pain, paraesthesia, constipation and 
personality disturbances. In this series, two subjects had had unexplained periods of 
depression and three had had migraines. The authors do however advise caution in view of the 
widespread nature of such conditions amongst the general population . 
.Denmark 
With (1983) described all cases of VP and HCP listed in the Denmark Porphyria Register at 
that time. The prevalence of VP was found to be slightly higher than that of HCP (20 and 11 
cases respectively) but considerably lower than that of AlP and PCT (153 and 131 
respectively). The male:female ratio was 6:14 in VP; this again suggests a greater propensity 
for females to present clinically than males. Of the 20 cases of VP, six had both skin disease 











Only 1 biochemically-positive asymptomatic subject had been registered. The prevalence of 
VP in Denmark appeared to be about 0.4 per 100 000. With suggested that a much higher 
percentage of these families must contain biochemically latent carriers since very few latent 
cases were proven amongst relatives. 
15.3 SKIN MANIFESTATIONS OF VARIEGATE PORPHYRIA 
Eales (1960) reported that more than 80% of patients with VP had skin disease, and that this 
was the presenting symptom in half (Eales 1974). The skin disease encountered in Eales' 
series (1980) may be regarded as typical of VP, and his description remains pertinent. A 
cardinal feature was the increased fragility of the skin of the sun-exposed surfaces of the face 
and the dorsal surfaces of the hands. Typically, even minor trauma led to detachment of the 
epidermis from the dermis with a resulting blister or raw area oozing serum. These lesions 
were described as healing rapidly with minimal scarring in the absence of infection, whereas 
secondarily affected lesions led to disfiguring pigmented scars or to areas of depigmentation. 
Occasional patients who suffered repeated trauma and constant exposure to the sun developed 
progressive pseudosclerodermatous changes on the hands and fingers. Facial features included 
hypertrichosis. 
Acute photosensitivity was not usually a feature of uncomplicated VP, but was described 
as occurring when VP was accompanied by intercurrent diffuse liver disease or biliary 
obstruction (Eales 1963). Under these circumstances, it manifested with massive formation of 
bullae thought to result from a high circulating porphyrin concentration following the 
deviation of porphyrin excretion from stool to urine. The presence of an immediate 
photosensitivity in patients with VP, more typical of EPP, has been reported in other studies 
and the responses to experimental irradiation have included erythema, weal formation, 
oedema and vesiculation (Mustajoki and Koskelo 1976, Levene 1968, Rimington et al 1967, 
Runge and Watson 1962). Mustajoki (1980) has suggested that the worsening of skin 
manifestations sometimes noted during pregnancy or during therapy with the oral 
contraceptive might also be explained on a basis ofhepatic dysfunction. 
The high proportion of patients with VP (80%) reported by Eales to have skin symptoms 
does not appear to be typical of the experience in more temperate climates. In Finland, skin 
fragility was reported in half of 45 patients and was mostly mild, with a history only being 
elicited on direct questioning (Mustajoki and Koskelo 1976). Interestingly, all patients had 
been diagnosed during an acute attack or during investigation of family members; none had 
had skin manifestations as their presenting symptom. In a subsequent report on 53 patients, 
Mustajoki (1980) reported that 29 (55%) had had no skin symptoms, whereas 45% (10 males 
and 14 females) had noted excessive fragility of the skin of the sun-exposed areas. This was 
particularly marked on the backs of the hands, though 6 subjects also had facial involvement 
and one reported skin problems in the legs. In all patients, skin fragility was first noted after 
puberty. Eight subjects reported that the skin was more fragile in summer whereas the other 
patients had not noticed a seasonal variation. Of the 15 patients who had had acute attacks, 7 
had had skin symptoms as well and 8 had not. Mustajoki also compared porphyrin values in 
patients with skin disease and those without. In general, urinary and faecal porphyrin 
excretion was higher in those with symptoms but there was a wide variation and statistical 
significance was only found for the urinary coproporphyrin. 
Other commentators have also reported relatively low levels of expression for skin disease 
in VP in North America and Europe (Holti et a11958, Hamnstrom et a11967, Taddeini and 
Watson 1968, Cochrane and Goldberg 1968, With 1969, Doss et al 1977, Fromke et al 1978, 
Doss et al 1978). This has led some commentators, including Mustajoki (1978), to postulate 











in South Africa as a result of the lower degrees of sun exposure. As discussed by Mustajoki 
and Koskelo (1976), the maximal irradiation in South Africa is similar to th~t i~ northern 
Europe in the height of summer, but has a considerably.longer durati?n. MustaJoki therefo~e 
postulated that the higher incidence of skin problems m South Africa was due to chromc 
exposure to strong sunlight. . . 
There is also experimental evidence that epidermal melanin protects agamst porphynn 
photosensitisation. The mean erythematous dose for light of several ~~~e~engths ~as assess.ed 
in a patient with both VP and vitiligo (Westerhof et al 1981). The vitIlIgmous skm, melanm­
free, had only one quarter the resistance to photosensitisation of normal skin at 405 nm and 
half the resistance at 310 nm and 500 nm. 
15.4 THE ACUTE ATTACK 
Pathogenesis 
The acute porphyrias include ALA dehydratase deficiency, AlP, HCP and VP. Both ALA 
dehydratase deficiency and AlP are marked by acute symptoms only, whereas HCP and VP 
may, in addition to a propensity to the acute attack, be associated with skin disease as well. 
The characteristic clinical picture of the acute attack is that it is episodic, mayor may not be 
associated with an obvious precipitating event (such as the administration ofporphyrinogenic 
medication or menstruation), and is marked by a typical constellation of symptoms; notably 
severe abdominal pain accompanied by few clinical signs and by an absence of peritonism, 
features of autonomic neuropathy (Yeung-Laiwah et al 1987, Blom and Atsmon 1996)­
particularly hypertension and tachycardia, vomiting, ileus and constipation (Kirsch et al 
1998). This may proceed to a typical motor neuropathy resembling the Guillain-Barre 
syndrome (McEneany et al 1993, Bont et al 1996). In severe cases, this leads to a severe 
flaccid quadriparesis and respiratory failure requiring ventilation. Pathologically, the neuronal 
injury is characterised by severe axonal necrosis though at times there may be a lesser element 
of demyelination as well (Windebank and Bonkovsky 1992, Cavanagh and Mellick 1965, 
Hierons 1957, Gibson and Goldberg 1956, Mustajoki and Seppl:ilainen 1975, Albers et al 
1978, Fliigel and Druschky 1977). The histological changes associated with acute neuropathy 
in VP appear to be no different from those with other forms of porphyria. The cardinal 
features are those of severe qualitative and quantitative changes in myelinated and 
unmyelinated fibres suggesting an axonopathy in keeping with the dying-back phenomenon 
(Thorner et al 1981). Once established, the neuropathy is slowly reversible and typically 
months to years are required before full function is regained. 
The pathogenetic mechanisms whereby the acute attack is established are poorly 
understood. The most likely hypotheses include ALA neurotoxicity and haem deficiency, 
acting either directly within the neuron or via a deficiency of one or more essential 
haemoproteins. The subject has recently been concisely and elegantly reviewed by Meyer et 
al (1998). 
ALA-induced neurotoxicity 
The observation that the acute attack is always accompanied by an elevation in ALA 
concentrations has led some authorities to suggest that ALA is itself neurotoxic. Typically 
ALA has been suspected in preference to PBG since acute lead poisoning, ALA dehydratase 
deficiency and hereditary tyrosinaemia type 1 deficiency, all of which are accompanied by 
elevated ALA levels but not by elevated PBG levels, result in a syndrome similar to the acute 
attack. There is little evidence that either PBG or the porphyrins are themselves neurotoxic. 











ALA excretion and are accompanied by clinical resolution. However, it has never been 
possible to prove a causal link between high ALA excretion and the acute attack. In particular, 
many asymptomatic patients (particularly with AlP) excrete levels of ALA in excess of those 
seen in other patients (typically those with HCP and VP) who are actively experiencing 
symptoms. Secondly, experimental administration of ALA to healthy volunteers, to subjects 
with AlP (Dowdle et a11968, Meyer et a11972, Shimizu et al 1978, Mustajoki et a11992) and 
to -experimental animals (Edwards et al 1984a, 1984b) does not precipitate the syndrome. 
Additionally, there is experimental evidence in rodents to suggest that the blood-brain barrier 
is poorly permeable to ALA (Meyer et al 1998). In patients with the acute attack, ALA 
concentrations in the CSF have been reported to be much lower than those measured 
simultaneously in blood, representing only 2-3% of blood levels (Percy and Shanley 1977, 
Bonkovsky et al 1971, Gorchein and Webber 1987). Though this may protect the central 
nervous system against the toxic effects of ALA, the peripheral nervous system would 
however remain exposed to the full blood ALA concentration, and levels at which in vitro 
effects on nerve function have been demonstrated (Bonkovsky and Schady 1982, Jordan et al 
1990). There are other lines of evidence to suggest that under certain circumstances ALA in 
vivo is detrimental. Administration into the cerebral ventricle has excitatory effects (Shanley 
et a11976, Pierach and Edwards 1978) and reduces seizure latency in rodents (Yeung-Laiwah 
et al 1987). There is also evidence that ALA at low concentrations can alter 
neurophysiological function, depress spinal reflexes and induce depolarization of muscle in 
animals (Bonkovsky and Shady 1982, Jordan et al 1990, Loots et al 1975, Nicoll 1976, 
Becker et al 1975), and is neurotoxic in chick embryos (Percy et al 1981). Yet ALA at 
considerably higher concentrations has not proved toxic to human spinal cord neurons in 
culture (Gorchein 1989). 
Researchers have also been struck by the similarity in chemical structure between ALA, 
the inhibitory neurotransmitter GABA and the excitatory neurotransmitter L-glutamic acid. 
Evidence of interaction between ALA and these neurotransmitters has been sought (Muller 
and Snyder 1977, Brennan and Cantrill 1979, Brennan and Cantrill 1981). There is some 
suggestion that ALA can act as a partial GABA-agonist in vitro, but there is as yet little 
evidence of an effect of ALA on the GABA-ergic system in vivo, though ALA has been 
shown to mimic the inhibitory effect of GABA on the rat pineal gland (Puy et al 1996b). This 
may have a clinical counterpart in that a marked decrease of both day and night-time 
melatonin concentrations has been shown in patients with AlP (Puy et aI1993). 
Haem deficiency 
The acute porphyrias appear to be characterised by intracellular haem deficiency, leading to 
derepression of ALA synthase activity and the overproduction of porphyrins and their 
precursors. Since haem plays a vital role in oxidative metabolism and is found in a wide 
variety of biological compounds, including haemoglobin, myoglobin, enzymes of the 
respiratory chain such as cytochromes b and c, and the cytochrome P450 system, it has been 
postulated that the acute attack may represent the clinical effects of intracellular (and more 
specifically intraneuronal) haem deficiency (Meyer et al 1998). There is experimental 
evidence in both normal humans and in porphyric patients of a functional deficiency in some 
haem-containing enzymes. Thus impaired cytochrome P450-mediated drug metabolism has 
been demonstrated in patients with porphyria (Mustajoki et al 1994, Anderson et al 1976, 
Ostrowski et a11983, Birnie et a11987, Tokola et a11988, Herrick et a11987, Mustajoki et al 
1992, Bonkovsky et al 1991), and a return to normal activity can be shown following the 
administration of exogenous haem. There is however no direct evidence for intraneuronal 
haem deficiency, and there is evidence that brain ALAS in rats is not directly induced by 











that the brain is passively affected by changes in haem synthesis occurring in extraneuronal 
sites, rather than being the prime seat of a disturbance in haem concentrations itself (De 
Matteis and Ray 1982). Secondly, when haem is administered exogenously both to humans 
and to rats, it has not been possible to detect a corresponding rise in the eNS haem content 
(Lamon et al 1979, De Matteis et al 1981). A reading of the available evidence therefore 
suggests that direct intraneuronal haem deficiency is unlikely to be the prime cause of the 
neuropathy associated with the acute attack. 
There is however a reasonable possibility that intracellular haem deficiency may indirectly 
play a role in nerve damage via a secondary deficiency in haemoproteins. Of particular 
interest is the enzyme tryptophan dioxygenase. This is the rate-limiting enzyme in the 
metabolism of tryptophan to kyurenine. Thus, when tryptophan dioxygenase activity 
decreases, the levels of tryptophan increase. Since tryptophan is the substrate for tryptophan 
hydroxylase, the effect is an increase in serotonin formation. This sequence of events has been 
shown indirectly as has its corollary in that administration of exogenous haem can prevent 
and reverse the increase in serotonin. Several investigators have demonstrated elevated blood 
levels of tryptophan and serotonin and increased urinary excretion of the serotonin metabolite 
5-HlAA in patients with AlP (Puy et al 1993, Bonkovsky et al 1991, Price et al 1959) and 
have shown that these changes in tryptophan metabolism could be reversed by the 
administration of haem. Thus in summary, though no causal relationship has been proven, 
there is experimental evidence to support a derangement in the concentrations of the 
neurotransmitter serotonin in patients with AlP, and to link this experimentally to haem 
deficiency. Since serotonin has a wide range of physiological actions in many organs of the 
body, including those which are the seat of the characteristic symptoms of the acute attack, 
there would appear to be a reasonable possibility that a haem-deficiency-induced elevation in 
serotonin levels may account at least in part for some of the features of the acute attack. 
Haemoproteins are also involved in mitochondrial electron transport. It has thus been 
postulated that haem deficiency might lead t  deficiencies in energy production, particularly 
in neuronal tissue leading to axonal degeneration. There is some evidence to support the 
postulate that energy production is impaired in porphyria. Muscle biopsy studies in patients 
with AIP have shown decreased cytochrome oxidase activity (Goldberg et aI1985), and blood 
lactate levels may be higher after glucose-loading in patients than in controls (Herrick et al 
1990). The evidence remains tenuous. In particular, known disorders of mitochondrial 
function such as the mitochondrial myopathies differ in symptomatology from the acute 
attack of porphyria. Other haemoproteins, including nitric oxide synthase, have also been 
implicated, but as yet there is little experimental evidence to support these hypotheses. 
Though various forms of porphyria are encountered in non-human mammals, there is, 
perhaps surprisingly no natural animal model of an acute porphyria in which these hypotheses 
can be tested. Meyer et al (1998) have produced PBG-deficient mice by a process of double 
gene-knockout; such mice are in effect compound heterozygotes for AlP. These mice showed 
evidence of neuropathy with slow movement, ataxia, impaired motor coordination and 
proprioceptive insensitivity. Electroneurophysiological and histological studies reveal axonal 
abnormalities. However, these features are seen in all mice including those who have not been 
treated with porphyrinogenic drugs (and have thus not been precipitated into an overt acute 
attack) and who presumably do not show the suddenly raised ALA levels characteristic of the 
acute attack. It is possible that the these mice are more a model of homozygous porphyria 
(which is known to be associated with vegetative dysfunction even in the absence of acute 
attacks as described above), rather than representing a true model for the acute attack per se. 
A strain of mice bearing the R59W mutation in the gene for PPO has recently been 
established by gene-knockout techniques and is now under study in our laboratory in 











Therapy of the acute attack 
The glucose effect 
Carbohydrate loading was the first specific therapy advocated for the acute porphyric attack. 
Early clinical studies suggested that approximately 75% of patients would respond favourably 
to intravenous or oral glucose administration (Rose et al 1961, Doss and Verspohl 1981, Doss 
et al1985). There is evidence that ALAS activity and porphyrin synthesis are repressed when 
liver cells grown in culture are exposed to porphyrinogenic medication in the presence of high 
carbohydrate concentrations. Carbohydrate intake also inhibits the induction of hepatic ALAS 
in experimental porphyria and in human AlP. Conversely, there is evidence that deficient 
carbohydrate intake and fasting may precipitated the acute attack of porphyria, and may even 
increase porphyrin excretion both in healthy subjects and in experimental rats (Lahav et al 
1984). This, the so-called glucose effect, is demonstrable in AlP, VP and even in non-acute 
porphyrias such as EPP and PCT (Doss and Verspohl1981). In addition to glucose, fructose 
and glycerol appear to share this ability to reduce porphyrin synthesis. No dose-response 
curve has however been shown for the effect of glucose in suppressing the induction of 
hepatic ALAS. 
Haem administration 
It has been known for over 30 years that administration of exogenous haem reduces ALAS 
activity in both experimental systems and in patients with porphyria, and there is now an 
extensive literature on the effects of haem administration in patients with porphyria. This 
effect is mediated via a repression of ALAS by a process of negative feedback. When first 
introduced into clinical practice (Bonkovsky et al 1971), haem was typically given in the form 
of haematin. Many reports followed attesting to the efficacy of haematin in aborting the acute 
attack (Lamon et al1979, Pierach et al1980, Bissell 1988, Watson 1975, McColl et al1981). 
Concerns about the safety of haematin, which appeared to be associated with transient 
coagulopathies, renal dysfunction, thrombophlebitis and AST elevation (McColl et al 1981, 
Pierach 1982, Pierach 1986, Goetsch and Bissell 1986, Dhar et al 1978) led to the 
introduction of haem arginate in which haem is coupled to arginine (Tenhunen et al 1987). 
This compound exhibits a greater stability then haematin and has a longer shelf-life; 
widespread experience and numerous clinical reports attest to a more favourable safety profile 
(Mustajoki et al 1986, Tenhunen et al1987, Tokola et al 1987, Volin et al 1988) and greater 
efficacy in rapidly reducing ALA and PBG levels in the acute attack (Kirsch et al 1998, Hift 
et al 1997, Elder et al 1997, Mustajoki et al 1986, Volin et al 1988). Haem arginate 
administration is typically followed within 48 hours by evidence of clinical resolution. It is 
however known that neuropathy is not reversed by the administration of haem (Pierach 1982, 
Mustajoki 1985), and haem must therefore be administered early in the course of the acute 
attack before the neuropathy has become established. 
Though haem arginate is effective in aborting the acute attack, the effect is short-lived. 
Typically ALA, PBG and porphyrin levels begin rising within 48 hours of the last of a four­
day course of inj ections (Timonen et al 1990a, Herrick et al 1989b). Thus the role of haem 
arginate is to abort a crisis rather than as a prophylactic measure in patients with porphyria. It 
has been suggested that weekly or monthly prophylactic injections of haem arginate may 
serve in some cases to suppress the clinical effects of porphyria in patients subject to repeated 
acute attacks (Lamon et al 1978). Yet porphyrin excretion, initially suppressed in four patients 
with stable VP given weekly infusions of haem arginate for four weeks, and returned to 
pretreatment levels, and there was no improvement in skin disease (Timonen et al 1990b). 
Since haem is known to induce the enzyme haem oxygenase and thus to mediate its own 











repeated use of haem arginate has led to an apparent decrease in efficacy, suggestive of 
tolerance, which has been improved by the inhibition of haem oxygenase. This is discussed 
below, and our experience is described in Chapters 18 and 19. 
Haem oxygenase inhibitors 
Since haem is catabolised by the enzyme haem oxygenase, itself induced by haem, the use of 
haem oxygenase inhibitors to maintain haem levels has been mooted. A number of substituted 
metalloporphyrins will inhibit haem oxygenase; these include tin protoporphyrin, tin 
mesoporphyrin and zinc mesoporphyrin. Tin protoporphyrin markedly inhibits the induction 
of hepatic ALAS by ally lisopropamide in adults rats; a dose of 50 Jlmol/kg body weight 
resulting in a 60% reduction in ALAS activity. This is accompanied by a decrease in the 
urinary excretion of ALA and PBG. At the highest dose, excretion was totally abolished 
(Galbraith et al 1985). In normal volunteers, administration of tin protoporphyrin results in a 
mean 38% decrease in serum bilirubin and a mean 47% decrease in biliary bilirubin 
(Berglund et al 1988). This is accompanied by an increased excretion of endogenous haem in 
bile for 48 hours. Tin protoporphyrin is rapidly cleared from plasma with a half-life of 3.4 
hours though the inhibition of haem oxygenase lasts for at least four days. The activity of 
microsomal haem oxygenase has been measured directly in liver samples and has shown to be 
diminished by tin protoporphyrin (Berglund et al 1988). This work has been extended to 
experimental studies in patients with acute porphyrias. Administration of both tin 
protoporphyrin and tin mesoporphyrin, whose potency in vivo is approximately 5 to 10 times 
greater (Drummond 1987), led to significant decreases in urinary ALA and porphyrin 
excretion in patients with AlP and VP (Galbraith and Kappas 1989). Experience has shown 
that tin protoporphyrin alone is of no value in reducing ALA and PBG excretion in patients 
with the acute attack (Dover et aI1993). Furthermore, the combination of haem arginate and 
tin protoporphyrin was no more effective than haem arginate alone in reducing ALA and PBG 
excretion in an attack but there was evidence that tin protoporphyrin prolonged the 
biochemical remission induced by haem arginate. 
Suppression ofmenstrually-induced exacerbations ofporphyria 
Recurrent acute attacks of porphyria related to the menstrual cycle are a problem in some 
female patients. The proportion of patients in whom this is a relevant factor is not known, 
though in the series of Kauppinen and Mustajoki (1992), approximately 30% of women with 
both AlP and VP reported an onset of abdominal pain prior to menstruation which might 
reflect an exacerbation of porphyria, though only two had actually required hospitalisation. 
Despite the belief that these premenstrual attacks are the results of rising oestrogen or 
progesterone, some patients have apparently improved while taking the oral contraceptive, 
including the two described above. Other patients have however suffered exacerbations on 
exogenous steroid therapy, leading to a search for safer and more effective therapy. Danazole, 
a synthetic steroid with weak androgenic activity and which decreases gonadotropin secretion, 
was administered to two female patients with AlP who were experiencing cyclical attacks of 
porphyria, but appeared to exacerbate the porphyria (Lamon et aI1979). 
In view of their efficacy in suppressing the normal hormonal fluctuations of the menstrual 
cycle, gonadotrophin-releasing hormone analogues appeared promising candidates for the 
treatment of menstrually-related acute attacks (Anderson et al 1984, Bargetzi et al 1989, 
Anderson 1989). Anderson et al (1990) assessed the use of daily gonadotrophin releasing 
hormone analogue administration in six female patients with well-documented AlP and 
frequent cyclical exacerbations. Premenstrual attacks of AlP were reduced or eliminated and 
the authors concluded that this provides a safe alternative to the use of oestrogen and 











releasing honnone (LHRH) analogue buserelin in 7 patients with apparent menstrually-related 
attacks of AlP. The median number of attacks fell from seven during the baseline observation 
period to three during treatment. The response was variable, and the greatest improvement 
was seen in those patients in whom the association between attacks and the menstrual cycle 
was strongest. 
Savage et al (1992) reported the use of a subcutaneous testosterone implant in a patient 
with life-threatening premenstrual attacks which were not adequately suppressed with 
gonadotrophin releasing honnone agonist therapy. Menstruation returned three months after 
discontinuation of buserelin and no serious attacks occurred thereafter. Repeated 
implantations were perfonned at 6 monthly intervals. The authors suggested that testosterone 
had had a beneficial clinical effect. 
Case reports continue to appear, reporting the beneficial effects of LHRH analogues in 
single female patients with cyclical porphyria. As expected, osteopaenia is noted (Yamamori 
et al 1999), though supplemental oestrogen in the fonn of low-dose oestrogen patches appears 
to be tolerated (De Block et al 1999). 
Other forms of therapy 
Propranalol, which is a useful agent in controlling the adrenergic overactivity of the porphyric 
crisis, has also been suggested in several case reports to have independent activity in 
suppressing porphyria (Flacks 1970, Atsmon and Blum 1970, Atsmon et al 1972, Blum and 
Atsmon 1976, Douer et al 1978a, Douer et al 1978b). This has not found widespread use, nor 
has the effect ever been convincingly shown in a series of patients. It is difficult to separate 
any effect of propranolol from the natural tendency of the acute attack to remit once patients 
are admitted to hospital, precipitating factors are removed and other potentially active therapy 
such as carbohydrates or haematin is in progress. 
15.5 	 CLINICAL FEATURES AND PROGNOSIS OF THE ACUTE 
ATTACK 
Initially the prognosis of patients suffering from acute attacks was believed to be very poor 
and mortality rates of 18-58% have been described (Waldenstrom 1937, Waldenstrom 1957, 
Goldberg 1959, Eales 1963, Darocha 1971, Sorensen and With 1971, Beattie and Goldberg 
1976, Moore et al 1987). However, no long-tenn follow-up studies had then been published 
and therefore the lifetime risks of manifest symptoms of porphyria amongst patients with both 
VP and AlP were not initially known. Later reports however suggest both a lower rate of 
occurrence of the acute attack as well as a more favourable outcome. 
Early South African experience 
Eales (1963) reviewed his experience with porphyria and reported a mortality of 22% for 
patients treated between 1939 and 1963. Seventeen years later, the mortality was significantly 
lower (Eales et al 1980). From 1963 to 1971, there had been only 3 deaths, and none from 
1971 to 1980. Eales attributed this improved survival to improved treatment-particularly the 
introduction of mechanically assisted respiration-and also to a falling incidence of the acute 
attack. The number of acute attacks, which had varied between 5 and 9 cases per year from 
1952 to 1968, fell dramatically to average about 2-4 per year. This striking decline was 
thought to be due to the initiation ofa family screening program in 1963. 
The review by Eales et al (1980) described the main clinical features of the acute attack in 











alone was 1: 1, the ratio for patients with acute attacks was 1 :3. The clinical features of the 
acute attack are listed in Table 15-2 and are depicted graphically in Figure 19-1 where they 
are contrasted with the figures observed during the course of the study reported in Chapter 18. 
The most cornmon features were abdominal pain, which was present in 100% of patients, 
tachycardia and hypertension, present in 83 and 63% of patients respectively, and vomiting 
and constipation, present in 78 and 64% respectively. Eales provides a memorable description 
of the abdominal pain which has stood us in good stead in distinguishing the pain of the 
porphyric crisis from that associated with other conditions: 
The pain was often described as being continuous, deep seated, gnawing, with fluctuations in intensity 
which often became intolerable, leading to incessant pleas for medicinal relief It could be relieved 
temporarily only with pethidine and morphine injections. Little relief was afforded by the conventional 
analgesics. It could be located in any quadrant of the abdomen but was most frequently situated in the 
upper abdomen, especially in the epigastrium but could also affect the central area or the right or left 
ileum fossae. Palpation often evoked complaints ofsevere tenderness which however was unassociated 
with true involuntary rigidity or rebound tenderness. In 23% ofpatients it was associated with severe 
backache and in a few patients it extended to the lower sternal area. (Eales et al 1980). 
Eales et al described neuropsychiatric features which might accompany the acute attack as 
follows: excessive over-reaction by the patient with hyperventilation; hysterical behaviour; 
and infrequent frankly psychotic behaviour. In many patients a severe confusional state 
associated with seizures. was present, and the authors believed that this was due to water 
intoxication (thus presumably accompanying hyponatraemia) which they ascribed to 
iatrogenic inappropriate fluid administration. 
Eales et al (1980)* Mustajoki (1980) 
(%)(%) 
Abdominal pain 100 95 
Abdominal tenderness 80 
Non-abdominal pain 70 
Backache 23 
Hypertension 63 60 
Tachycardia 9083 
• Vomiting 6578 
I Constipation 8064 
Epileptic seizures 27* 25 
I Psychiatric symptoms 36* 40 
Motor disturbances 62* 80 
Cranial nerve abnormalities 32* 20 
Respiratory muscle paralysis 27 80 
Objective sensory disturbance 4020* 
Red urine 80 
Table 15-2. Symptoms and signs of the acute attack reported from South Africa and 











Neurological involvement was common in their series. In approximately 65% of cases, 
neuropathy was noted. Typically, this was preceded by aching pains in the limbs which were 
regarded as a precursor to motor paralysis. Though arreflexia was sometimes evanescent and 
reversible, it was usually followed by the development of profound flaccid quadriplegia 
affecting the proximal musculature of the pelvic and shoulder girdles. 27% of the patients in 
this series demonstrated involvement of the bulbar centres controlling respiration and heart 
action; though presumably it was profound paralysis of the diaphragm and chest wall 
resulting in respiratory failure rather than any problem with the central control of respiration 
that the authors intended. 
Electrolyte disorders in the acute attack 
Most patients described by Eales et al showed evidence of an elevated serum urea during the 
acute attack. Additionally the authors described a strikingly high incidence of hyponatraemia 
and hypochloraemia, with a substantial though less striking incidence of alkalosis and 
hypokalaemia. This confirmed their findings in several previous reports (Eales 1963, Eales 
and Dowdle 1971). The incidence ofhyponatraemia in particular was dramatic, with 95% of 
patients showing this feature and 51 % of patients having severe hyponatraemia, as defined by 
a serum sodium <120 mmolll. In one group of patients, there was evidence of gross sodium 
depletion in the absence of marked urinary losses. The cause here was thought to be gastric 
sodium loss coupled with poor sodium intake. A second group had a high urinary sodium 
excretion. One possibility was a primary renal tubular sodium-losing state which the authors 
ascribed to a direct effect of ALA on the renal tubule. The second possibility was the 
syndrome of inappropriate ADH secretion (SIADH); the basis for which was poorly 
understood in 1980. The authors expressed doubts as to whether this syndrome would play 
any role in porphyria. 
Precipitants ofthe acute attack 
Many of the acute attacks described in this series were thought to have been precipitated by 
drugs. Table 15-3 indicates those drugs which had been implicated. 
Drugs Exposures (n) Only 
precipitant (n) 
Barbiturates 81 31 
Analgesics 16 5 
Sulphas 16 5 
Non-barbiturate hypnotics 15 4 
Unidentified sedatives 14 10 
Miscellaneous 12 3 
Anticonvulsants 10 5 
Alcohol (acute abuse) 9 4 
Hormonal 6 4 
Table 15-3. Drugs thought to have been instrumental in inducing the acute attack, as 











The Finnish experience 
Mustajoki (1980) described his experience with the acute attack of VP. The mean age at the 
onset of the first attack in the 18 patients who had had such an episode was 33; the youngest 
patient was 20 and 4 patients were aged more than 40. Twelve patients had had acute 
symptoms once, 5 patients twice and one patient three times during their lives. barbiturates 
were implicated in 4 patients and infection in two. In the remaining 12 patients no 
precipitating factors could be traced or the history was inadequate. Fourteen patients had 
experienced neurological symptoms of whom ten had received barbiturates during an 
established acute attack, before the appearance of paresis. Two had also been given 
sulfonamides and one had been given meprobamate. 
The symptoms and signs of the acute attack are listed in Table 15-2. Abdominal pain 
occurred in all but one patient and was usually associated with constipation and vomiting. 
Motor weakness was present in 80% of the cases and respiratory muscle paralysis in 40%. 
Seizures were noted in 25%. 80 patients were reported as having psychiatric symptoms, often 
mild, but a quarter of the patients were frankly delirious and psychotic. Seven patients (39%) 
died during an acute attack. Of the 48 patients still alive at the end of 1978, nine had had an 
acute attack previously whereas the others had always been asymptomatic. 
Since Dean (1971) had suggested that the ancestors ofporphyric families did not exhibit 
any excess mortality until after modern drugs became available, Mustajoki (1980) attempted 
to determine whether life expectancy for patients with VP had been higher before the modern 
era of readily-available drug therapy, and consequent increased likelihood of exposure to 
potentially porphyrinogenic medication. He assessed the life-expectancy of 13 obligate gene 
carriers; eleven of whom had died before 1920 and a further two of whom had died before 
1940. This he compared to the life expectancies of 66 matched controls, subjects from the 
same family who appeared not to carry the VP gene, and whose birthdates were within 10 
years of those of the carriers.There was a slight but non-significant difference in life 
expectancy; the mean age at death of the carriers being 62.1 and of the controls 65.1. None of 
the gene carriers had died before the age of 40, and more than ten of them had lived longer 
than 50 years. 
The frequency of the acute attack in these Finnish patients was similar to that reported in 
South Africa by Eales (1963). Mustajoki (1980) showed that half of these attacks had 
occurred before 1960, when there was a poor understanding of porphyria in Finland, and that 
the prognosis had improved considerably since that time. He had also observed that subjects 
with latent VP appeared to be at low risk ofdeveloping symptoms since only two patients had 
experienced symptoms once the diagnosis of porphyria had been established. He advanced 
two theories to explain this: firstly, that education and information about the precipitating 
factors had allowed them to avoid acute attacks; secondly, that many patients with VP would 
remain symptom-free throughout their lives in any event, their identification as 
biochemically-positive for VP being incidental. His series included 12 asymptomatic subjects 
aged more than 50. 
In a subsequent paper, Kaupinnen and Mustajoki (1992) conducted a prospective study 
amongst patients with AlP and VP, and coupled this with a retrospective review of the risk 
factors for the acute attack. The authors introduced an important principle when they divided 
their patients in the follow-up cohort into two groups. The first comprised those patients in 
whom porphyria was only diagnosed following a first acute attack; the second comprised 
those in whom the diagnosis had been established as a result of family screening before the 
first attack developed. The Finnish Porphyria Registry, which had been founded in 1966, 
contained details of 195 patients with AlP from 39 families and 73 patients with VP from 14 











VP, who were still alive in 1970, were followed to assess their natural history. A strength of 
this study is that it includes both patients with symptoms and those without and thus gives 
information about the prognosis amongst unselected patients with acute porphyria in general; 
most previous studies had included a selected group-those who expressed symptoms. 
Prognosis ofthe acute attack 
31 patients died during an acute attack, of whom 29 died before 1974. Only 2 subjects died 
thereafter, both were women, not included in this follow-up, who were believed to have been 
treated inadequately in their local hospitals. Before 1967,44% of attacks were associated with 
paralysis whereas only 18% were associated with paralysis after 1967. The difference is 
statistically significant. Of the 16 patients who developed paralysis after 1967, porphyria had 
not been diagnosed in twelve at the time of the attack. Of the 4 patients who are known to 
have porphyria before they develop the attack associated with paralysis, two were heavy 
drinkers and the other two were believed to have received inadequate treatment. The 
difference in frequency of deaths during the acute attack prior to 1966 and after 1966 is also 
highly significant. During the period of follow-up, 13.6% of patients had a subsequent acute 
attack. An interesting finding of this study was that the likelihood of an acute attack was 
significantly higher in patients who had had previous attacks than in those who had not. This 
difference was statistically significant. No difference in the risk of an attack could be shown 
between those with AlP and those with VP. 
Thus acute attacks had become less frequent and mortality significantly lower during the 
two decades prior to pUblication. Severe attacks accompanied by paralysis had also become 
less frequent. This supports the opinions expressed by other authors (Bonkovsky and Schady 
1982, Kappas et a11989, Tschudy and Lamon 1980) that the prognosis for patients with AlP 
and VP has improved with time. The authors suggest three reasons why the prognosis had 
improved. Firstly, disease was now detected earlier because of better diagnostic testing and an 
increased awareness amongst doctors. Secondly, treatment of the acute attack had improved. 
Thirdly, asymptomatic patients diagnosed early were able to take precautions and, in the event 
of acute symptoms, the acute attack was recognised and treated more quickly. 
Prevalence ofacute symptoms by self-reporting 
Questionnaires were sent out to all patients requesting information on symptoms of their 
porphyria. 75 patients (47% of the total group, 56 with AlP, 19 with VP) reported some 
symptoms which they had interpreted as due to their porphyria. Those who had had acute 
attacks previously reported more symptoms and there was a male predominance (56% vs 
32%); the difference was statistically significant. Fewer than 14% of patients with AlP or VP 
in this study experienced acute attacks requiring hospitalistation. The authors correctly 
caution that this figure of 47% may be excessive as a result of symptoms due to other causes 
being ascribed to the porphyria. However, they do conclude that milder symptoms of 
porphyria may occur much more frequently than severe acute attacks, and are more common 
amongst patients who have had a previous attack than amongst those who have not. 
Precipitating factors for acute symptom by self-reporting 
Kaupinnen and Mustajoki's subjects reported the following factors as having contributed to 
their symptoms: infection (29%), alcohol (25%), fasting (12%), drugs (10%), menstruation 
(30%). An interesting finding was that acute symptoms were often associated with several 
simultaneous precipitating factors. An important corollary was that many of the patients 
regularly use drugs, many of which were believed to be unsafe in porphyria, yet remained 











anaesthesia. It further appeared that moderate use of alcohol seldom causes problems, though 
heavy drinking may be associated with an increased risk of the acute attack. 
Thus the authors drew the important conclusion that, though patients were frequently 
exposed to precipitating factors, these were seldom associated with serious problems. They 
therefore suggested that strict avoidance of all known precipitating factors was unnecessary 
amongst patients with AIP or VP unless they were prone to the acute symptoms. This latitude 
however extends only to patients in the quiescent phase, and not to those who have had 
frequent attacks or who are experiencing an acute attack currently. 
Menstrual effects, pregnancy and sex hormone therapy 
30% of 95 women had cyclical symptoms suggestive of porphyria, though the authors suggest 
that some of these symptoms were probably not related to porphyria. The symptoms were 
described as abdominal pain accompanied by pain in the extremities a few days before 
menstruation and extending through the first few days of the menstrual period. It was often 
associated with constipation. The frequency varied from 3-12 times per year. No difference 
could be found in the appearance of this symptom in those who had previous attacks and 
those who had not. These findings were not confined to patients with AIP, and 31 % ofwomen 
with VP also reported these symptoms. Two patients required hospitalisation repeatedly in the 
premenstrual phase because of acute attacks, and these were prevented by the administration 
of the oral contraceptive. Pregnancy was uneventful in 92% of cases. Acute symptoms 
however developed in 14 pregnancies (8%) in 12 women (9 with AlP, 3 with VP). The acute 
attack followed delivery in seven of these pregnancies. Of 12 women who had had symptoms 
of porphyria previously, four subsequently became pregnant without aggravation of the 
porphyria. A single patient reported symptoms of porphyria during all three of her 
pregnancies, but porphyria had not been diagnosed until after this series ofevents. 
44 of 95 women (46%) had used sex hormone preparations either for contraception or for 
menopausal symptoms. Six of these women (14%) had had suggestive symptoms during the 
taking of these preparations though only 2 (4.5%) had had an actual acute attack requiring 
hospitalisation. Thus the authors concluded that cyclical symptoms were relatively common 
but that menstrually induced acute attacks requiring hospitalisation were rare. Pregnancy was 
rarely associated with the aggravation of porphyria, and most pregnancy-associated attacks 
had occurred in patients not y t known to have porphyria, which may indicate that other 
precipitating factors were also present. Oral contraceptives appeared generally safe for 
patients with porphyria and fewer than 5% had experienced an acute attack during their use. 
Operations and anaesthesia 
In total, 142 of 158 patients (90%) had had local anaesthesia for dental or other minor 
procedures without any complications. Ninety (57%) had undergone 163 operations while in 
an asymptomatic phase, but there were only3 post-operative acute attacks (1.8%). All of these 
were in patients with a history ofprevious acute attacks. 
Other associations with porphyria 
There was evidence that hypertension and renal failure were more common amongst patients 
with porphyria than amongst the general popUlation, and a clear association was shown 
between hepatocellular carcinoma and AlP. Cardiovascular disease and diabetes were not 
over-represented. 43 of the 158 patients (27%) reported neuropsychiatric symptoms during 
the asymptomatic phase though only three had actually received psychiatric care. The age­
and sex-specific prevalence rates of these symptoms were no higher amongst patients with 
porphyria than in the general Finnish popUlation with the exception of females with porphyria 











The influence of anaesthesia and pregnancy on porphyria, and the associations of 
hypertension, renal disease, psychiatric symptoms and carcinoma are described in more detail 
later in this chapter. 
Causes ofdeath 
96 subjects were deceased by the time this study was terminated. Porphyria had been the 
cause in 31 cases (32%), with a mean age of death of 36 years (range 17-67). There were 8 
cases with carcinoma and 5 cases of other malignancies, whereas the other deaths were due to 
a variety of causes. 
The United States 
More recently a study has been published from America (Jeans et al 1996) assessing the 
cumulative survival of 136 patients with AIP who were hospitalised for porphyric attacks 
between 1940 and 1988. At the time of diagnosis, patients had an average age of 32 years 
(range 9-75); the male:female ratio was 43:93. Recurrent attacks were the rule, and were 
experienced by 109 patients. At the time of follow-up, 19 males (44%) and 31 females (33%) 
were deceased. Compared to age-matched controls, the standardised mortality ratio was 3.2. 
Most deaths had occurred during the initial porphyric attack (20%) or a subsequent attack 
(38%). Interestingly, suicide had occurred in five subjects. There was evidence for improved 
survival in the group who had had acute attacks after 1971, the year in which haematin 
became available, though this did not reach statistical significance. 
Current opinion on the incidence of the acute attack 
Currently acute attacks are relatively uncommon; and most patients with any of the acute 
porphyrias will never experience an attack at all. Indeed, the incidence of acute symptoms has 
been estimated to be 10-20% for AIP (Kappas et alI995), 30% for HCP (Martasek 1998) and 
9%, our own initial estimate, for VP (Kirsch et al 1998). No large series of patients with the 
acute attack have appeared recently, though single case reports highlighting aspects of 
management, such as anaesthesia, pregnancy and the puerperium (Wenger et al 1998), 
complications such as paralysis and metabolic disturbances, and alternative forms of therapy, 
such as somatostatin combined with plasmapharesis (Medenica et al 1997), antioxidant 
administration (Thunell et al1997) and cimetidine (Rogers 1997) continue to appear. 
Anaesthesia and porphyria 
That porphyria is unpredictable in its response to agents known to be capable of inducing the 
acute attack is shown by the work of Mustajoki and Heinonen (1980), who studied the effects 
of anaesthesia in Finnish patients with AlP or VP. They identified 37 patients (23 with AlP, 
14 with VP) who had previously suffered acute symptoms, but were free of symptoms at the 
time of anaesthesia. These 37 patients received a total of 62 general anaesthetics. None 
developed an acute attack, despite the use of potentially dangerous medication. Specifically, 
18 patients (11 with AIP, 7 with VP) received barbiturates during 29 anaesthetic exposures; 4 
of these patients had received barbiturates on 2 occasions, and 2 patients had received 
barbiturates 4 and 5 times respectively without ill effect. By contrast, 14 patients underwent 
general anaesthesia in the presence of acute symptoms of porphyria. Ten of these patients 
underwent laparotomy or appendicectomy and no cause for abdominal symptoms, which 
presumably were due to porphyria, was found. Ten of these patients receive thiopental. In 












The conclusion drawn from this study is that patients in a latent stage of porphyria incurred 
only a slight risk of progressing to a porphyric crisis during anaesthesia, even where powerful 
inducing agents such as barbiturates are administered. In contrast, administration of such 
agents to patients who are already in an established acute attack is extremely hazardous. Thus 
the authors suggest that drugs known to induce acute porphyria may in many instances be 
safely used in patients with quiescent forms of these diseases; which in tum implies that case 
reports indicating safe use of a particular agent in an individual porphyric are of relatively 
little value. Precipitation of the acute attack is a complex event, and probably involves the 
synergistic results ofmore than one factor. 
Pregnancy and porphyria 
Initial reports on the outcome of pregnancy in patients with the acute porphyrias were 
disquieting (Nielsen and Nielsen 1958). Thus Hunter (1971) reviewed 72 reported cases with 
a total maternal mortality of 27%; amongst primigravidae, maternal mortality was 52%, 
though Bloch (1965) had reported a better outcome for VP. Brodie et al (1977) analysed the 
obstetric histories of 50 women with acute porphyria: 39 with AlP, 8 with HCP and 3 with 
VP. 54% of patients with AIP had an acute porphyric attack in pregnancy and the puerperium 
though only 24% of pregnancies were affected. The figure for VP was 1 of 3 patients in a total 
of 8 pregnancies. Two-thirds of the acute attacks occurred antenatally and one-third after 
delivery. The total fetal wastage was 13% and babies born following an acute attack were 
smaller than those with an uneventful pregnancy. Pregnancy was thought to be safer in 
patients with HCP than with AIP since 25% of the patients had had an attack but only 4 of 26 
pregnancies were affected. Fetal wastage was 16%. 
Of the 50 women, 25% had an initial diagnosis of porphyria made only during pregnancy 
or in the puerperium. However, the attack rate was stated to be no different in those diagnosed 
during pregnancy as compared with those in whom the porphyria was known before 
pregnancy. Thus, the authors suggested that inadvertent administration of medication alone 
was not the most important factor. In only 8 attacks were porphyrinogenic drugs implicated 
and these were usually barbiturates. There was one maternal death in this series. The total 
fetal wastage of 9% compares well with the 12% abortion rate quoted from a survey of 
normal women at the time. Thus the fetus did not appear to be deleteriously affected. Brodie 
et al postulated that the high incidence of acute attacks in pregnancy was most likely 
hormonal in origin. The article concludes that despite the high rate of attack during pregnancy 
in this study, the mortality was low and this therefore suggested that the porphyric pregnancy 
has a better prognosis for both mother and fetus than a reading of the earlier literature would 
suggest. Case reports of acute attacks occurring during pregnancy and the puerperium 
continue to appear (Keung et al2000). 
15.6 OTHER ASSOCIATIONS WITH PORPHYRIA 
Psychiatric manifestations 
Crimlisk (1997) has recently reviewed the associations between porphyria and psychiatric 
illness. The first indication that there might be an association was the description by Karlbling 
et al (1961) which reported that 35 of 2500 psychiatric patients admitted to a short term 
psychiatric unit screened positively for PBG with the Watson Schwartz reaction. Twelve of 
these were reported to have manifest AIP on clinical grounds. This gave a point prevalence of 
0.48%. A follow-up study 11 years later in Australia (McEwin 1972) used a quantitative PBG 











nearly 4000 psychiatric patients by the Watson Schwartz reaction, confinning positive results 
by the measurement of 24-hour excretion of ALA and PBG. 70 patients screened positive, of 
whom 8 were thought to have manifest AlP on the basis of further tests which included PBG 
deaminase assay. A further 10 positive patients were thought to have AIP though no 
association could be made between their clinical picture and the condition since the absence 
of raised urinary porphyrin precursors suggested quiescence. They concluded that the point 
prevalence for AIP was 0.21 %. The psychiatric diagnoses included schizophrenia, schizo­
affective disorder and atypical psychosis. It is currently believed that the studies may well 
have overestimated the presence of porphyria in view of the deficiencies of Watson-Schwarz 
screening for PBG alone as a diagnostic test for porphyria. In no study was any control group 
employed and the prevalence of porphyria in the community from which the patients admitted 
to these institutions were drawn is unknown. Nor has the eventual outcome of these patients 
been reported. It is not known whether withdrawal of psychotropic medication in any way 
modified their clinical histories. The link between porphyria and overt psychosis in the 
absence of the acute attack remains unproven. 
The association between porphyria and psychiatric illness, supposedly identified by the 
demonstration of an excess of porphyria among psychiatric poulations, has become a 
commonplace in both the medical and the lay literature, yet careful studies in unselected 
populations of porphyric patients have failed to lend significant support. Wetterburg's study 
in Swedish patients (Wetterburg 1967) had suggested that neuropsychiatric symptoms are not 
associated with AlP or VP in remission. The study by Kaupinnen and Mustajoki (1992) 
confinned these findings, though there was a suggestion of a slightly increased risk of 
generalized anxiety in females during early middle age. Since this was purely based on a self­
reported questionnaire, the case was thought to remain unproven. 
Patience et al (1994) undertook a study to detennine whether major mental illness co­
segregated with acute intennittent porphyria in families where the two conditions are found. 
They identified 16 individuals who had had psychiatric contact from the case records of 344 
consecutive patients held by the porphyrias research group in Glasgow. Twelve of these were 
available for study. Of these twelve probands, 9 were asymptomatic carriers of AlP. Forty 
relatives were interviewed for a history of mental illness and for current symptoms. No 
association was found between AIP and schizophrenia or manic-depressive illness. Only one 
patient with schizophrenia was identified amongst these 344 SUbjects. Bipolar illness was 
identified in two families with AlP but failed to co-segregate with the disease. The 
commonest psychiatric diagnosis assigned in these patients was generalised anxiety. 
In contrast, confusion and psychosis occurring as part of the acute attack are reported in 
reliable series (Elder et al 1980, Mustajoki 1980), but this does not appear to extend to 
patients with quiescent porphyria. 
Hypertension and renal failure 
An association between hypertension, renal disease and AlP has been suggested, though the 
data on which these claims are made have always been difficult to interpret. In a large family 
with acute porphyria (Church et al 1992), a prospective study showed a significant difference 
between mean systolic and diastolic blood pressure and plasma creatinine between porphyric 
and non-porphyric subjects. Five of 19 porphyric subjects in the third generation died of the 
complications of chronic hypertension, with renal failure in three. Overall, 62% of those 
subjects tested had hypertension and 50% showed renal impainnent; neither hypertension or 
renal failure were noted in the apparently non porphyric subjects. Yet this extraordinarily 













second inherited condition which, interestingly, must co-segregate with porphyria in this 
family. 
A recent population-based case-control study based on mortality data '(Andersson and 
Lithner 1994) suggested that hypertension is more common in patients with severe AlP (56%) 
in comparison with controls and patients with latent AlP (23% and 16% respectively). Renal 
disease did not appear more common in patients with AlP than in controls, though renal 
function was impaired in 3 of 8 patients with severe recurrent AIP; one of these however had 
another cause for this in the form of nephritis in association with systemic lupus 
erythematosus. Hypertension was commonly registered on the death certificates of patients 
with manifest AlP (68%), compared with 21 % of those with latent AlP; however neither 
myocardial infarction nor stroke were more common. The authors suggest that hypertension is 
more common in patients with manifest AlP than in those with latent AlP or control subjects. 
By contrast, they found no evidence of an association between hypertension or renal disease 
and VP. 
Subclinical neuropathy 
Severe motor neuropathy is a well recognised complication of the severe or untreated acute 
attack of porphyria. Indeed, most of the symptoms of the acute attack are ascribed to an 
autonomic neuropathy. Arising from the observation that a subclinical neuropathy may be 
present despite an absence of symptoms in lead poisoning (Seppalainen and Hemberg 1972), 
Mustajoki and Seppalainen (1975) investigated peripheral nerve conduction velocities in 20 
patients with AlP, 5 with VP and 25 age- and sex-matched controls. Only nine of these 
porphyric patients had never had symptoms of porphyria. A further thirteen had had 
symptoms of acute porphyria 1-12 years earlier (acute neurological symptoms or acute 
abdominal symptoms) and two of these showed slight neurological deficits. The other three 
subjects complained of recurrent non-specific pains or paraesthesiae. The results suggested a 
subclinical neuropathy. The conduction velocity of slow motor fibres of the ulnar nerve, and 
the sensory conduction velocity of the median and ulnar nerves were significantly slower in 
patients when compared with controls. The conduction velocity of slower fibres was the same 
in subjects who had had previous acute symptoms and those who had not. Motor and sensory 
conduction velocity showed a trend towards lower values in those who had had acute 
symptoms as compared to those who had not, but the difference was not significant. Nine 
patients were studied with electromyography. One of these had no prior symptoms and was 
normal. The other eight had all had prior symptoms and showed changes compatible with 
denervation. No correlation could be shown with age, sex, type of porphyria or the excretion 
levels of porphyrins. 
In their discussion, Mustajoki and Seppalainen (1975) state that abnormalities in the 
conduction velocity of slower fibres were also evident in porphyric patients who had never 
had symptoms. These results are however not given directly, and the frequency or importance 
of this finding cannot be assessed from this report. The authors make the point that the tests of 
neuronal function they employed are more sensitive than the usual routine tests used in 
neurophysiological laboratories which may explain why they found abnormalities even in 
asymptomatic patients; others have reported normal motor conduction velocities or rapidly 
reversible abnormalities even in patients with neurological manifestations (Simpson 1962, 
Maytham and Eales 1971). That patient who have previously experienced an acute attack 
retain objective neurological deficits years later is perhaps not surprising. A more interesting 
conclusion from this study is that patients who have never experienced symptoms may 
demonstrate a subclinical neuropathy. Insufficient data are given in this paper to assess the 












however, are the histological findings in sural nerve biopsies of 2 patients with Hep reported 
by Di Trapani et al (1984). They found evidence of axonal degeneration in 2 patients with 
Hep, one of whom had had an acute attack six months before, the second of whom had never 
experienced an acute attack though he had clinical and electrophysiological evidence of 
chronic progressive neuropathy. 
Similar results have subsequently been presented for other patients with AlP (Kochar et al 
2000). In a study of 25 patients, all of whom had had previous acute attacks and were now in 
the latent phase, 19 demonstrated one or other abnormal neurophysiological parameter, which 
included reduced motor and sensory nerve conduction velocities, late responses and median 
nerve somatosensory evoked potentials. Reduced nerve conduction velocity appeared to have 
no relationship with age, sex, or duration of illness or the number of attacks which had been 
experienced. Others have failed to demonstrate reliable abnormalities in patients with latent 
AlP and in those with no symptoms whereas obvious changes were present in patients with 
clinical neuropathy (Flugel and Druschky 1977). 
Tests of autonomic functions have also been reported in acute intermittent porphyria. 
Y eung-Laiwah et al (1985) reported evidence of both parasympathetic and sympathetic 
dysfunction during the acute attack in subjects with AlP, which improved during remission. 
However, mild parasympathetic dysfunction was also detectable doing remission and in latent 
asymptomatic AIP. 
Hepatocellular carcinoma 
An association between hepatocellular carcinoma and AIP in Sweden has been suggested by 
Lithner and Wetterberg (1984). Kauppinen and Mustajoki (1988) searched the Finnish 
register of porphyrias and recovered details of 82 patients, of whom 63 had AlP and 19 VP, 
who had died since 1929. The cause of death was reported as hepatocellular carcinoma in 7 
AIP patients and 1 VP patient. This gives a relative risk of dying of hepatocellular carcinoma 
of 61. There is a strong association with AIP, and at first sight the relative risk must be greatly 
increased in VP (1 patient of 8). The authors caution however that no conclusions can be 
drawn on the basis of one patient. Insufficient details were available for the importance of 
other risk factors for hepatocellular carcinoma to be adequately assessed. Thus hepatitis B 
surface antigen was tested in only one patient, who was negative. One patient had a history of 
hepatitis and a period of alcohol consumption. There were however no grounds to believe that 
factors other than AlP had been present in these patients. More recent studies have confirmed 
the increased risk of cancer in AlP and peT, largely as a result of an excess of hepatocellular 
carcinoma, though a small excess of lung cancer (and of mortality from cirrhosis and 
emphysema) was found. Any association with VP was not specifically assessed (Linet et al 
1999). 
A case report from Tidman et al (1989) reported the onset of porphyric skin disease in a 70 
year old female in whom a hepatocellular carcinoma was diagnosed. Investigation of 
porphyrin excretion patterns was thought to demonstrate a pattern typical of VP. One notes 
however that the plasma emission scan was maximal at 620 nm, which would suggest peT 
rather than VP. The authors suggest that the most likely explanation for the association in this 
patient was that the tumour was coincidental, but resulted in some intrahepatic cholestasis 
with reduced biliary excretion of porphyrins aild precipitation of the cutaneous syndrome as 
has previously been described for VP (Fowler and Ward 1975). A second possibility was that 
the hepatocellular carcinoma resulted in a tumour-induced secretion of porphyrins as a true 
paroneoplastic phenomenon. This association has previously been reported for peT (Solis et 
al 1982, Grossman and Bickers 1978) but is rare. No definitive diagnosis was however 














An association between EPP and cholelithiasis has been recognised since the first report by 
Magnus et al (1961). Gallstones associated with EPP contain protoporphyrin (Cripps and 
Scheuer 1965), which is to be expected since EPP is associated with the increased biliary 
excretion of protoporphyrin. Herrick et al (1991) reported four patients with VP who were 
diagnosed as having cholecystitis. Gallstones were recovered at surgery in two patients; the 
first contained an excess of protoporphyrin, the second was not assayed but fluoresced under 
ultraviolet light. VP is associated with the increased excretion of protoporphyrinogen in bile 
(Bloomer et al 1990), and the authors postulated that protoporphyrinogen undergoes auto­
oxidation to protoporphyrin in bile with consequent stone formation. 
15.7 THE CLINICAL STUDIES 
The clinical features of VP, the syndrome of homozygous VP and the pathogenesis, 
presentation and management of the acute attack have been reviewed in this chapter. Our 
personal experience with the clinical presentation of VP is described in the following 
chapters. In Chapter 16, we describe the South African experience with HVP. In Chapter 17, 
the clinical features ofVP in a large family, fully characterised by the presence or absence of 
the R59W mutation, are described. In Chapter 18, a personal experience with the acute attack 
ofboth AlP and VP is described. Brief conclusions are drawn at the end of each chapter and a 













HOMOZYGOUS VARIEGATE PORPHYRIA: THE SOUTH 
AFRICAN EXPERIENCE 
16.1 INTRODUCTION 
The syndrome resulting from homo-allelic inheritance of a single mutation or hetero-allelic 
inheritance of two mutations in the PPO gene (HVP) appears to be distinct from the clinical 
syndrome accompanying heterozygous VP (Chapter 15). It is noteworthy that HVP does not 
appear to be common in South Africa despite the very high prevalence of the R59W mutation. 
Our experience with HVP in South Africa is described. 
16.2 OBJECTIVES 
• 	 To describe the clinical features associated with the syndrome ofhomozygous VP. 




Four patients with biochemical evidence ofVP in whom we have diagnosed HVP on the basis 
ofclinical appearance and DNA studies are described. 
Biochemical diagnosis 
Urine, stool, plasma and erythrocyte porphyrins were analysed by quantitative thin-layer 
chromatography and quantitative fluoroscanning as described in Appendix 1. 
PPO activity 
In the first subject, PPO activity was determined on Epstein-Barr virus transformed 
lyrnphoblasts, using the methods described in Appendices 2 and 3. 
Identification of mutations 
The mutations discussed in this chapter have been described in Chapters 3 and 4. The R59W 
and R168C mutations were first identified in cloned sequences derived from lyrnphoblasts of 
the first subject. The R59W mutation was identified in the remaining three subjects by AvaJ 
restriction assay. The Y348C and R138P mutations were first identified by 
SSCPlheteroduplex analysis and confirmed by direct automated sequencing. For family 
studies, the R59W mutation is identified by AvaJ restriction assay, the R168C mutation by 
BsaJJ restriction assay, the Y348C mutation by Mae/II restriction assay and the R138P by 














The porphyria diagnostic service at UCT has diagnosed HVP in 4 subjects. The DNA findings 
are summarised in Table 16-1, and the patients are described below. 
Family Subject Allele I Allele II 
I LO R59W R168C 
II CvdM R59W Y348C 
III DdP R59W R138P 
AN R59W R138P 
Table 16-1. Summary of the molecular [mdings in three families in whom HVP has 
been recognised. 
Proband 1: LO 
Clinical description 
This female child was born in 1986. Severe photosensitivity was noted from birth, when she 
developed severe blistering of the face and hands during phototherapy for neonatal jaundice. 
Porphyria was not diagnosed until the age of 9 months, when porphyrins were sent to the 
UCT laboratory for screening. As she grew older, she showed evidence of blisters, erosions 
and scars on the hands and face (Figure 16-1). In contrast with heterozygous VP, skin disease 
was also apparent on the scalp, with consequent loss of hair. Skin changes were also noted in 
areas not exposed to the sun, and the skin was thickened and infiltrated on the proximal arms 
and legs, and on the trunk and buttocks. Skin biopsies from sun-exposed areas were abnormal 
with striking perivascular PAS-positive non-fluorescent hyaline deposits in the papillary and 
upper-reticular dermis. Features of acute and chronic photo-damage with basket weave 
hyperkeratosis, epidermal atrophy, necrotic keratinocytes and marked dermal solar elastosis 
were also present. Histological changes were also noted in the non-exposed skin but were less 
marked, consisting largely of hyaline deposits around papillary dermal vessels. During the 
first seven years of life, she experienced a recurring problem of staphylococcal skin infection, 
particularly of the fingers, which was complicated by septicaemia on several occasions. 
Permanent cloxacillin prophylaxis proved highly effective in preventing these infections and 
was continued until the age of9. 
Other obvious features were severe myopia and a pendular nystagmus. Particular striking 
is the severe brachydactyly (Figure 16-2). The fingers and toes are markedly foreshortened. 
This has resulted in severe functional impairment such that she cannot grasp a pencil nor use a 
pair of scissors. Radiographs (Figure 16-3) showed brachydactyly with broad short 
metacarpals and phalanges and a delayed bone age. Of particular concern to the parents was a 
tendency to self-mutation; particularly compulsive gnawing and biting of the damaged 
fingers. This did not appear to be accompanied by pain. Furthermore, her parents had 
observed that the child had on several occasions bumt her fingers on a stove without any 
apparent discomfort. A paediatric neurologist confirmed the presence of a gross sensory 
neuropathy of the hands and feet. Electrophysiological studies of nerve conduction 











with a sensory neuropathy. No motor abnormalities were demonstrable. This is in marked 
contrast to the typical neuropathy accompanying the acute attack of heterozygous VP, which 
is predominantly motor. Histology was performed on a sural nerve biopsy. A paucity of small 
unmyelinated and myelinated fibres was shown as well as some Wallerian degeneration, but 
the most noticeable feature was a marked widening of the nodal gaps with a loss of Schwann 
cell cytoplasm over the gap in keeping with early segmental demyelination. Neurological 
development was delayed and at 6 years her perceptual and motor development were about 1 
year behind the expected stage of development. She demonstrated appropriate verbal skills 
and, in all other respects, normal intelligence. Though she was reported to have had infrequent 
complex partial seizures; electroencephalography is normal and the evidence for this is not 
convmcmg. 
She is currently 13 years old (Figure 16-4). She remains in a good health. The skin and 
finger changes are more severe and she is of small stature. She is performing adequately at a 
special school for the physically handicapped. She is reported to have behavioural 
abnormalities including a reduced attention span, hyperactivity and a low threshold for 
frustration. She has been receiving methylphenidate (Ritalin®) with good effect and with no 
apparent deterioration of porphyria. In the past five months she has begun menstruating. This 
is not been associated with any aggravation of porphyria. At no stage has she suffered 
symptoms suggestive of an acute attack. 
Biochemical results 
The results are compatible with VP (Table 16-2). An levated erythrocyte protoporphyrin 
concentration is additionally noted. 
PPO activity 
A severe reduction in activity to less than 10% of the control value was demonstrated in the 
proband. Her mother showed a 50% reduction in activity in keeping with heterozygous VP. 
PPO activity in her father was reduced by approximately 25%, which is significantly less than 
the 50% reduction shown in a large group of heterozygous South African patients with VP 
(Meissner et aI1986). 
DNA studies 
These are fully described in Chapters 3 and 4. The proband is an R59WIR168C compound 
heterozygote (Meissner 1996). The mother carries the R59W mutation and expresses VP 
biochemically though she is asymptomatic. The father, who is originally of Dutch and 
German descent, carries the R168C mutation and is both biochemically and clinically silent. 
Family studies 
There was no family history ofVP in either the maternal or the paternal lineages. The proband 
has 2 younger siblings. Neither has shown clinical or biochemical evidence ofVP. The elder 
sibling carries neither the R59W or the R168C mutation: the younger child has yet to be 
tested. 
Proband 2: CvdM 
The second subject is currently aged 7 years. She is of Afrikaner descent, the daughter of 
unrelated parents. She first presented at the age of 10 months with severe skin disease 













Subjects ULN LO CvdM DdP AN 
Urine precursors (umo1/10 mmol creatinine) 
ALA <45 16 16 106 84 
PBG <16 9 8 106 24 
Urine (nmol/10 mmol creatinine) 
Uroporphyrin <20 31 12 1464 384 
C7 <1.5 0 18 570 222 
C6 0 0 178 55 
C5 0 6 1296 203 
Coproporphyrin <240 101 177 4538 478 
Stool (nmol/g dry weight) 
Uroporphyrin <1.7 5 2 33 0 
C7 0 0 73 0 
C6 0 0 120 0 
Pseudo C5 0 23 376 130 
C5 13 2 161 0 
Isocoproporphyrin 0 0 114 0 
Coproporphyrin <50 67 69 1212 620 
C3 0 0 634 0 
Protoporphyrin <200 698 432 1804 407 
Plasma (nmol/l) 
Uroporphyrin <2.5 2 2 13 10 
C7 0 0 4 0 
C6 0 0 10 0 
C5 0 0 0 0 
PU 0 20 23 26 
Coproporphyrin <1.0 26 0 0 0 
Protoporphyrin <4.5 46 44 16 51 
Red cells (nmol/l) 
Uroporphyrin 0 0 0 -
C7 0 0 0 -
C6 0 0 0 -
C5 0 0 0 -
Coproporphyrin <80 0 0 0 -
Protoporphyrin <800 4406 5500 2580 -













The subject shows a clinical picture markedly similar to that of LO. She has obvious skin 
changes in sun-exposed areas compatible with a diagnosis of VP: blisters, scars, pigmentary 
changes and milia. Unexposed skin also appears to have an abnormal consistency. She has 
marked brachydactyly (Figure 16-5), photo-onycholysis, myopia, nystagmus, a sensory 
neuropathy and problems with concentration but is otherwise of normal intelligence. She has 
never experienced symptoms suggestive of an acute attack. 
Biochemical results 
These are shown in Table 16-2. The results are compatible with VP. The erythrocyte 
protoporphyrin is additionally raised. 
DNA studies 
These are described in Chapter 4 and in a subsequent publication (Corrigall et al 2000). The 
proband was found to be a R59WN348C compound heterozygote. The R59W mutation is 
carried on the maternal allele and the previously umeported Y348C mutation on the paternal 
allele. Several maternal and paternal family members carry the R59W and Y348C mutations 
respectively. The Y348C mutation was shown to be a de novo mutation in the father. 
Family studies 
Neither parent reports a family history of VP, and neither was aware of porphyria prior to 
diagnosis in the child. The proband's mother demonstrated a positive biochemical porphyrin 
profile for VP whereas the father's was normal. He did however demonstrate a small peak on 
plasma porphyrin scanning. The results of genetic and biochemical testing are summarised in 
the pedigree shown in Figure 4-20. No relative has ever experienced clinical symptoms of 
porphyria. Her mother (R59W-positive) and a paternal half-brother (Y348C-positive) show a 
biochemical profile compatible with VP, whereas no other first-degree relatives have 
biochemical evidence for VP either on TLC or on plasma fluoroscanning. 
Patients 3 and 4: DdP and AN 
Clinical description 
Proband 3 is a young mixed-race female patient who first presented to our unit at the age of 
19 with an acute porphyric crisis. No diagnosis of porphyria had been made either in the 
proband or the family before this. She is currently 26 years old. She has subsequently 
experienced two mild acute attacks. She has otherwise remained in good health, and has two 
healthy children. Her skin disease is unusually severe in comparison with that of typical 
patients with VP. Her hands and face show evidence of chronic blistering, thinning and 
atrophy of the skin and hypertrichosis (Fig 16-6). She shows deformities of the hands with a 
degree of shortening of the fmgers and deformities of the finger joints (Figure 16-7), though 
reasonable function is maintained. She shows no ocular, developmental or neurological 
abnormalities. The clinical features are considerably less marked than those of probands 1 and 
2, and the possibility ofHVP was not initially entertained. 
Patient 4 is her 23 year-old sister. She developed typical skin changes of VP at the age of 
19. Since VP had ready been described in her sister, the diagnosis was made promptly. The 
skin disease is typical of VP and would be classed as moderately severe. There are no finger 
deformities and no evidence of skeletal, ocular or neurological disorder. She has never 












Both patients show a porphyrin profile compatible with VP (Table 16-2); the sample shown 
for DduP was taken during the her first acute attack and therefore shows elevated ALA and 
PBG concentrations. Her erythrocyte protoporphyrin is additionally elevated. 
DNA studies 
Initially these two subjects were diagnosed as VP, unqualified, though the skin disease was 
felt to be unusually severe in Proband 3. When DNA testing became possible, both were 
confirmed to carry the R59W mutation. However, we subsequently considered the possibility 
of a second mutation in DduP in view of the unusually severe phenotype. SSCPIHD analysis 
followed by direct automated sequencing revealed an additional R138P mutation in DdP and 
subsequently in AN (Chapter 4). Both are therefore R59WIR138P compound heterozygotes. 
Family studies 
Both Proband 3's prepubertal sons have been shown to carry the R59W mutation. Patient 4's 
13-year-old-daughter is negative for the R59W mutation and carries the R138P mutation. 
Biochemical testing has confirmed VP in the mother, and was negative in two brothers. The 
father has refused testing. Family studies are incomplete. 
16.5 CONCLUSIONS IN BRIEF 
The clinical, biochemical and molecular features of four subjects with HVP have been 
described. No subject is an R59W homozygote: all are compound heterozygotes heteroallelic 
for the R59W and a second mutation. There is evidence of considerable phenotypic variation, 
ranging from severe abnormalities in the R59WIR168C and R59WIY348C compound 
heterozygotes to milder abnormalities in the R59WIR138P compound heterozygotes. 
Furthermore, clinical severity was itself variable in two sisters carrying the R59WIR138P 











Figure 16-1. Proband 1: The face ofLO as a young child. Marked skin disease is evident. 
































THE CLINICAL AND BIOCHEMICAL EFFECTS OF THE 
R59W MUTATION IN A SINGLE FAMILY 
17.1 INTRODUCTION 
The proportion of subjects carrying a VP-associated mutation who express the disease, either 
biochemically or clinically, is not known with certainty. Some subjects who express VP 
biochemically appear to remain asymptomatic thoroughout their lives and it is known that 
other "silent" subjects have normal stool porphyrin excretion profiles. Such cases were 
initially identified as obligate carriers who had transmitted the defect to the next generation 
despite themselves or who were shown to have reduced PPO activity in lymphoblast PPO 
assays (Meissner et al 1986) yet appeared normal on biochemical testing. More recently, 
silent carriers have been directly identified by the demonstration of a VP-associated mutation 
associated with normal porphyrin excretion patterns (Chapter 5). 
Two previous studies have attempted to assess the extent to which VP is clinically 
expressed in South Africa. Eales et al (1980) suggested that 90% of patients with VP 
experienced acute attacks, skin disease or both. A later survey (Rift et al 1997) indicated that 
there had been a change over the period between the two studies, with a decreasing proportion 
experiencing acute attacks, correspondingly more experiencing skin disease only and a large 
group being clinically silent but detected as a result of the investigation of affected families 
(Table 13-1). 
Skin Acute Both Latent i 
Eales et al (1980) 52% 17% 21% 10% 
i Rift et al (1997) 45% 10% 9% 38% 
Table 17-1. Frequency of clinical manifestations ofVP in Cape Town as reported in 
1980 and 1997. 
In both studies, the sample population consisted of patients proven biochemically to have 
VP, and are therefore weighted in favour of those with biochemically manifest disease. Silent 
carriers would not be included since they would have been undetectable before the advent of 
DNA testing. Furthermore, there is a strong element of ascertainment bias in that a 
substantial proportion of patients are tested as a result of their symptoms. To determine the 
true prevalence of symptoms among an unselected VP population, it is appropriate to test all 
members of a sufficiently large family or group of families, such that both symptomatic and 
asymptomatic gene carriers stand equal chances of been identified. This information is then 
correlated with the presence of biochemical and clinical abnormalities. 
Accordingly, with simple and accurate methods for the identification of the R59W 
mutation at our disposal, we initiated a study to determine the degree to which carriage o~ the 













• 	 To characterise a single family in tenns ofR59W carriage. 
• 	 To detennine the prevalence of biochemical expression associated with the R59W 
mutation 
• 	 To detennine the prevalence and nature of clinical symptoms arising from VP. 
• 	 To detennine the effect of age, menarche, menstruation and menopause on clinical 
symptoms. 
• 	 To identify associations between VP and other medical illnesses. 
17.3 METHODS 
Subjects 
We chose a family which had been studied by Professor Eales 20 years previously. Key 
people within this family were contacted and, with their help, the family tree was revised and 
updated (Figure 17-1). All family members were contacted by letter and their participation 
invited. As far as possible, parents were tested for the R59W mutation first; where they tested 
negative, subsequent generations in that line were not examined further. 
DNA analysis 
Genomic DNA was extracted from peripheral whole blood by the method of Parzer and 
Mannholter (1991). Exon 3 was amplified using the primers listed in Table 4-1. 
Approximately 1 ~g of peR product was digested with Ava} using a sufficient quantity to 
allow for complete digestion, at the temperature and for the time recommended by the 
manufacturers of the enzyme. The products were then electrophoresed on a 6% 
polyacrylamide gel and visualised by ethidium bromide staining. Pre-and post-digestion 
products for both patient and a control were always included in the gel. The technique is fully 
described in Appendix 4-13. 
Biochemical analysis 
Urine, stool and plasma porphyrin concentrations were measured by the methods described in 
Appendix 1. 
Plasma fluoroscanning 
Plasma was diluted 1: I 0 with phosphate-buffered saline and the emission spectrum was 
scanned from 580 nm to 650 nm with the excitation monochromator set at 405 nm. The 












A questionnaire in both English and Afrikaans, reproduced in Appendix 10, was sent to all 
subjects. It was designed with the following intentions: 
• 	 To collect essential demographic data. 
• 	 To obtain information about the diagnosis; in particular, whether previous biochemical 
testing for porphyria had been undertaken. 
• 	 To determine whether the subject had ever experienced acute symptoms. 
• 	 To determine whether the subject had ever experienced cutaneous symptoms. 
• 	 To identify any effect of ageing, menarche, puberty, menstruation and the menopause 
on clinical expression. 
• 	 To identify any association between VP and a history ofhypertension, heart disease and 
psychiatric or emotional illness. 
Those who did not return the questionnaire initially were sent a reminder and further 
questionnaire. At the conclusion of the survey, those subjects who were R59W -positive but 
had not yet returned their questionnaires were contacted telephonically and the questionnaire 
was completed over the telephone. 
Data handling 
All data were entered into a Microsoft Access database. Statistical analyses were performed 
with the Statistica software package. 
17.4 RESULTS 
Inheritance of the R59W mutation 
75 members of this extended family were tested. Following the exclusion of those found to 
belong to non-informative branches of the family, 62 subjects were included. These are 
shown, classified by DNA status, sex and age, in Table 17-2. Five obligate carriers in 
generation I and two subjects in generation II are deceased. All living subjects have been 
tested with the exception of three subjects in generation III who declined to participate. Of the 
subjects enrolled, 55 were aged 16 or more and are classified as "adult" in the following 
analysis. The autosomal dominant mode of transmission is confirmed. Excluding the two 
positive females in generation I (since they, unlike the succeeding generations are not 
randomly tested), there are 29 DNA-negative subjects and 31 DNA-positive subjects. 39.4% 
of the males and 67% of the females tested positive for the R59W mutation. The difference is 
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Figure 16-], Abridged pedigree illustrating 4 generations of the R59W-positive family. R59W-positive subjects are indicated by a solid symbol, R59W-negative subjects 

by a shaded symbol and subjects who decline testing by an open symbol. A diagonal slash indicates that the subject is deceased. R59W -positive subjects are further 

characterised as follows: 

B+ Positive VP profile on TLC. B- Negative VP profile on TLC. B+O Positive VP profile previously documented but currently negative. 

S+ Positive plasma fluorescence scan. S- Negative plasma fluorescence scan. S? Equivocal plasma fluorescence scan. 

X VP clinically expressed. 0 VP clinically silent. 















Any age Adults> 16 years ! 
Female Male Female Male ! 
Untested 4 7 1 ! 





13 17 12 ! 
_ .............. _-­
Table 17-2. Results of DNA testing in the extended family. The 12 subjects not 
tested include 9 subjects in generations I and II who are deceased and 3 subjects in 
generation III who declined to participate. 
Correlation with stool biochemistry 
44 adult subjects provided adequate specimens for biochemical analysis (Table 17-3). Of 
those RS9W-negative, 16 (89%) had negative stool biochemistry, while a further 2 (11%) 
showed equivocal results. Of the RS9W-positive subjects, 14 (S4%) had positive stool 
biochemistry, a further 3 (12%) had equivocal results and 9 (3S%) were unequivocally 
negative, giving a significant false-negative-rate. Negative stool results were not confined to 
younger subjects; the mean age of the RS9W-positive subjects with normal stool porphyrin 
profiles was 43 (range 21-64). Furthermore, three female subjects, aged SO, 56 and 64, who 
currently are biochemically negative, are known to have tested positive biochemically 
previously. 
Correlation with plasma fluoroscanning 
87.5% of the R59W-positive subjects were positive for a peak at 625 nm by plasma 
fluoroscanning, while all the R59W-negative subjects had normal scans. Plasma 
fluoroscanning is thus more sensitive than stool porphyrin analysis in the detection of carriers. 
Two subjects with plasma scan results have not been tested biochemically. In those subjects 
in whom both tests were performed, plasma fluoroscanning was shown to be more sensitive. 
10 R59W -positive subjects with a stool profile diagnostic of VP, 8 subjects with a normal 
profile and 2 subjects with an equivocal profile had a positive plasma fluoroscanning result. 
Three subjects, aged 57, 64 and 73 had negative plasma scans. One of these had a normal 
stool profile, the second was equivocal and the third had not been tested. However, three other 
subjects, though counted here as positive, demonstrated very small peaks, of the order of a 2 
mm deflection only. All had normal biochemistry. 
Experience with previous testing 
Only 7 of 11 (64%) of R59W-negative respondents and 14 of 28 (50%) of R59W-positive 
respondents reported having been tested previously by stool porphyrin analysis. Thus, even 
within a large well-characterised family known to carry VP, a high proportion of potential 
carriers had not previously offered themselves for testing. Of the R59W -negative group, five 
(71 %) were aware of a previous negative result on porphyrin analysis, one had been given an 
equivocal result and one had been tested but was unaware of his result. Of the R59W-positive 
group, 10 (71 %) were aware of a previous positive result on biochemical testing, three knew 













Table 17-3. Biochemical results and plasma fluoroscanning correlated with DNA 
status in adults. (Note that the number of patients tested by porphyrin analysis and 
by fluoroscanning differ, and percentages rather than absolute numbers should be 
compared.) 
Clinical symptoms of VP 
No subject aged less than 16 had experienced either skin disease or acute symptoms. The 
discussion which follows is therefore limited to those aged 16 or more. 
Acute attacks 
Clinical details were available on 28 of the 29 R59W-positive adults (97%). The results of the 
study are summarised in Figure 17-2. Only one patient had had an unequivocal acute attack. 
This was a single attack in a female patient, then aged 35, in 1965 for which she was treated 
in hospital for 3 weeks. At that time she had already been aware of typical skin lesions for 5 
years. The attack was not complicated by paralysis and there has been no recurrence. A 
further 5 subjects reported that they suspected that they had previous acute attacks. Two of 
these could quite clearly be ruled out as having had acute attacks on the basis of an atypical 
history. The evidence in the remaining two subjects is not compelling and is regarded at best 
as equivocal; were these acute attacks at all, we would classifY them as mild, with no 
recurrence and no complications such as neuropathy. Both had skin disease. Assuming that 
perhaps one of these attacks was genuine, a reasonable estimate would be that acute attacks 
were experienced in approximately 2 (7.1 %) of these subjects, with a minimum of 1 (3.6%) 
and a maximum of3 (10.7%). 
When specifically asked about experiences with abdominal pain, 6 of 28 R59W-positive 
subjects (21.4%) and 2 of 11 R59W-negative subjects (18%) reported experiencing significant 
abdominal pain in the past. The difference is not statistically significant (p=O.74, t\2), 
indicating that a mere history of abdominal pain is an extremely unreliable diagnostic 
indicator ofacute symptoms in VP. 
Skin disease 
Of the 28 R59W-positive subjects, 11 had a history of unequivocal photocutaneous sensitivity 
compatible with VP: A further 3 described skin symptoms which seemed unlikely to represent 
porphyric skin disease. From this study therefore, it appears that the proportion of patients 
with R59W-positive VP experiencing skin disease is 39.3%. The skin disease was most 
marked on the dorsal surfaces of the hands In 10 subj ects and on the face in one. In addition 
to involvement of the hands, skin disease was reported on the face, forearms and feet in 3, 2 
and 4 subjects respectively. 
Sex and skin disease 
~kin disease was exp~rienced in 8 of 14 females as opposed to 3 of 11 males (57% vs 27%). It 
IS unc!ear whet~er thIS r~fl7cts a true sexual bias or is an artefact produced by small numbers. 
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Figure 17-2. Results of the clinical study. 
Age and skin disease 
There is also no significant difference in age between those subjects showing skin disease and 
those who do not (Figure 17-3). The average ages and standard deviations are 44.1±17.3 and 
40.4±18.0 respectively. The difference is not statistically significant (p=O.6, t test). There 
appeared to be a strong association between advancing age and a subjective perception of 
improvement in skin disease. The ages of the 5 oldest subjects (3 female, 2 male) range from 
48 to 73; four of these (3 female, 1 male) reported an improvement in skin disease as they had 
grown older. One of these are females was postmenopausal; the other two were not. None of 
the subjects younger than 45 had noticed any improvement in their skins. It therefore appears 
that the skin disease of VP has a tendency to improve as the patient ages, but that that this 
effect is not evident until after the age of45. 
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Of 28 R59W-positive respondents, 7 (25%) reported problems of anxiety or depression and 
most had consulted a doctor for this. By contrast, none of 11 R59W-negative respondents 
reported these problems. The difference is however not significant (p=0.26, Yates-corrected 
x2). 
Other medical problems 
There were no associations between R59W status and hypertension or heart disease. 
17.5 CONCLUSIONS IN BRIEF 
We have confirmed that neither biochemical nor clinical evidence of VP will be found in 
subjects aged less than 16 years. We have shown that approximately 35% of DNA-positive 
adults will show no biochemical evidence for VP on stool porphyrin testing. Plasma 
fluoroscanning is more sensitive with a false-negative rate of 12.5% and thus, as with stool 
porphyrin chemistry, becomes more likely in older subjects. Approximately 60% of all adults 
with VP are asymptomatic, experiencing neither skin nor acute symptoms. Furthermore, in 
contrast with hospital-based studies, the acute attack ofVP is now a rare in event in the lives 
of most of families carrying VP, with a single confirmed attack in a single subject in this 












THE ACUTE ATTACK: A PERSONAL SERIES 
18.1 INTR,ODUCTION 
The last large series of acute attacks are those those reported by Eales (1980), Mustajoki 
(1978, 1985) and Kaupinnen and Mustajoki (1992). These reports documented a high rate of 
serious complications of the acute attack, but suggested that the prognosis has improved with 
time. Our experience with all acute porphyric crises treated at Groote Schuur Hospital over a 
12 year period is reviewed here. 
18.2 OBJECTIVES 
• To describe the acute attack ofporphyria as seen at Groote Schuur Hospital. 
• To describe the clinical features and compare these with those reported previously. 
• To identify the precipitating factors, clinical consequences, therapy and outcome. 
• To compare the clinical features ofAlP and VP. 
18.3 METHODS 
Subjects 
All patients admitted to Groote Schuur Hospital with a diagnosis of the acute porphyric attack 
during the period 1 July 1986 to 30 April 1999 were admitted and treated under our direct 
supervision. A diagnosis of the acute attack was based on the following grounds: 
• Severe abdominal pain 
• Minimal or absent abdominal tenderness 
• Frequently accompanied by nausea, vomiting and anorexia 
• A clinical presentation essentially identical to a previously documented attack 
• Absence of any other cause for the symptoms. 
All first attacks, as well as any attack with atypical features or in which there was doubt 
about the diagnosis, were further confirmed by a positive Watson-Schwartz test and 
confirmed by the direct measurement of urine PBG concentrations. 
Methods 
Laboratory diagnosis 
Urine was screened for PBG with the Watson-Schwartz test and ALA and PBG 
concentrations were determined by iron-exchange chromatography. The diagnosis of 
porphyria was proven in every patient by quantitative thin-layer chromatography. All methods 
are described in Appendix 1. 
Clinical data 












• 	 Possible precipitating factors, with particular reference to drug exposure, menstruation, 
infection and pregnancy. 
• 	 Duration of the symptoms before presentation. 
On admission 
• 	 Symptoms: pain, nausea, vomiting and constipation. 
• 	 Physical examination, with particular reference to abdominal tenderness, pulse rate and 
blood pressure. 
• 	 Measurement ofserum sodium, potassium, urea and creatinine. 
While in hospital 
• 	 Frequent clinical examination, never less than once daily and, in the early stages of an 
attack, more frequently, with daily recording of clinical condition in the hospital notes. 
• 	 Recording of all complications, with particular reference to neuropathy, paralysis, 
seizures or confusion and ofphlebitis at the site of infusion of haem arginate. 
• 	 Frequent recording ofpulse and blood pressure. 
• 	 Repeat estimations of sodium, potassium, urea and creatinine in patients who failed to 
improve rapidly or in whom initial values had been significantly abnormal. 
• 	 Recording of all drugs administered with times and doses. 
Summarisation 

At the conclusion of the study, all folders were reviewed and the following data extracted, 

summarised and recorded on data sheets. 

• 	 Length ofhospital stay. 
• 	 Highest blood pressure and pulse rate observed during the admission and the day on 
which the highest value occurred. 
• 	 Lowest sodium or potassium, and highest urea or creatinine observed during the 
admission and the day on which the lowest sodium was measured. 
• 	 A retrospective assessment of the severity of symptoms for each day of the admission, 
based on a reading of the clinical notes for that particular day and made without 
reference to the pethidine requirements for that day. This was recorded on the 
following scale: 
• 2 severe pain 
• 1 = moderately severe pain or pain which had clearly lessened in intensity 
• 0 = substantially pain-free or pain which had markedly lessened in intensity. 
• 	 The number ofdays till disappearance ofpain. 
• 	 Total number ofdoses of antiemetics and beta-blockers received. 
• 	 Total dose of pethidine given per day. In the few instances where other opiates such as 
morphine or fentanyl had been administered, the dose was converted to the equivalent 
dose ofpethidine thus: 100 J.1g fentanyl=IO mg morphine=IOO mg pethidine. 
• 	 Daily dose of haem arginate and the number of days on which haem arginate had been 
given. 
• 	 Number ofdoses of tin protoporphyrin given. 
Information storage, retrieval and statistics 
At the conclusion of the study, a master list was made of all patients admitted with acute 
porphyria during the study period correlated with diagnosis, sex, date of birth, diagnosis and 
total number of admissions for the acute attack. All data were entered into a Microsoft Access 
database. Data were analysed using Microsoft Access and statistical comparisons were 











distribution, comparisons were made with the Student's t-test, otherwise the Mann-Whitney U 
test was employed. 2x2 tables were analysed by N2• Sequential data were analysed by one-way 
ANOV A. The specific tests employed are stated in the text. 
18.4 RESULTS 
All subjects admitted to Groote Schuur Hospital with an acute attack during the period of the 
study have been included with two exceptions. One patient (HK) remained almost 
continuously in hospital with severe, essentially unrelenting porphyric crises. She experienced 
more than 100 sequential attacks prior to her death. She is not included in the following 
analyses as her over-representation would distort the data. A second patient (MJ) gradually 
developed a similar profile during the course of the study. Having suffered her first attack in 
1992, she had by late 1996 suffered 33 acute attacks. Data pertaining to these attacks, which 
were more typical of AIP in that she experienced periods free of pain and was able to return 
home bet.ween attacks, have been retained, but details of later attacks, during which she was 
hospital-bound, are not included. The course of both these patients is described in detail later 
in this chapter. 
Twenty-five individual patients were treated for the acute attack during the study period; 
15 with AIP (13 female, 2 male) and 10 with VP (5 female,S male). These data are 
















Table 18-1. Incidence of the acute attack. *One subject (HK) is counted as a patient 
with AlP, but her attacks have been censored as explained above. 
Patients and demography 
Following exclusion of data specific to HK, details of 112 attacks experienced by 24 
individuals were analysed. The female:male ratio is significantly higher in AlP than VP 
(p<0.0001, N2). The mean age of the patients, averaged across all attacks, is shown in Figure 
18-1. The distribution is skewed towards a younger age, and patients with AIP are younger 
than those with VP (Figure 18-2). The difference in age is significant (p<0.0001, Mann­















Figure 18-1. Age incidence for all attacks. 
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Figure 18-2. Age distribution, comparing ALP with VP. 
Number of attacks experienced per patient 
The average number, median number and range of attacks are shown classified by sex and 
diagnosis in Table 18-2. 
VP AlP All 
Male Female Total Male Female Total Total 
n 5 5 10 2 12 14 24 
Mean 3.6 1.4 2.5 7 6 6.1 4.6 
Median 2 1 1 7 2.5 2.5 1 
Minimum 1 1 1 1 1 1 1 
Maximum 8 3 8 13 33 33 33 
Table 18-2: Average number, median number and range of attacks classified by sex 
and diagnosis . 
Several patients had repeated attacks: these are commoner in AlP (Figure 18-3). The 











to recurrent attacks then females. This assumption is probably valid for VP, though the 
difference is not statistically significant (p=0.2, Mann-Whitney U test), but the apparent high 
frequency of acute attacks in males with AIP is not valid since the mean and median are 
derived from just two male patients, one of whom had 13 attacks (Figure 18-4). 
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Figure 18-4. Number of admis
categorised by sex and diagnosis. 
sions in the acute attack per individual patient, 
Presenting symptoms and signs 
The median duration of symptoms before admission was 2 days (range 0-18 days) and was 
unaffected by diagnosis. The clinical features are shown in Figure 18-5. The most common 
presenting symptom is severe abdominal pain. Though very prevalent, it is not invariable, and 
3 of 112 attacks were accompanied either by no pain or by mild pain that was not particularly 
troublesome. Nausea and vomiting are common. Constipation by comparison was rarely a 
prominent symptom. Tachycardia and hypertension, are frequent, but may not be noticeable at 
the time of the first presentation, since they tend to become more obvious during the ensuing 
days, on average reaching a maximum 48 hours after admission. Systolic blood pressure 
tended to be the most sensitive parameter: it was elevated above 120 (a generous upper limit 
of normal in view of the predominately young and female population) in 67% at the time of 
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Figure 18-5: Clinical features of the acute attack (%). The figures for hypertension 
and tachycardia reflect the incidence at any stage of the attack; for neuropathy and 
seizures, the development of new or further manifestations during the attack. 
Admission Highest value 
at any stage 
Pulse: mean (SD) (Imio) 85(15.4) 92(14.2) 
Percentage ofadmissions with pulse >90 23.6% 39.6% 
Systolic blood pressure: mean (SD) (nunHg) 137 (21.6) 154(22.1) 
Percentage ofadmissions with systolic > 120 67.9% 91.5% 
Diastolic blood pressure: mean (SD) (nunHg) 85 (15.6) 92(14.2) 
Percentage ofadmissions with diastolic >80 46.2% 72.6% 
Table 18-3. Tachycardia and hypertension: mean values at admission and mean of 
the highest value recorded at any stage.; percentage of attacks in which the normal 
limit was exceeded. 
Precipitating factors 
The most likely precipitants of the acute attack are shown in Table 18-4, and are analysed 
graphically by sex and diagnosis in Figure 18-6. 
VP AlP 
Male Female Total Male Female Total All 
Hormonal - 0 0 - 12 12 12 
Drugs 13 3 16 3 8 11 27 
Infection 0 0 0 1 1 2 2 
Pregnancy - 1 1 - 0 0 1 
Unknown 5 3 8 10 52* 62 70 
Totals 18 7 25 14 73 87 112 
Table 18-4: Suspected precipitants of the acute attack. *Many of these may be 

















AlP females VP females AlP males VP males 
11 Menses 11 Drugs 0 Infection 0 Pregnancy 11 Unknown 
Figure 18-6. Relative importance of various precipitating factors by diagnosis and sex. 
The most striking finding is the significant proportion of hormonally-related attacks in AlP 
and the high proportion of attacks in female AlP patients for which no precipitating factor 
could be proven. It is likely that some or even most of these may be related to the hormonal 
cycle. Drugs are frequently the precipitating factor in VP, and probably in males with AIP as 
well. These points are discussed in Chapter 19. 
Drugs were implicated in 27 instances and comprised the following: alcohol (9 instances), 
cannabis (9 instances), combined oral contraceptive pill or progesterone (3 instances), 
erythromycin (1 instance), rifampicin or rifampicinlINHlpyrazinamide combination (2 
instances), non-steroidal anti-inflammatory (type unknown, 1 instance) and phenytoin (l 
instance). Particularly striking are the drugs of abuse, alcohol and cannabis, which may 
frequently be taken in combination. Indeed, these were responsible for most of the recurrent 
attacks in males (Table 18-5); reflected here are only those attacks in which there was clear 
evidence of exposure, but it is likely that they were implicated in other attacks as well. 
Subject Sex Diagnosis Drugs Implicated 
in n attacks 
Total number of 
attacks experienced 
CK M AlP Cannabis, alcohol 3 13 
CH M VP Cannabis, alcohol 5 8 
DA M VP Cannabis, alcohol 6 6 
Table 18-5: Effect of drugs of abuse in inducing repetitive attacks in male patients 
with porphyria. 
Biochemical and electrolyte disturbances 
Hyponatraemia was common during the attack (Table 18-6), and 39.3% recorded a sodium 
value below 135 mmoVI at some stage of the admission. Severe hyponatraemia (Na<125 
mmoVl) was noted in 5 admissions: three of these admissions were accompanied by seizures 
and four were accompanied by neuropathy. The lowest sodium values noted were 100 and 
104 mmoVI. Elevated urea values were very common, and were present at the time of 
admission in 64%. This is likely to reflect dehydration, and values typically improved rapidly 











At time of 
admission 
LowesUhighest 
value at any stage 
Sodium: mean (SD) (mmoVl) 136 (4.6) 134 (6.1) 
Percentage with a value <135 mmoVl 26.6% 39.3% 
Potassium: mean (SD) (mmolll) 4.2 (0.5) 4.1 (0.5) 
Percentage with a value <3.5 mmolll 6.5% 9.8% 
Urea: mean (SD) (mmHg) 7.9 (2.9) 8.0 (2.9) 
Percentage with a value >6.7 mmolll 63.0% 64.1 % 
Table 18-6: Biochemical abnormalities. Mean (SD) values at admission and mean 
of the lowest (sodium, potassium) or highest (urea) value recorded during 
admission; percentage ofattacks in which the normal limit was transgressed. 
There, were no significant differences between patients with AlP and VP in these values 
with the exception of the serum potassium, where the values of 4.2 and 3.7 mmolll for AlP 
and VP respectively were significantly different (p=0.001, Mann-Whitney U test). There is no 
obvious explanation for this. Since creatinine concentrations were similar in the two groups, it 
is unlikely to relate to differences in renal function. The biochemical values in males and 
females were similar. 
The mean ALA and PBG values noted at the time of admission were significantly higher in 
AIP than in VP. Mean (SD) values were, for AIP and VP respectively, for ALA, 386.1 




Seizures were encountered in 6 attacks (5 AlP, 1 VP). Three of these were associated with 
. hyponatraemia. Two episodes, in a single patient with severe AlP (MJ), appeared to relate to 
the use oflarge doses ofpethidine; 1975 mg total dose in one attack, and 10650 mg total dose 
in the second. In each case, the seizure was preceded for several hours by myoclonic jerks, 
which are typical of pethidine-induced seizures. Similar seizures were encountered in patient 
HK. 
Neuropathy 
Neuropathy developed at some stage in 11 of the 24 patients: 8 with AlP (57%) and 3 with 
VP (30%). However, in nearly all cases, neuropathy developed before admission to Groote 
Schuur Hospital, usually under the care of another hospital, and in most cases before 
porphyria had been diagnosed. In only 2 of 112 admissions did neuropathy supervene during 
the course of admission to Groote Schuur Hospital: in neither case had haem arginate been 
administered. In most cases neuropathy was limited to mild weakness of the extremities 
manifesting as wrist-drop and foot-drop. Only one patient developed a flaccid quadriparesis 
requiring ventilation. Neuropathy is discussed in more detail In Chapter 19. 
Therapy 











Admissions Median number of 
doses or dosage* 
Range 
metics 61 (54.5%) 3 doses 1-17 
Beta-blockers 39 (34.8%) 6 doses 1-32 
Haem arginate 75 (67.0%) 4 doses 1-8 
Total dose 500mg 125-1252mg 
Tin protoporphyrin 4 (3.6%) 3 doses 2-4 
Pethidine or other opiate 1031103*'" (100%) 1200mg 50-10650mg 
Table 18-7: Drugs used in the treatment of the acute attack. *Antiemetics, beta­
blockers and tin protoporphyrin) are reported in standard doses (prochlorperazine 
6.25 mg by injection, metoclopramide 10 mg by injection, propranalol 40 mg orally 
or atenolol 50 mg orally; pethidine and haem arginate in mg. ** Records were 
incomplete in 9 cases. 
Antiemetics and beta-blockers were administered in 54% and 35% or admissions 
respectively. The pain of the acute attack is severe. Opiates were universally required; the 
total dose required varied widely from 50 mg to over 10 000 mg, with a median dose of 1200 
mg. Doses of75-100 mg, hourly, 2-hourly or 4-hourly were frequently required. 
Figure 18-7 shows the median daily requirement for pethidine, which is significantly 
associated with hospital day (p<0.0001, Kruskal-Wallis ANOVA). (The lower requirement on 
day 1 is artefactual since many patients were admitted in the afternoon or night, and hence 
were not present for a full 24 hours.) It is seen that the pain is worst on the second day, tends 
to persist for days 3 and 4, and thereafter improves rapidly. This is mirrored by a highly 
significant decrease in symptoms as shown in Figure 18-8 (p<0.0001, Kruskal-Wallis 
ANOVA). 
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Figure 18-8. Mean daily severity score by hospital day. 
Haem arginate 
Haem arginate was used in 75 admissions (67%). The first few patients were treated with a 
dose of 3 mglkg. Thereafter a standard dose of 125 mg, irrespective of body mass, was used. 
In 40 instances (53%) a full4-day course was given; in 23 (31%), treatment was stopped after 
3 doses following rapid improvement. In 8 cases only 1 or 2 doses were used. In 5 cases, 5 
doses were given. In 4 cases, a second course of haem arginate was given, following an 
inadequate response to the first course, with a total of 6-8 doses. Patient MJ, with severe AlP, 
was responsible for 6 of the instances where more than 4 doses were used, and tin 
protoporphyrin was additionally used in three of these. The other three patients who required 
additional haem arginate all had AlP, and received 5 doses. 
The median time for starting haem arginate was 2 days, that is on the day following 
admission, with a range of 1-12. Figure 18-9 shows the symptom score by treatment day, 
ranging from day 8 pre-treatment (-8) to day 8 post-initiation of haem therapy (+8). Clearly 
seen is the effect of haem arginate on severity score; values remain high until the initiation of 
haem therapy, whereafter they fall. Figure 18-10 shows the pethidine requirement before and 
after initiation of haem therapy. In this case pethidine requirement rises steadily until the 
decision is taken to commence haem therapy, whereafter the requirement falls. This 
interesting pattern is likely to represent the influence of those patients whose attacks were 
initially judged relatively mild, as shown by relatively low pethidine requirement. However, 
symptoms failed to improve and in many cases deteriorated as the attack progressed, until 
haem therapy was instituted. The decline in both severity score and pethidine requirement are 





j 1.0 .... , .................. .•••,1- ' 

i: ! . . 
!Haem treatment 
~ ~ ~ ~ ~ 4 ~ ~ 1 234 5 6 7 e 
Day of treatment 











-6 .s -4 -3 -2 -1 1 2 3 4 5 6 7 8 9 10 
Treatment day 
Figure 18-10. Effect of initiation of haem therapy (day +1) on pethidine requirement. 
Duration of hospitalization 
The median time till resolution of symptoms was 6 days (range 1-19, interquartile range 
[IQR] 4-7). The median length of hospital stay was 7 days (range 1-56, IQR 5-9). Three 
patients who remained longer than 30 days all had severe, complicated or unresolved attacks: 
1 developed profound quadriparesis requiring ventilation; a second moderate paralysis 
complicated by staphylococcal septicaemia requiring prolonged intravenous therapy; a third 
was HIV positive and her course was complicated by intracranial infection. 
Relative severity of AlP and VP 
Some markers of severity of the acute attack are summarised in Table 18-8. Blood pressure, 
pulse and haem arginate requirement were significantly higher in patients with AIP than in 
patients with VP. No significant difference could however be shown in the length of 
admission or in the time taken for the patient to improve after admission. 
AlP VP 
Mean sn. n Mean sn n p 
Maximal systolic BP 156.5 22.00 83 145.7 20.63 23 0.036 
Maximal diastolic BP 98.2 16.09 83 86.7 14.74 23 0.002 
Maximal pulse rate 93.3 14.18 83 85.2 12.75 23 0.015 
Doses of haem arginate 3.9 1.14 69 2.7 0.90 11 0.002 
Pethidine requirement 1746 1620 83 1278 1053 20 0.22 
Length of admission (days) 8.3 6.8 87 8.0 9.4 25 0.89 
Interval before improvement 6.3 3.3 85 5.4 3.7 25 0.21 












Three patients in this series have"died. Their histories are summarised here. 
Patient CK 
This 22 year old man was proven to have AIP following an acute attack in a provincial 
town. He is the cousin of patient HK, whose history follows. He was admitted to Groote 
Schuur Hospital 13 times over a period of25 months with acute attacks. In three of these, the 
use of recent cannabis was proven by the demonstration of positive urinary cannabinoids, and 
collateral history suggested that this was a major contributory factor to his recurrent attacks. 
His course was considerably complicated in that he returned to his home town, 800 km from 
Cape Town, between attacks, and his attacks would begin while there. Despite efforts to 
arrange for continuity of care and a reliable supply of haem arginate for him, his treatment 
was inconsistent. His local hospital was reluctant to provide haem arginate in view of its 
expense and the belief that his problem was largely self-induced by his continuing use of 
cannabis and alcohoL He would therefore return voluntarily to Groote Schuur Hospital with 
established acute attacks. After 29 months, he developed a further attack at home during 
which a neuropathy developed. Haem arginate was not given and he died. Whether the death 
was primarily due to paralysis or to a metabolic disturbance is unknown. 
PatientHK 
This 25 year-old woman was admitted to the intensive care unit of a hospital in a 
provincial town with severe flaccid quadriparesis and respiratory failure. She reported having 
experienced bouts of unexplained abdominal pain over the preceding months, and her mother 
had died of a similar and similarly undiagnosed complaint many years previously. Urine and 
stool samples were sent to our laboratory and a diagnosis of AIP was established. After 
several months, during which time she recovered sufficient muscle power to breathe 
spontaneously, she was transferred to Groote Schuur hospital for rehabilitation. With 
intensive physiotherapy, she recovered sufficiently to walk with crutches. Her course was one 
of increasing severity and frequency of the acute attack. Initially, attacks were experienced at 
approximately three-weekly intervals. Over the course of several years, the interval between 
attacks progressively shortened until she was essentially hospital-bound. 
Several of these attacks were extremely severe. On two occasions she required admission 
to the intensive care unit. During one episode, she developed severe metabolic disturbance 
with low serum levels of sodium, porassium, magnesium and calcium, accompanied by 
massive losses of these cations in the urine. She was rescued with haem arginate, ventilation 
and supportive care. However, her attacks became progressively more frequent and her 
pethidine requirement high. This led to frequent clashes between patient and nursing staff 
who were not always convinced that her incessant demands for pethidine were warranted by 
any actual pain. However, on every occasion when haem arginate was withheld, objective 
evidence of the acute attack would followed shortly, usually by a deterioration in neuropathy 
and increasing weakness of the extensors of the hands and feet, confirming that her 
complaints were genuine. 
Her course was complicated by a number of problems. She developed tuberculosis in 
hospital; choice of antituberculous therapy was difficult. Since she was in any event more or 
less continually in a state of the acute attack, it was difficult to show any association between 
specific drugs and an aggravation ofher porphyria. Eventually she received only streptomycin 
and ethambutol, which is a very poor combination for the treatment of tuberculosis. The 
radiological lesions cleared, only to relapse within 6 months. She then received nine months 
treatment with streptomycin, ethambutol and amoxycillin-clavulinate. Despite this unusual 
therapy, she recovered. A lack of venous access became a problem. On many occasions she 











she received a number of surgically implanted central venous catheters and synthetic 
arteriovenous fistulae. On several occasions she developed staphylococcal graft sepsis. This 
required treatment repeatedly with vancomycin or flucloxacillin without any obvious 
aggravation of her porphyria. 
Experience showed that she could not cope without haem arginate and any delay in 
administering it resulted in an aggravation of neuropathy. With time, the response to haem 
arginate became incolJ?plete, with little reduction in symptoms. Tin protoporphyrin, (a method 
for preparation of which was kindly shared with us by Professor Michael Moore) was 
produced in our hospital pharmacy and was added to her therapy. This was beneficial; her 
symptoms would improve more rapidly and more completely after the combination. A pattern 
of treatment was established whereby every alternate course of haem therapy would require 
the co-administration of tin protoporphyrin for an improvement in her symptoms. Thus it 
appeared that the effects of tin protoporphyrin persisted for 3-4 weeks, while haem arginate 
was required every 10-14 days. 
Three other modalities of therapy were attempted. Prophylactic administration of haem 
arginate in the interval between attacks proved useless. Parenteral GnRH agonist therapy for a 
period of six months was not accompanied by any reduction in the frequency or severity of 
attacks despite documented amenorrhoea. On one occasion, a subcutaneous implant of 
testosterone was performed as suggested by Savage et al (1992) but was ineffective. 
This course continued for 5 years. Finally her condition deteriorated to the point that she 
was never pain-free with an ongoing requirement for massive doses of pethidine. Haem 
arginate, even with tin protoporphyrin, failed to clear her symptoms, though it would appear 
to prevent a deterioration to the point of severe neuropathy and paralysis. Finally, following a 
series of discussions between patient, medical and nursing staff, chaplain and ethicist, a 
decision was taken to scale down the intensity of therapy. No further haem arginate was 
given, and she died, well-sedated, of respiratory failure. 
Patient MJ 
This young woman with AlP first presented with an acute attack aged 22. Over the 
following four years, she experienced 33 acute attacks; these attacks are incorporated in the 
series described above. Thereafter, her course converged with that of HK. The intervals 
between admissions shrank until she too was permanently hospital-bound. She required 
alternating cycles of haem arginate and haem arginate plus tin protoporphyrin to reduce the 
intensity of her attacks. Though she developed a foot-drop and wrist-drop, she never became 
paralysed or required intensive care unit admission. She required a series of surgically 
implanted venous cannulae for venous access; a subcutaneous injection port proved the most 
effective route of access. Ultimately she too was never pain-free and her quality of life 
became intolerable. A decision was taken to scale down the intensity of therapy and she died 
of respiratory failure. 
Autopsy findings 
Autopsies were performed in both HK and MJ. Unexpected findings were noted in the 
livers, which had a slate-grey or green colour. Bridging fibrosis without cirrhosis was noted 
histologically. There was heavy iron staining in acinar zone 3, in Kupffer cells and in splenic 
macrophages. An additional pigment was seen in the liver parenchyma which was P AS­
negative and did not fluoresce. Interestingly, the bone marrow contained no excess of iron. In 
MJ, the kidneys showed glomerular sclerosis and iron pigment was noted within the cells of 











Comment on the autopsy findings 
Neither patient had received blood transfusions but showed large amounts of iron in the 
reticulo-endothelial cells of liver and spleen. This appeared to cause no problem during life, 
and is thought to reflect iron-loading from intravenous haem administration. An unusual 
feature in both was the presence of an abnormal pigment. This may represent tin derived from 
tin protoporphyrin. It is our intention to determine tissue iron and tin levels in these patients 
spectrophotometric ally . 
18.5 CONCLUSIONS IN BRIEF 
Significant differences between patients with VP and AlP have been shown, particularly in 
terms of the factors precipitating the acute attack. The major complications of severe 
neuropathy: seizures and respiratory paralysis are now rare. The mortality is currently low. In 
some patients, particularly with AlP, recurrent attacks are a problem. The treatment of the 
acute attack has been described and some evidence provided to suggest that haem arginate is 
indeed efficacious. These results, with further description of some of the more interesting 













DISCUSSION: THE CLINICAL FEATURES OF VARIEGATE 
PORPHYRIA 
In the preceding three chapters, three aspects of the clinical presentation of variegate 
porphyria were reported: the syndrome of homozygous variegate porphyria, the clinical 
penetrance and presentation in a single large R59W-positive family, and a personal 
experience with the recognition and management of the acute porphyric crisis. The 
observations described in these chapters are now discussed. 
19.1 	 THE SYNDROME OF HOMOZYGOUS VARIEGATE 
PORPHYRIA (HVP) 
We had initially diagnosed HVP in our first patient, the proband LO, on the basis of her 
clinical features and the age ofpresentation, supported by the demonstration of extremely low 
PPO activity in EBV -transformed lymphoblasts. This was before it became possible to test for 
mutations in the PPO gene directly. A description of this patient, together with details of a 
second patient from the United Kingdom, was published in a paper in which we summarised 
the clinical features of HVP as a syndrome clearly distinct from that of typical heterozygous 
VP (Hift et al 1993b). The clinical and biochemical details of eight previously reported cases 
of HVP and of the four described in Chapter 16 are summarised in Table 19-1. Once DNA 
testing for mutations within the PPO gene became feasible, she was shown to be a compound 
heterozygote, as have our three subsequent patients. 
Probands 1 and 2 conform to the pattern of clinical expression of homozygous and 
compound heterozygous VP (HVP) arising early in life ("early-onset HVP") established by 
several reports (Kordac et a11984, Murphy et a11986, Coakley et a11990, Norris et a11990, 
Gandolfo et al 1991, Mustajoki et al 1987, Hift et al 1993b). The clinical features of early­
onset HVP may therefore be summarised as follows (Table 19-2). Additionally we have now 
provided evidence that, as exemplified by Probands 3 and 4, HVP may present later in life 
("late-onset HVP"), with the features noted in Table 19-3. One case, described by Coakley 
(1990), was so exceptional that we suggested in our earlier review (Hift et al 1993b) that the 
diagnosis might have been mistaken. This child first showed signs of disease at the age of 12 
years (10 years later than any of the other cases reported at that time), had no photosensitivity, 
experienced severe acute attacks and is the only patient to have died. The biochemical 
findings were also exceptional; a normal stool protoporphyrin was accompanied by a 
markedly raised coproporphyrin. With the benefit of a further 7 years' experience, we have to 
qualify our initial reluctance to accept the diagnosis. As described in Chapter 10, a raised 
faecal coproporphyrin in the absence of a raised protoporphyrin appears to be an acceptable 
diagnostic marker for VP. Secondly, as Probands 3 and 4 demonstrate, we now have evidence 
that HVP may be recognised for the first time after childhood, and may indeed be complicated 
by the acute attack. Without precedent however is the lack of photosensitivity. It is possible 
that Coakley's patient represents a form ofHVP intermediate between the severe, early-onset 
form and the more benign, late-onset form described here, though the lack of photosensitivity 
would be most surprising. DNA studies on surviving family members would confirm the 
diagnosis, a method used to diagnose homozygous AlP retrospectively in a child who had 











Author 1 1 2 2 3 4 5 6 7 7* 8* 8* 8* 
Sex male female male female male female male female male female female female female 
Age at onset <1 mo <1 mo 2 yr 9mo <1 mo 18 mo <12 mo 12 yr 5mo <1 mo 1Omo 19 yr 19 yr 
Mental retardation y Y N N N Y Y Y Y N N N N 
Fits y Y nd Y N Y Y Y Y ? N N N 
Developmental delay nd nd nd nd Y nd Y Y Y Y Y N N 
Nystagmus Y Y N N N nd nd nd Y Y Y N N 
Growth retardation nd nd Y Y Y N nd nd Y Y Y N N 
Photosensitivity Y Y Y Y Y Y Y N Y Y Y Y Y 
Hand deformities nd nd Y Y Y Y Y nd Y Y Y Y N 
Retarded bone age nd nd nd Y nd nd nd nd N Y Y N N 
Acute attacks N N N N N N N Y N N N Y N 
Death N N N N N N N Y N N N N N 
PPO activity* 
Proband 0.16 0.17 0.05 nd 0.08 0.14 0.20 0.17 0.46 0.1 nd nd nd 
Mother 0.49 0.49 0.47 nd 0.56 0.68 0.60 0.50 nd 0.5 nd nd nd 
Father 0.53 0.53 0.28 nd 0.48 0.66 0.50 0.50 nd 0.75 nd nd nd 
Biochemistry 
Urine ALA 1.4 2.5 <1 nd 0.1 nd 0.6 19.4 nd 0.4 0.4 2.4 1.9 
Urine PBG 1.0 1.7 <1 nd 0.1 nd 0.9 105.6 nd 0.6 0.5 6.6 1.5 
Urine uroporphyrin 8.0 6.3 4.9 nd 0.7 8.1 2.9 131.0 6.7 0.9 0.6 73.2 19.2 
Urine coproporphyrin 1.2 1.3 1.0 1.0 0.4 1.2 2.3 12.9 0.4 0.3 0.7 18.9 2.0 
Faecal coproporphyrin 6.7 4.5 2.1 4.4 4.5 4.4 1.2 3.8 5.9 4.4 1.4 24.2 12.4 
Faecal protoporphyrin 12.6 7.3 2.9 1.8 5.8 1.4 2.0 0.02 3.0 1.8 2.2 9.0.2 2.0 
RBC protoporphyrin nd nd 1.8 21.61 8.1 6.8 5.3 nd 7.3 21.6 6.9 3.2 nd 
Table 19-1. Summary of the clinical and biochemical features in all patients with the homozygous VP syndrome described thus far. The references are as follows (1) Kordac et al 
1984; (2) Murphy et a11986; (3) Mustajoki et a11987; (4) Norris et a11990; (5) Gandolfo et a11991; (6) Coakley et a11990; (7) Hift et a11993; (8) Corrigall et a12000. The four 















Table 19-3. Characteristic features of late-onset HVP. 
Molecular biology of HVP 
The prevalence of R59W-positive VP is believed to be sufficiently high in the white 
Afrikaner population of South Africa for homo zygotes to have emerged. Yet no such patients 
have been identified, and we postulated that the homozygous state of the founder South 
African mutation would prove to be lethal. Indeed, in our paper reporting the first South 
African case of HVP, we wrote: "No case has yet been described in South Africa. We had 
previously believed that the homozygous state might be lethal. It is probable that HVP, like 
the heterozygous condition, is subject to variable expressivity, and that only the less-severely 
affected fetus will survive till birth. It is also possible that some cases of HVP will turn out to 
196 
Aspect Clinical features Comment 
I Sex Male or female 
Age at onset Days-months 





Behavioural abnormalities Hyperactivity 
! Dermatological features Photosensitivity Severe 
Abnormalities of non-sun-exposed skin 
Skeletal abnormalities Growth retardation 
Brachydactyly 
Finger joint deformities 
Retarded bone age 
Acute attacks Not a feature 
Life expectancy No evidence yet for reduced life expectancy 
Table 19-2. Characteristic features of early-onset HVP. 
Aspect Clinical features Comment 
Age at onset Mid to late adolescence 
Neurological features Nil 
Dermatological features Photosensitivity Moderate-Severe 
Abnormalities of non-sun-exposed skin Absent 
Skeletal abnormalities Brachydactyly Variable 
Finger joint deformities Variable 










be compound heterozygotes rather than true homozygotes when testing at the gene level is 
possible. It is an interesting observation that all the parents of the cases described thus far 
appear to have been latent carriers as none are reported to have expressed VP clinically." (Hift 
et aI1993b). 
Since the advent of DNA analysis for VP, these predictions have been proved correct. With 
respect to our original case (LO), we suggested that the parents would be found to carry 
different mutations, and that the paternal mutation would be associated with a less severe 
impairment of activity. This we predicted on the basis of the father's lack of biochemical 
expression of VP, on the grounds that his PPO activity was reduced to lesser extent than was 
that of his wife, and on the premise that the combination of a less severe mutation and the 
South African founder mutation might allow some residual activity in the proband, thus 
bypassing our belief that the homozygous state would appear to be lethal. Indeed, she was 
proven to be an R59WIR168C compound heterozygote. All three subsequent patients with 
HVP have also proved to be compound heterozygotes. 
There is evidence to suggest that some residual PPO activity is always present in the 
surviving homozygote or compound heterozygote. The R59W mutation exhibits essentially 
zero catalytic activity (Meissner et al 1996, Dailey and Dailey 1997), whereas the R168C 
mutation does appeared to be associated with some residual activity. This is consonant with 
experience in homozygous AlP, HCP and PCT (Elder 1997). Thus, as suggested by Whatley 
et al (1999), mutations that abolish activity are lethal in homo zygotes and are found only in 
heterozygous VP, while the milder mutations are not clinically apparent in heterozygotes but 
may present with homozygous VP. Those mutations that abolish activity include frameshift 
mutations, those that induce premature stop codons and some missense mutations at 
particularly crucial sites. It is possible that some missense and splice-defective mutations may 
fall into an intermediate category causing VP with a low clinical penetrance. The Y348C 
mutation we demonstrated in the family of Proband 2 may represent such an intermediate 
mutation, since at least one family member expressed VP biochemically. The R168C and 
R138P mutations however would appear to fit Whatley et aI's definition of "mild". 
This point has further been stressed by Roberts et al (1998). In none of 5 HVP patients did 
parents or other relatives manifest VP clinically. Clinically silent VP is more common than 
overt disease (Chapter 17, Kirsch et al 1998) and PPO mutations are sufficiently frequent in 
European populations for rare cases of homozygosity and severe PPO deficiency to occur 
outside consanguineous unions. Indeed, one of the mild mutations in Roberts's study (G358R) 
was present in two HVP patients, one from the Czech republic and one from the UK. Two 
patients had both a chain termination or splice mutation and a missense mutation that were 
shown by family studies to be carried on the same allele. One of the two is mutant alleles in a 
Finnish compound heterozygote (Kauppinen etal 1997), P256R, was also observed in the 
United Kingdom in association with a splice mutation carried on the same allele; this 
mutation, which affects a poorly conserved residue, is a polymorphism present in about 10% 
of the French population (Whatley et aI1999). 
This suggests that this and perhaps other relatively mild mutations may not be uncommon 
in the general population. Yet none of the mutations shown in their HVP subjects were 
present in a large group of western European patients with VP. The inference from their 
experience is that HVP results from the conjunction of two mutations, neither of which is 
associated with complete inactivation of the enzyme, and neither of which is thus sufficient in 
its own right to result in clinically expressed VP in the heterozygous state. This is in contrast 
to our experience in South Africa and to that in Finland-two high prevalence areas subject to 
VP founder effects-where the more severe mutations in subjects with compound 











Furthermore, Roberts et al (1998) provide evidence to support the hypothesis that at least 
one mutant allele must code for a protein with residual catalytic activity in HVP. Seven 
mutations were identified in this study: Four were missense mutations and the fifth a 12 bp 
insertion coded for the inserted sequence KANA. In this fifth case, sequence from the other 
allele was barely detectable. Differential quantitation of the mRNA produced from each allele 
in expression studies showed that about 90% of the mRNA produced by this patient was 
derived from the mutant allele. The complementary mutation was identified as a T to G 
transversion in intron 11, which segregated independently of the KANA allele and is situated 
in the polypyrimidine track of the exon 12 spice acceptor site. It was suggested that this 
mutation is likely to impair splicing efficiency with formation of an unstable, abnormal 
mRNA species. The remaining mutation, in intron seven, was associated with the complete 
deletion of exon 7. Both these intronic mutations were believed to result in complete loss of 
activity of the protein coded by that allele. 
The four missense mutations and the KANA mutant were screened for residual PPO 
activity by testing their ability to rescue the growth of a hemG (pPO gene )-deficient SAS38X 
strain ofE. coli. This strain requires very low levels of PPO to grow normally; therefore even 
low-activity mutants will complement it successfully. Four mutant PPO clones were able to 
rescue growth, and their activities relative to that ofnormal human PPO expressed in the same 
strain ranged from 9.5-25% of normal. Only the Gl69E mutation failed to sustain growth, 
suggesting that it is non-functional. It was also the only mutation of those identified in this 
paper that alters a highly conserved residue unchanged in human, mouse and a number of 
prokaryotic species. These results are summarised in Table 19-4, where those mutations able 
to rescue growth are indicated by a tick and those unable to do so, by a cross. 
Subject Allele I Allele II 
I D349A " D349A " II A433P A433P " III G358R I "" G169E X IV G358R " Intron 7 X V A219insKANA " Intron 11 X 
Table 19-4. Mutations identified in 5 western European cases ofHVP (Roberts et al 
1998). A tick <",f) indicates that the mutation appears to encode a protein with 
measurable residual activity. A cross (x) indicates that the protein appears to be non­
functional or absent. 
Two of the subjects are homozygotes: in each case the mutation is associated with residual 
activity. Three subjects are compound heterozygotes and in each case one of the alleles 
encodes a protein with residual activity. Thus, in summary, all five of these patients had a 
mutation which preserved some PPO activity on at least one allele. Severe mutations that 
abolished PPO activity or markedly decreased the concentration of normal mRNA were 
always allelic to milder mutations. 
Mutational analysis in our subjects is consonant with these conclusions. We have shown 
that the R59W mutation is associated with a near-absence of catalytic activity. Though this 
has not been directly measured in the case of the R168C, Y348C and R138P mutations, the 
observation that no clinical disease has been shown to be associated with the heterozygous 
state and that biochemical expression is unusual or absent would suggest that they are not 











the R168C and Y348C mutants is in progress. Clearly some activity must be preserved to 
maintain the vital function of haem biosynthesis. But, as stated by Roberts et al (1998), what 
has been surprising in all these disorders has been the substantial loss of activity that can be 
tolerated albeit at the cost of disease of variable severity. Their study also showed no 
correlation between the presence of severe manifestations of VP and the extent of residual 
PPO activity. Indeed, the highest PPO activities, as determined by prokaryotic expression, 
were present in both the most and the least severely affected patients. Nor is the mechanism 
whereby point mutations in the PPO gene produce the variable non-porphyric features of 
homozygous VP known. Short stature and neurological defects are often present in 
homozygous variants of AlP and HCP, which may suggest that certain early stages of 
development are critically dependent on haem biosynthesis. Furthermore, as exemplified by 
the two sisters described in Chapter 16, DdP and AN, genotypically identical but 
phenotypically dissimilar, factors beyond the PPO gene must also influence clinical 
expreSSIOn. 
Our demonstration of late-onset HVP accompanied by the acute attack and also by urine 
and stool porphyrin profiles more typical of heterozygous VP (Table 19-1) also suggests that 
the lack of acute symptoms in early-onset HVP is more a feature of the prepubertal state than 
of HVP per se. Our first proband, LO, has recently begun menstruating. It is possible that she 
may now be prone to acute symptoms, and we now take all possible precautions to avoid this . 
19.2 THE BIOCHEMICAL AND CLINICAL EXPRESSION OF VP 
The study described in Chapter 17 is the first large kindred to be fully investigated by DNA 
testing as well as by biochemical and clinical analysis. Altogether 62 informative members of 
the family were tested and 33 were R59W-positive, which is, as expected, in keeping with an 
autosomal dominant mode of transmission. The sex imbalance in favour of females is 
probably fortuitous. The difference is not statistically significant. Nor has there ever been 
evidence to suggest that males are less likely than females to carry VP or to survive 
postnatally. Indeed, most studies have suggested that females are more likely to be clinically 
affected than males, at least in terms of acute symptoms. 
The correlation of R59W status with stool biochemistry is in keeping with the findings 
described in Chapter 10. Diagnosis by urine and stool biochemistry was insensitive: only 52% 
of adult subjects showed unequivocal positive stool biochemistry and 36% were in fact 
unequivocally negative. Nor was the performance of stool biochemistry related to age; false­
negative results could be found at any age, and several older patients who had been 
unequivocally positive previously now demonstrated normal stool excretion patterns. 
In this family, the diagnostic uti lity of plasma fluoroscanning is confirmed. 87.5% of adult 
subjects who are R59W-positive were correctly diagnosed by plasma fluoroscanning, and 
100% of those who are R59W-negative were correctly diagnosed as such. Interestingly, all 
three false-negative results were obtained in older patients (aged 57-73) who had previously 
shown positive biochemistry that, with age, had reverted to a normal excretion pattern. 
Plasma fluoroscanning gave no positive results in children aged less than 16. Taken together, 
these results suggest that stool porphyrin testing alone will only detect approximately 50% of 
patients carrying the R59W mutation, but that the detection rate rises to nearly 90% if plasma 
fluoroscanning is substituted for porphyrin testing. Neither is however 100% sensitive, and it 
appears that children and older subjects who have had VP for many years in particular are 
prone to false-negative results. 
It is disturbing that only 50% of R59W-positive and 64% of R59W-negative respondents 
were aware of having been tested for porphyria previously. Two members recalled having 











this is a large family which has been known to carry porphyria for decades, and many of its 
older members have participated in several studies with the VCT Porphyria Centre. Indeed, 
every member of this family, when contacted, was aware of the presence of porphyria within 
the larger family. This suggests a high degree of complacency about porphyria amongst the 
South African VP population. Yet at the same time, this study may provide the explanation 
for this complacency. Since only one acute attack (35 years previously) and no deaths from 
porphyria had occurred in four generations, it would appear that many members do not regard 
VP as of any personal relevance. 
62 informative members of the family were tested genetically. All were asked to provide 
clinical details in response to a questionnaire. The return rate was very low for those who had 
tested negative; in most cases these subjects, being aware of their status and asymptomatic, 
attached little importance to their answers. 26 of 29 R59W positive subjects returned the 
questionnaire, and a further 2 subsequently provided the information telephonically. Thus 
reliable information was forthcoming in 97% of those positive for the mutation. Patients were 
aware of their DNA status when they replied which has the potential to bias the answers, but 
this does not appear in practice to have been a problem. The questionnaire was designed to 
allow the patient to describe possible acute symptoms or skin symptoms in a manner which 
would allow us to distinguish symptoms typical of porphyria from those less likely to be 
significant. In the case of equivocal answers, the respondent was contacted telephonically and 
further questioned. Thus the final conclusions in terms of the prevalence of symptoms are 
reliable. 
17 of these 28 adult patients were and always had been completely asymptomatic (60.7%). 
This is considerably greater than the 38.3% reported by us in 1996 and the 10% reported by 
Eales et al in 1980 (Figure 19-1). In large measure the difference between the present study 
and the 1996 study is the incorporation of many more true silent cases, i.e. subjects who 
would not have been recognised as DNA-positive by stool porphyrin testing in 1996 but who 
are now readily identifiable by genetic testing. This lack of ascertainment bias also allows the 
surprising, though perhaps not entirely unexpected, finding that the acute attack is a rare event 
amongst unselected patients with VP. It would appear to have affected only one, or perhaps 
two, individuals on a single occasion during their lifetimes. The low incidence of acute 
symptoms cannot be attributed to better education about porphyria alone, since this study has 
shown that approximately 50 to 60% of subjects even within a well-studied family are 







Eales et al Hift Present 
II Skin II Acute • Both II Latent 
Figure 19-1. Proportions of patients expressing clinical symptoms in Cape Town: 
before 1980 (Eales et al 1980), 1997 (Hift et al 1997) and as revealed by genetic 











Though Mustajoki (1980) reports an approximately equal sex-incidence of skin disease in 
his Finnish patients with VP (10 males and 14 females), females appeared more likely to 
experience skin disease in our family. Most reports do however suggest a higher incidence of 
acute symptoms in females. Since the prevalence of acute attacks was extremely low in this 
study, this point cannot be taken further here. 
Since the presence or absence of skin disease does not, after puberty, correlate with age, 
other factors must be responsible for this phenotypic difference. Clearly the elevated levels of 
endogenous sex steroids present after puberty cannot be responsible for skin disease alone 
since not all post-pubertal subjects, male or female, develop it. Similarly, 4 of 5 subjects aged 
48 and older had noted an improvement in skin disease, of whom two were females as yet 
premenopausal and one was male. This parallels the tendency we had noted for stool 
porphyrin excretion to decrease with advancing age; three subjects in the study who currently 
have normal stool porphyrin excretion patterns are known to have been positive previously. 
This improvement, both clinical and biochemical, with age is unexplained. 
Currently active skin disease was nearly always accompanied by unambiguously 
diagnostic stool porphyrin profiles; in one woman only was an equivocal profile present. The 
converse did not hold true: 50% of patients without skin disease showed normal biochemistry, 
whereas 33% had a typical VP profile and 17% an equivocal result. The skin disease 
experienced by these subjects was typical of previous descriptions of VP. It was most marked 
on the dorsal surfaces of the hands and in two-thirds was limited to the hands. The face, 
forearms or feet were also affected in the remainder. 
In this study, no apparent association with hypertension, renal disease or heart disease was 
apparent. However a small study such as this would be unlikely to detect any such association 
unless the magnitude were extraordinarily large, as in the family described by Church et al 
(1992). Rather, large epidemiological studies such as those by Andersson and Lithner (1994) 
are required to prove such an association, and these have not yet been attempted in South 
Africa. An interesting finding is the large number of our R59W-positive subjects who report 
minor psychiatric symptoms such as anxiety and depression. The difference between the 
prevalence of this in our DNA-positive and DNA-negative subjects is however not 
statistically significant. Though claims for significant psychiatric symptoms in association of 
porphyria have been made (McEwin 1972, Tishler et al 1985), studies in cohorts of patients 
with both AlP and VP have not confirmed this (Wetterburg 1967); Kaupinnen and Mustajoki 
(1992) found a slight excess of generalised anxiety during early middle age. 
19.3 THE AC TE ATTACK 
Our experience with all patients admitted with acute symptoms of porphyria to a single 
hospital over a period of 12 years is reported in Chapter 18. The UCT Porphyria Service 
enjoys a reputation for excellence in South Africa, and patients with particularly severe 
problems are likely to be referred to us for diagnosis and management. Thus our experience is 
to a degree biased toward the more severe patient. A further potential source of bias includes 
socio-economic circumstances. In South Africa, the wealthier and the medically-insured 
community usually make use of private health services, whereas the remainder are served by 
state hospitals, including the academic hospitals such as our own. Patients requiring special 
expertise are however referred to an academic hospital such as Groote Schuur Hospital. VP in 
particular is largely a disease of white people in South Africa, who tend to use the private 
sector. Yet there are no institutions or doctors other than our own with any particular expertise 
or interest in porphyria. Since our advice has been sought in the few instances where haem 
arginate has been used elsewhere in South Africa, we are aware of most patients experiencing 











the country. This has been an infrequent occurrence, and we believe that our experience is 
generalisable to the experience of the country as a whole. 
Clinical features 
The cardinal features of the acute attack, pain, vomiting and autonomic symptoms, have not 
changed since those described in previous series (Figure 19-2). Thus pain remains the most 
common presenting feature and is almost invariable. Particular striking however are the 
exceptions. Three patients developed unusual manifestations following attacks in which pain 
was not prominent, and are described below. Hypertension was even more common in this 
series than has previously been described, with a systolic blood pressure in excess of 120 mm 
Hg being recorded at some time during more than 90% of admissions, while only 68% will 
have it at the time of presentation, suggesting that it is a manifestation which becomes 
progressively more frequent as the acute attack progresses. Tachycardia is less common; and 
a pulse rate exceeding 90/minute was present in less than half of all admissions. Nausea and 
vomiting are common. Constipation was not a prominent feature in our patients at the time of 
admission, which may reflect the short period between onset of symptoms and presentation. 
The most striking changes however are in the rate of major complications of the acute attack: 
seizures, neuropathy and respiratory failure. These are discussed later in this chapter. 
Respiratory failure 
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Figure 19-2. The symptoms and signs of the acute attack as reported by Eales et al 











Painless attacks: unusual and misleading presentations ofporphyria 
Patient FW 
This 27 year-old woman was not known to have porphyria. She was admitted to hospital in 
our absence with abdominal pain; and as part of her investigations, a Watson-Schwartz 
reaction was perfonned and was positive. VP was subsequently confinned biochemically, and 
an elevated ALA and PBG were shown in keeping with an acute attack. When assessed by us 
48 hours after admission, her abdominal pain had abruptly ceased, though her serum sodium 
was 114 mmolli. There were no signs of neuropathy. The disappearance of the pain was 
interpreted as an improvement in her condition, and haem arginate was withheld. Within 
hours, she developed severe flaccid quadriparesis. She required prolonged ventilation in the 
intensive care unit and had a prolonged convalescence, though recovery was eventually 
complete. 
Patient MH 
This 32 year-old man was not previously known to have porphyria, though he was 
eventually shown to belong to a family known to have VP. He was admitted to another 
hospital with abdominal pain, and was found to have a positive Watson-Schwartz reaction. 
Our opinion was requested. At this stage his abdominal pain had abruptly ceased though he 
complained of discomfort in the legs. Neurological examination was nonnal. Haem arginate 
was withheld. He developed a moderately severe quadriparesis within hours. Ventilation was 
not required and recovery, though slow, was complete. 
Comment 
As suggested by Figures 18-7 and 18-8, recovery from the acute attack is usually a smooth 
process with a gradual lessening of pain over 72 or more hours. These two cases were 
exceptional in that the abdominal pain stopped abruptly. In both, quadriparesis followed very 
rapidly. In the first, the low serum sodium should have alerted us to the severity of the attack. 
We have therefore learnt that a sudden cessation of abdominal pain may be an ominous sign 
portending the onset of motor neuropathy. The reason for this is unknown. Secondly, we have 
learnt to recognise discomfort in the legs and buttocks as a warning of impending neuropathy. 
An abrupt cessation of abdominal pain, complaints of discomfort in the legs and 
hyponatraemia mandate the immediate administration of haem arginate. 
Patient NG 
This 25 year-old woman is a member of a family known to carry VP. She had been 
biochemically tested at the age of 16 and was found to be negative. She had not been tested 
subsequently. She now presented to a private physician with a sudden onset of confusion and 
abnonnal behaviour. At no stage was pain of any description present. No cause for the 
confusion could be found, and there were no other objective neurological abnonnalities. A 
brain CT scan was nonnal. Testing for the R59W mutation was positive. Unfortunately the 
urine was not tested for the presence of PBG. In a telephonic consultation, we were asked 
whether this was compatible with the acute attack of porphyria. We suggested that it was not, 
since no other patient in this series had presented with confusion in the absence of a 
demonstrable cause, and a presentation without pain was highly exceptional. We suspected a 
primary psychiatric disorder. Within 7 days she had recovered completely. We examined her 
two weeks later in the porphyria clinic at Groote Schuur Hospital. She is a bright, appropriate 
young person with no evidence or history of mental illness. She now complained of severe 
discomfort over her entire body. This was accompanied by a mild glove-and-stocking sensory 
loss and hyperaesthesia, in keeping with a diagnosis of causalgia or complex regional pain 











of the intense discomfort caused by the material against the skin. We have seen this syndrome 
previously in two patients with AlP, following a documented acute attack, though in these 
cases the attack had been typical, with severe abdominal pain and no confusion. Accordingly, 
it would appear in retrospect that NG did indeed suffer an acute attack ofVP. Porphyria is an 
unusual cause of an acute confusional state without the classic features of the acute attack 
such as abdominal pain, constipation and vomiting, though isolated cases of AIP presenting 
with confusion have been reported (Tan and Yeow 1988). Perhaps porphyria indeed deserves 
the title the little imitator which Waldenstrom bestowed upon it. 
Electrolyte abnormalities 
A high proportion of patients (64%) demonstrated an elevated urea on admission. There was 
no further increase following admission, and in most cases resolution was prompt. This is 
most likely due to dehydration since there was a rapid improvement following admission to 
hospital, and all our patients receive intravenous normal saline-dextrose following admission. 
AlP has however been associated with chronic renal failure, and both patients with severe, 
recurrent AlP (HK and MJ) demonstrated chronically raised creatinine levels. Hyponatraemia 
is common; 26.6% of our patients demonstrated hyponatraemia on admission and nearly 40% 
had low sodium concentrations at some stage of the admission. This may in part be due to 
dehydration, though the slower response to intravenous normal saline as compared to urea 
suggests that other factors may be operative, as has been suggested by Eales (1980). Severe 
hyponatraemia is dangerous and is a marker of a particularly severe attack. Of five admissions 
complicated by severe hyponatraemia, four were complicated by the onset of neuropathy; the 
fifth patient (AS) experienced seizures and a very severe course which is described below. In 
these patients, urine sodium concentrations were high, suggesting either renal salt-wasting or 
the syndrome of inappropriate ADH secretion. In each case the serum sodium failed to 
improve in response to fluid restriction alone; and rose only after the infusion of hypertonic 
saline. In two instances, this large urinary sodium loss was accompanied by marked kaliuresis 
and calciuresis, suggesting a primary tubular defect. It is therefore our impression that the 
hyponatraemia of the acute porphyric attack is due to renal salt-wasting rather than to SIADH 
despite suggestions in the literature linking SIADH to the hyponatraemia of the acute attack 
(Lipschutz and Reiter 1974, Farese et a11979, Chogle et aI1980). It is therefore our practice 
to correct severe hyponatraemia ab initio with hypertonic saline. Rapid correction of 
hyponatraemia in AlP has resulted in central pontine myelinolysis and cortical laminar 
necrosis (Susa et al 1999), and correction must therefore be slow. 
An unusually severe attack accompanied by an adrenergic crisis 
Patient AS is described here as the autonomic features of her presentation were so extreme as 
to suggest a phaeochromocytoma. She is a member of a family known to have AlP . She was 
admitted to a country hospital following a spontaneous abortion at the age of 22. There she 
developed abdominal pain and hypertension. She was transferred to Groote Schuur Hospital. 
On admission, the serum sodium was 130 mmol!l, systolic blood pressure 230 mmHg and 
diastolic blood pressure 130 mmHg; pulse rate was 144/minute. She appeared to have little or 
no abdominal pain, but was drowsy and confused. A brain CT scan showed multiple areas of 
attenuation in keeping with ischaemia or infarction. Her serum sodium declined to 120 
mmol!l and she developed seizures. The blood pressure and pulse remained extremely 
elevated and failed to respond to high doses of beta-adrenergic blockers. The degree of 
hypertension and tachycardia, as well as the encephalopathy and neurological deficits, were 
unprecedented in our experience of the acute porphyric crisis. We considered the possibility 
of a co-incidental phaeochromocytoma. She was admitted to the intensive care unit, intubated 











and haem arginate. Magnesium sulphate was highly effective in controlling both the 
adrenergic features and the seizures. Recovery was rapid and she was discharged from 
hospital, neurologically intact and completely asymptomatic, after a total admission of just 9 
days. 
Clearly this severe adrenergic crisis was due to porphyria. Acute hypertension mimicking 
phaeochromocytoma as the main presenting feature of AlP has been reported (Bravenboer 
and Erkelens 1989). The neurological deficits and defects noted on CT scanning in our patient 
appear to reflect reversible cerebral ischaemia, which has occasionally been described in AlP. 
Sudden, permanent occipital blindness was reported in a 28 year-old woman who developed a 
severe attack of AlP accompanied by convulsions and peripheral neuropathy (Lai et al 1977). 
Examination of the brain showed extensive infarction in both occipital lobes consistent with 
anoxia. Cerebral vasospasm as well as transient brain lesions presumably due to ischaemia, 
have also been reported in AlP (Black et al 1995, Kupferschmidt et al 1995). Multiple 
cerebral lesions have been seen on MRI in both cerebral hemispheres during an attack of AlP 
accompanied by seizures and hallucinations. Both the clinical and MRI lesions regressed 
following treatment, which would suggest that vascular mechanisms may underlie the 
pathogenesis of cerebral dysfunction in AlP (King et al1991). 
Though magnesium sulphate has been suggested for the control of seizures in AlP (Taylor 
1981, Sadeh et al 1991), it was primarily used in our patient since it is the standard agent 
employed at Groote Schuur Hospital for the peri-operative management of of 
phaeochromocytoma where it controls adrenergic overactivity smoothly and reliably. 
Magnesium sulphate worked extremely well in patient AS, and we now recommend its use in 
any patient in whom the adrenergic or cerebral features dominate the presentation. 
Complications 
The rate of complications of the attack is markedly lower in this series than in those described 
by Eales et al (1980) and Mustajoki (1980). In most cases neuropathy was mild and was 
limited to wrist-and foot-drop; only one patient required mechanical ventilation. 
This remarkable improvement in outcome requires explanation. Other authorities have 
commented upon an increasingly favourable outcome for the acute attack (Bonkovsky and 
Schady 1982, Kappas et al1989, Tschudy and Lamon 1980, Kaupinnen and Mustajoki 1992). 
The admissions described here are all recorded over a recent period, largely in the 1990s. 
Earlier series by contrast included patients from the 1960s to the 1980s. During this time, 
several factors have changed which may have led to a better outcome. There is a greater 
awareness and understanding of porphyria among both doctors and patients. Diagnostic tests 
for porphyria and for the acute attack have become more reliable and accessible. Patients 
understand their illness better and are perhaps more likely to present to hospital early. 
Management protocols for the acute crisis have been refined and specific therapy, haem 
arginate, is now available. 
A striking finding in this study is that most episodes of neuropathy, seizures and paralysis 
occurred during the first admission, or during an admission before the diagnosis had been 
established. Similar observations have been made elsewhere. Thus, of a series of 9 patients 
with AlP admitted to a Taiwanese hospital, six developed neuropathy, six had autonomic 
dysfunction, five had mental changes, four had seizures, two had hyponatraemia and one died 
of intractable seizures (Chen et al 1994). Such experiences suggest that it is not the disease 
which has become milder, but our ability to manage it which has improved. 
Haem arginate 
A large body of evidence supports the contention that haem arginate is highly effective in 











al 1980, McColl et al 1981, Mustajoki et al 1986, Tenhunen et al 1987, Tokola et al 1987, 
Bissell 1988, Volin et al 1988, Hift et al 1997). The only controlled trial (Herrick et al 1989b) 
was unable to show a significant difference in outcome. Yet Figures 18-9 and 18-10 strongly 
support the hypothesis that haem arginate is responsible for a rapid and reliable improvement 
in symptoms. These figures include only those patients who, on the basis of their symptoms, 
were given haem arginate; those admissions in which symptoms settled spontaneously (33%) 
are not included. Mean severity scores had not improved for up to 8 days, and improvement 
began promptly once haem arginate was given. Similarly, in these patients, pethidine 
requirements rise progressively until haem arginate therapy is given, following which a 
statistically significant and marked reduction in pethidine requirements is noted. 
Despite the suggestion that haem arginate infusion is associated with a lower rate of 
thrombophlebitis than haematin (Mustajoki et al 1986, Tenhunen et al 1987, Tokola et al 
1987), haem arginate infusion was frequently followed by severe thrombophlebitis at the drip 
site. Phlebitis complicated 14 of 79 infusions, particularly early in this series when haem 
arginate was administered in saline. A change from plastic to glass infusion bottles did not 
help. Administration in human serum albumin however appeared to be associated with a far 
lower rate of phlebitis, and we accordingly established this as our standard practice. Renal 
failure and coagulopathy, as reported for haematin were not encountered. 
No serious complications such as hyponatraemia, neuropathy or seizures developed in any 
patient once haem arginate had been started; in each case, complications had developed prior 
to administration of haem arginate, or were present at the time of admission. The only 
exceptions were the two most severe patients, MJ and HK, d scribed in Chapter 18. 
Tin protoporphyrin 
We have accumulated some experience in the use of tin protoporphyrin. We believe it to be 
effective in maintaining the efficacy of haem arginate in the face of frequent dosing which, in 
our experience, may lead to the development of tolerance and consequent therapeutic failure. 
In contrast to the experience of Dover et al (1993), we have found no evidence that the attack­
free interval is significantly prolonged by its use. A further observation is with regard to its 
safety. Despite the administration of as many as 120 doses of 25 Ilg, there has been no clinical 
evidence of toxicity. When patients HK and MJ were on two occasions inadvertently exposed 
to sunshine within 48 hours of administration, marked skin erythema was noted in sun­
exposed areas. Marked darkening of the skin was also noted over time. We have however 
noted the appearance of apparent iron overload and the accumulation of an unusual pigment, 
which may represent tin, in the livers of both patients who received large amounts of haem 
arginate and tin protoporphyrin. Definitive identification of this pigment is awaited. 
Neuropathy 
Though neuropathy was an unusual development during those acute attacks managed by us in 
Groote Schuur Hospital, it was already present in several patients who had had their first 
attack elsewhere. In all cases, the neuropathy was largely reversible. Three patients who had 
been severely quadriparetic (of whom two were transferred to us during the recovery phase, 
and one, FW, had developed paresis under our care, improved with physiotherapy and 
orthopaedic supports; all regained the ability to walk. A noticeable phenonomen amongst 
those patients with recurrent AlP and pre-existing neuropathy was what we have termed the 
"barometer" phenomenon: within 2-3 days of the start of a recurrent attack, wrist dorsiflexion 
tended to become both subjectively and objectively weaker; following haem arginate 
administration and resolution of the attack there was a prompt and complete return to the 
status quo ante. The clinical impression was that these patients operate just below a threshold 











nerve function deteriorates, but this initial deterioration is immediately reversible provided the 
metabolic defect is rapidly repaired. Only if the crisis was neglected, did a more long-lasting 
deterioration in function become apparent. In the light of this observation, it is our standard 
practice to ensure that every patient with a history of previous neuropathy receives haem 
arginate without delay, whereas other patients are allowed 24 hours to determine whether 
spontaneous remission will occur. 
Unusual forms ofneuropathy 
In addition to patient NG described above, two patients demonstrated unusual patterns of 
autonomic and sensory neuropathy. 
Patient GW 
This young woman with AlP was first diagnosed after experiencing an acute attack in 
another centre. This was unaccompanied by motor neuropathy. She thereafter began 
complaining repeatedly of chronic, unbearable pain. Her physician labelled these as acute 
attacks and admitted her on several occasions, treating her pain with pethidine. Yet samples 
sent to our laboratory failed to reveal any further elevation in PBG during these admissions, 
and the possibility of opiate-addiction was raised. She was then referred to us for an opinion. 
Questioning quickly revealed that her problem, like that of NG, as one of a causalgia, or 
complex pain syndrome. She gave a graphical description of tight clothing or a crease in the 
bed sheets causing an unbearable sensation of pain. Though careful electrophysiological 
testing failed to reveal evidence of motor or sensory nerve dysfunction, our neurologists 
believed that her symptoms were in keeping with a residual small-fibre sensory neuropathy, 
which is difficult to detect in the laboratory. With adequate explanation, reassurance and 
simple analgesics, she required no further opiates and her condition improved over several 
months. 
Patient TR 
This 29 year-old woman with recurrent menstrually-associated attacks of AlP had a mild 
wrist-drop, which improved. Striking however were peripheral features of autonomic nerve 
dysfunction: light stroking of the dorsal surface of the forearm would bring about dramatic 
pilo-erection ("goose bumps") and profuse sweating in that arm. 
Seizures 
Seizures were rare in this series. In most cases, a precipitating factor was evident. In three 
cases, seizures accompanied severe hyponatraemia; the association between encephalopathy 
and seizures in porphyria and hyponatraemia has been noted previously (Dixon 1997, Usalan 
et al 1996). In two further instances, the seizures were typical of those associated with high 
doses of pethidine, and one patient had received no less than 10650 mg of pethidine during a 
single admission. Pethidine is metabolized in vivo to norpethidine, a metabolite which is 
epileptogenic (Schwark et al 1986, Czuczwar and Frey 1986, Armstrong and Bersten 1986, 
Hagmeyer et al 1993, Adair and Gilmore 1994, Kussman and Sethna 1998, McHugh 1999), 
and pethidine-related seizures hve been reported in a patient with HCP (Deeg and Rajamani 
1990). Similar seizures were noticed in patient HK, and were typically preceded by myoclonic 
jerks. Both the seizures and the myoclonus were easily abolished by clonazepam, and we now 
prescribe clonazepam routinely in any patient whose pethidine requirements are unusually 
high. 
Recent evidence indeed suggests that seizures are not as common in porphyria as was 
previously thought. Swedish investigators contacted a large group of patients with AlP and 
sought evidence for epilepsy (Bylesjo et al 1996). Just 10 of 268 patients (3.7%) reported 











four had had secondarily generalised partial seizures. In six patients, seizures were associated 
with an acute attack of AIP, and three patients had been severely hyponatraemic. This 
supports our contention that seizures in porphyria are largely a feature of the acute attack 
itself rather than the result of any latent tendency; furthermore, that in a substantial 
proportion, an immediate initiating event, typically hyponatraemia or the use of large amounts 
of pethidine, is present. 
Variations in the profile of the acute attack: AlP versus VP 
VP is much more common in South Africa than AlP. Over the period of this study, we have 
diagnosed 687 patients with VP and 48 with AIP. Yet the ratio of patients with acute attacks 
of VP to patients with AIP is 10:14 and the difference is highly significant (p<0.00001, ~2). 
This suggests that the acute attack is more prevalent amongst patients with AIP than with VP. 
The symptoms of the acute attack of both AIP and VP are essentially the same, yet the patient 
profile is dissimilar, and they appear to differ in average degree of severity. Young females 
predominated in AlP, whereas the sex-ratio was equal in VP. Patients with VP were older 
than those with AlP. Recurrent attacks were also more likely in AlP than in VP. Recurrent 
attacks were particularly a feature of females with AIP, whereas a similar predisposition was 
not shown in females with VP. The reason for these interesting findings may lie largely with 
the precipitating factors. As shown in Figure 18-6, two important patterns are evident. Firstly, 
acute attacks in males with VP are largely related to drug exposure, and the number of 
recurrent attacks is dominated by two subjects who abused both cannabis and alcohol (Table 
18-5). Once this pattern had been recognised, the patients were counseled and the frequency 
of attacks diminished. Indeed, with each further attack, a history of additional alcohol and 
cannabis abuse was obtained. Patient DA experienced 6 attacks over a period of 15 months, 
and CH experienced 5 attacks over a period of just 6 months, yet since the end of this short 
period, neither has required further admission. This suggests that the acute attacks arose in 
response to some exogenous factor, of which the exposure to alcohol and cannabis appear 
most likely. Similarly, one male subject with AIP, CK, described in detail in Chapter 18, 
experienced 13 attacks over a period of 25 months. He was unforthcoming about his habits, 
but was reported by his relatives to abuse cannabis and alcohol (even within the hospital); 
urine cannabinoids were positive, proving exposure to cannabis, on the three occasions late in 
his course on which they were sought. It would appear probable that more than just those 
proven three of his attacks were induced by drug exposure. The effect of cannabis on haem 
synthesis has not been reported, whereas several authors have discussed the effects of alcohol 
on porphyrin metabolism. Alcohol-induced changes have been shown in the enzymes of haem 
synthesis (Gajdos 1968, McColl et al 1980, Moore et al 1984). The acute effects of alcohol in 
AlP have been studied in an Indian population where 34 teetotal patients with AlP in 
remission were given 60 ml of 30% ethanol. The Watson-Schwartz test for porphobilinogen 
became positive in half of these patients, and in approximately one quarter a clinical attack 
was precipitated (Saksena et alI991). Though alcohol in moderation is probably safe, there is 
evidence that alcoholic binges may be associated with acute attacks (Thunell et al 1992, 
Kauppinen and Mustajoki 1992). 
Despite the high prevalence of porphyria, and VP in particular, precipitation of the acute 
attack by drugs appears to be rare in Cape Town. With the exception of these three substance­
abusers, only 13 episodes in 12 years could be ascribed to drugs. This observation is in 
keeping with the conclusion that, in the stable patient with porphyria, administration of drugs 
known to be porphyrinogenic rarely results in mischief (Mustajoki and Heinonen 1980). 











AlP, probably by default since a high proportion of patients with AlP had either menstrually­
related attacks or attacks of unknown cause. 
The second striking feature is the proportion of females of AlP in whom attacks appeared 
to be menstrually-related. Coupled with this is the high proportion of cases in females in 
which the cause was unknown. It is possible that many of these may have reflected 
menstrually-related attacks, since our criteria were stringent and we have not recorded attacks 
as menstually-related unless there was a clear and reproducible relationship between the onset 
of menstruation and the onset of the attack, which typically predated the onset of menstruation 
by 2-3 days. If the remainder of these attacks in females with AlP were indeed hormonally 
induced, the relationship is not clear-cut and is difficult to prove. In many cases, a clear 
temporal relationship could not be established. Furthermore, the results of treatment with 
GnRH agonists in three patients have been contradictory. One subject with AlP, patient TR, 
experienced severe monthly attacks, requiring hospitalisation and associated with a 
neuropathy, with a clear association between the onset of menstruation and the onset of pain. 
She received GnRH agonist therapy with a complete absence of attacks for two years. 
Following cessation of therapy, she rapidly fell pregnant and has remained well ever since. 
Despite occasional episodes of mild pain, she has not required further hospitalisation. Two 
other subjects, HK and MJ, described in detail in Chapter 18, failed to respond to GnRH 
agonist therapy. Both became amenorrhoeic and suppression of oestrogen and progesterone 
was documented. Despite this, acute attacks continued. In the case of MJ, acute attacks 
initially continued at intervals of approximately four weeks, more or less coinciding with the 
expected onset of menstruation despite amenorrhoea. This is unexplained. The published 
experience with GnRH agonist therapy bears out this incomplete and not entirely explicable 
response to menstrual suppression; Herrick et al (1990) report a poorer response in patients in 
whom the relation between symptoms and menstruation is less typical. 
A further point of interest arising from this study is the very low prevalence of acute 
attacks in pregnancy; with just a single attack, with a good outcome, arising in pregnancy in 
this series. Nor are we aware of any other attack in pregnancy having occurred elsewhere in 
South Africa during the past 12 years. Even patient TR, who required 24 months ' GnRH 
agonist therapy to control typical menstrually-related attacks, had an uneventful pregnancy 
shortly after discontinuing therapy. 
Severity ofthe attacks 
The severe attack of VP could be just as severe as the AlP, as exemplified by FW, who 
developed hyponatraemia, seizures and profound quadriparesis requiring ventilation. 
However, it is our impression that the average acute attack of AlP is more severe than that of 
VP. Thus the mean systolic and diastolic blood pressures and the pulse rate and the proportion 
of patients requiring haem arginate were all significantly higher in AlP than in VP (Table 18­
8. Though a lower requirement for pethidine, average hospital stay and duration of symptoms 
were shown in VP, the spread is wide and the differences not statistically significant. The rate 
of significant complications is equivalent in VP and AlP: 5.7% and 4% for seizures, 9.2% and 







































CONCLUSIONS AND FUTURE WORK 
20.1 THE DIAGNOSIS OF VARIEGATE PORPHYRIA 
The work described in Section 1 of this dissertation has important consequences for the 
diagnosis of variegate porphyria in South Africa. The high prevalence of this mutation 
amongst the VP popUlation of South Africa suggests a more important role for DNA testing in 
the first-line diagnosis of patients suspected of carrying VP than it has in countries where the 
disease is more heterogeneous. 
We have shown in Section 2 that the sensitivity and specificity of traditional 
chromatographic examination of urine, stool and plasma for a diagnosis of VP are less than is 
desirable even in a specialised laboratory such as ours. We have also shown the deficiency of 
screening tests for first-line diagnosis, a technique which unfortunately persists in some 
laboratories in South Africa. An important consequence of this work has been the 
confirmation that as many as 30% of all adults carrying the R59W mutation are not detectable 
by urine and stool porphyrin analysis. The increased sensitivity shown by fluoroscanning 
indicates that this is a more reliable (and indeed easier) test for the routine porphyrin 
diagnostic laboratory. We have now altered our diagnostic approach in that all samples 
submitted to the UCT laboratory are first tested by plasma fluoroscanning, and stool 
chromatography is not performed unless the fluoroscanning is positive except under special 
circumstances. 
It is clear that the non-specialised laboratory offering screening, non-quantitative and even 
quantitative chromatography is placed at a disadvantage in interpreting faecal porphyrin 
analysis. Experience has suggested that no South African laboratory other than the UCT 
laboratory is prepared or able to undertake the rigorous biochemical analyses required for 
anything approaching an accurate diagnosis. It is therefore our duty to provide guidance in the 
most appropriate and correct use of the diagnostic techniques available for the diagnosis of 
VP. This we have already begun, and the work continues. The standard approach we are 
recommending makes use of two of the newer diagnostic techniques discussed in this 
dissertation: demonstration of the R59W mutation by Ava} restriction analysis and the use of 
diagnostic plasma fluoroscanning. These techniques have the added advantage of requiring a 
blood specimen only. Thus, with the promotion and acceptance of our recommendations, we 
believe that simpler and more accurate diagnosis of VP is possible in other South African 
laboratories without the necessity to set up TLC or HPLC porphyrin separation and 
quantitation protocols. Our laboratory will continue to retain a central role in the maintenance 
of standards, the refinement of diagnostic techniques and the identification ofnon-R59W VP 
families and the mutations they carry. An important function of our laboratory is the 
comprehensive diagnostic, counselling and treatment service we offer. Since this 
comprehensive service is unlikely to be provided elsewhere, a possible deleterious aspects of 
the decentralisation of accurate testing for VP may be the uncoupling of diagnosis from 
education and advice on management. 
An important task which remains is the education of clinicians and clinical pathologists in 
the correct use of the DNA test, as outlined in the algorithms in Chapter 6 and Appendix 6. In 
particular, it must be understood that a negative R59W test will not exclude patients with 












VP. Additionally is important that the limitations of DNA testing in assessing clinical severity 
are understood. This is an educational task with which we continue. 
20.2 	 FURTHER RESEARCH REGARDING THE MOLECULAR BASIS 
FOR VARIEGATE PORPHYRIA 
Possible mechanisms for exploiting the genetic homogeneity for VP we have shown include 
the pursuing of structure-function relationships. As a first step, it is appropriate to recreate to 
these mutations by site-directed mutagenesis and then to express the mutant protein. Work is 
currently underway in our laboratory on the expression of the R168C, R59W and Y348C 
mutations. Such work may also throw light on genotype-phenotype relationships. An 
important avenue of research is the creation of an animal model for the elucidation of the 
clinical features of the porphyrias. An R59W -positive gene-knockout mouse model has been 
developed by Professor Harry Dailey and a colony is now established in our laboratory. These 
mice have been shown to have urine and stool porphyrin profiles in keeping with VP, and 
investigative work will commence shortly. 
We are now in a position to establish more accurate prevalence data for VP in South 
Africa. Whereas Dean's figures were based on the results of thousands of stool porphyrin 
screenings, it is possible to reproduce this work more accurately and more easily by the 
application of the Ava} restriction assay to a representative population. Simultaneous use of 
SSCPlheteroduplex analysis would indicate the prevalence of non-R59W PPO mutations and 
polymorphisms. 
An important goal of molecular biology research in all the porphyrias, as with genetic 
disorders generally, is the identification of safe and effective forms of gene therapy. For most 
of our patients with VP, this is not a priority at present, since, as described in this thesis, most 
are little troubled by their illness. It would however be of particular value in patients with 
HVP, in those with AIP with frequent and debilitating crises, and perhaps in those few of our 
patients with heterozygous VP in whom the skin disease is more than usually disfiguring. 
20.3 	 FURTHER STUDIES OF THE BIOCHEMICAL FEATURES OF 
VARIEGATEPORPHYlUA 
An interesting conclusion from this work is that the classic diagnostic stool porphyrin profiles 
described by the foremost authorities in the past may have led to an overly-simplistic belief 
that the diagnosis of VP by stool porphyrin testing is simple and clear-cut. This did not take 
account of the marked variability in stool porphyrin excretion patterns, particularly of the 
variation in stool protoporphyrin. It is now necessary to validate our new diagnostic criteria 
prospectively in larger numbers of subjects, normal and with VP. An increased reliance on a 
raised stool coproporphyrin may result in the misdiagnosis of HCP, a condition which is 
extremely rare in South Africa and was not encountered in the series of patients in which 
these criteria were established. 
It is clear that very little is known ofporphyrin handling within the bowel. Kinetic work on 
the excretion, reabsorption and enterohepatic cycling of porphyrins may provide interesting 
results: this may additionally have clinical implications for the use of sorbent therapy such as 











20.4 THE CLINICAL FEATURES OF V ARIEGATE PORPHYRIA 
The work of Chapter 17 has confirmed that the majority of patients with the R59W mutation 
are asymptomatic. Particularly encouraging is the extremely low prevalence of acute attacks. 
Thus we now have objective evidence to suggest that variegate porphyria is clinically not as 
severe a problem as the early literature may suggest. We can only speculate as to the cause of 
the apparent improvement in the well-being of our VP patients. We believe that in part the 
difference is one of ascertainment: symptomatic patients draw attention to themselves 
whereas those who are biochemically or clinically silent do not. However, it is probable that 
at least some of the favourable clinical outcome for VP is due to the educational and support 
efforts of our Centre, particularly with improved diagnostic efforts, and active education 
programme and our important work of the extension and maintenance of the drug-safety 
database (Appendix 9). Such work must continue, and research into the mechanisms of drug­
induction of porphyria, and of more accurate models for the prediction of porphyrinogenicity 
is required. 
Our study is unable to demonstrate which factor or factors are responsible for expression, 
or conversely non-expression, of VP in subjects carrying the R59W mutation. This is an 
important and potentially fertile field for further research: it would appear reasonable to direct 
initial studies into the impact of factors such as endogenous hormones, low-grade exposure to 
potentially porphyrinogenic compounds and genotypic variation in haem-containing enzymes 
such as the cytochrome P450 group on haem requirement. This may ultimately lead to the 
discovery ofnew forms of therapy based on the modulation of the activity of these enzymes. 
Our description of a large series of patients with the acute attack in Chapter 18 provides an 
overview of the presentation and management of this potentially fatal complication in the 
modem era. An important task is for us to educate clinicians both within South Africa and 
elsewhere who may be called upon to manage the patient with the acute attack in the light of 
our experience. By providing a comprehensive description of the clinical features of the acute 
attack as currently seen, and by recommending those forms of therapy which have contributed 
to a successful outcome in a high proportion of our patients, we may contribute to an 
improved prognosis for patients with porphyria generally. This educational task has already 
begun. 
20.5 RESEARCH INTO THE ACUTE ATTACK 
The central question as to how porphyria brings about in the classic neurovisceral features of 
the acute attack has not yet been satisfactorily answered. Further research into this question is 
required; intracellular haem deficiency, and possibly haem-deficiency of major haem­
containing enzymes systems such as tryptophan dioxygenase, require further study. Our 
R59W-positive mouse model provides one experimental model which we intend to exploit. 
20.6 HOMOZYGOUS VARIEGATE PORPHYRIA 
We have extended the clinical description ofHVP to include two subjects with a milder form 
of the syndrome, which we have termed the late-onset form of HVP. We have supported the 
proposition that a "lethal" mutation in HVP is always balanced by a less deleterious mutation 
on the second allele, since we have not encountered an R59W-positive homozygote, and we 
have provided evidence that the three additional mutations in our subjects appear to be less 
deleterious to the host than the our R59W mutation. The natural history and life expectancy of 
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BIOCHEMICAL METHODS EMPLOYED IN THE UCT PORPHYRIA 
DIAGNOSTIC LABORATORY 
INDEX 
1.1 Watson Schwartz reaction before urine PBG 
1.2 Screening test for urinary porphyrins 
1.3 Screening test for stool porphyrins 
1.4 Thin-layer chromatography 
1.5 Plasma fluorescence scanning 
1.1 WATSON-SCHWARTZ SCREENING TEST FOR PBG 
Reagents 
• Ehrlich's aldehyde (4-dimethylaminobenzaldehyde 2 g made up to 100 ml with 6N HCI) 
• Chloroform. 
Method 
Approximately 1 ml of Ehrlich's aldehyde is added to 1 ml of urine in a test tube. The 
resulting mixture is inspected for the development of a pink to red colour. The result is 
subjectively reported on a scale negative, trace, +, ++. In the event of a positive result, 2 ml 
chloroform are added and mixed; the tube is allowed to stand or gently spun until the aqueous 
and organic phases have separated. Urobilinogen will extract into the chloroform layer; PBG 
into the aqueous layer. If necessary, the aqueous layer is pipetted off, mixed with a further 
equal volume of chloroform and the process continued until there is compete partition ofthe 
red colour into one or other layer. 
1.2 SCREENING TEST FOR URINARY PORPHYRINS 
Reagents 
• Dean's solution: equal volumes ofglacial acetic acid, diethyl ether and amyl alcohoL 
Method 
4.5 ml of urine are mixed with 2 ml of Dean's solution; shaken and separated by gentle 











1.3 SCREENING TEST FOR STOOL PORPHYRINS 
Reagents 
• 	 Dean's solution 
• 	 Hydrochloric acid. 
Method 
A small volume of stool, approximately pea-sized, is carefully mixed and 4.5 ml of Dean's 
solution are added. The mixture is shaken and separated by gentle centrifugation. The 
supernatant is observed under ultraviolet light. The supernatant is poured off and 2 ml 1.5N 
hydrochloric acid are added; the tube is shaken and allowed to separate. The lower phase is 
examined under ultraviolet light. 
1.4 THIN-LAYER CHROMATOGRAPHY 
Equipment 
• 	 Fluoroscanning photodensitometer 
•. 	 Peak integrator and chart recorder 
Reagents 
• 	 5% sulphuric acid/methanol solution 
• 	 17% ammonia solution 
• 	 Chloroform 
• 	 Separating solvent: carbon tetrachloride, dichloromethane, ethyl acetate, ethyl propionate 
(2:2:1:1, v/v/v/v) 
• 	 Enhancing solvent: chloroform, dodecane, hexadecane (18: 1 : 1, vIv Iv) 
• 	 Porphyrin standards, containing equal proportions of uroporphyrin, C7, C6, C5, 
coproporphyrin and mesoporphyrin methyl esters (Porphyrin Products, Logan, Utah, 
USA). 
Preparation of specimens 
Urine porphyrins 
A volume of 3 ml of urine is esterified in 30 ml of a 5% sulphuric acid/methanol solution 
overnight at room temperature in the dark. The reSUlting mixture is transferred into a 
separating funnel and the pH neutralised with 17% ammonia solution. The solution is then 
extracted into a total volume of 20 ml of chloroform. Where large amounts of porphyrin are 
present, more chloroform is used. All volumes used are noted. 
Stool porphyrins 
Approximately 300 mg of stool is esterified in 30 ml of a 5% sulphuric acid/methanol solution 
at room temperature in the dark overnight. The wet weight of the stool sample is determined 
and noted; a further aliquot is weighed, dried overnight at 60°C and its dry weight 
determined: the wet:dry weight ratio of the sample can therefore be calculated. The stool 











into a separating funnel. The pH is neutralised with 17% ammonia solution. The porphyrins 
are then extracted into a total volume of 45 ml of chloroform. Where large amounts of 
porphyrin are present, more chloroform is used. All volumes used are noted. 
Plasma porphyrins 
3 ml of plasma is esterified in 30 ml of a 5% sulphuric acid/methanol solution at room 
temperature in the dark overnight. The esterification mixture is centrifuged at 800 g. for 15 
min. The supernatant is transferred into a separating funnel. The pH is neutralised with 17% 
ammonia solution. The porphyrins are then extracted into a total volume of 45 ml of 
chloroform and transferred to a small glass bottle. This is left open and the sample is allowed 
to evaporate to dryness. Immediately prior to chromatography, I ml of chloroform is added 
and the container gently agitated to redissolve the porphyrins. All volumes used are noted. 
Quantitative thin layer chromatography 
Immediately prior to chromatography, the volume of the porphyrin extract in chloroform is 
noted. Using a Hamilton micro syringe, precise aliquots of each extract are applied as a spot 
on Merck silica gel- 60 TLC plates. 30 to 50 III of stool extract, 100 to 300 III of urine extract 
and 50 to 100 III of plasma extract are applied to the plate. The precise volume applied is 
predicted by reference to the initial screening results with Dean's solution; in the presence of 
large amounts of porphyrin, smaller volumes are applied so as to reduce the quenching of 
fluorescence. The volume applied is noted. A constant stream of warmed air is blown over 
the working area to aid evaporation of the chloroform during application to the plate. On each 
plate, two lanes are reserved for porphyrin methyl ester standards. Samples are run in a further 
nine lanes. 
Plates are allowed to stand upright in a bath containing a small volume of separating solvent. 
The plate is removed when the solvent front approaches the top of the plate, typically after 45 
to 60 min, and is then dipped in an enhancing system in order to increase the yield of 
fluorescence. 
The plates are then scanned on a fluoroscanning photodensitometer connected to an integrator 
and recorder unit. Excitation and emission wavelengths of 399 nm and 620 nm are employed. 
Individual porphyrin esters are identified by direct comparison of the retention times with 
those of the standards. The area under the curve for each peak of fluorescence is calculated by 
the integrator. 
All appropriate data, including the fluorescence detected, the fluorescence associated with 
each standard, the volume of sample applied to the plate and the volume or mass of initial 
sample are all entered into the computerised porphyrin database, which thereafter 
automatically calculates the concentrations of each individual porphyrin in the individual 
samples according to the following formulae. 
Calculation of porphyrin concentration 
Urine 
Porphyrin concentration (nmo1l10 mmol creatinine) = [(SNSV)/(pA/PV)] * [VF*CIIV] * 
10lUC 
(The concentrations ofurine porphyrins are corrected for the degree ofurinary 












Porphyrin concentration (nmoVg dry weight) = [SAlSV)/(PAlPV)] * 
[VF*C)**(WW/DW)/WS] 
Plasma 
Porphyrin concentration (nmoVlitre) = [(SAlSV)/(PAlPV)] * [VF*C/IV] 
Where 
SA peak area ofpeak of sample porphyrin 
P A peak area ofrelevant standard porphyrin 
VF = volume of sample applied to TLC plate (J.ll) 
PV = volume of relevant porphyrin standard applied to TLC plate (J.ll) 
VF = final volume ofchloroform extract from sample (ml) 
IV = initial sample volume ofurine (ml) 
IW = initial sample wet weight of stool (g) 
C = relevant porphyrin ester standard concentration (nmoVl) 
WW = wet weight of stool sample (g) 
DW = dry weight of stool sample (g) 
SW wet weight of stool sample esterified (g). 
DC = measured urinary creatinine concentration (mmoVl) 
1.5 PLASMA PORPHYRIN FLUOROSCANNING 
Equipment 
Spectrofluorometer (Hitachi 650-109 Fluorescence spectrophotometer, Hitachi Koki Co. Ltd, 
Japan) equipped with red-sensitive photomultiplier and chart recorder. 
Reagents 
• Phosphate-buffered saline: 0.9% saline, 0.01 M sodium phosphate, pH 7.4. 
Method 
Plasma is separated from blood collected into heparin or EDTA by centrifugation. 1ml of 
plasma is diluted with 9 ml of phosphate-buffered saline. Samples are transferred to 1 cm 
path-length optical glass cuvettes for spectrofluorometry. The fluorescence spectrophotometer 
is zeroed against phosphate-buffered saline at an excitation wavelength of 405 nm and 
emission wavelength of 620 nm, with the monochromator slit width set at 5 nm. The emission 













PREPARATION OF EBV-TRANSFORMED L YMPHOBLASTS 
Transformation medium 
Fresh Ham FlO medium with 15% fetal calf serum is added to semi-confluent cultures of the 
EBV-producing marmoset cell line B95/S (Miller and Lipman 1973). The Ham FlO medium 
is removed after four days, and cells are removed by centrifugation and filtering through a 
0.45 11m membrane filter. The filtrate is then added to further equal volume of Ham F of 10 
medium with 15% fetal calf serum. This medium is effective for at least three months when 
stored at 4°C. 
Transformation of lymphoblasts 
A 20 ml sample of heparinised blood is taken from the subject and diluted with a one-third 
volume of Ham FlO nutrient medium. Lymphocytes are isolated by layering 10 ml aliquots of 
the diluted blood on to 5 ml of Histopaque solution (Sigma) followed by centrifugation at 
1500 g for 20 min. The leukocyte band at the interface is gently removed by pipette, ished 
twice in Ham FlO and is then re-suspended in 3 ml of the transformation medium. The cells 
are then incubated at 37°C in a 5% carbon dioxide environment in a 25 cc tissue culture flask. 
Volumes of 0.5-1 ml of medium are added on alternate days until rapid multiplication of 
transformed lymphoblasts allows passage into new flasks. This generally requires 7-21 days. 
Secondary culture can be maintained as a suspension in Ham FlO containing 10% fetal calf 
serum at densities of 1-5x106 cells/ml. A proportion of transformed lymphoblasts are frozen 













PROTOPORPHYRINOGEN OXIDASE ASSAY 
Our assay method (Meissner et al 1986) relies on the quantitation of the fluorescent product 
(protoporphyrinogen) resulting from the oxidation of the non-fluorescent substrate 
(protoporphyrinogen) by the enzyme PPO and is based on the assay described by Brenner and 
Bloomer (1980) and Jacobs and Jacobs (1982). 
3.1 EQUIPMENT 
1. 	 Hitachi 650-10 S fluorescence spectrophotometer (Hitachi Koki Co. Ltd, Japan). 
2. 	 Hitachi U-Il00 UV NIS spectrophotometer (Hitachi Koki Co. Ltd, Japan). 
3. 	 Waterbath (Memmert, Laboratory & Scientific, Cape Town, South Africa). 
4. 	 Reaction vessel: a round-bottomed flask with a long side arm. 
5. 	 PHmeter 
6. 	 Ultraviolet light source. 
3.2 REAGENTS 
7. 	 Protoporphyrin IX (porphyrin Products, Logan, UT, USA) 
8. 	 Assay buffer: 
100mM TrisIHCI, 3 mM dithiothreitol, 1 mM EDTA, 1% Tween 20, pH 8.1 
9. 	 Cuvette buffer 
As for assay buffer but without Tween 20 
c 
10. 	Protoporphyrin IX (Porphyrin Products, Logan, UT, USA). 
3.3 METHOD 
Preparation of substrate 
1. 	 Dissolve 12 mg protoporphyrin IX in 30 ml40 mM KOH in 20% ethanol (freshly 
prepared) by stirring in the dark. 
2. 	 Filter protoporphyrin stock through 0.45 Ilm filter. Determine concentration of 
protoporphyrin by measuring absorbance of a 11100 dilution of the solution in 2.7 N HCI 
at 408 nM and using the extinction coefficient of 262: 
protoporphyrin concentration (IlM) = OD4os/262 X 105 
3. 	 Dilute protoporphyrin stock to obtain 20 ml of 100-125 J..lM protoporphyrin and use it to 
calibrate the fluorometer. 
4. 	 Prepare a 4% sodium-mercury amalgam for the reduction ofprotoporphyrin to 
protoporphyrinogen. Weigh out 1.8 g Na and 43.2 g Hg. Cut mercury into small pieces 
and place the pieces in the reaction vessel. Run a continuous flow ofnitrogen through the 
side arm. Add sodium piece by piece. The reaction may occur spontaneously. Ifnot, heat 











amalgam is completely liquid. Pour the amalgam into a mortar and chop it is with a 
spatula until it solidifies. Grind the pieces with a mortar into small granules. 
5. 	 Reduce the protoporphyrin to protoporphyrinogen. Working in the dark, place 20 ml of 
diluted protoporphyrin in a boiling tube with a glass stopper. Add halfthe amalgam. 
Shake well. Allow gas to escape from time to time. Add the rest of the amalgam. Shake 
well and check fluorescence under ultraviolet light. Continue shaking until there is no 
further decrease in fluorescence. Filter the protoporphyrinogen solution through a 0.45 Jlm 
filter. 
6. 	 Immediately the correct the pH of the protoporphyrinogen solution to 8.1 by the addition, 
drop-wise, of 2 M MOPS. 
7. 	 Immediately start assay reaction by adding 100 JlI of this to each tube. 
Assay procedure 
1. 	 Add 25 to 100 JlI of sample as necessary to each assay to and add assay buffer to a total 
vol of 900 Jll. 
2. 	 Prepare a corresponding blank for each assay to by substituting the sample with an equal 
Volume of sample heated to 80°C for 10 min. 
3. 	 Prepare cuvette tubes containing 900 III of cuvette buffer: 1 tube per sample, including 
blanks, per time point. 
4. 	 Pre-incubate samples in assay tubes in the waterbath at 30°C for 20 min. 
5. 	 Calibrate fluorometer. Zero against water. Make 1110 dilution ofproto stock in assay 
buffer. Make a further 11250 dilution of this and prepare tubes for a standard curve as 
follows. Read fluorescence. 









1000 	 o 
6. 	 Add substrate (100 Ill) to assay tubes. Mix and allow to stand for 10 min at 30°C before 
taking first reading. 
7. 	 At each time point transfer 100 III from the assay tube into a cuvette tube and read 
fluorescence. Use 4 time intervals up to 40 min. 
Determination of activity 
8. 	 Use the customised spreadsheet (Lotus 123) to calculate kinetic activity. (subtract the rate 
of autooxidation, measured by the change in fluorescence in the blank tubes, from the rate 
ofoxidation observed in each sample, corrects this value for dilution factors and converts 
the value to nmoVmllh comparison with the standard curve. 
9. 	 Determine the protein concentration in the initial samples using the Bio-Rad assay. 












ANALYTICAL METHODS FOR THE DETECTION OF MUTATIONS 
INDEX 

4.1 Extraction of RNA from lymphoblasts 
4.2 Reverse transcriptase-polymerase chain reaction (RT -PCR) 
4.3 Polymerase chain reaction (PCR) of cDNA 
4.4 6% non-denaturing polyacrylamide gel electrophoresis 
4.5 Qiaex II agarose gel extraction protocol 
4.6 Manual sequencing of PCR product 
4.7 Genomic DNA extraction 
4.8 DNA purification procedure 
i 
I 4.9 Mutational analysis 
4.10 Polymerase chain reaction of genomic DNA 
I Single-stranded confonnational polymorphism (SSCP) and 
heteroduplex (HD) analysis 
4.11 
4.12 Direct sequencing ofPCR product 
4.13 Restriction analyses 
4.1 EXTRACTION OF RNA FROM L YMPHOBLASTS 
Equipment 
1. 	 Jouan KR422 centrifuge, Saint-Herblain, France 
2. 	 Microfuge Force 14, Denver Instruments, Laboratory & Scientific, Cape Town, SA. 
Reagents 
1. 	 Diethylpyrocarbonate (DEPC) H20 (0.05%) 
2. 	 Stock solution (autoclaved) 
Guanidinium thiocynate 50 g 
Distilled H20 (DEPC treated) 58.6 ml 
0.75 M Na citrate, pH7 3.5 ml 

10% sarkosyl 5.3 ml 

3. 	 Solution A 
Add 72 III mercaptoethanol to 10 ml of the above stock solution. 
4. 	 Water saturated phenol 
Melt solid phenol. Add DEPC H20 to top ofphenol and shake. Allow to settle and 











hydroxyquinaline. This imparts a straw colour and allows one to differentiate between !he 
layers. 
Method 
1. 	 Gloves are worn and RNAse-free pipette tips used at all times. All glassware and solutions 
must be treated with 0.05% DEPC-an RNAse inhibitor-and are autoclaved before use. 
2. 	 Transfer cell culture to 50 ml sterile capped centrifuge tubes. 
3. 	 Spin at 400 g for 10 min at 4°C. 
4. 	 Pour off supernatant and drain tube by standing on clean paper towel for a few min. 
5. 	 Add 10 ml Hanks Balanced Salt Solution (HBSS), re-suspend pellets and transfer to 1.5 
ml microfuge tubes. 
6. 	 Respin at 2000 g for 10 min and discard saline, once again draining off as much fluid as 
possible. 
7. 	 Add 1 ml of solution A. Lyse the cells by drawing up and down 6 times through a 1 ml 
disposable pipette tip. Transfer and divide sample between two 1.5 ml microfuge tubes. 
8. 	 Add the following reagents, mixing after each addition: 
60 III 2M Na acetate 
600 III H20 saturated phenol 
120 III chloroform/isoamyl alcohol (49:1 v/v). 
9. 	 Shake vigorously for 10 seconds and coolon ice for 15 min. 
10. Microfuge at 14000 g for 15 min at 4°C. 
11. Remove aqueous phase (DNA and protein are in interphase and phenol layer) and add 
600 III isopropanol (stored at -20°C) and leave overnight at -20°C. 
12. Pellet by microfuging at 14000 g for 20 min at 4°C. 
13. Discard supernatant and drain tube by inverting on paper towel. Ish pellet with 1 m170% 
cold ethanol. 
14. Pellet RNA by microfuging at 14000 g for 20 min. 
15. Add 500 III of 70% ethanol and freeze sample at-70°C in 10 aliquots. 
16. When required for RT-PCR, spin down precipitate from an aliquot, discard the 
supernatant and dissolve the dried precipitate in 10 III H20. Use 1 III for RT PCR (1-2 Ilg). 
4.2 	 REVERSE TRANSCRIPTASE-POLYMERASE CHAIN 
REACTION (RT-PCR) 
Equipment 
1. 	 Hybrid Omnigene thermal cycler, Teddington, UK.. 
2. 	 Force 14 microfuge, Denver Instruments, Laboratory & Scientific, Cape Town, SA. 
Reagents 















3. 	 lOx concentrated PCR buffer solution: 
500 mM KC1, 10 mM Tris, pH 8.3 (Stratagene, La Jolla, USA) 
4. 	 Deoxynucleotide Triphosphates (dNTPs), (promega, Madison, USA). 
Method 
1. 	 Take equal volumes ofdATP, dCTP, dGTP and dTTP (all 100 mM) and dilute and 
combine to make a stock solution containing 2.5 mM of each dNTP. 
2. 	 In a sterile microfuge tube on ice, prepare the following mixture to a total volume of20 
Jll: 
lOx buffer 2 Jll 
DTT lOx 2 Jll 
dNTP 4 Jll 
Oligo (dT) 100 mM 2 Jll 
RNAsin 1 Jll 
MMLV-RT 0.25Jll (50 units) 
RNA (-3 I-tg) 1 Jll 
Distilled H20 7.75 Jll 
3. Perform the PCR on the Omnigene thermocycler using the following temperature profile: 
Temperature Time No. of cycles 
37°C 60 min 
I95°C 5 min 
5°C 5 min in 
4. 	 Check that RT-PCR product is specific on a 6% polyacrylamide gel (see Appendix 4. 4). 
4.3 POLYMERASE CHAIN REACTION (PCR) OF eDNA 
Reagents 
1. 	 Primers (Genosys Biotechnologies (Europe) Ltd, Pampisford, Cambridgeshire, UK) were 
designed to cover the entire cDNA PPO sequence (Nishimura 1995; Dailey H personal 
communication) using Primer Designer for Windows, Soft Packaging version 2, Scientific 
and Education Software. 
Fragment 1. PF1CATCATGGTATGGCTATGCC 

(533 bp) PR1AGACTGTCCATGGCTAGAGA 

Fragment 2. PF 2 CTGCATGCCCTACCCACTG 

(410 bp) PR2 TTCAAGGCCTGAGGCAACA 

Fragment 3. PF3 ACTTCGTGGAGGTCTAGAGA 

(389 bp) PR3 CCGTCCTGCTCAGGGAAAGCAAC 

Fragment 4. 	 PF4GTGCCATCTTCAGAAGATCC 

(455 bp) P~ TCAGCTGTTAGGTTCTGTGC 

2. 	 Taq DNA polymerase, Promega, Madison, USA. 












1. 	 In a sterile 1.5 ml microfuge tube make the following mixture (scale up according to the 
number ofPCR reactions required. Allow sufficient to include a blank). 
2. 	 Using disposable sterile filtered tips, prepare the following PCR reaction mixture to a total 
volume of 47 ~l: 
Volume (~l) Final concentration 
10 x buffer 5 Ix 
Mg Chloride solution (25 mM) 5 1 x 
DNTP mix (2.5 mM) 2 100 ~M 
Primer forward 2 l~M 
Primer reverse 2 l~M 
Taq DNA polymerase 0.2 1 unit 
Sterile H20 30.8 
3. 	 Add 47 ~l of the mixture to 0.6 ml microfuge tubes on ice. Add 3 ~l DNA (RT-PCR 
product) to each tube. Vortex tubes. Microfuge briefly then overlay with mineral oiL 




Time (min) No. of cycles 
Initial Denaturation 94 1 1 
Denaturation 94 1 
32Annealing (see below) 51-65 0.5 
Extension 72 1 
Final extension 72 5 1 





5. 	 Analyse the PCR product on 6% acrylamide gel to assess purity (see Appendix 4.4). 
6. 	 Run product on MS8 (2%) agarose (see Appendix 4.5) and extract the PCR product using 











4.4 	 60/0 NON-DENATURING POLYACRYLAMIDE GEL 
ELECTROPHORESIS· 
Equipment 
1. 	 SE600 vertical slab gel electrophoresis unit, (Hoefer Scientific Instruments Pharmacia 
Biotech, Cambridge, UK). 
2. 	 PS1200 DC power supply, (Hoefer Scientific Instruments Pharmacia Biotech, Cambridge, 
UK). 
3. 	 Uvitec gel documentation system, (Uvitec, Cambridge, UK). 
Reagents 
1. 	 10 x TBE (TrislBorateIEDTA), lL 
890 mM Tris base 
890 mM boric acid 
20 mM EDTA, pH 8.0 
2. 	 Ethidium Bromide: 
Stock solution 1 mg/ml, stored in the dark. For use add 200 JlI of stock solution to 200 ml 
H20. 
3. 	 Sucrose sample solution: 30 g Sucrose 
10 mg bromophenol blue 
5 ml 0.5M Na2 EDT A 
Make up to 50 ml with water. 
4. 	 100 bp DNA ladder, (Promega Corporation, Southampton, UK). 
Method 
1. 	 To a 100 ml beaker add: 
a) 5 ml TBE lOx 
b) 10 ml A-Bis-A solution (30% acrylamide, 0.8% bisacrylamide) 
c) 500 JlI ammonium persulphate (10%) 
d) 50 JlI TEMED 
e) Make up to 50 ml with distilled water. 
2. 	 Pour into the space between the clamped 2 glass gel plates (1.5 mm spacers) mounted in 
the gel casting stand. 
3. 	 Insert a 20 sample bay spacer comb and allow to set. 
4. 	 Assemble upper buffer chamber on top of gel plate. Fill upper buffer chamber with 500 ml 
Ix TBE. 
5. 	 Fill lower buffer chamber with 2 L of Ix TBE. 
6. 	 Load PCR producted diluted 1: 1 with sucrose sample solution into sample bays using a 
Hamilton syringe. 
7. 	 Load 10 JlI ofDNA marker (diluted 1:1 with sucrose sample solution) in a bay (100 bp 
DNA ladder). 
8. 	 Run at 150 V for ± 2 h. 
9. 	 Stain gel in ethidium bromide for 7 min. Rinse in water and then visualize under UV light. 











4.5 QIAEX II AGAROSE GEL EXTRACTION PROTOCOL 
Reagents 
1. 	 Qiaex II Gel extraction kit, Southern Cross Biotechnology, Cape Town, South Africa. 
Method 
1. 	 Place gel slice in 1.5 ml microfuge tube. 
2. 	 Add 3 volumes of buffer QXl to 1 vol ofgel. 
3. 	 Resuspend the Qiaex II silica particles by vortexing for 30 sec. 
4. 	 Add 10 ).11 Qiaex II to tube. 
5. 	 Incubate at 50°C for 30 min with vortexing every 2 min to keep Qiaex in suspension (this 
solubilizes the agarose and binds the DNA). 
6. 	 Centrifuge samples for 1 min in microfuge (14000 x g) and remove supernatant. 
7. 	 Ish pellet with 500 III of buffer QXl (vortex to suspend pellet). 
8. 	 Centrifuge for 1 min in microfuge. 
9. 	 Ish pellet twice with 500 ).11 of buffer PE (vortex to suspend pellet and centrifuge for 1 
min). 
10. Remove supernatant after each ish. 
11. Air dry pellet for ± 15 min until white. 
12. Elute DNA from pellet with 20 III of sterile H20. (after adding water, vortex and allow to 
stand at RT for 30 min). 
13. Centrifuge for 1 min. Carefully remove supernatant which contains purified DNA. 
14. Quantitate DNA on Gene Quant. 
4.6 MANUAL SEQUENCING OF PCR PRODUCT 
Equipment 
1. 	 Gel sequencing apparatus, Whitehead Scientific, Brackenfell, South Africa 
2. 	 LKB 2197 power supply, LKBfPharmaciaBiotech, Cambridge, UK 
3. 	 Gel drier SEl160, HoeferfPharmacia Biotech, Cambridge, UK. 
Reagents 
1. 	 Sequenase PCR product sequencing kit (United States Biochemical, Cleveland, Ohio, 
USA). 
2. 	 Gel slick (FMC Bioproducts, Rockland, USA). 
3. 	 Medical X-ray film (Cronex 10 g 354 x 430 mM), Protea Electro-Medical Services, South 
Africa under licence from E.I. du Pont de Nemours Co. Inc. 
4. 	 Cronex Xtra life intensifying screens (Protea Electro-Medical Services, Cape Town, South 
Africa). 












Casting of sequencing gel 
1. 	 Clean plates with alcohol followed by acetone. 
2. 	 Coat upper plate with 1 ml gel slick. Allow to dry for 5 min then wipe offwith tissue. 
3. 	 Assemble plates. 
4. 	 Prepare gel solution: 
21 g urea, 5 ml lOx TBE, 10 ml (30% acrylamide/O.S% bis) in 50 ml. H20. Filter through 
O.S J.1m filter. Add 500 J.11 10% ammonium persulphate and 50 J.11 TEMED. 
5. 	 Pour gel into space between plates and insert comb (ensure no air bubbles are present). 
6. 	 Allow to set and stand for at least 2 h prior to use. 
Enzymic pre-treatment of PCR product 
(Exonuclease 1 removes residual single-stranded primers and extraneous single-stranded 
DNA produced by the PCR and shrimp alkaline phosphatase the remaining dNTPs). 
1. 	 To 5 J.11 (± 2-5 pmol) ofPCR amplification mixture in a 0.6 ml microfuge tube add 1 J.1lof 
exonuclease 1(1 unitlJ.11). Mix and incubate for 15 min at 37°C. 
2. 	 Heat at SO°C for 15 min to inactivate the exonuclease. Spin on ice and microfuge briefly. 
3. 	 Add 1 J.11 Shrimp alkaline phosphatase. Mix and incubate for 15 min at 37°C. 
4. 	 Heat at SO°C for 15 min to inactivate phosphatase. Microfuge briefly and coolon ice. 
5. 	 To a 0.6 microcentrifuge tube add the following: 
Treated PCR product 5 J.11 (2-5 pmol) 
Primer (either forward or reverse) 1 J.11 (5 pmol) 
Distilled H20 4 J.11 
6. 	 Mix, cover with drop of oil and microfuge briefly. 
7. 	 Denature by heating at 99.9°C for 3 min in a thermo cycler. Immediately place in an 
ice/water bath for 5 min. Store on ice. 
8. 	 Label and fill 4 tubes with 2.5 J.11 ofeach dideoxy termination mixture (G,A,T & C) for 
dGTP sequencing. 
9. 	 Dilute the labelling mixture 1:5 in distilled H20 (i.e. 2 J.11 + S J.11 H20). 
10. Pre-warm the 4 termination tubes at 37°C for 1 min. 
11. 	Prepare the labelling reaction. To a 0.6 ml chilled microfuge tube add: 
Chilled annealed DNA mixture 10 J.11 
Reaction buffer 2 J.11 
0.1 M DTT 1 J.11 

Diluted labelling mix (1/5) 2 J.11 

[aP32]dATP 0.5 J.11 

Sequenase DNA polymerase 2 J.11 

12. Vortex and incubate at room temperature for 5 min. 
13. 	 To each of the 4 termination tubes add 3.5 J.11 of the labelling reaction. Vortex and 
incubate at 37°C for 10 min in the thermocycler. 











15. 	 Heat to 75°C for 2 min immediately before loading on to a assembled sequencing gel (in 
the order G, A, T and C). Load 3 JlI ofreaction mixture per lane. 
16. 	 Pre-run sequencing gel in lxTBE for ± 'l2 h at 55°C. (One can run 1 or 2 loadings at 
different time intervals). Run at 60 watt (constant), 2000 volts for approximately 1.5 hs till 
dye front reaches the bottom of the gel. 
17. 	 Remove the gel from the apparatus and remove the top plate. Remove spacers and cover 
gel with blotting paper. Press blotting paper onto the gel and then lift. The gel should peel 
offon to the blotting paper. 
18. 	 Dry the gel immediately on a gel drier (cover surface of gel with plastic wrap). 
19. 	 Place the gel in the radiographic casette with intensifying screen. Place photographic 
film on top and expose at -70°C for 48 hs about 1 week prior to development. 
4.7 	 GENOMIC DNA EXTRACTION (PARZER AND MANNHOLTER, 
1991) 
Equipment 
1. 	 Hitachi himac centrifuge SCR 20 BA, Hitachi Koki Co. Ltd, Japan. 
2. 	 Waterbath, Memmert, Laboratory & Scientific, Cape Town, South Africa 
3. 	 Gene Quant, Pharmacia Biotech, Cambridge, UK 
Reagents 
1. 	 Cell lysis buffer: 




10 mllM Tris pH 7.6 

10 ml Triton X 100 

Make up to 1 litre with H20. Store in fridge. 

2. 	 Freeze mix: 
17.8 g Trisodium citrate 
2.4 g NaH2 P04 
2.8 g Na2 HP04 

1 g Na azide 

400 ml glycerol 

Make up to 1 litre with H20. Store in fridge. 

3. 	 Ish buffer: 
10 mM NaCI, 10 mM EDTA pH 8.0. Store in fridge. 
4. 	 Sarcosyl solution: 
20% laurylsarcosinate. Store in aliquots in freezer. 
5. 	 Ammonium acetate solution: 
7.5 M. Store in aliquots in freezer. 
6. 	 Proteinase K solution: 
10 mg/ml. Store in aliquots in freezer. 
7. 	 DNA storage buffer (TE): 
1 M TrislHCI 











8. 	 Ice cold ethanol: 
(Store in fridge) 
Method 
1. 	 Collect blood in 2x5 ml EDT A tubes. Spin at 1500 x g for 10 min. Remove buffy layer 
and add to 2 ml freeze mix solution. Mix well by inversion. Store in freezer. 
2. 	 Thaw sample in freeze mix at 37°C for 10 min. 
3. 	 Add sample to 50 ml cell lysis buffer and incubate on ice for 15 min. 
4. 	 Spin at 6800 g for 10 min. Discard supernatant. 
5. 	 Resuspend in 50 ml ish buffer. 
6. 	 Spin at 6300 g for 10 min. Remove supernatant and discard. 
/7. 	 To pellet add: 
350 )11 sarcosyl solution 
250 )11 ammonium acetate 
3.5 ml guanidinium HC 
8. 	 Mix, then add 125 )11 proteinase K and incubate at 60°C for 15 min. 
9. 	 Remove and coolon ice. 
10. 	 Add 10 ml ice cold ethanol. Invert and leave on ice for a minimum of 10 min. 
11. 	 Remove DNA with glass hooks made from a pasteur pipette and place in 1 ml Tris EDT A 
(TE) buffer. 
12. Incubate at 37°C for 1 h. 
To test purity: 
Make a 1 in 20 dilution of DNA in H20. Read OD at 260 and 280 nM. The OD ratio 260:280 
should be approximately 1.8. 
4.8 DNA PURIFICATION PROCEDURE 
Equipment 
1. 	 Force 14 microfuge, Denver Instruments, Laboratory & Scientific, Cape Town, South 
Africa. 
Method 
1. 	 Briefly vortex 100 )11 extracted DNA. 
2. 	 Add 100 )11 1 :49 v/v isoamyl alcohol: chloroform (chilled to -20°C). 
3. 	 Vortex briefly. 
4. 	 Spin in microfuge at 14000 g for 10 min at 4°C. 
5. 	 Transfer top layer to new tube. 
6. 	 Add 250 )11100% ethanol (chilled to -20°C) + 10 )11 3M Na acetate, pH 5.2. 











8. Spin in microfuge at 14000 g for 10 min at 4°C. 
9. Carefully decant supernatant without disturbing precipitate. 
10. Ish precipitate with 70% ethanol (chilled to -20°C). 
11. Spin in microfuge at 14 000 g for 10 min. 
12. Invert on paper towel and allow precipitate to dry completely. 
13. Reconstitute in 50 III distilled H20. 
4.9 MUTATIONAL ANALYSIS 
Genomic DNA is amplified by the polymerase chain reaction (PCR), using exon specific 
primers. Primers were designed with the Primer Designer for Windows software package 
(Soft Packaging version 2, Scientific & Education Software), and the PPO genomic sequence 
retrieved from Genbank (accession No. X99450). The primers used for the amplification of 
the 13 PPO exons are as follows. All primers were obtained from Genosys Biotechnologies 
(Europe) Ltd, Pampisford, Cambridgeshire, UK. 
Exon 1. 	 DFI 5'CCGCCAATCCAGATGTAGG 
DRI 5'AACT AAGTGTGCACGGATGG 
Exon 2. 	 DF2 5'TCTGCCTGTCCATATCGC 
DR2 5'ATTAAATGAAGCTCCCTC 
Exon 3. 	 DF3 5'GAATATGCCTCTTCCCCTCCCC 
DR3 5'CACAACCTCTCCTAGACATCCC 
Exon 4. 	 SF4 5'CCTCTTCTGAGGGCATGTGG 
S~ 5'GAGGGCACAGTAAAAGGAGC 
Exon 5. 	 SFs 5'GAGGTATGTCAGGAGCTTCC 
SRs 5'GATTTGAACAGGGAGCTCTG 
Exon 6. 	 DF6 5 'TATCCCACCCTCATTCCCT ACCA 
D~ 5'ATTGAATAGCACCCCTTGTCC 
Exon 7. 	 SF7 5'TGTGAGCCACTGCATCCAG 
SR7 5'CAGGTTCATTACACTCCAGG 
Exon 8. 	 SFg 5'CTCATCAAATTCTCAGGTTCTGG 
SRs 5'TGTGGTCCTGCTGACCCAGG 
Exon 9. 	 SF9 5'CCTTCTGAGTCAGGCCTCTGC 
SR9 5'GGATTACAGGTGTGAGCCACCA 
Exon 10. 	 SF10 5'AGAGCCCTTTCCTTCTGACGCATG * 
SRlO 5'TGGCCTTGCCTACAATGGAGCAC 
Exon 11. 	 SF11 5'GTGGCATTTCCAGAGGGCTCC 
SRll 5'GGAGAGCTGAGGGAAGTTTATCC 
Exon 12-13 	 SFI2-13 5 'CTGGATCCTCTCCTCTCTTC 
SR12-13 5'TAGAACAGCCAGACCAAGCC 
* Note: SRlO must be heat denatured (1 min at 95°C, chill on ice 2 min) immediately before 











Dissolve each primer in 1 ml sterile distilled H20. Make 25 J-LM stocks of each primer. Freeze 
in small aliquots and store at -20°C. 
4.10 POLYMERASE CHAIN REACTION OF GENOMIC DNA 
Equipment 
1. 	 Sterile eppendorf tubes, sterile filtered tips and sterile water must be used for the PCR 
reaction. 
2. 	 Robocycler gradient 40 (temperature cycler), Stratagene, Cambridge, UK. 
3. 	 or Hybaid Omnigene thermal cycler, Teddington, UK. 
4. 	 Force 14 microfuge, Denver Instruments, Laboratory & Scientific, Cape Town, South 
Africa. 
Reagents 
1. 	 Deoxynucleotide Triphosphates (dNTP's), Promega Corporation, Southampton, UK. 
2. 	 dNTP stock solution: 
Take equal volumes of dATP, dCTP, dGTP and dTTP (aU 100 mM), dilute and 
combine to make a stock solution containing 2.5 mM of each dNTP. 
3. 	 Forward primer and reverse primer (both 25 IlM). 
4. 	 Polymerase solution: 
a) Taq DNA polymerase (5 units/ill) 
b) Thermophilic DNA polymerase 10 x buffer, magnesium free. 
c) Magnesium chloride solution, 25 mM (Promega Corporation, Southampton, UK). 
5. 	 Sterile water 
6. 	 Mineral oil 
Method 
1. 	 Prepare the following reaction mixture In a sterile 1.5 ml microfuge tube on ice, using 
sterile filter tips. 
H~aJ concentration 
10 x buffer 5 III 
Magnesium chloride solution (25 mM) 5 JlI 1 x 
dNTP mix of 4 dinucleotide triphosphates (2.5 mM each) 1 Jll 50 JlM (each) 
Primer forward (25 JlM) 1 Jll 0.5 JlM 
Primer reverse (25 JlM) 
Taq DNA polymerase 
Sterile water 
1 Jll 0.5 IlM 
0.2 ";f 1 un'"SO "' 
31.8 JlI 
Scale these volumes up to make sufficient mixture to allow for 45 J-LI for each PCR 











2. 	 Aliquot 45 III of the mixture into 0.6 ml microfuge tubes on ice. Add 5 III of DNA (± 200 
ng/1l1). (5111 ofH20 is added to the blank). Briefly vortex tubes, centrifuge briefly to collect 
the sample at the bottom of the tube. 
3. 	 Overlay with drop of mineral oil. Place tubes in thermocyc1er and start PCR reaction, 
using the temperature profiles shown in the following table (Table A) for exons 
1,2,3,6,7,8,9,10,11,12-13. 
Table A: 
Temperature Time No. of cycles 











Final extension noe 7 1 
Table B: 
Exon Annealing temperature °C BP size 
57 365 
2 65 167 
3 65 252 
4 65 180 
5 65 247 
6 65 317 













































Final extension noc 8 
4. 	 Analyse the PCR products for all 13 exons on a 6% acrylamide gel. It is essential that a 
pure PCR product is obtained (single band) for SSCPlheteroduplex analysis. Check that 
the PCR product is the correct size by comparison with a DNA marker. 
4.11 	 SINGLE STRANDED CONFORMATIONAL POLYMORPHISM 
(SSCP) AND HETERODUPLEX (HD) ANALYSIS 
Equipment 
1. 	 SE600 vertical slab gel electrophoresis unit, PS1500 DC power supply, Hoeffer Scientific 
InstrumentslPharmacia Biotech, Cambridge, UK. 
2. 	 Techni dri block BD-2D, Laboratory & Scientific, Cape Town, South Africa. 
3. 	 Hybaid Omnigene thennal cycler, Teddington, UK. 
Reagents 
1. 	 MDE gel solution, FMC BioProducts, Rockland Maine, USA. 
2. 	 Sample loading buffer: 
95% fonnamide 
lOmMNaOH 
20 mM EDTA pH 8.0 
0.02% bromophenol blue 
0.02% xylenecyanol 
Method 
Casting ofMDE gel 
3. 	 Clamp 2 glass gel plates (using 1 mm spacers) and mount in the gel casting stand. 
4. 	 Prepare MDE solution as below: 
15 ml 2xMDE 
1.8 ml lOx TBE (final concentration=0.6x TBE) 

3 ml glycerol (final concentration=10%; for gels without glycerol replace the 3ml 

glycerol with H20) 

Add distilled water to a final volume of 30 ml. 












6. 	 Cast approximately 1 cm of fast-setting gel. Take 5 ml ofthe MDE solution and add 20 )ll 
10% ammonium persulphate and 20 )ll TEMED. Mix and pour between 2 clamped plates, 
using 1 mm spacers. 
7. 	 Allow to set for approximately 10 min. 
8. 	 To the remainder ofthe MDE solution, add 175 )l11O% ammonium persulphate and 17.5 
)ll TEMED. 
9. 	 Pour on top of the gel apparatus plug until the space between glass plates is almost filled. 
10. 	 Insert a 1 mm comb and allow to set for 1 h. 
11. 	Once set, remove the comb and mount the upper tank chamber, fill with 500 ml 0.6x 
TBE. 
12. 	 Fill lower tank chamber with 4.51 ofO.6x TBE. 
13. 	Prepare samples for loading as below: 
a) 5 )ll PCR product + 5 )ll sample loading buffer. 
b) Denature for 5 min at 95°C in thermo cycler. 
c) Chill on ice for 5 min. 
14. 	 Load samples immediately. 
15. 	 Run at room temperature between 150 and 400 V depending on the size of the PCR 
product. It is vital that good separation is achieved, otherwise aberrant mobility shifts may 
be missed. 
16. 	 In addition, run gels in the absence of glycerol (10%). Halve the voltage in the absence of 
glycerol. 
17. 	 Stain gels as follows. 
Silver staining 
1. 	 Remove MDE gel from between the 2 gel plates and rinse in tray in distilled H20. 
2. 	 Rinse with 0.1 % AgN03 and then gently agitate in 0.1 % AgN03 for 20 min. 
3. 	 Rinse gel well in distilled H20. 
4. 	 Agitate in the following solution in a fume cupboard for for 20 min: 
30gNaOH 
0.2 g Na borohydride 

20 ml 15% formaldehyde. 

5. 	 Rinse in enhancer (7.5 g NaC03 II distilled H20). 
6. 	 Rinse in distilled H20 and visualize on light box. Seal in clear plastic. (These gels cannot 
be dried as they crack.) 
4.12 DIRECT SEQUENCING OF PCR PRODUCT 
Run PCR product on 1.5% agarose gel as described below. 
Equipment 
1. 	 Horizontal mini-gel systems (Mgu-202T), (CBS Scientific Company Inc., Del Mar, USA). 












1. 	 MS-S Agarose, Whitehead Scientific, Brackenfell, South Africa. 
Method 
1. 	 Insert gel tray between tapered baffles. 
2. 	 Microwave agarose (0.75 g /50 ml TBE) for approximately 1 min. Mix well. Add 100 ~l 
of ethidium bromide (1 mg/ml). Mix and pour into gel tray and insert comb. 
3. 	 Allow to set for 1 h. 
4. 	 Remove comb and tapered baffles. 
5. 	 Add 250 ml1x TBE to fill both reservoirs of gel tank and to cover surface of gel by ± 3 
mm. 
6. 	 Load PCR product diluted 1:0.5 (product/sample solution v/v). 
7. 	 Place safety cover on unit. 
S. 	 Run at 100 V for ± 1.5 hs. 
9. 	 Rinse gel in distilled H20 and visualize under UV light. Excise the DNA band from the 
gel with a sterile scalpel blade, taking care to minimise time of exposure of DNA to UV 
light).. 
10. Extract DNA from agarose using a Qiaex II gel extraction kit as described in Appendix 
4.5. 
For sequencing 
Use 5 ~l of primer solution (1.1 pmoV~I; 30 ng/~l). 
Direct sequencing is performed with a Big Dye terminator cycle sequencing kit on an ABI 
prism 377 DNA sequencer, by the Core DNA sequencing facility of the University of 
Stellenbosch. 
4.13 RESTRICTION ANALYSES 
Equipment 
1. 	 Techni dry block BD-2D, Laboratory & Scientific, Cape Town, South Africa .. 
2. 	 Force 14 microfuge, Denver Instruments, Laboratory & Scientific, Cape Town, South 
Africa. 
Further equipment as for the 6% non-denaturing gel electrophoresis (Appendix 4.4). 
Method 
All volumes quoted below are for a single digestion reaction. These volumes should be scaled 
up to allow for the number of digests required. Include a positive and negative control in each 













(Promega Corporation, Madison, USA). This is used for identification ofR59W in exon 3 and 
recognises the following sequence: 
5' C' -I,.(T/C) CG(A/G)G3' 
3' G (A/G) G C (TIC) tC5' 
Wild type: 252 bp product, 1 cutting site: digestion products of 168 bp and 84bp. 
Mutant: the cutting site is abolished. 
1. Prepare the digest as follows: 
Buffer B lOx 2.0 f.ll 
Bovine serum albumin (BSA) 10 mg/ml 0.20 f.ll 
Distilled H20 7.3 f.ll 
Ava 1(10 units/J.!1) 0.5 f.ll 
Total 10 f.ll 
2. 	 Mix and microfuge briefly. In a 0.6 ml microfuge tube add 10 f.ll ofthe above mixture 
and 10 f.ll PCR product (1 - 1.5 f.lg) . Mix. Layer mineral oil on top ofmixture and 
microfuge briefly. Incubate at 37°C for 4 h. 
EaeI 
(Roche Diagnostics Pty Ltd, Randburg, South Africa). This is used for the identification of the 
L15F mutation in ex on 2 and recognises the following sequence: 
5' p/GGCCPu 3' Py (CIT)· 
3' Pu CCGGtPy 5' Pu (A/G) 
Wild type: 167 bp, 1 cutting site: digestion products of 85 bp and 82 bp. 
Mutant: the cutting site is abolished. 
1. 	 Prepare the digest as follows: 
Buffer A (lOx) 2 f.ll 
Distilled H20 14.5 f.ll 
EAE 10 units/f.ll 0.5 f.ll 
Total 	 17 f.ll 
2. 	 To the above, add 3 f.ll PCR product (300 ng 450 ng). Layer with oil. Mix. Microfuge 
briefly. Incubate at 37°C for 5 h. 
HpaII 
(prom ega Corporation, Madison, USA). This is used for the identification of the c769delG; 
770T-A mutation in exon 7 and recognises the following sequence: 
5' CJ.CGG 3' 
3' GGCtC 5' 
Wild type: 272 bp, 1 cutting site: digestion products of200 bp and 72 bp. 
Mutant: the cutting site is abolished. 











Buffer A (10x)2 ~l 
BSA (10 mg/ml) 0.2 ~l 
Distilled H20 7.55 ~l 
Hpa II (1 0 units/~l) 0.25 ~l 
Total 10 ~l 
2. 	 To the above add 1 0 ~l PCR product (1-1.5 ~g). Layer with oil, mix and microfuge 
briefly. Incubate at 37°C for 3 hs. 
Mae III 
(Roche Diagnostics Pty Ltd, Randburg, South Africa). This is used for the identification of the 
Y348C mutation in exon 10 and the Q375X mutation in exon 11 and recognises the following 
sequence: 
5' .l,GTNAC 3' [N = Pu or Py] 
3' CANTG5' 
Y348C 
Wild type: 223 bp, 1 cutting site: digestion products of 146 bp and 77 bp. 

Mutant: an additional cutting site is created: digestion produc ts of 96 bp, 50 bp and 77 bp. 

Q375X 
Wild type: 257 bp, 1 cutting site: digestion products of 161 bp and 96 bp. 
Mutant: the cutting site is abolished. 
1. 	 Prepare digest as described below. 
Incubation buffer (2x) 1 0 ~l 
Distilled H20 2.25 ~l 
Mae III (2 units/~l) 0.25 ~l 
Total 12.5 ~l 
2. 	 To the above add 7.5 ~l PCR product (750 ng - 1125 ng). 
Mix, layer mineral oil on top ofmixture. Microfuge briefly. Incubate at 55°C for 4 hs. 
BsaJI 
(New England Biolabs, Beverly, MA, USA). This is used for the identification of the R168C 
mutation in exon 6 and recognises the following sequence: 
5' C.l,CNNGG 3' . 
3' GGNNCtC 5' 
Wild type: 317 bp, 2 cutting sites: digestion products of 195 bp, 106 bp and 16 bp. 
Mutant: 1 cutting site is abolished: products of 106 bp and 211 bp. 
1. 	 Prepare digest as described below. 
NE buffer (lOx) 2 ~l 
Distilled H2 0 7 ~l 
BsaJI 2.5 units/~l 1 ~l 











2. 	 To the above 1 O~l, add 1 0 ~l PCR product (1 - 1.5 ~g). Incubate at 60°C for 3 hs. 
MvaI 
(Roche Diagnostics Pty Ltd, Randburg, South Africa). This is used for the identification of the 
537del AT mutation in exon 6 and recognises the following sequence: 
5' CC-!-(AlT)GG 3' 
3' GG(T/AhCC 5' 
Wild type: 317 bp, no cutting site. Undigested product remains. 
Mutant: a cutting site is created: products of 158 and 157 bp. 
1. 	 Prepare digest as described below. 
Buffer H (1 Ox) 2.0 ~l 
Distilled H20 7.5 ~l 
Mva I 1 0 units/~l 0.5 ~l 
Total 10 ~l 
2. 	 To the above add 1 0 ~l PCR product (1 - 1.5 ~g). Mix. Overlay with oil. Microfuge 
briefly. Incubate at 37°C for 3 h. 
3. 	 These digestion products are best visualised on 1 % agarose. On 6% polyacrylamide, 
electrophoresis produces aberrant bands running above the predigested product, 
apparently as a result of the deletion. 
BsiYl 
(Roche Diagnostics Pty Ltd, Randburg, South Africa). This is used for the identification of the 
V290M mutation in exon 8 and recognises the following sequence: 
5' CCNNNNN-!-NNGG 3' 
3' GGNNtNNNNNCC 5' 
Wild type: 197 bp, 1 cutting site: digestion products of 107 bp and 90 bp. 
Mutant: the cutting site is abolished. 
1. 	 Prepare digest as below. 
BufferM 2 ~l 
Distilled H20 7.75 ~l 
BsiY1 (1 0 units/~l) 0.25 ~l 
Total 10 ~l 
2. 	 To 5 ~l of the above, add 10 ~l PCR product (1- 1.5 ~g). Mix. Cover with mineral oil. 















Mutated or \.".".<,",u 
.......UI.lVllU"'-U et al 1986). 
APPENDIX 
COMPLETE GENOMIC FOR HUMAN PPO, PRIMERS 
FOR DNA ANALYSIS OF MUTATIONS 
table on the following the genomic sequence 
Robreau AM, Rosipal R, Nordmann Deybach J-C). The comments are 
al (Genbank accession No X 99450), Puy et al (1996), Taketani et al (1995), 
(1995),: 
lower case letters. • Intronic sequences are 
• Exonic sequences are pnr.tp/i by upper case letters and are shaded, ex on number 
appears in Column 
are denoted by 
the relevant exon. 
• forward ( sense) primers used in 
• reverse (antisense) primers are by a single 
• are printed in bold type and are outlined by a box: the relevant 
• bold italic type, and are 1\.1\...111<'11'-,'-' by a number preceded 
interacts with factor Spl 
#2 Sequence to TGATAG which to binding site of 
cell-specific transcriptional factor GAT A-I. 
#3 inverted to CCAA T (overlapping #3). 
#4 to GGGCCGG signal. 
#5 (overlapping #4). 
#6 initiation site. 
#7 
are all potential regulatory elements within promoter region, 










A B: Sequence C 
1 taagaggtga tagagaactg gcccaaaatt ggagtcttct tgggacccaa gttccctctc 
61 taacaggtgg gggcgctctc agagccgagg gggaaggttt cggggatggt gctggacccg 
121 gacctgtgtc ccccagcagt gaaggttatg tactgggagg aaaagaggaa aggcatactt 
181 gagtgaggct gcgtgcaggc tctggggcga ctggtttggt cggcgatggg ggagtgccac 
241 tgttgacaaa cactgggtac gttgccgggc ggccctagct cccgtaggcc cggtctgttg #1 
301 ctaacatcaa ggagctgttt atggagccgc ctccccgtgg actggcctta agtgtcccta #2 
361 tctattctcc ctacgaccaa agctcctgcg gccttccctc tagggttgtc accctagctg 
421 gacctggtaa gcttgtgctg gggaacgcta actccagcat taagcgctcg ccgcctcggt 
481 
541 
cctgaggagg gcagtgacgg gtacggccgc tcactcccag ctcggcgcta acacggttaa 
cctccagctc ttacagctgc cgtcgctccg cctctgccag ttcaatgttt tattggtgaa #3 
601 cgtgatccgg ggccttccaa gtcccgccaa tccagatgta ggagaggtag ggttaggcgc #4,#5 
1 661 GTGCCGCGAG AACAGAGTGG ACGGAGAGTA GGAGAGACCG AAAAGGCTGG GGGTGGGAGT 
721 AGCGGATTTG AAGCACTTGT TGGCCTACAG AGGTGTGGCA AGCAGAGCAC CTCAGAACTC 
781 AGGCGTACTG CCCGCCGCCC GAGCCCTGCG AGGGCCGATA GCGAGGGTGT GGCCCTTATC 
841 TGCACCCAGC AGAGCGCCGG CGGGGTACGG TCTTAGGACC TCGATCTCCT TCTCCCTCAT 
901 TTTCTCTCAT CCCTACCTAT TGTGGgtgag tcctggcccc tggacgggga cctcgctgtt 
961 ccaccagccc atccgtgcac acttagtttc ccctaaagca gtgagtggcc gggatagaac 
1021 tcaaaaccgg cggggcttct ggagcgcagg ttgtccccgg tctgcctgtc catatcgccc 
2 1081 cctttccccc agGTTTCCGC ATG3GCCGGA CCGTGGTCGT GCTGGGCG~ GGCATCAGCG #6, L15F 
1141 GCTTGGCCGC CAGTTACc§:: CTGAGCCGGG CCCCCTGCCC CCCTAAGgtg agtgctccac H20P 
1201 ttgtgccaga gggagcttca tttaatgctc ttcccatttc catcaaaagc tagatggatc 
1261 ctggccctct gaatatgcct cttacccctc cctactgacc tctcggcggc ggctacaggc 
3 1321 ggtgcgtgca gtgtctctcc ctcttgtcgc cagGTGGTCC TAGTGGAGAG CAGTGAGCGT 
1381 CTGGGAGGCT GGATTCGCTC CGTTCGAGGC CCTAATGGTG CTATCTTTGA GCTTGGACCT 
1441 SFGGGAATTA GGCCAGCGGG AGCCCTAGGG GCCCGGACCT TGCTCCTGgt gagaggcttg R59W 
1501 tgggatgtct aggagaggtt gtggaggggg cttccattgg ggaatagagt ttaggggagg 
1561 aagtatgttt ggtgggtcag atcttccctt agtttctcct cttctgaggg catgtggaga 
4 1621 gcagGTTTCT GAGCTTGGCT TGGATTCAGA AGTGCTGCCT GTCCGGGGAG ACCACCCAGC 
1681 TGCCCAGAAC AGGTTCCTCT ACGTGGGCGG TGCCCTGCAT GCCCTACCCA CTGGCCTCAG 
1741 gtaacaccag cacctccgct ccttttactg tgccctcatc ctcatatgcc ttccatttct 
1801 ttcttctttt cttttttttt tttttttttt tttttttgag acggagtatc gctctcgccc 
1861 aggatggagt gcaatggcgc gatcttggct cactgcaact tccgcctttc gggttcaagc 
1921 gattctcctg cctcagcctc ccgagtagct gggactacag gtgcctacca ccacgtctgg 
1981 ctagtttttg tat t tt tagt agagatgggg tttcaccata ttggccaggc tggtcttgaa 
2041 ctcctgacct tgtgatccgc ccgcctcggc ctgccaaagt gctgggatta caggcgtgag 
2101 ccaccacgcc cgacctgcct tccatttctt catctccctg tcagccttcc cagcaaaagg 
2161 aagccaaatg agtggaaatg accccagcgc ctggagctgg ggag;g;tatgt caggagcttc 
5 2221 
2281 
~ccctcacta tgcctttctc catgcagGGG 


















A B: Sequence C 
2401 ccaaacctct tccctcctaa accagctgca gagctccctg ttcaaatcta ccacctaggg 
2461 gctcttctgt atcatttggg gatgccctct tctcttcata ccccaccccc tcataattcc 
2521 caaaactcat tattgggagt gaaggccttc atttccatcc gtcacagtgg gaatgtcccc 
2581 caacccaaac cctatcccac cctcattccc taccaaatag gggctgtgga aatcagtcag 
2641 tgtagattat tttttcgctc cttagtccta gtctcaccct taagGTGGCG TCTCTAGCCA 
6 2701 TGGACAGTCT CT~GTGGA GTGTTTGCAG GCAACAGCCG TGAGCTCAGC ~AGGTCCT R168C, 
537deiAT 
2761 GCTTTCCCAG TCTCTTCCAA GCTGAGCAAA CCCATCGTTC CATATTACTG GGCCTGCTGC 
2821 TGGGGGCAGg tgagggggat tgattcagag ggtgaaaaat attaagtact gccaaagtga 
2881 gggagtgggg acaaggggtg ctattcaatg attctttttt tcttttttga gacggagtct 
2941 tgctctgctg cctaggctgg agtgcagtgg tgcaatctca gatcggctcg ctgcaacctc 
3001 cgcctcccag attcaagcaa ttctcctgcc tcagcctctt aagtagctgg gattacaaac 
3061 atgtgccacc actcccagct aatctttgta tttttttgta gagatgcagt ttcactatgt 
3121 tggccaggct ggtctcaaac tcctgacctc aagtgatcca cccgcctcgg cctcctaaag 
3181 tgctgggatt acaggt<Jt~p gccact<Jcat ccagcctcaa tgattcttct ttgcttcctc 
7 3241 tgcagGGCGG ACCCCACAGC CAGACTCAGC ACTCATTCGC CAGGCCTTGG CTGAGCGCTG 
3301 GAGCCAGTGG TCACTTCGTG GAGGTCTAGA GATGTTGCCT CAGGCCCTTG AAACCCACCT 
3361 GACTAGTAGG GGGGTCAGTG TTCTCAGAGG CCAGCC~ TGTGGGCTCA GCCTCCAGGC c769deiG 
,770T~A 
3421 AGAAGGGCGC TGGAAGGTAG GGGAAOccct ggagtgtaat gaacctgtca gtgtttccat 
3481 ctttatccaa gtggcttaac taggccaggg ccgataggac tggagttcct cattgttttt 
3541 gtgccttaga agctacttag acatgggcta ccccagaatc ctaggcccta tttgtgaacc 
3601 ttcctcaaag agcctatgca agtctgtgga tagaagtagt acttataagt ggcttagaga 
3661 taggggaaag aacccagct  cactgaacat ttcagaacag ccacactggc ctgtctggtc 
3721 cacttcctgg agtacacaga ggaatgattt tttgtgaagt ctacatagtc acccaatctc 
3781 ttcatcctgg gtcagtacac agtctccccg gccacatggg tgcctgggaa actgagagtg 
3841 aggcaccaga agtctctttt cactcatcaa attctcattt tctgggtctc tcaaatgttt 
8 3901 tcatgctctc agGTATCTCT AAGGGACAGC AGTCTGGAGG CTGACCACGT TATTAGTGCC 
3961 ATTCCAGCTT C~gtaatgg aatagccacc ttccccttcc ccaaccccta ccagtgagaa V290M 
4021 gcaaaagcta taccttcctg ggtcagcagg accacaccat gcccctgaac tggtcatctc 
4081 tatgggagtc taatcccaaa gaggactgac aactgtaatg ggaatgcctt ct<Jagtcag<J 
9 4141 cctct<Jcctg atctctagrI'G CTCAGTGAGC TGCTCCCTGC TGAGGCTGCC CCTCTGGCTC 
4201 GTGCCCTGAG TGCCATCACT GCAGTGTCTG TAGCTGTGGT GAATCTGCAG TACCAAGGAG 
4261 c:CCATCTGCC TGTCCAqgta tgataaaggg acggagaggc tgggcatggt ggctcacacc 
4321 tgtaatccca gcattttggg aggccgaggt gggcagataa caaggtcagg agttcgagac 
4381 cagcctggcc aacatggtga aaccccatct ctatgaaaaa tacaaaaatt agccaggtgt 
4441 ggtggcttgc acctgtaatc tcagctactc gggaggctaa ggcaggagaa tcgcttgaac 
4501 ccaggaggtg gaggttgcag tgagctgaga tctcgccatt acactccagc ctgggtgaca 
4561 gagtgagact ctgtcccccc caccccccca aaaaaatggg aaggagagac agcctcagct 
10 4621 agagcccttt ccttct<Jacg catgaatgtc cttctctcca gGGATTTGGA CATTTGGTGC 
4681 CATCTTCAGA AGATCCAGGA GTCCTGGGAA TCGTG~GA CTCAGTTGCT TTCCCTGAGC Y348C 












C A B: Sequence 
4801 catttccaga !;!ggctcctct gtgctccatt gtaggcaagg ccagactgat cagtgctata 
11 4861 ttccctcctt agGTGATGCT GGGAGGTTCC TGGTT GA CACTGGAGGC TAGTGGCTGT Q375X 
4921 GTCTTATCTC AGGAGCTGTT TCAACAGCGG GCCCAGGAAG CAGCTGCTAC ACAATTAGGA 
4981 CTGAAGGAGA TGCCGAGCCA CTGCTTGGTC CATCTACACA AGgtaagttg ggataaactt 
5041 ccctcagctc tccactgaag gccttgaaga cagagactgg aacatttgtc actgtatgtc 
5101 agccaaggcc taggacatca ataataaact tttccctgca tcctctcctc tcttctcagA 
12 5161 ACTGCATTCC CCAGTATACA CTAGGTCACT GGCAAAAACT AG.gtaagt tg ggaaaacagc 
5221 tgggctgagg agggccaagg acatcagacc cccagctaaa acattccttt catcctttcc 
13 5281 ttccagAGTC AGCTAGGCAA TTCCTGACTG CTCACAGGTT GCCCCTGACT CTGGCTGGAG 
5341 CCTCCTATGA GGGAGTTGCT GTTAATGACT GTATAGAGAG TGGGCGCCAG GCAGCAGTCA 
5401 GTGTCCTGGG CACAGAACCT AACAGCTGAT CCCCAACTCT CATTCATGAA AATAAAAATT #7,#8 












GlliDELINES RECOMMENDED BY THE UCT PORPHYRIA 
DIAGNOSTIC LABORATORY TO SOUTH AFRICAN DOCTORS AND 
LABORATORIES FOR THE DIAGNOSIS OF VP 
A RATIONAL APPROACH TO THE DIAGNOSIS OF PORPHYRIA 

IN SOUTH AFRICA 

RJ HIFT, D MEISSNER, PN MEISSNER 
1 INTRODUCTION 
Since the publication in May 1996, of the R59W mutation prevalent in South Africans 
with variegate porphyria, there have been numerous enquiries about the relevance of 
this to the diagnosis of VP. The DNA based test which is now available can identify 
beyond doubt at any age, from newborn, the specific gene defect for VP in the 
majority of South African VP subjects. 
However, the advent of this DNA test has served to highlight the immediate need to 
reassess our diagnostic approach to the porphyrias and to make it as rational as 
possible. It is essential to realise that DNA based testing will be no more than an 
adjunct, albeit an important one, to conventional biochemical testing and can replace 
it only in appropriate circumstances. 
2 INDICATIONS FOR R59WTESTING 
The R59W test is only appropriate as the single test under two circumstances: 
1. 	For detection of VP carriage in a family known to carry the 
R59W mutation 
2. 	 If result is positive in a patient with characteristic skin 
disease. 
In all other circumstances, R59W DNA testing must either be preceded, or followed, 
by accurate biochemical quantitation of porphyrins. Any laboratory which merely 
provides a negative R59W result for VP when asked to exclude porphyria and does 
not proceed to the porphyrin quantitation essential for excluding all types of 











3 ACCEPTABLE BIOCHEMICAL METHODS FOR PORPHYRIA DIAGNOSIS 
The only acceptable method of porphyrin diagnosis is by porphyrin quantitation using 
high-performance liquid chromatograpy or thin-layer chromatography coupled 
with fluorometric detection and quantitation. Qualitative methods and solvent 
extraction are not acceptable except, perhaps, where results are strongly and 
unequivocally positive. Negative, doubtful and low-level positive results are 
unacceptable and must be followed by chromatographic confirmation. No patient 
must under any circumstances be labelled as porphyric or not porphyric on the basis 
of less accurate tests. 
Only if this is accepted will we correct the present shambles where large numbers of 
people have been incorrectly labelled as having VP on the basis of inadequate 
testing. 
4 IMPORTANCE OF FAMILY STUDIES 
R59W testing is most appropriate when used for the detection of latent R59W­
positive VP in family studies. A window of opportunity has now opened for the 
effective management of porphyria in South Africa and it is now essential that testing 
is consistently applied. 
5 CHOICE OF DIAGNOSTIC INVESTIGATION 
The decision as to which test should be employed first depends on the following 
questions: 
1. Is the patient symptomatic? 
2. Is there a proven family history of porphyria? 
5.1. If the patient is being investigated for symptoms suggestive of porphyria; 
i.e. skin disease, abdominal pain or neuropathy. 
It is axiomatic that patients who are symptomatic from porphyria always have 
disturbed porphyrin biochemistry. Under these circumstances, biochemical testing is 
the appropriate first investigation as it will: 
1. 	Confirm porphyria 
2. 	 Indicate the type of porphyria present (VP, AlP, HCP, PCT or the 
rarer erythropoietic porphyrias) 
3. 	 Indicate the degree of activity of the porphyria (quiescent, 











The R59W test does no more than indicate the presence or absence of a specific 
mutation. In particular 
1. 	A positive result does not prove that a patient's symptoms are 
caused by porphyria 
2. 	 A negative result does not exclude a diagnosis of porphyria, 
whether VP or otherwise. 
However, it may under some circumstances be appropriate to perform the R59W test 
as a screening test, provided that it is always supplemented by biochemical testing 
where appropriate, as suggested below. Additionally, where a review of the patient's 
symptoms suggests that they are not compatible with porphyria, then it may not be 
necessary to test further, or at all. 
5.1.1 	 Where a patient is investigated for cutaneous symptoms 
Alternative A: 
Perform urine, stool and plasma porphyrin estimation. This will reveal the 
characteristic changes of VP, HCP, PCT, EPP or CEP. 
Negative biochemistry: Porphyria is excluded as a cause of the skin 
disease. 
Positive biochemistry: A pr per diagnosis can be made and the 
patient treated or counseled further. 
Alternative B: 

Perform the R59W DNA-based assay. 

Negative R59W: Porphyria is NOT excluded. Perform 
plasma biochemistry 
urine stool and 
Positive R59W: VP is confirmed. It is not necessary 
biochemistry if skin disease is typical. . 
to check 
5.1.2 	 Where a patient is investigated for "acute" symptoms such as 
abdominal pain or neuropathy 
Biochemical testing is mandatory, as even a positive R59W result does not prove 
that a patient's symptoms are due to porphyria, and a negative result does not 











5.1.2.1 	 For a suspected acute attack 
Perform an urgent Watson-Schwartz reaction with Ehrlich's aldehyde, and follow 
up with quantitation of ALA and PBG. Thereafter confirm the type of porphyria 
present by either biochemical porphyrin quantitation, or by a R59W test followed by 
porphyrin quantitation if R59W negative. 
5.1.2.2 	For a history of recurrent abdominal pain, neuropathy etc 
Perform urine, stool and plasma porphyrin estimation. This will reveal the 
characteristic changes of VP, AlP or HCP. 
Negative biochemistry: Porphyria is eXcluded as a cause of the 
symptoms 
Positive biochemistry: A proper diagnosis can be made and the 
patient treated or counseled further. 
5.2. 	 Where patients are asymptomatic, but are investigated because of a 
postive family history of porphyria. 
Approximately 50% of blood relatives of a proven index case of variegate porphyria 
should be gene carriers. Many of these will however be latent. Some will be 
detectable by biochemical porphyrin estimation where others will be entirely silent. 
Here DNA-based testing is entirely appropriate as a first line of investigation. Results 
are interpreted as follows: 
5.2.1 	 If an index case within that family is known with 100% confidence to 
carry the R59W mutation 
Perform the R59W test. 
Negative R59W The patient is not a carrier, the disease is absent and 
their children and subsequent descendants will not need 
testing. 
Positive R59W Carriage of the VP gene is confirmed. The patient should 
be counselled and managed as appropriate thereafter. 
Supplemental biochemical testing is not needed except to 
assess symptoms or for research purposes. 
5.2.2 	 Where VP in the family is proven or suspected, but the nature of the 
mutation is not satisfactorally established. 











Negative R59W: 	 Porphyria is NOT excluded. Follow up with urine, stool 
and plasma biochemistry, including ALA and PBG, and 
preferably test the original proband to confirm 
porphyria. Patients with confirmed VP but who are R59W 
negative should be referred to us for mutational analysis. 
Positive R59W: 	 VP is confirmed. The family should be labelled as a 
"R59W positive" family. 
5.2.3 	 Where the family is known to have a porphyria other than R59W­
positive VP 
R59W testing is unnecessary. Perform urine, stool and plasma porphyrin estimation. 
This will reveal the characteristic changes of VP, AlP, HCP, PCT or the rarer 
erythropoietic porphyrias, but may fail to detect true latent porphyria. More sensitive 
testing may be possible in some families where a mutation other than R59W has 
been identified, or by enzyme assays. 
6 SPECIMENS 
For DNA testing: 10ml EDTA blood. This must NOT be frozen. It should reach our 
laboratory within 48 hours from Monday to Thursdays and not on a weekend. 
For biochemical testing: Stool 10g, Urine 30 ml, Blood (heparinised) 10 ml. All in 











ISSUED BY THE UCT DIAGNOSTIC 

the result fonn issued by the UCT Porphyria Diagnostic 
on the following page. This is generated automatically by the database 
the chromatographic readings and was programmed by the 
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Address FITZROYSTR 25 Doctor: 
GOODWOOD 
Tel 5912539 Tel Bleep 
Specimen Date 26/05/1997 
Clinical Data: family project 
Send Report.. To DOREEN MEISSNER 
--- --- ------------- -- --- PORPHYRIN PLASMA SC.LE- ­
Plasma scan Peak present: 625nm = High Positive 
PORPHYRIN BIOCHEMISTRY 
URINE STOOL PLASMA RBC 
Porphobilinogen NEG 
Urobilinogen N 
Screen NEG ++ NEG 
Bacteriochlorop~yll y 
Creatinine 5.3 mmol/l 
ALA 11.1 «45) umol/l0 mmol creat 
PBG 3. a «16) umol/l0 mmol creat 
Uroporphyrin 0.0 «20) 0.0 (<1.7) 
7-COOH Porphyrin 0.0 (<1.5) 0.0 
6-COOH Porphyrin 0.0 0.0 
Pseudo 5-COOH Porphyrin 0.0 
5-COOH Porphyrin 0.0 0.0 
Isocoproporphyrin/PU 0.0 
Coproporphyrin 155.0 (<240) 75.9 «50) 
3 COOH Porphyrin 0.0 
Protoporphyrin 387.3 «200) 
Units nmol/ nmol/ .. 

10 mmol creat g dry mass 
, 
Porphyrin diagnosis: 11 Variegate porphyria 
------------ DNA ASSAY ------ --- --- ---- -------- ---­
VP DNA Study: R59W POSITIVE 
Genetic Diagnosis: 3 R59W positive: biochemically expressed variegate porphyria 
------ --- COMMENTS --- --- --­
Lab Comments: Urine porphyrins may have been obscured by pigments. 
Interpretation: This confirms the presence of the R59W gene mutation, the common 












SPECIMEN VALUES USED FOR THE DETERMINATION OF THE 
AGREEMENT BETWEEN EXPERT OBSERVERS. 
Shown in the table on the following page are the sets ofporphyrin results presented to the 
three observers (A, B and C) and the diagnoses they assigned to each set as described in 
Chapter 8. These specimen sets represent genuine values determined on routine specimens by 
the diagnostic laboratory. 
The diagnostic codes are as follows: 
For screening results 
1 The screenings suggest a normal result. 
2 The screenings are equivocal- could be either normal or VP 
3 The screenings suggest either VP or peT 
4 The screenings strongly suggest VP. 
For TLC results 
There is no doubt about the biochemical diagnosis either VP or normal. 
1 The trace is unequivocally normal 
4 The trace is unequivocally diagnostic of VP 
There is an element ofdoubt about the biochemical diagnosis as results are not unequivocally 
diagnostic. 
2 There is a suspicion that VP may be present, but the probability is low. 

















A B C A B C Urine Stool ALA PBG Uro C7 C6 C5 Copro Uro C7 C6 Ps5 C5 Copro C3 Proto 
1 
 1 1 1 
 1 1 1 
 NEG NEG 1.3 0 0 0 0 19 0 151.67 0 0 0 102.4 
2 
 1 1 1 
 1 1 1 
 NEG NEG 0 0 0 0 0 9 0 56 

3 
 2 1 2 
 1 1 1 
 1.1 0 0 0 0 25 0 157.7+ 
4 
 1 1 1 
 1 1 1 
 NEG NEG 0 0 0 0 0 9.1 0 28.24 0 0 0 98.9 
5 
 1 1 1 
 1 1 1 
 NEG NEG 16 0 0 0 88.4 0.9 0 0 0 0 5.4 0 49.2 
6 
 2 1 1 
 1 1 1 
 0 0 0 0 0 6.9 0 51
+/- NEG 10 0 0 0 65.5 
7 
 2 1 3 
 + +3 3 1 
 0 0 0 8.6 6.1 71.6 0 129.E0 0 0 0 86.5 
8 
 2 1 1 
 0 0 0 0 0 7 0 241.32 1 1 
 NEG +/­
9 
 3 2 4 
 4 2 2 
 NEG ++ 1.3 0 0 0.7 0 17.7 0 418.110 0 0 0 180.5 
10 
 1 1 1 
 1 1 1 
 0 0 0 0 0 9.3 0 54.1+/- NEG 3 0 0 0 78.8 
11 
 2 1 2 
 4 4 4 
 +/- + 0 0 0 78.3 22.3 200.4 0 369.734 11.9 0 20.3 69.4 
12 
 pas4 4 3 
 4 4 4 
 +++ +++ 0 0 0 23 7.2 344.2 0 429.366 23.4 14 0 0 0 557.7 
13 
 3 2 4 
 4 4 1 
 LOWNEG ++ 0 0 0 16.1 3.7 59 0 238
5 0 0 0 35.2 
14 
 2 1 2 
 2 1 1 
 NEG + 0 0 0 0 0 20.9 0 267.3 NEG8.6 1.3 4 0 0 0 21.8 
15 
 2 1 1 
 4 3 4 
 NEG +/­ 1.6 0 0 3.6 4.6 34.3 0 619.!:0 0 0 0 37.5 
16 
 1 1 1 
 1 1 1 
 NEG NEG 0.5 0 0 0 0 12.3 0 81.6 
17 
 2 1 2 
 1 1 1 
 + NEG 7.3 0.3 1 0 0 0 51.6 0 0 0 0 0 4.2 0 54.7 
18 
 1 1 1 
 1 1 1 
 NEG NEG 1.2 0 0 0 0 9 0 84.1 
19 
 2 1 1 
 1 1 1 
 NEG +/­ 1.7 0 0 0 0 18.7 0 157.85 0 0 0 20.1 
20 
 2 1 2 
 4 1 2 
 +/- + 0 0 0 3 3.4 29.7 0 356.510.9 3.9 1 0 0 0 30.1 
21 
 2 1 1 
 1 1 1 
 NEG +/­ 0 0 0 0 0 9.8 0 101.69.2 2.4 4 0 0 0 21.5 
22 
 pas3 2 4 
 4 4 4 
 +/- ++ 0 0 0 16 3.8 79.8 0 332
19.8 1.7 22 0 0 0 72.8 
23 
 2 1 1 
 1 1 1 
 +/- +/­ 0 0 0 0 0 8.3 0 71.17 0 0 0 54.1 
25 
 1 1 1 
 1 1 1 
 NEG NEG 0 0 0 0 0 7 0 26.1 
26 
 1 1 1 
 1 1 1 
 NEG NEG 0 0 0 0 0 3.2 0 69.66.9 1.1 0 0 0 0 19.2 
27 
 3 4 4 
 2 2 3 
 NEG +++ 1.3 0 0 0 0 12.6 0 427.90 0 0 0 17 

28 
 3 2 3 
 3 4 4 
 +/- ++ 0 0 0 0 0 93.9 0 298.721 0 0 0 363.5 
31 
 2 1 1 
 1 1 1 
 + NEG 0 0 0 0 0 5.3 0 62.59.1 3.8 4 0 0 0 41.3 
32 
 1 1 1
2 1 1 















PlasmaKey Screen StoolUrine 
Screening TLC 
A B C Urine StoolA B C ALA PBG Uro C7 C6 C5 Copro Uro C7 C6 Ps5 C5 Copro C3 Proto 
++ +++4 4 4
34 
 4 4 4 
 12.5 0 0 40.8 0 160.1 0 633.665.6 40.8 120 36.1 9.6 56.4 240 

35 
 1 1 1 
 NEG NEG 0 0 0 0 0 4.4 0 14.81 1 1 
 6 0 0 0 81.2 
+/- ++3 2 2 
 4 4 3
37 
 29.4 8.2 8 0 0 0 27.1 0 0 0 18.4 8.6 40.2 0 405.5 
+++3 4 4
38 
 4 4 4 
 0 0 0 15.9 0 82.3 0 616.3 
2 1 1 
 NEG + 0 0 0 0 0 7.4 0 79.139 
 1 1 1 
 8 0 0 0 13.6 
40 
 1 1 1 
 1 1 1 
 NEG NEG 0 0 0 0 0 10.5 0 21.4 
NEG1 1 1 
 1 1 1
41 
 0.7 0 0 0 0 8.4 0 76.6 
2 1 1 
 3 1 1 
 NEG +/­ 0 0 0 1 1 21.8 0 239.2
42 
 5 0 0 0 131 

NEG +++3 4 4 
 4 4 4
43 
 12.9 2.5 0 0 0 0 58.8 0 0 0 13.9 0 39.5 0 940.2 
++ +++4 4 4 
 4 4 4
44 
 30.7 14.1 22 0 0 0 176.7 0 0 0 42.1 6.6 158.7 0 797.5 
NEG NEG45 
 1 1 1 
 1 1 1 
 0.6 0 0 0 0 4.5 0 35.8 
+/- ++46 
 3 2 2 
 4 1 1 
 0.7 0 0 3.3 3.4 25.6 0 222.95 0.8 0 0 24 

NEG+1- +47 
 2 1 2 
 1 1 1 
 11.4 1.2 0 0 0 0 106.4 0 0 0 0 0 21 0 129.1 
2 1 1
48 
 1 1 1 
 +1- NEG 0 0 0 0 0 22.8 0 70.810.8 2.1 8 0 0 0 51.9 
49 
 1 1 1 
 NEG NEG1 1 1 
 0 0 0 0 0 5.9 0 54.5 
2 1 1 
 1 1 1 
 NEG +1­ 4.6 0 0 0 0 9 0 185.750 
 17 0 0 0 268.8 
NEG2 1 1 
 NEG + 1.6 0 0 8.3 5.9 46.7 0 458.852 
 4 3 4 
 16.5 4 0 0 0 0 312.6 
2 1 1 
 +1- NEG53 
 1 1 1 
 6 0 0 0 118.4 0.8 0 0 0 0 16.3 0 34.2 
2 1 1 
 1 1 1 
 +1- NEG54 
 14 0 0 0 311.1 1.3 0 0 0 0 16 0 72.2 
2 1 1 
 2 2 1 
 +1- NEG 0 0 0 0 0 55.5 0 98.755 
 49 0 0 0 340.7 
1 1 1 
 1 1 1 
 NEG 0.2 0 0 0 0 10.1 0 41.857 

1 1 1 
 1 1 1 
 0 0 0 0 0 18.1 0 98.4NEG NEG58 
 8 0 0 0 26.5 
2 1 1 
 NEG +1­59 
 1 1 1 
 12.2 4.4 14 0 0 0 333.3 2.2 0 0 0 0 19 0 202.3 
0 0 0 0 0 7.1 0 85.41 1 1 
 1 1 1 
 NEG NEG60 
 8.3 1 4 0 0 0 24.3 

+ ++ NEG0 0 0 51.7 13.6 113.9 0 540.161 
 3 2 2 
 4 4 4 
 32.5 9.7 3 0 0 0 121.2 
0 0 0 0 0 11.6 0 73.2 NEG1 1 1 
 NEG NEG62 
 1 1 1 
 10 3.2 16 0 '0 0 111.2 
0 0 0 0 0 32.2 0 263.5 NEG63 
 2 1 1 
 2 1 2 
 NEG + 3.5 2.1 8 0 0 0 91 

0 0 0 0 0 16.5 0 103.5+1- +1­2 1 1 
 1 1 1
64 
 12 0 0 0 121.3 
+ +++3 4 4 
 4 4 4 
 0 0 0 123.1 36 96 0 1713 POS
65 


















































































































69 2 1 2 2 1 3 NEG + 0 0 0 0 0 22.5 0 380.54.3 3.5 13 0 0 0 133.4 
70 2 1 1 1 1 1 0 0 0 0 0 14.4 0 121.2NEG +/­ 5.9 1.8 24 0 0 0 102.1 
71 2 1 2 2 1 1 NEG + 0 0 0 0 0 27.3 0 231.57.8 3.1 0 0 0 0 110.2 
72 2 1 1 2 1 1 +/- +/­ 0 0 0 0 0 35.8 0 191.70 0 0 0 21.1 
73 1 1 1 1 1 1 NEG NEG 0 0 0 0 0 23.3 0 4 
74 2 1 1 1 1 1 NEG +/­ 0 0 0 0 28.8 0 0 0 0 0 25.2 0 191. 
75 2 1 1 2 1 1 NEG +/­ 0 0 0 0 0 39.7 0 204.4 0 0 0 236.7 
76 1 1 1 1 1 1 NEG NEG 0 0 0 0 0 7.2 0 49.12 0 0 0 89.4 
77 1 1 1 1 1 1 NEG NEG 0 0 0 0 0 23.3 0 41 
78 2 1 1 1 1 1 NEG +/­ 0 0 0 0 0 25.2 0 191.80 0 0 0 28.8 
'2 1 179 2 1 1 NEG +/­ 0 0 0 0 0 39.7 0 204.74 0 0 0 236.7 
80 1 1 1 4 1 1 NEG NEG 0.6 0 0 1.9 2.3 9.6 0 142.67 0 0 0 81 
81 2 1 1 4 4 4 NEG + 4.1 0 0 21.6 7.9 105.1 0 497.14 2.5 0 0 211.1 
82 1 1 1 1 1 1 NEG NEG 0 0 0 0 0 14.1 0 580 0 0 0 30.1 
84 3 2 2 4 2 3 0 0 0 11.3 0 21.6 0 922.7NEG ++ 4.2 2 9 0 0 0 133.7 
85 2 1 1 1 1 1 +/­ 0 0 0 0 0 11.9 0 47.3 
4 4 486 4 4 4 0 0 0 51.1 0 221.2 0 615.2++ +++ 354 156.6 37.9 200.6 721.3 
87 2 1 1 1 1 1 0 0 0 0 0 14.2 0 116.3NEG +/­ 7 2.1 0 0 33.3 
88 1 1 1 1 1 1 0 0 0 0 0 11.3 0 34.6NEG NEG 6 0 0 0 13.8 
89 2 1 2 2 1 2 2.1 0 0 0 0 13.9 0 479NEG + 38 0 0 0 226.4 
90 2 1 2 4 1 2 1.7 0 0 1.8 3.2 18.6 0 167.9NEG + 
91 2 1 2 3 1 2 NEG + 3 0 0 0 0 33.9 0 388.9 
92 4 4 4 4 4 4 0 0 0 54.5 20.9 120.9 0 10741+ +++ 20.9 4.1 29 9.6 2 6.3 203 
93 2 1 1 1 1 1 + NEG 11 0 0 0 134.6 0 0 0 0 0 4.6 0 137 
94 2 1 1 1 1 1 +/- +/­ 1 0 0 0 0 3 0 44. 13 0 0 0 22.5 






























A B C 
Diagnosis 
TLC 
A B C 
-----------­
Screen 
Urine Stool ALA PBG Uro 
Urine 




Ps5 C5 Copro C3 Proto 
Plasma 
96 1 1 1 3 1 1 NEG NEG 0 0 0 0 95.6 0 0 0 1.5 3 29.1 0 106.3 
97 1 1 1 2 1 1 NEG NEG 13 3.1 0 0 147.8 1 0 0 0 0 19.3 0 244.9 
98 3 4 4 4 4 4 NEG +++ 23.8 0.7 14 0 0 0 20.3 0 0 0 56.1 19.5 236.4 0 1604 
99 3 4 4 4 3 4 NEG +++ 0 0 0 9.3 2.3 22.2 0 903.1 
100 2 1 2 2 1 2 + 0 0 0 0 0 17.2 0 318.4 
101 4 4 3 4 4 4 +++ +++ 16.3 3.7 568 219.2 17.7 43 268.5 0 0 0 200.4 28.2 400.4 0 2559 
102 3 2 2 1 1 1 ++ NEG 19.8 4.2 16 2.5 0 10.9 131.4 0 0 0 0 0 26.5 0 27.3 
103 2 1 1 1 1 1 +/­ +/­ 10 0 0 0 19.4 0.6 0 0 0 0 19.8 0 63.2 
104 4 4 4 4 4 4 ++ +++ 39.5 20.5 12 0 0 0 164.7 0 0 0 17.9 5.5 114.3 0 382.8 
105 2 1 1 1 1 1 NEG +/­ 5 1.8 0 0 57.1 0.5 0 0 0 0 19.6 0 108.1 
107 1 1 1 3 NEG 7 56.7 20.7 0 30.2 12.1 0 31.6 
109 3 2 2 1 1 1 +/­ ++ 8.2 1.9 0 0 0 0 19.5 0 0 0 0 0 3.9 0 139.1 
110 1 1 1 1 1 1 NEG 29 0 0 0 247.5 0 0 0 0 0 30.1 0 81.5 
112 3 2 2 4 3 3 + ++ 13.4 2.9 14 6.3 0 1.5 18.9 1.3 1.5 0 0 0 71.7 0 267.1 
113 3 2 2 4 2 3 NEG ++ 8.1 1.8 5 0 0 0 50.8 1.2 0 0 2.3 3 37.4 0 278.6 
114 3 2 2 4 3 3 NEG ++ 7 1.4 3 0 0 0 69.6 0 0 0 3.4 2 22.8 0 546.6 I 
115 1 1 1 1 1 1 NEG NEG 10.6 2.1 6 0 0 0 27.6 0 0 0 0 0 9.8 0 33 
116 1 1 1 1 1 1 NEG NEG 18.7 1.9 0 0 0 0 17.2 0 0 0 0 0 9 0 143.9 
117 3 4 4 4 4 4 NEG +++ 36.3 7.1 21 0 0 0 199.4 0 0 0 89.4 29.8 305.1 0 2354 
118 2 1 2 1 1 1 NEG + 10.5 0.8 33 0 0 0 83 0 0 0 0 0 12.6 0 197.3 
119 1 1 1 1 1 1 NEG NEG 0 0 0 0 78.6 1.4 0 0 0 0 16.7 0 86.7 
120 1 1 1 1 1 1 NEG NEG 17.8 1.2 1 0 0 0 19.4 0 0 0 0 0 4.1 0 17.6 
121 1 1 1 1 1 1 NEG NEG 28.9 8.9 12 0 0 0 306.5 0 0 0 0 0 8.7 0 30.5 
122 2 1 1 1 1 1 + NEG 24.4 4.9 11 0 0 0 85.6 0 0 0 0 0 14.8 0 81.3 
123 1 1 1 1 1 1 NEG NEG 16.5 3.6 5 0 0 0 47.7 0 0 0 0 0 11.7 0 71.7 
124 2 1 1 1 1 1 +/­ NEG 12.4 4.5 14 0 0 0 210.7 0 0 0 () 0 12.2 0 12 
125 2 1 2 4 4 4 NEG + 17.6 3.8 19 3.5 0 0 69.7 0 0 0 46.8 17.6 217.7 0 662.2 
126 3 2 2 4 4 4 NEG ++ 11.1 3 0 0 0 0 155 0 0 0 0 0 75.9 0 387.3 



















































A a C 
1 1 1 
1 1 1 
2 1 1 
2 1 1 
1 1 1 
2 1 1 
3 4 4 
1 1 1 
1 1 1 
2 1 1 
2 1 1 
1 1 1 
2 1 1 
1 1 1 
2 1 1 
2 1 1 
4 4 4 
2 1 2 
3 3 3 
2 1 2 
3 2 2 
2 1 1 
3 2 2 
1 1 1 
3 4 4 
2 1 2 
3 4 4 
3 2 
2 1 1 
A a C 
1 1 1 
1 1 1 
4 3 2 
1 1 1 
2 1 2 
2 3 3 
4 4 4 
1 1 1 
1 1 1 
1 1 1 
1 1 1 
1 1 1 
2 1 1 
1 1 1 
4 4 4 
1 1 1 
4 4 4 
4 3 3 
4 4 4 
3 1 2 
4 4 4 
4 4 4 
3 3 3 
1 1 1 
4 4 4 
2 1 1 
4 4 4 
3 1 1 

































































































































































































































































































Ps5 C5 Copro 
0 0 8.4 
0 0 13.3 
25.9 7.3 29.1 
0 0 5.4 
0 0 15 
0 0 102 
45.8 0 160.3 
0 0 10.2 
0 0 3.8 
0 0 4.6 
0 0 3 
0 0 12.2 
0 0 24.8 
0 0 26 
85.9 27.1 239 
0 0 18.2 
75.5 14.1 357.7 
1.8 2 27.9 
15 16.9 244.1 
6.7 6.7 38.8 
8.6 9.9 62.9 
11.4 11.4 52.1 
0 0 46.2 
0 0 13.3 
55.1 34.8 368 
0 0 25.5 
33.9 0 189.3 
0 10 11.8 




























































Screen Urine Stool Plasma 
A B C A B C Urine Stool ALA PBG Uro C7 C6 C5 Copro Uro C7 C6 Ps5 C5 Copro C3 Proto 
166 2 1 1 2 1 2 +/­ NEG 9 0 0 0 132.8 0.9 0 0 0 0 21.1 0 245.9 
167 2 1 1 1 1 1 +/­ NEG 3 0 0 0 37 1.7 0 0 0 0 13.2 0 94.5 
168 3 4 2 1 1 1 + ++ 0 0 0 0 0 4.7 0 57.6 
169 2 1 1 1 1 1 +/­ NEG 12 0 0 0 118.6 0 0 0 0 0 9.9 0 32.6 
170 2 1 1 1 1 1 + NEG 9 0 0 0 131 2.9 0 0 0 0 36.3 0 54.9 
171 2 1 2 4 4 4 NEG + 14 2.5 0 0 211.1 4.1 0 0 21.6 7.9 105.1 0 497.5 
172 1 1 1 1 1 1 NEG NEG 0 0 0 0 30.1 0 0 0 0 0 14.1 0 58 
173 1 1 1 1 1 1 NEG NEG 2 0 0 0 26.5 0 0 0 0 0 25 0 171.1 
174 1 1 1 2 1 2 NEG NEG 7.3 2.3 10 0 0 0 131.4 0 0 0 0 0 11.9 0 274.4 
175 2 1 1 1 1 1 +/­ 0 0 0 0 0 31.3 0 149 
176 3 4 4 3 3 3 NEG +++ 7.2 0.7 8 0 0 0 25.2 0 0 0 0 0 34.7 0 966.7 
177 2 1 1 2 2 2 NEG +/­ 28 0 0 0 225.6 0 0 0 0 0 8.6 0 419.7 
178 2 2 2 3 3 + + 17.5 2.9 0 0 0 0 358.3 1.2 6.5 3.1 0 29.8 30 0 121.1 NEG 
179 2 1 1 3 +/­ +/­ 329 178.2 0 0 148.3 0.6 6.5 7.7 0 18.3 19.4 0 117 NEG 
180 1 1 1 2 2 1 NEG NEG 10 0 0 0 134.6 0 0 0 0 0 47.3 0 198.7 NEG­
181 1 1 1 1 1 1 NEG NEG 6 0 0 0 136.4 0 0 0 0 0 22.4 0 146.7 
182 2 1 1 3 2 2 NEG + 0 0 0 0 0 36 0 457.9 
184 2 1 1 1 1 1 NEG +/­ 0 0 0 0 0 4.9 0 29.7 
188 2 1 1 1 1 1 +/­ +/­ 14 0 0 0 106.4 0 0 0 0 0 16.4 0 75 
189 2 1 1 3 1 2 +/" + 21 4.4 0 0 105.6 0 0 0 0 0 31 0 407.8 
190 2 1 1 1 1 1 NEG +/­ 0 0 0 0 141.3 5.6 0 0 0 0 38.3 0 74.4 
191 2 1 1 2 1 2 + 7 0 0 0 134.4 2.3 0 0 0 0 39.8 0 248.8 
192 2 2 2 3 3 + + 25.4 7.9 36 11.5 0 17.9 148.7 0 0 0 0 0 112.8 0 204.6 
193 3 2 2 4 4 4 +/­ ++ 17 3.3 0 0 0 0 146.9 0 0 0 0 0 60.3 0 333.3 
195 3 1 3 1 ++ NEG 1.7 13.2 10.5 0 10 11.8 0 24.6 
197 2 1 2 4 4 2 +/­ + 0 0 0 0 279.4 0 0 0 53.7 16.3 87.5 0 425.1 NEG 
202 2 1 1 3 1 1 +/­ +/­ 7.8 1.5 7 1.9 0 1.3 72.5 1 0 0 1 0.9 31.7 0 194.1 
203 4 4 3 4 4 4 +++ +++ 72.1 13 32 7.7 0 40.1 597.8 0 0 0 77.9 64.9 557.2 0 1106 POS 
















A B C 
Diagnosis 
TLC 
A B C 
Screen 
Urine Stool ALA PBG Uro 
Urine 
C7 C6 C5 Copro Uro C7 C6 
Stool 
Ps5 C5 Copro C3 Proto 
Plasma 
207 2 1 1 
210 2 1 1 
211 3 2 2 
212 2 1 1 
213 2 1 2 
214 1 1 1 
215 1 1 1 
216 1 1 1 
217 2 1 1 
218 2 1 2 
219 3 2 2 
221 2 1 1 
222 2 1 1 
223 2 1 1 
224 3 2 2 
225 2 1 1 
226 2 1 2 
227 4 4 4 
228 1 1 1 
230 3 2 2 
232 2 1 1 
233 3 2 2 
236 2 1 1 
238 2 1 1 
239 1 1 1 
241 2 1 1 
244 2 1 1 
248 4 4 3 
251 2 1 1 
1 1 1 
1 1 1 
4 3 3 
1 1 1 
3 3 3 
1 1 1 
1 1 1 
1 1 1 
1 1 1 
3 3 3 
4 4 4 
1 1 1 
1 1 1 
1 1 1 
4 4 4 
1 1 1 
2 2 1 
4 4 4 
1 1 1 
3 3 3 
1 1 1 
4 4 4 
1 1 1 
4 1 2 
1 1 1 
1 1 1 
2 2 1 
4 4 3 
1 1 1 
NEG +/­
+/­ +/­ 5 
NEG ++ 4 
+/­ + 6 




+/­ NEG 8.6 3.9 2 
+/­ + 1 
+/­ ++ 
NEG +/­
+/­ +/­ 0 
+/­ NEG 5 
+/­ ++ 0 
+/­ +/­ 9 
+/­ + 2 
++ +++ 
NEG NEG 
+/­ ++ 3 
NEG + 
+ ++ 0 




























































































































































2.1 	 2.4 
0 0 










17.8 	 8.1 
0 0 
0 0 
















































































































PlasmaScreen StoolKey Urine 
Screening TLC 
A B C Urine StoolA B C ALA PBG Uro C7 C6 C5 Copro Uro C7 C6 Ps5 C5 Copro C3 Proto 
0 0 0 0 0 32.2 0 101
NEG +/­2 1 1 
 1 1 1
252 

NEG +/­2 1 1 
 1 1 1
253 
 0 0 0 0 0 10.4 0 60.9 
+/- ++ 0 0 0 1.5 0 17.4 0 343.23 2 2 
 2 1 2
256 
 9.9 4 5 0 0 0 39.8 

NEG +/­ 0 0 0 0 0 27.5 0 161.52 1 1 
 1 1 1
257 

+/- + 0 0 0 16.2 8.1 209.8 0 235.82 1 2 
 4 4 4 
 24.7 2.8 227 159.6 32.9 38.2 373.2260 

2 1 1 
 1 1 1 
 NEG +/­ 14.6 2.5 0 0 0 0 107
262 
 0 0 0 0 0 28.7 0 166.3 
0 0 0 0 0 21.7 0 19.51 1 1 
 1 1 1 
 NEG NEG 32.4 11.9 0 0 0 0 130.4263 

1 1 1 
 1 1 1 
 NEG NEG 1.6 0 0 0 0 29.1 0 28.718.8 7.3 37 0 0 0 215.3266 

0 0 0 0 0 18.5 0 70.42 1 1 
 1 1 1 
 NEG +/­267 

+/- ++ 0 0 0 51.1 21.9 335.6 0 1109
3 2 2 
 4 4 4
269 
 0 0 0 0 209.8 
0 0 0 0 0 15.8 0 101.22 1 1 
 1 1 1 
 NEG +/­270 

+/- + 2.6 17.9 9.5 0 14 15.4 0 36.52 1 2
274 
 3 1 
 341 135.1 18.4 18.8 38.7 
0 0 0 0 0 32.9 0 147.42 1 1 
 1 1 1 
 NEG +/­275 

1 1 1 
 3 1 1 
 NEG NEG277 
 0 0 0 0.9 0 14.7 0 224.8 
NEG+/- + 0 0 0 1.7 1.3 12.8 0 204
2 1 2 
 3 1 2
278 
 2 0 0 0 81.4 
NEG+/- +/­2 1 1 
 1 1 1 
 0.1 0 0 0 0 11.7 0 124.4280 
 6 0 0 0 71 

+/- + 0 0 0 19.4 7.8 115.2 0 326.12 1 2
282 
 4 4 4 
 23 27.3 0 9.7 177.1 
0 0 0 35.3 6.3 55.3 0 295.62 1 2 
 NEG +4 4 4
284 

++ ++ 0 0 0 61.3 18.4 77.6 0 296.1287 
 3 4 3 
 4 4 4 

++ +/­3 2 
 0.7 2.4 2.4 0 3.5 20.8 0 18.7288 
 3 
 260 110 8.7 25.8 84.5 

0 0 0 0 0 23.9 0 706.62 1 2 
 NEG +2 2 3 
 7 0 0 0 95.3289 

NEG1 1 1 
 NEG NEG 0 0 0 0 0 9.3 0 43.11 1 1
291 
 2 0 0 0 0.6 
NEG NEG 0 0 0 0 0 7.4 0 70.61 1 1 
 1 1 1
292 

9.6 0 0 0 8 87.7 0 114.7+++ +3 2 
 3 4 
 331.2 0.4 1329 469.8 381.8 431.5 556.6293 

+++ ++ 0 0 0 16.6 6.6 146 0 361
3 4 2 
 4 4 4 
 27.8 3.8 31 0 0 0 369.7295 

NEG +++ 0 0 0 82 20.1 131.9 0 1153 POS3 4 4 
 4 4 4 
 10 0 0 0 425.5296 

NEG +/­ 0 0 0 0 0 32.8 0 141.22 1 1 
 1 1 1
297 

0 0 0 0 0 26.6 0 417.1NEG +/­2 1 1 
 2 3 3 
 22 0 0 0 834.5299 

0 0 0 0 0 30.5 0 41.41 1 1 
 1 1 1 
 NEG NEG 5 0 0 0 12.3301 



















Screen Urine Stool Plasma 
A B C A B C Urine Stool ALA PBG Uro C7 C6 C5 Copro Uro C7 C6 
----------------------------­
Ps5 C5 Copra C3 Proto 
302 2 1 2 2 1 1 NEG + 0 0 0 0 42.3 0 0 0 
-----------------------------­
0 0 45.3 0 88.4 
303 1 1 1 1 1 1 NEG NEG 0 0 0 0 0 27.9 0 140 
304 3 2 2 4 4 4 +/­ ++ 11 0 0 0 424.4 0 0 0 70.1 18 86.6 0 259.7 
305 2 1 2 1 1 1 NEG + 15 3.7 8.5 1.6 39.8 1 0 0 0 0 7.2 0 118.9 
306 3 2 2 2 2 1 NEG ++ 35 20 0 0 28 0 0 0 0 0 17.5 0 247 
307 1 1 1 1 1 1 NEG 0 0 0 0 0 8.1 0 33.4 
308 3 2 2 4 4 4 NEG ++ 172 245.3 146.2 174.4 300.3 7.1 36.7 47.5 0 42.1 71.5 0 461.5 
309 2 1 1 3 1 1 +/­ +/­ 15 0 0 0 74.7 0 0 0 3.7 1.4 26.5 0 34.5 
310 2 1 1 4 1 1 +/­ 2.1 0 0 3.4 3.7 19.5 0 290.1 
313 3 2 3 +++ NEG 17.6 3.3 670 295.5 42.7 115.4 117.2 6.7 21.3 12.3 0 36.7 18.7 0 30.2 
315 3 2 2 4 4 4 NEG ++ 0 0 0 57.3 23.6 198.9 0 267.5 
317 3 2 2 4 4 4 +/­ ++ 31 15.7 18 0 0 0 97.3 0 0 0 31.1 9 165.1 0 413.2 
318 2 1 2 3 1 2 NEG + 0 0 0 14.6 5.9 34.3 0 105.8 
320 2 1 1 1 1 1 NEG +/­ 0 0 0 0 0 16.7 0 47.2 
321 1 1 1 1 1 1 NEG NEG 27.4 5.7 22 0 0 0 162.7 0 0 0 0 0 33.7 0 185.1 
324 2 1 1 1 1 1 +/­ NEG 9.5 0.8 4 0 0 0 45.6 0 0 0 0 0 17 0 40.5 
326 1 1 1 1 1 1 NEG NEG 9.1 0.9 0 0 0 0 218.7 1 0 0 0 0 26.1 0 92.2 
332 1 1 1 2 1 1 NEG NEG 1.1 0 0 0.6 0 19.3 0 75.3 
335 1 1 1 2 1 1 NEG NEG 1.1 0 0 0.6 0 19.3 0 75.3 
336 2 1 1 1 1 1 NEG +/­ 0 0 0 0 0 11.7 0 59.7 
340 2 1 2 4 4 4 + 7.4 29.7 22.6 0 66.6 60.8 0 389.5 
342 2 1 2 2 2 2 NEG + 4.4 0 0 0 0 43.8 0 274.6 
343 3 2 2 3 2 3 ++ 0.7 0 0 7.8 0 6.7 0 676 
344 2 1 1 4 2 2 +/­ +/­ 5 0 0 0 102.5 1.2 0 0 0 2.1 31.1 0 380 
345 3 1 2 4 1 2 +/­ + 6.4 2.6 6 0 0 0 108.4 0 0 0 0.9 0.7 26.7 0 26Q.4 NEG 
348 1 1 1 1 1 1 NEG NEG 0 0 0 0 0 9.9 0 42 
351 3 2 2 4 4 4 + ++ 16.7 2.8 46 6.2 0 0 93.6 0 0 0 51.5 14 242.1 0 397.3 
352 2 1 1 1 1 1 NEG +/­ 0 0 0 0 0 35.7 0 106.4 


















Screen Urine Stool Plasma 
A B C A B C Urine Stool ALA PBG Uro C7 C6 C5 Copro Uro C7 C6 Ps5 C5 Copro C3 Proto 
359 2 1 1 4 1 1 +/­ +/­ 5 0 0 0 101.5 1.1 0 0 2.1 1.2 25.2 0 200.5 
360 2 1 1 2 1 1 NEG +/­ 19.4 5.7 0 0 0 5.5 1.7 7.1 0 69.5 













DRUG SAFETY DATABASE 
The UCT Porphyria Centre maintains an extensive and comprehensive drug-safety database. 
The author has been principally responsible for the creation and software programming of this 
computerised database, as well as for the evaluation of the clinical and laboratory data on 
which the recommendations are based. An innovation introduced by the author has been the 
replacement of the traditional safe, contentious, unsafe categories with those which 
recommend directly whether they should be used, avoided or used with caution. A major 
function of our Centre is the provision of drug safety information to patients, doctors and 













\0 	 DRUG SAFETY IN PORPHYRIA o 
INTRODUCTION 
Drugs are the most common factor 
precipitating the acute attack of porphyria, a 
potentially fatal condition. Thus it is 
essential to identify those drugs which may 
precipitate the acute crisis and avoid 
prescribing them to porphyries, except 
where no safer alternative exists and the 
indication outweighs the risks. 
This list which follows contains most drugs 
available in South Africa at present. Note 
that new drugs are constantly being 
introduced, and the absence of a drug from 
this list does not mean that its safety can be 
assumed. Drugs are listed by generic name 
and trade names must be cross-checked 
against these. The information presented 
here has been obtained by examining data 
from the literature (itself based on clinical 
experience as well as animal and in vitro 
experiments), from personal experience 
and by the examination of drugs for 
structure, structural similarity and routes of 
metabolism. Such information cannot be 
guaranteed to prove valid under aI/ 
circumstances, and the list should serve as 
a guide only. 
Responsibility cannot be taken for errors or 
for any adverse experience that may be 
encountered. The Lennon Porphyria 
Information Centre of the MRC/UCT Liver 
Research Centre, University of Cape Town, 
offers advice on all aspects of the diagnosis 
and management of porphyria, as well as 
maintaining a database of drug safety. It 
may be contacted at: 
• Phone 	 (021) 4066332 
• Fax 	 (021) 4486815 
USE OF THESE LISTS 
As a general rule, all topical preparations 
are safe. Thus any agent may be 
prescribed for external dermatological use 
or for instillation into the nose, ears or eyes, 
for gargling or, in the case of asthma, for 
administration by nebuJisation or metered­
dose inhaler. Caution should however be 
exercised when the risk of systemic 
absorption is high, as in dermatological 
preparations applied to large areas of 
denuded skin. The following list omits all 
agents used only by these routes, and 
comprises only those intended for systemic 
use. The following are the status terms 
used in the list. 
Use Likely to be safe and 
may be used freely. 
UWC Use with caution: 
Though safety is not 
established beyond 
doubt, the evidence 
suggests that the drug is 
unlikely to prove unsafe 
in practice. 
UWECO Use with extreme 
caution only: There is 
evidence to suggest that 
the drug may yet prove 
unsafe in practice, or 
grounds to suspect this 
may be so, or too little 
evidence to suggest that 
it may be safe. Such 
drugs should only be 
used if the expected 
benefits strongly 
outweigh the risks, and 
an adverse outcome 
must be anticipated. 
Avoid 	 There is evidence that 
such drugs have 
precipitated acute 
attacks in patients, or 
other grounds for 
believing that the risk of 
an acute attack is high. 
NDIAvoid 	 No data/Avoid: There is 
too little evidence to 
draw a conclusion, and 
it is wisest to regard the 
drug as potentially 
hazardous. 
Note that the description Use with extreme 
caution only (UWECO) is not an invitation 
to use the drug; it is a warning that it should 
only be used with great reluctance, and is 
potentially unsafe. 
CHOICE OF DRUG FOR A PORPHYRIC 
No porphyric patient should receive any 
medication unless it is felt to be absolutely 
vital. Many drug-related problems involve 
medication which was not strictly necessary 
in the first place. Beware of compound 
medications: particularly analgesics: though 
the paracetamol and codeine in them may 
be acceptable, often one of the "lesser" 
ingredients, such as meprobamate, is not. 
When a prescription is necessary, select 
drugs in the order; Use, UWC, UWECO, 
NDIAvoid, Avoid. Before using any drug 
labelled UWECO, Avoid or NDIAvoid, 
doctors must satisfy themselves that a very 
real need for the drug exists and that no 
safer alternative is possible; they should 
inform the patient fully of the potential 
danger of the drug and get the patient's 
consent, preferably in writing; they should 
advise the patient on what symptoms to 
expect should the porphyria become more 
active (for practical purposes, the 
development of any abdominal pain) and 
should advise the patient to stop the drug 
immediately under these circumstances. 
Darkening of urine may indicate a rise in 
porphyrin precursors and hence an incipient 
acute attack. 
Where the risk is particularly great, such as 
with anticonvulsants and antituberculous 
therapy, the patient should be monitored 
biochemically during the early stages of 
treatment. This is best performed by daily 
estimations of urinary ALA and PBG by a 
quantitative technique, or failing this, urine 
PBG screening with Ehrlich's aldehyde. Any 
rise in these precursors is strong 
presumptive evidence of an incipient acute 
attack, and treatment should be ceased 
forthwith. 
Information on the outcome of drug 
treatment in porphyric patients is always 
welcome and will assist with the 
improvement of the drug safety database. It 











LISTING BY USE 
















































































































Meclofenamic acid UWC 
Cefixime UWC 
Sevoflurane UWC 









































































Procaine Use Pethidine Use 
Amoxycillin Use 
Tetracaine Use Phenylbutazone Avoid 
Ampicillin Use Antibiotics: macrolides and 
Piroxicam UWC Benzathine benzylpenicillin Use tetracyclines 
N 
\0,.... 





















































Ooxycycline Avoid Methenamine Use 






















































































































































Sulfamerazine Avoid Atovaquone NO/Avoid Xipamide UWECO 
























































































Dihydralazine Avoid ACipimox UWC Tinzaparin Use Ketotifen UWC 
Diltiazem UWC Bezafibrate UWC Tranexamic acid Use Oxtriphylline Avoid 
Doxazosin UWC Clofibrate UWC Urokinase Use Salbutamol Use 
Enalapril UWC Colestipol Use Warfarin Use Theophylline UWECO 
Esmolol Use Colestyramine Use 
















































































Antihistamines and anti-allergics 
















































































































































































Omeprazole UWECO Polyethylene glycol UWC Temazepam Use Pimozide ND/Avoid 
Oxethazaine ND/Avoid Psyllium Use Triazolam Use Pipotiazine Use 
Pantoprazole UWC Senna Use Triclofos UWC Risperidone ND/Avoid 
Pirenzepine Use Sodium lauryl Zopiclone ND/Avoid Sulpiride UWECO 














































Betahistine UWECO Belladonna Avoid Fluoxetine UWC Gabapentin Use 
Buclizine ND/Avoid Dipyrone Avoid Fluvoxamine UWECO Lamotrigine ND/Avoid 
Cinnarizine UWECO Hyoscine UWECO Imipramine UWECO Mesuximide Avoid 
Cyclizine Use Hyoscine butyl bromide Avoid Lofepramine UWECO Oxcarbazepine Avoid 
Dimenhydrinate Avoid Mebeverine UWECO Maprotifine UWC Phenobarbital Avoid 
Domperidone Use Propantheline Use Mianserin Use 'Phenytoin Avoid 
Granisetron ND/Avoid Moclobemide ND/Avoid Primidone AVOid 





Constipation, diarrhoea and 



























































Diphenoxylate Use Ketazolam UWC Chlorpromazine Use Pizotifen NO/Avoid 
Ispaghula husk Use Loprazolam UWC Clotiapine NO/Avoid Sumatriptan UWC 
Kaolin Use Lorazepam Use Clozapine UWC 








































Bromocriptine UWECO Liothyronine Use Mesterolone UWECO Cytarabine NO/Avoid 
Carbidopa NO/Avoid Metergoline Avoid Mestranol UWECO Oacarbazine NO/Avoid 
Levodopa UWC Octreotide Use Metenolone NO/Avoid Oactinomycin Use 
Orphenadrine Avoid Ornipressin UWC Methyltestosterone UWECO Oaunorubicin UWC 
Pergolide NO/Avoid Propylthiouracil Use Nafarelin Use Oocataxel UWECO 
Selegiline UWECO Somatostatin Use Nandrolone NO/Avoid Ooxorubicin UWC 
Trihexyphenidyl Avoid Somatropin UWC Norethisterone Avoid Epirubicin UWC 
Tetracosactide Use Norethynodrel UWECO Estramustine NO/Avoid 
Central muscle relaxants and Vasopressin Use Norgestrel UWECO Etoposide NO/Avoid 








































Methylphenidate Use Cyproterone UWC Tibolone UWECO Ifosfamide UWECO 

























































































































































































































































Sodium fluoride Use 
Thiamine Use 
Ursodeoxycholate Use 













Acarbose NO/Avoid Anistreplase UWC Bromocriptine UWECO Cefuroxime UWC 
Acebutolol Use Antilymphocyte Buclizine NO/Avoid Cephalexin UWC 
Acetazolamide Use immunoglobulin Use Bumetanide Use Cephalothin UWC 
Acetohexamide UWECO Antithrombin iii Use Bupivacaine Use Cephradine UWC 
Acetylcysteine Use Aprotinin NO/Avoid Buprenorphine Use Cetirizine UWC 
Aciclovir Use Asparaginase UWC Buserelin Use Chlorambucil Avoid 
Acipimox UWC Aspirin Use Buspirone NO/Avoid Chloramphenicol Avoid 
Acitretin UWECO Astemizole UWECO Busulfan UWECO Chlordiazepoxide UWECO 
Acrivastine Nil yet Atenolol Use Cabergoline Avoid Chlormezanone UWECO 
Albendazole UWC Atovaquone NO/Avoid Calcitonin Use Chloroquine Use 
Albumin Use Atracurium UWC Calcium carbimide NO/Avoid Chlorphenamine Use 
Alclofenac UWC Atropine Use Calcium carbonate Use Chlorpromazine Use 
Alcuronium UWC Auranofin UWECO Cannabis Avoid Chlorpropamide UWECO 
Alendronic acid UWC Aurothiomalate UWECO Captopril UWC Chlortalidone UWC 

















Allopurinol Use Azithromycin UWECO Carbocisteine NO/Avoid Cilazapril UWC 
Alprazolam UWC Baclofen UWECO Carboplatin UWC Cimetidine UWC 
Alteplase UWC Barium sulphate Use Carmustine NO/Avoid Cinnarizine UWECO 
Aluminium salts Use Belladonna Avoid Carteolol Use Cinoxacin UWECO 

















Amikacin Use Benzathine benzylpenicillin Use Cefadroxil UWC Citalopram UWC 
Amiloride Use Benzbromarone UWECO Cefalexin UWC Clarithromycin UWC 
Aminocaproic acid Use Benzylpenicillin Use Cefalotin UWC Clavulanate Use 
Aminoglutethimide Avoid Betahistine UWECO Cefamandole UWC Clemastine Avoid 
Aminoglycosides Use Betamethasone UWC Cefazolin UWC Clindamycin Avoid 
Aminophylline Avoid Bethanechol NO/Avoid Cefepime UWC Clobazam UWC 
Amiodarone Avoid Bezafibrate UWC Cefixime UWC Clobutinol NO/Avoid 
Amitriptyline UWECO Biperiden NO/Avoid Cefotaxime UWC Clodronic acid UWC 
Amlodipine UWECO Bisacodyl UWC Cefoxitin UWC 'Clofazimine NO/Avoid 
Amoxycillin Use Bismuth Use Cefpodoxime UWC Clofibrate UWC 
Amphetamines UWECO Bleomycin NO/Avoid Cefradine UWC Clomethiazole UWC 
Amphotericin UWC Blood coagulation factors Use Ceftazidime UWC Clomiphene Use 
Ampicillin Use Bretylium NO/Avoid Ceftibuten UWC Clomipramine UWC 































Clotiapine ND/Avoid Dicycloverine Use Epirubicin UWC Fluorescein Use 
Cloxacillin Use Didanosine ND/Avoid Epoietin alfa Use Fluoride Use 
Clozapine UWC Diethylcarbamazine ND/Avoid Ergometrine Avoid Fluorouracil UWC 
Co-trimoxazole Avoid Difenoxin Use Ergotamine Avoid Fluoxetine UWC 
Codeine Use Diflunisal Use Erythromycin Avoid Fluoxymesterone ND/Avoid 
Codeine phosphate Use Digoxin Use Esmolol Use Flupentixol UWECO 
Colchicine Use Dihydralazine Avoid Estradiol UWECO Fluphenazine Use 
Colestipol Use Dihydrocodeine Use Estramustine ND/Avoid Flurazepam UWECO 
Colestyramine Use Dihydroergotamine Avoid Estriol UWECO Flurbiprofen Use 
Corticotropin Use Diltiazem UWC Estrone UWECO Flutamide UWECO 
Cortisone Use Dimenhydrinate Avoid Ethambutol Use Fluvastatin UWECO 
Cromoglicic acid Use Dimercaprol Use Ethamsylate Avoid Fluvoxamine UWECO 
Cyanidanol-3 ND/Avoid Dimethicone Use Ethinylestradiol UWECO Formestane UWECO 
Cyclizine Use Dinoprost UWECO Ethionamide Avoid Foscarnet ND/Avoid 
Cyclopenthiazide Use Dinoprostone UWECO Ethosuximide UWECO Fosfestrol UWECO 
Cyclophosphamide UWECO Diphenhydramine Use Ethylestrenol ND/Avoid Fosfomycin ND/Avoid 
Cyproheptadine ND/Avoid Diphenoxylate Use Etidronic acid UWC Fosinopril UWC 
Cyproterone UWC Dipipanone Use Etofylline Avoid Furosemide UWC 
Cytarabine ND/Avoid Dipyridamole Use Etomidate Avoid Fusidic acid Use 
Dacarbazine ND/Avoid Dipyrone Avoid Etoposide ND/Avoid Gabapentin Use 
Dactinomycin Use Dirithromycin UWECO Etretinate Avoid Ganciclovir Use 
Dalteparin Use Disopyramide UWC Etynodiol UWECO Gemcitabine ND/Avoid 
Danazol Avoid Distigmine Use Famciclovir Use Gemfibrozil UWC 
Dantrolene UWECO Disulfiram ND/Avoid Famotidine UWC Gentamicin Use 
Dapsone Avoid Dobutamine Use Fedrilate ND/Avoid Gestodene UWECO 
Daunorubicin UWC Docataxel UWECO Felodipine UWECO Gestrinone ND/Avoid 
Demeclocycline UWECO Domperidone Use Fenbufen Use Glibenclamide UWECO 
Desferrioxamine Use Dopamine Use Fenfluramine UWECO Gliclazide UWECO 
Desipramine UWECO Dosulepin UWECO Fenofibrate UWECO Glipizide UWC 
Desmopressin UWC Doxazosin UWC Fenoprofen Use Glucagon Use 
Dexamethasone Use Doxorubicin UWC Fentanyl Use Glucose Use 
Dexchlorpheniramine Use Doxycycline Avoid Finasteride UWECO Glyceryl trinitrate Use 
Dexfenfluramine Avoid Doxylamine ND/Avoid Flavoxate ND/Avoid Glycopyrronium Use 
Dextran Use Droperidol Use Flecainide ND/Avoid Gnrh agonists Use 
Dextromethorphan Use Dydrogesterone UWECO Flucloxacillin Use Gold UWECO 
Dextropropoxyphene Use Econazole UWECO Fluconazole UWECO Gonadorelin Use 
Dextrose Use Enalapril UWC Flucytosine Use Goserelin Use 
Diazepam UWC Enflurane UWC Fludrocortisone UWC Granisetron ND/Avoid 










Guaifenesin UWECO Kaolin Use Mazindol NO/Avoid Mianserin Use 
Halofantrine NO/Avoid Ketazolam UWC Mebendazole UWC Miconazole Avoid 
Haloperidol Use Ketoconazole Avoid Mebeverine UWECO Midazolam UWC 
Halothane Use Ketoprofen UWC Mebhydrolin NO/Avoid Minocycline UWECO 
Heparin Use Ketorolac UWECO Meclofenamic acid UWC Minoxidil UWECO 
Hetastarch Use Ketotifen UWC Medrogestone UWECO Misoprostol UWECO 
Hexoprenaline UWC Labetalol Use Medroxyprogesterone UWECO Mitomycin NO/Avoid 
Hydralazine UWECO Lacidipine UWECO Mefenamic acid UWC Mitoxantrone NO/Avoid 
Hydrochlorothiazide Use Lactitol Use Mefloquine UWC Mivacurium UWC 
Hydrocortisone Use Lactulose Use Melarsoprol NO/Avoid Moclobemide NO/Avoid 
Hydroxycarbamide UWECO Lamivudine UWECO Meloxicam UWC Morphine Use 
Hydroxyprogesterone UWECO Lamotrigine NO/Avoid Melphalan UWC Nabumetone NO/Avoid 
Hydroxyzine UWECO Lanatoside Use Mepivacaine UWC Nadolol Use 
Hyoscine UWECO Lansoprazole UWECO Meprobamate Avoid Nafarelin Use 
Hyoscine butyl bromide Avoid Leuprorelin Use Mepyramine UWC Nalbuphine Use 
Ibuprofen Use Levamisole NO/Avoid. Mercaptopurine UWECO Nalidixic acid Avoid 
Idarubicin UWECO Levodopa UWC Mesalazine Use Naloxone Use 
Ifosfamide UWECO Levonorgestrel UWECO Mesterolone UWECO Nandrolone NO/Avoid 
Imipenem NO/Avoid Levothyroxine Use Mestranol UWECO Naproxen Use 
Imipramine UWECO Lhrh Use Mesuximide Avoid Nefazodone UWECO 
Immunoglobulins Use Lidocaine Use Metenolone NO/Avoid Neostigmine Use 
Indapamide UWECO Lincomycin UWECO Metergoline Avoid Netilmicin Use 
Indinavir UWECO Liothyronine Use Metformin Use Niclosamide NO/Avoid 
Indomethacin Use Lisinopril UWC Methadone Use Nicotinic acid UWC 
Indoramin NO/Avoid Lithium Use Methaqualone UWECO Nifedipine UWECO 
Insulin Use Lofepramine UWECO Methenamine Use Nimodipine UWECO 
Interferon UWC Lomefloxacin UWECO Methocarbamol NO/Avoid Nimorazole UWECO 
lotalamic acid UWC Lomustine NO/Avoid Methotrexate UWC Nitrazepam UWECO 
Ipecacuanha NO/Avoid Loperamide Use Methoxsalen NO/Avoid Nitrendipine UWECO 
Iron salts Use Loprazolam UWC Methylcellulose Use Nitrofurantoin UWECO 
Isoaminile NO/Avoid Loracarbef UWECO Methyldopa Avoid Nitroprusside UWC 
Isoflurane UWC Loratadine UWC Methylphenidate Use Nitrous oxide Use 
Isoniazid UWECO Lorazepam Use Methylprednisolone Use Nitroxoline NO/Avoid 
Isoprenaline UWC Lormetazepam UWC Methyltestosterone UWECO Nizatidine UWC 
Isosorbide UWC Losartan NO/Avoid Methysergide Avoid Norethisterone Avoid 
Isotretinoin UWECO Lymecycline UWECO Metoclopramide UWC Norethynodrel UWECO 
Ispaghula husk Use Lynestrenol UWECO Metolazone UWECO Norfloxacin UWECO 
Isradipine UWECO Magaldrate Use Metoprolol Use Norgestrel UWECO 
Itraconazole UWECO Magnesium salts Use Metrifonate NO/Avoid Nortriptyline UWECO 
Ivermectin NO/Avoid Mandelamine Use Metronidazole UWECO Noscapine UWC 
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Ofloxacin UWECO Perindopril UWC Procaine penicillin Use Sertraline NO/Avoid 
Olsalazine UWC Perphenazine UWC Procarbazine UWECO Sevoflurane UWC 
Omeprazole UWECO Pethidine Use Prochlorperazine Use Silymarin NO/Avoid 
Ondansetron NO/Avoid Phenazopyridine NO/Avoid Progesterone UWECO Simethlcone Use 
Oral contraceptives UWECO Phendimetrazine UWECO Proguanil Use Simvastatin UWECO 
UWC Phenelzine UWECO Promethazine Use Sodium acid phosphate Use 
Orphenadrine Avoid Phenobarbital Avoid Propafenone NO/Avoid Sodium bicarbonate Use 
Oxamniquine NO/Avoid Phenoxymethylpenicillin Use Propantheline Use Sodium fluoride Use 
Oxaprozin UWC Phentermine UWECO Propofol Use Sodium lauryl sulphate Use 









































































































Pamidronic acid UWC Pivampicillin UWECO Quinine Use Streptokinase Use 

















Paroxetine UWC Polygeline Use Rifabutin UWECO Sulfadimethoxine 
Avoid 
Pectin Use Pravastatin UWECO Rifampicin UWECO Sulfadimidine 
Avoid 
Pemoline UWECO Prazepam UWC Risperidone NO/Avoid Sulfadoxine Avoid 
Penicillamine Use Praziquantel UWECO Ritodrine NO/Avoid Sulfafurazole Avoid 











































































































































































































The questionnaire completed by the members of the large R59W-positive family described in 











Form A. For those testing positive. 
QUESTIONNAIRE 
The questions which follow are designed to allow us to detennine more about the effect that 
porphyria has on our patients. Please be kind enough to answer it fully and truthfully. The 
infonnation is strictly confidential, and will not be shown to anyone other than the 
investigators. 
In the case of children, it is perfectly acceptable for the parent to complete the fonn on behalf 
of the child. 
The first set of questions allows us to check that we have your records correct and lets us find 
out more about you. 
1. 	 What is your name? 
2. 	 How old are you now? 
3. 	 When were you born? 
4. 	 Are you male or female? 
5. What is your father's name? 
6. 	 What is your mother's name? 
7. 	 What work do you do? 
The following questions tell us more about a diagnosis and how it was made. 
8. 	 Had you had porphyria tests before the ones 
done by us as part of this study? 
Ifyes, answer these questions 
9. 	 Where were they done? 
10. 	 Were they positive or negative? 
11. 	 Did you think you had porphyria before 
you received your gene test result? 
Ifso, answer these questions 
12. 	 You assumed you had porphyria because 
there was "porphyria in your family" 
13. 	 Because you had been told previously that 











14. 	 Because you were experiencing symptoms 
which you believed were due to porphyria 
Ifso ....... . 

15. 	Describe these symptoms. 
The following questions tell us more about your complaints 
Acute attacks 
16. 	Do you believe you have ever had an acute 
attack? 
Ifso, for each attack, provide the following 
details 
17. At what age did you have yor first attack? 
18. 	 W ri te down the year of each attack. 
19. 	 Describe the symptoms you experienced. 
20. 	 Did you notice whether you had dark 
urine? 
21. 	 Were you in hospital? 
22. 	 Did you develop paralysis? 
23. 	 How long did the attack last? 
24. 	 Can you write down the names of any 
medicines that you believe have made 
your porphyria worse? 
Ifso, answer this question 
25. 	 Give brief details of each. 
Skin disease 
26. Do you believe you suffer from porphyric skin 
disease? 
Ifso, answer these questions 
27. 	 Have you at any stage experienced the 
"typical" skin lesions, that is blisters and 













28 . Is your face affected? 
29. Are your hands affected? 
30. Are your forearms affected? 
31. Are your feet affected? 
32 . How old were you when you first 
became aware of skin disease? 
33 . Have you developed any other form of 
skin problem which you believe is 
related to porphyria? 
Ifso .. . .. . 
34. Describe it. 
35 . Do you suffer from any other skin 
disease? 
Ifso ..... 
36. Name it or describe it. 
If you are more than 40 years old. 
37. Have 	 you noticed any change In your 
porphyria as you get older? 
Ifso ... .. . 
38. Please describe the changes. 
The following questions are for females only. 
39. Are 	 you old enough to have started 
menstruating? 
Ifso, answer these questions 
40. Did you notice any change in your 
porphyria after puberty? 
Ifso ... .. . 
41. Describe the changes. 
42. Do you believe that your periods have or 
had any effect on your porphyria? 











43. Describe the changes. 
44. Have you experienced the menopause 
("change of life")? 
Ifso, answer question 45 
45. Has there been any change in your . 
porphyria since then? 
Ifso .. .. : 
46. Please describe the effect. 
The following questions are for males only. 
47. Have you undergone puberty? 
Ifso, answer this question 
48. 	 Did you notice any change in your 
porphyria after puberty? 
Ifso ... ... 
49. 	 Describe the changes. 
The following questions tell us more about any other illnesses you may have. 
50. Do you suffer from hypertension (high blood 
pressure)? 
51 . Do you suffer from heart disease? 
Ifso ..... 
52. 	 Please give more details. 
53 . Have you ever been treated for anxiety, 
depression or any other emotional or mental 
illness? 
Ifso .. . .. . 
54. 	 Give more details. 
55 . Have you ever consulted a doctor about 
abdominal pain, whether due to porphyria or 
not? 
Ifso ... ... 











Please teU 1l&how to eoatact you With a view to 8I'fugIDg to see I4U In October. 
57. Phone: (home)? 
58. Phone (work)? 
59. Fax? 
60. Email? 
61. Other? 
62. Address? 
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